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The  potential  for  chemoprevention  of  breast  cancer  depends  on  the  benefits  being 
achieved  at  reasonable  cost.  This  study  assesses  the  economics  of  chemoprevention  of 
breast  cancer  with  tamoxifen  within  the  context  of  the  International  Breast  Cancer 
Intervention  Study  (IBIS)  and  published  data  on  outcomes. 
Anonymised  trial  data  are  used  to  measure  direct  resource  costs  based  on  the  pattern 
of  service  delivery  in  the  IBIS  clinics.  Changes  in  morbidity  are  measured  as  the 
differences  in  use  of  resources  for  hospital  visits,  procedures  undertaken  in  hospital, 
use  of  prescribed  medications  and  visits  to  GPs  between  women  in  the  2  arms  of  IBIS. 
Changes  in  quality  of  life  are  assessed  using  the  SF  36.  Information  on  the  personal 
costs  to  the  women  themselves  was  gained  through  a  postal  questionnaire. 
A  sensitivity  analysis  assesses  the  effects  on  cost  effectiveness  of  alternative 
assumptions  about  the  duration  of  the  protective  effect  of  tamoxifen  (5,10  or  15  years) 
beyond  the  treatment  period.  Other  alternative  assumptions  explored  include  different 
models  of  service  delivery,  differences  in  personal  costs  to  the  women  themselves  and 
in  their  risk  status. 
Tamoxifen  chemoprophylaxis  for  breast  cancer  has  a  cost  of  less  than  £5000  per 
discounted  life  year  gained  for  women  at  high  risk  for  the  disease  assuming  that  the 
protective  effect  persists  for  at  least  10  years.  This  result  is  sensitive  to  the  risk  status 
of  the  women  since  the  number  needed  to  treat  (NNT)  would  be  high  for  women  at 
low  absolute  risk  of  breast  cancer.  The  model  of  service  delivery  is  also  important.  No 
significant  differences  in  morbidity  between  the  groups  were  found.  Hospital  visits  for 
benign  breast  disease  or  gynaecological  symptoms  and  the  use  of  beta  blockers  may 
merit  further  investigation.  There  appear  to  be  no  effects  on  quality  of  life. 
Chemoprevention  of  breast  cancer  could  be  delivered  through  general  practice  with 
minimal  specialist  support.  The  potential  may  be  limited  because  of  the  need  to  target 
women  at  high  risk  in  order  to  make  efficient  use  of  resources  for  this  common 
condition. 1ae  of  oaten  s 
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Introduction 
This  thesis  is  concerned  with  the  economics  and  policy  implications  of  use  of  the  drug 
tamoxifen  to  prevent  breast  cancer  in  women  at  high  risk  for  the  disease.  The  work 
has  been  developed  alongside  the  International  Breast  Cancer  Intervention  Study 
(IBIS)  1'  Results  from  other  chemoprevention  studies  are  also  used  particularly  the 
NSABP  P-12. 
Economic  analysis  requires  detailed  information  about  the  effects  of  an  intervention 
on  survival  and  general  health  as  well  as  information  about  changes  in  resource  use 
arising  directly  from  the  intervention  and  for  the  target  population.  In  this  case  it  will 
include  the  resource  consequences  of  delivering  a  service  for  tarnoxifen 
chemoprophylaxis,  possible  changes  in  health  care  resources  due  to  side  effects  of  the 
intervention  and  resource  implications  for  the  women  themselves  both  in  terms  of 
changes  in  personal  costs  incurred  or  in  quality  of  life.  In  order  to  inform  the  policy 
implications  an  understanding  of  acceptability  and  likely  uptake  among  the  target 
population  is  also  needed  as  well  as  comparative  information  on  alternative  means  of 
reducing  mortality  and  morbidity  from  breast  cancer. 
The  information  needed  on  the  efficacy  of  the  intervention  has  been  based  on  target 
assumptions  developed  within  IBIS  and  from  the  findings  of  NSABP  P-1.  Detailed 
information  on  use  of  hospital  services  and  medications  has  been  taken  from  the  data 
collected  from  women  enrolled  in  IBIS.  The  information  has  been  used  to  develop 
methodologies  for  understanding  the  resource  consequences  of  changes  in  morbidity 
for  women  taking  prophylactic  tamoxifen. 
Other  specific  studies  used  to  inform  the  economic  analysis  include  detailed 
measurements  of  the  resources  used  in  delivering  the  intervention  based  on  the 
models  adopted  within  IBIS  centres  and  a  study  of  the  resource  consequences  for  the 
women  themselves.  This  latter  study  was  carried  out  by  means  of  a  questionnaire  sent 
5 to  women  enrolled  in  IBIS.  Information  was  collected  on  the  costs  of  IBIS  to  the 
women  themselves,  on  quality  of  life  and  on  use  of  primary  care  services. 
It  was  not  possible  to  use  unblinded  information  from  IBIS  since  the  trial  has  not  yet 
completed.  It  was  however  possible  to  obtain  data  sets  separated  into  2  anonymised 
groups.  This  enabled  understanding  of  the  significance  of  any  differences  in  resource 
use  between  the  2  groups.  Conclusions  have  been  drawn  about  the  key  factors 
affecting  the  cost  effectiveness  of  tamoxifen  prophylaxis  and  its  likely  range  given 
currently  available  information.  Once  the  trial  has  been  concluded  the  methodology 
and  approach  developed  here  can  be  used  to  conclude  the  economic  analysis. 
Information  to  inform  policy  has  been  developed  from  a  detailed  review  of  the 
published  literature  on  the  aetiology  of  breast  cancer  and  the  impact  of  current 
therapeutic  interventions.  A  discussion  of  the  potential  for  primary  prevention  with 
dietary  intervention  is  also  included. 
IBIS  is  continuing  to  recruit  towards  its  target  of  7,000  women  with  the  aim  of 
providing  crucial  information  on  the  impact  of  tamoxifen  on  both  incidence  and 
mortality  from  breast  cancer.  As  a  consequence  it  may  also  be  possible  to  address 
questions  concerning  the  characteristics  of  the  women  most  likely  to  benefit  from 
prophylactic  tamoxifen  and  the  nature  of  tumours  which  do  arise.  Such  information 
would  contribute  to  more  detailed  understanding  of  the  cost  effectiveness  of  the 
intervention  for  women  at  different  levels  of  risk  of  breast  cancer.  As  part  of  the 
continuing  data  collection  further  information  will  be  available  on  the  use  of 
medications  and  hospital  services  by  women  in  IBIS.  This  will  contribute  to  the 
analysis  of  resource  consequences  of  changes  in  morbidity  for  women  taking  long 
term  tamoxifen  enabling  refinement  of  current  estimates.  Detailed  information  will 
also  be  available  on  serious  adverse  consequences  of  the  drug  and  specific  side 
effects. 
Breast  cancer  is  a  major  public  health  problem.  It  is  the  most  frequent  malignancy 
and  the  leading  cause  of  death  from  cancer  for  women  over  the  age  of  35  in  the  UK  as 
well  as  the  rest  of  Western  Europe  and  North  America3.  The  major  known  risk  factors 
associated  with  breast  cancer  include  reproductive  factors  and  family  history4.  Since 
these  are  not  easily  amenable  to  modification  by  behavioural  or  lifestyle  interventions 
6 the  emphasis  for  reducing  the  burden  of  mortality  and  morbidity  from  breast  cancer 
has  focused  on  early  detection  and  treatment,  and  palliation  of  advanced  disease. 
Until  recently,  the  impact  of  therapeutic  interventions  on  population  mortality  from 
breast  cancer  in  England  and  Wales  has  been  slight  with  mortality  rates  continuing  to 
rise.  The  steady  upward  trend  in  mortality  from  breast  cancer  is  however  beginning 
to  reverse  as  more  systematic  efforts  are  made  to  implement  effective  diagnostic  and 
therapeutic  interventions  and  with  possible  changes  in  the  distribution  of  risk  factors 
in  younger  cohorts  in  the  population  5,6 
Interest  in  chemoprevention  of  breast  cancer  has  been  stimulated  by  good  evidence  of 
a  decrease  in  contralateral  breast  cancer  incidence  following  use  of  tamoxifen  in 
adjuvant  therapy  and  the  increasing  understanding  about  the  role  of  available 
oestrogen  and  other  growth  factors  in  the  aetiology  of  breast  cancer7.  A  number  of 
trials  are  underway  to  investigate  the  impact  of  use  of  tamoxifen  on  incidence  and 
mortality  from  breast  cancer  in  women  at  high  risk  for  the  disease  Z,  8'ß.  Risk 
assessments  are  based  on  family  history  or  a  summary  score  of  reproductive  factors. 
The  largest  of  these  trials,  NSABP  P-1  has  published  findings  of  a  reduction  in 
incidence  of  about  50%  for  women  at  increased  risk  of  breast  cancer.  Though  these 
results  have  not  been  replicated  in  smaller  trials  published  subsequently,  the  findings 
from  NSABP  P-i  do  seem  to  be  robust.  They  are  internally  valid  and  are  consistent 
with  findings  by  the  Early  Breast  Cancer  Triallists  Collaborative  Group7of  a 
preventive  effect  of  tamoxifen,  reducing  by  47%  the  incidence  of  cancer,  in  the 
contralateral  breast  for  women  taking  adjuvant  tamoxifen.  The  lack  of  confirmatory 
results  in  the  smaller  trials  may  be  due  to  a  younger  population,  to  poor  compliance  in 
one  of  the  studies  and  to  differences  in  the  risk  profile  of  the  populations  recruited'. 
None  of  the  trials  provide  reliable  data  on  mortality.  There  are  various  possible 
outcomes  associated  with  tamoxifen  chemoprophylaxis  for  breast  cancer.  These 
include  delaying  or  preventing  the  onset  of  disease  and  in  reducing  mortality  from 
breast  cancer.  Reductions  in  the  incidence  of  disease  or  a  delay  in  the  appearance  of 
breast  cancer  may  not  be  associated  with  a  survival  benefit  though  there  may  be  a 
benefit  in  terms  of  shortening  morbidity  associated  with  the  disease.  It  is  likely 
however  that  the  relationship  between  the  benefit  derived  from  breast  cancer 
7 chemoprevention  and  the  cost  of  the  intervention  will  be  sensitive  to  variations  in  a 
number  of  parameters.  These  will  include  the  magnitude  and  duration  of  the 
intervention,  reduction  in  risk  of  breast  cancer  and  breast  cancer  mortality  rates.  The 
outcome  cost  per  life  years  gained  estimated  in  this  thesis  will  be  sensitive  to  breast 
cancer  free  life  years.  The  emphasis  on  mortality  in  deriving  an  appropriate  outcome 
measure  allows  comparison  with  other  studies  of  cost  effectiveness.  At  this  stage 
empirical  information  is  available  only  on  incidence.  Long  term  follow  up  will  be 
needed  in  fully  determining  the  value  of  this  intervention  in  relation  to  alternative 
health  outcomes. 
Published  breast  cancer  chemoprevention  trials  have  to  date  provided  some 
information  on  the  side  effects  of  long  term  use  of  tamoxifen  in  healthy  women 
though  none  has  quantified  the  potential  benefits  of  the  intervention  in  relation  to  the 
risks  of  increased  morbidity  or  mortality  from  other  conditions  or  the  economic  costs 
of  the  intervention.  Even  where  tamoxifen  chemoprophylaxis  for  breast  cancer  is 
shown  to  be  effective  it  may  not  be  cost  effective  particularly  if  associated  with 
increased  resource  use  required  to  manage  side  effects  or  because  of  possible  changes 
to  quality  of  life.  Indeed  the  cost  of  targeting  an  eligible  population  and  administering 
prophylactic  tamoxifen  may  be  substantial.  A  small  proportion  of  the  total  population 
is  at  high  risk  of  breast  cancer  yet  the  number  of  women  at  increased  risk  is  large  with 
the  possibility  of  profound  effects  on  the  use  of  health  care  resources. 
As  discussed  earlier,  the  main  focus  of  this  study  is  to  determine  the  cost  effectiveness 
of  tamoxifen  chemoprophylaxis  for  breast  cancer  and  to  understand  how  important 
the  main  costs  are  in  offsetting  the  potential  benefits  of  the  intervention.  Preliminary 
studies  have  suggested  that  a  reduction  of  less  than  1%  in  quality  of  life  could  offset 
potential  survival  gains10.  Other  commentaries  on  this  subject  have  concluded  that 
there  may  be  only  a  small  potential  gain  in  survival  in  relation  to  adverse  effects  such 
as  increased  risk  of  thromboembolism  and  endometrial  cancer"  or  a  substantial 
overall  cost  of  service  delivery  where  the  acquisition  costs  of  tamoxifen  are  high'2"3. 
Without  a  full  cost  effectiveness  analysis  it  remains  unclear  at  what  level  of  use 
tamoxifen  chemoprophylaxis  could  produce  sufficient  benefit  to  cover  the  cost  of 
service  delivery  or  indeed  generate  cost  savings  within  the  health  service. 
8 The  information  needed  for  the  cost  effectiveness  analysis  covers  three  broad 
categories  of  resource  use.  Firstly,  there  are  the  costs  involved  in  delivering  a  service 
for  prophylactic  tamoxifen.  This  includes  the  costs  of  identifying  and  targeting 
women  with  sufficient  risk  of  breast  cancer  to  be  eligible  for  prophylaxis  and  the  cost 
of  running  clinics  for  administering  the  drug  and  for  monitoring  and  follow  up. 
Secondly  there  may  be  resource  implications  arising  from  changes  in  the  pattern  of 
use  of  health  services  because  of  adverse  or  indeed  beneficial  effects  of  long  term  use 
of  tamoxifen.  This  requires  information  on  changes  in  the  use  of  hospital  services, 
visits  to  general  practitioners  and  use  of  medications  by  women  taking  tamoxifen. 
Thirdly  information  is  needed  on  the  costs  incurred  by  the  women  themselves  in 
attending  clinics  or  health  centres  to  receive  tamoxifen  or  for  a  follow  up  visit.  These 
personal  costs  include  the  cost  of  travel,  the  cost  of  time  off  work  and  other  costs 
involved  as  well  as  changes  in  the  quality  of  life  of  women  taking  long  term 
tamoxifen. 
Collecting  information  on  resource  use  within  the  context  of  a  randomised  trial  is  of 
considerable  value  since  data  can  be  compared  directly  between  the  2  arms  of  the 
trial.  For  the  cost  effectiveness  analysis,  information  collected  from  women  recruited 
to  IBIS  on  the  use  of  resources  is  combined  with  standard  unit  costs  for  elements  of 
service  delivery,  treatment,  drug  use  or  for  the  women's  personal  costs  in  order  to 
estimate  the  marginal  costs  of  tamoxifen  chemoprophylaxis  for  breast  cancer.  The 
costs  are  applied  to  the  resources  used  differently  between  the  2  arms  of  the  trial  using 
Healthcare  Resource  Groups  (HRGs)  14  for  the  pattern  of  use  of  health  services 
including  the  cost  of  mammography,  the  British  National  Formulary  (BNF)  15  for  use 
of  medications  -  including  the  cost  of  tamoxifen  in  the  UK  and  staffing  costs 
principally  for  the  assessment  of  service  delivery.  The  cost  of  breast  cancer  is 
estimated  from  an  analysis  of  resource  use  based  on  the  findings  of  the  Thames 
Cancer  Registry  (TCR)  Audit  of  Breast  Cancer  in  North  Thames  16.  For  each  category 
of  resource  use  comparison  is  made  for  the  purpose  of  validating  the  data  where 
possible  with  routine  sources  of  information  for  the  general  population. 
9 Because  as  yet  there  is  no  reliable  information  on  the  impact  of  tamoxifen 
chemoprophylaxis  on  mortality  the  initial  assessment  of  cost  effectiveness  is  based  on 
cost  per  breast  cancer  prevented.  A  more  useful  measure  for  comparison  with  other 
cost  effectiveness  studies  is  the  cost  per  life  year  gained.  For  this  analysis  net 
incidence  is  estimated  from  the  results  of  NSABP  P-1  for  the  potential  impact  of 
tamoxifen  chemoprophylaxis  within  a  cohort  of  women  at  high  risk  for  breast  cancer. 
Projections  of  survival  benefits  are  included  in  the  sensitivity  analysis.  The  effects  of 
discounting  future  costs  and  benefits  are  examined  using  a  baseline  discount  rate  of 
5%.  This  was  chosen  over  higher  rates  to  avoid  unduly  minimising  the  impact  of  a 
l  preventive  intervention  7'  1  s't  9 
The  impact  of  changes  in  a  number  of  aspects  of  resource  use  on  cost  effectiveness  is 
also  assessed  in  the  sensitivity  analysis.  They  include  the  cost  of  service  delivery,  the 
risk  status  of  the  women,  changes  in  morbidity  and  the  personal  costs  borne  by  the 
women  themselves. 
The  detailed  analysis  presented  here  is  unique  in  studies  of  breast  cancer 
chemoprophylaxis  since  it  provides  an  examination  of  the  resource  consequences  of 
changes  in  morbidity  for  women  taking  tamoxifen  prophylaxis  and  measures  both 
changes  in  quality  of  life  and  personal  costs  of  the  intervention  to  the  women 
themselves.  The  findings  have  important  implications  for  the  use  of  breast  cancer 
chemoprevention  with  tamoxifen  or  its  derivatives. 
A  full  understanding  of  the  potential  role  of  tamoxifen  chemoprophylaxis  for  reducing 
the  burden  of  breast  cancer  must  be  considered  against  the  background  of  current 
interventions  for  reducing  mortality  and  morbidity  from  breast  cancer  and  within  the 
context  of  changing  trends  in  incidence  and  mortality.  These  aspects  of  the  study  are 
considered  in  Chapter  1  with  further  discussion  made  in  Chapter  7  within  the  context 
of  the  conclusions  on  cost  effectiveness  of  tamoxifen  chemoprophylaxis. 
Chapter  2  reviews  the  evidence  underpinning  the  rationale  for  tamoxifen  as  an  agent 
for  chemoprevention  of  breast  cancer  assessing  also  the  potential  side  effects  of  the 
drug  based  on  evidence  mainly  from  adjuvant  studies  though  including  some  work 
10 from  prevention  trials.  Chapters  3,4,5  and  6  analyse  the  resource  use  involved  in 
tamoxifen  chemoprophylaxis  needed  for  the  cost  effectiveness  analysis. 
Chapter  3  sets  out  findings  from  a  study  of  the  costs  of  service  delivery  for  tamoxifen 
chemoprophylaxis  based  on  the  model  of  delivery  used  within  IBIS  but  discussing 
also  other  possible  options  for  safe  and  effective  service  delivery  including  care  in 
general  practice.  Chapters  4  and  5  provide  an  analysis  of  the  resource  consequences 
of  changes  in  the  morbidity  of  women  taking  tamoxifen  chemoprophylaxis  measured 
through  changes  in  use  of  hospital  services  and  use  of  medications  respectively. 
Chapter  6  sets  out  the  results  from  the  study  of  health  status  and  quality  of  life  for 
women  in  the  2  arms  of  IBIS  and  includes  the  results  of  the  analysis  of  personal  costs 
borne  by  the  women  themselves. 
Finally,  in  chapter  7  the  costs  of  tamoxifen  chemoprophylaxis  including  the  costs  of 
service  delivery,  the  costs  of  morbidity  and  the  personal  costs  to  the  women 
themselves  are  combined  and  set  alongside  information  on  effectiveness  derived  from 
IBIS  and  from  the  NSABP  P-1  study  to  produce  a  consolidated  estimate  for  cost 
effectiveness. 
Much  of  the  information  used  in  this  thesis  is  derived  from  collaboration  with 
Professor  Jack  Cusick  and  his  team  at  the  International  Breast  Cancer  Intervention 
Study  (IBIS).  In  Chapter  3  details  of  the  pattern  of  work  and  models  of  service 
delivery  were  developed  entirely  by  the  author  through  site  visits  and  interviews  with 
study  co-ordinators  in  each  centre.  In  Chapters  4  and  5  information  for  the  economic 
analysis  of  tamoxifen  chemoprophylaxis  for  breast  cancer  was  derived  from  data 
collected  within  the  protocol  for  IBIS  designed  and  run  by  Professor  Jack  Cusick  and 
others  at  the  Imperial  Cancer  Research  Fund  (ICRF).  The  questions  used  to  elucidate 
resource  use  within  the  study  -  those  concerned  with  the  rate  of  use  of  hospital 
services  and  the  use  of  medications  by  women  recruited  to  the  trial  -  were  added  to 
the  trial  protocol  with  the  help  of  Professor  Charles  Normand  at  the  London  School  of 
Hygiene  and  Tropical  Medicine.  Extraction  of  data  needed  for  the  analysis  was 
undertaken  by  Dr  Rob  Edwards,  senior  statistician  responsible  for  data  collection  in 
IBIS.  Accuracy  and  validation  of  the  data  used,  its  analysis  and  the  conclusions 
drawn  are  entirely  the  responsibility  of  the  author.  The  author  developed  the  self- 
11 completed  questionnaire  used  in  Chapter  5  to  gather  information  concerning  the 
quality  of  life  and  personal  costs  of  IBIS  to  the  women  themselves.  Clare  O'neill  the 
co-ordinator  of  IBIS  also  contributed  questions  to  the  questionnaire  seeking  views 
from  the  women  on  their  personal  involvement  in  IBIS,  their  understanding  of  breast 
self  care  and  satisfaction  with  services  for  breast  cancer.  Analysis  and  discussion  of 
these  latter  questions  is  not  included  in  this  thesis.  The  questionnaire  was  piloted  in 
collaboration  with  Clare  O'neill,  mailed  to  the  women  in  the  study  from  the  IBIS 
office  with  data  entry  completed  by  the  IBIS  data  clerks.  The  analysis  and 
conclusions  drawn  were  the  responsibility  of  the  author.  Chapter  7  draws  on 
information  developed  by  the  Thames  Cancer  Registry  Audit  of  Breast  Cancer  in 
order  to  derive  an  estimate  of  the  current  average  cost  of  breast  cancer  care  for  use  in 
estimating  cost  effectiveness  of  tamoxifen  chemoprophylaxis.  Drafts  of  the  thesis 
were  commented  on  by  the  advisory  panel  including  Dr  Jack  Cusick  at  ICRF, 
Professor  Klim  Mcpherson  and  Professor  Charles  Normand  at  the  London  School  of 
Hygiene  and  Tropical  Medicine. 
12 Chapter  One 
Background  and  Literature  Review 
The  context  for  chemoprevention:  Trends  in  incidence  and  mortality 
This  chapter  sets  out  the  context  for  tamoxifen  chemoprophylaxis  of  breast  cancer. 
The  possible  impact  of  a  preventive  intervention  for  women  at  high  risk  for  breast 
cancer  is  assessed  against  the  background  of  recent  trends  in  incidence  and  mortality 
of  the  disease.  The  scope  for  prevention  is  compared  with  current  options  for  reducing 
mortality  and  morbidity  from  breast  cancer.  These  include  treatment  of  early  breast 
cancer,  interventions  used  in  treating  advanced  disease  and  findings  from  the 
population  based  mammography  screening  programme.  The  prospects  for  primary 
prevention  are  included  focussing  particularly  on  the  limited  evidence  available  of  a 
possible  role  for  dietary  fat. 
The  crude  mortality  from  breast  cancer  for  England  and  Wales  (1996)  is  70  per 
100,000  women.  There  are  about  25,000  new  cases  of  breast  cancer  per  year  in 
England  and  Wales  and  12,000  deaths20.  A  reduction  in  mortality  of  35%  from  breast 
cancer  as  heralded  for  chemoprevention  by  some  authors  would  have  substantial 
public  health  significance  potentially  reducing  the  death  rate  to  around  40  per  100,000 
per  year  preventing  more  than  5000  deaths  per  year'.  Such  a  broad  scale 
improvement  is  unlikely  from  tamoxifen  chemoprophylaxis  however  since  the 
intervention  is  aimed  at  high  risk  women  in  the  age  range  40-65  while  over  60%  of 
breast  cancer  deaths  are  in  women  aged  65  and  over.  '  Moreover  a  reduction  in  breast 
cancer  mortality  in  the  younger  age  range  may  have  the  effect  of  delaying  rather  than 
preventing  mortality  overall. 
13 Trends  in  mortality 
Figure  1  shows  the  changes  in  mortality  from  breast  cancer  for  women  in  5-year  age 
bands  including  death  rates  up  until  1996  from  1979.  The  data  on  which  the  chart  is 
based  are  shown  in  Table  1.  Reduction  in  mortality  can  be  seen  in  women  in  the 
middle  age  range  particularly  from  age  45-49  up  until  aged  60-64  where  the 
downward  trend  appeared  later  from  the  mid  1980s.  The  trend  is  also  evident  though 
not  as  striking  in  women  aged  65-69  and  70-74. 
Figure  1 
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14 Data  in  Figure  1.  from  Breast  cancer  Deaths  in  England  and  Wales  in  5-year  age  bands  from  1979- 
1996  (using  ICD9  code  no  174).  Published  by  ONS  Mortality  Statistics  Section.  Population  figures 
for  England  and  Wales  ONS20. 
Table  1.  BREAST  CANCER  DEATH  RATES  per  100,000 
1  15  year  age  bands 
Time Period  35- 
39 
40- 
44 
45- 
49 
50- 
54 
55-59  60- 
64 
65- 
69 
70- 
74 
75-79  80-84  85plus 
1979-1981  15  31  55  77  92  106  116  130  152  187  253 
1982-1984  15  30  53  78  97  105  122  137  157  191  280 
1982-1984  15  29  51  76  94  115  123  146  170  216  280 
1988-1990  15  29  50  72  94  109  128  143  170  216  322 
1991-1993  13  27  45  68  85  103  120  138  170  222  311 
1994-1996  13  25  42  64  77  90  109  130  154  201  271 
The  rate  of  decline  in  mortality  in  the  UK  has  been  less  than  that  seen  in  the  recent 
downward  trends  or  levelling  of  previously  upward  trends  seen  in  many  other 
countries  world-wide  particularly  Australia,  Austria,  Canada,  FRG,  Greece,  The 
Netherlands,  Sweden,  Switzerland  and  the  USA'-  Mortality  from  breast  cancer  in  the 
UK  remains  the  highest  amongst  comparable  countries  in  Western  Europe,  USA, 
Australia  and  New  Zealand.  The  decline  in  overall  mortality  in  England  and  Wales 
began  around  1985  following  declines  in  the  early  1980s  in  many  comparable 
Western  European  countries'.  An  overall  increase  in  mortality  from  breast  cancer 
began  in  the  post  war  years  but  was  predominantly  in  the  50-54  year  olds  with 
increases  in  mortality  for  women  aged  60-64  not  occurring  until  the  1960s  or  the 
1970s  for  older  women.  By  the  mid  1970s,  mortality  had  begun  to  fall  in  women 
under  50  but  was  still  rising  in  those  over  60.  For  women  aged  55-69  mortality  rose 
from  about  83  per  100,000  in  the  early  1960s  to  level  off  at  around  107  per  100,000  in 
the  mid  1980s.  Though  changing  very  little  during  the  late  1980s  mortality  in  this  age 
group  fell  steeply  after  1990  and  in  1994  was  12  %  lower  than  in  1987. 
For  women  aged  40-59  the  decline  in  breast  cancer  mortality  has  been  linked  to 
increased  fertility  during  the  post  war  years.  Beral  has  suggested  that  the  reduction  in 
15 mortality  is  due  to  a  change  in  the  risk  profile  for  women  because  the  average  age  at 
first  birth  and  the  proportion  of  childless  women  declined  after  the  Second  World 
Warb.  Other  authors  have  concluded  that  the  trends  may  also  be  due  to  improvements 
in  survival  because  of  earlier  detection  of  tumours'`'  and  better  treatment  regimen'`'. 
The  extent  to  which  the  decline  in  mortality  has  been  the  result  of  the  introduction  of 
mammographic  screening  in  1987  is  still  the  subject  of  much  debate.  Quinn' 
concluded  in  an  analysis  of  trends  in  breast  cancer  incidence  and  mortality  until  1994 
that  the  reduction  in  mortality  is  unlikely  to  be  due  to  screening. 
The  decline  in  breast  cancer  mortality  in  many  developed  countries  appears  at  least  in 
part  to  be  due  to  birth  cohort  effects  or  period  effects°.  Average  mortality  patterns 
conceal  trends  in  different  age  cohorts  of  women23.  In  order  to  assess  this  effect  the 
data  in  Table  1  and  Figure  1  were  recalculated  to  show  mortality  by  birth  cohort  from 
women  born  in  1912-1916  to  1952-56  from  age  40-44  to  age  85-89.  The  results  are 
shown  in  Figure  2. 
Figure  2.  Mortality  rate  (per  100,000)  by  birth  cohort 
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85-89 An  upward  trend  in  mortality  continued  for  women  until  the  birth  cohorts  born  in  the 
1930s  for  the  age  groups  40-54.  These  women  would  have  experienced  their  peak 
fertility  in  the  50s  and  60s  not  delaying  child  bearing  unlike  earlier  cohorts  who  were 
reaching  their  20s  and  30s  in  the  war  years.  A  peak  in  trends  in  mortality  is  seen  for 
women  aged  55-59  born  in  earlier  birth  cohorts  (1925-1929)  and  for  women  aged  60- 
64  for  birth  cohorts  born  in  the  1920s.  Younger  women  aged  from  40-44  to  50-54 
born  in  the  1930s  see  a  reduction  in  mortality  at  an  average  of  20%.  Similar 
reductions  are  seen  in  the  older  age  groups  though  these  appear  earlier  from  birth 
cohorts  1925-1929  for  women  aged  55-59  and  from  birth  cohorts  1920-1924  for 
women  aged  60-64. 
These  data  are  consistent  with  the  hypothesis  that  widespread  improvements  in 
treatment  for  breast  cancer  rather  than  the  screening  programme  underlie  recent 
reductions  in  mortality.  The  effects  are  consistent  across  all  age  groups  and  not  seen 
only  in  the  screened  age  groups.  The  drug  tamoxifen  was  introduced  into  breast 
cancer  treatment  regimen  in  1973  and  has  been  shown  in  successive  large-scale 
studies  to  increase  survival  for  women  of  all  ages24.  The  rate  of  reduction  in  mortality 
found  in  randomised  controlled  trials  is  around  50%.  This  is  higher  than  the  20% 
shown  across  all  age  groups  in  the  figure  above  but  is  consistent  when  allowing  for 
the  possibility  of  undertreatment  of  older.  A  meta-analysis  emphasising  the 
'  importance  of  treating  younger  women  with  tamoxifen  was  not  published  until  1998. 
A  screening  effect  might  be  expected  to  appear  some  5-7  years  after  the  development 
of  the  programme  for  women  who  were  first  screened  aged  50-54  in  1987  but  the 
downward  trend  in  breast  cancer  mortality  began  well  before  the  development  of  the 
screening  programme  and  is  not  significantly  higher  in  the  older  age  groups.  Finally  a 
screening  effect  may  well  delay  the  development  of  breast  cancer,  yet  the  downward 
trend  is  seen  in  all  age  groups. 
The  overall  impact  of  the  reduction  in  breast  cancer  mortality  shown  in  Figure  2  is  an 
average  reduction  for  younger  women  under  50  of  21.5%,  for  women  aged  50-64  of 
around  33%  and  for  women  over  65  of  around  12  %.  For  women  in  the  age  group 
17 targeted  for  tamoxifen  prophylaxis  (45-64)  the  reduction  in  breast  cancer  mortality 
rates  since  the  mid  1980s  represents  about  1000  breast  cancer  deaths  prevented  per 
year  (assuming  a  rate  of  around  84  per  100,000  and  12,000  deaths  per  year  for  this  age 
group  in  the  mid  1980s  compared  with  a  rate  of  around  68  per  100,000  in  the  most 
recent  figures). 
Chemoprevention  with  tamoxifen  by  contrast  would  be  targeted  at  only  a  proportion 
of  these  women  though  the  mortality  reduction  is  estimated  to  be  greater.  Comparing 
the  same  population  with  the  rates  prevailing  in  the  mid  80s  and  assuming  that 
chemoprevention  is  targeted  towards  one  third  of  all  women  with  an  efficacy  of 
around  33%25.26  the  numbers  of  breast  cancer  deaths  prevented  might  be  less  than  half 
of  those  actually  seen  from  changing  trends  in  breast  cancer  mortality.  Clearly  the 
costs  in  terms  of  the  disbenefits  of  the  intervention  need  to  be  considered  carefully  in 
fully  evaluating  the  effect.  The  potential  for  enhancing  the  downward  trend  in  breast 
cancer  mortality  is  considerable.  Careful  analysis  will  be  needed  to  fully  evaluate  the 
effect  against  the  current  improving  trends  in  breast  cancer  mortality  and  the  further 
potential  for  more  appropriate  application  of  adjuvant  tamoxifen. 
Trends  in  Incidence 
The  incidence  of  breast  cancer  in  the  female  population  in  the  UK  increased  by  about 
2%  each  year  from  the  late  1950s  to  the  late  1980s.  From  1988,  after  the  introduction 
of  the  screening  programme  the  annual  rate  of  increase  more  than  doubled  to  nearly 
4.5%  until  1991;  there  was  virtually  no  change  in  incidence  between  1991  and  1992. 
In  1992  the  age  standardised  incidence  of  breast  cancer  in  women  in  England  and 
Wales  was  102  per  100,0000  about  a  40%  increase  from  74  per  100,0000  in  197427. 
Age  specific  incidence  rates  for  breast  cancer  rise  rapidly  with  age  though  unlike  other 
common  cancers  the  rate  of  increase  declines  after  age  50  around  the  age  of  the 
menopause.  Currently  approximately  one  in  14  women  in  the  UK  will  develop  breast 
cancer  by  age  75.  A  similar  pattern  in  incidence  of  breast  cancer  is  seen  in  other 
Western  European  countries28. 
18 Table  2  shows  the  lifetime  risk  of  breast  cancer  (Cumulative  incidence  (%))  in  1992 
for  the  most  recent  data  available,  in  1987  at  the  time  of  the  development  of  the  NHS 
Breast  Screening  Programme  and  in  1982  prior  to  the  introduction  of  the  breast 
screening  programme. 
Table  2:  Lifetime  risk  of  Breast  Cancer  (cumulative  incidence)  in  1982  and  1992. 
Rate  per  annum  Rate  over  5  years  Cumulative 
Incidence 
per  100,000  per  100,000  (%) 
Age  group  1982  1992  1982  1992  1982  1992 
30-  25  30  125  150  0.1  0.2 
35-  50  50  250  250  0.4  0.4 
40-  100  100  500  500  0.9  0.9 
45-  150  175  750  875  1.6  1.8 
50-  150  240  750  1200  2.4  3 
55-  175  250  875  1250  3.3  4.2 
60-  190  265  950  1325  4.2  5.6 
65-  200  265  1000  1325  5.2  6.9 
70-  220  270  1100  1350  6.3  8.2 
75-  225  300  1125  1500  7.4  9.7 
80-  250  300  1250  1500  8.7  11.2 
85-  300  330  1500  1650  10.2  12.9 
90-  310  360  1550  1800  11.7  14.7 
95-  320  400  1600  2000  13.3  16.7 
Based  on  A  ge  specific  incidence  rates  per  100,000 
The  table  shows  the  lifetime  probability  of  acquiring  breast  cancer  for  women  in  each 
age  category  according  to  life  expectancy.  For  women  aged  30  the  life  expectancy  is 
83  years.  Reading  against  the  80-  category  shows  that  the  probability  of  acquiring 
breast  cancer  has  risen  from  8.7%  (1  in  11)  in  1982  to  11.2%  (1  in  9)in  1992.  If  the 
women  lives  longer  then  the  rate  increases  to  12.9%  (1  in  8) by  age  85  assuming  that 
the  1992  incidence  rates  continue  throughout  her  lifetime. 
19 The  impact  of  the  NHS  Breast  Cancer  Screening  Programme  on  registration  rates  can 
be  seen  clearly  in  Figure  3.  Age  specific  incidence  rates  for  breast  cancer  are  plotted 
for  cohorts  of  women  by  5  year  age  groups. 
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The  increase  in  the  incidence  rate  of  registration  of  breast  cancer  since  the 
development  of  the  NHS  Breast  Screening  Programme  can  be  seen  for  women  aged 
50-64  -  the  screened  age  group.  Incidence  figures  are  often  difficult  to  ascertain 
20 because  of  problems  due  to  reporting  error.  Nevertheless  the  changed  trend 
demonstrated  here  is  likely  to  be  due  directly  to  early  detection  by  the  breast  screening 
programme  rather  than  a  true  increase  in  breast  cancer  risk. 
Treatment  effectiveness  for  early  breast  cancer:  systemic  therapy 
Evidence  for  reducing  rates  of  death  and  recurrence  from  early  breast  cancer  with 
systemic  adjuvant  therapies  including  use  of  tamoxifen,  ovarian  ablation, 
chemotherapy  (and  polychemotherapy)  and  immunotherapy  -  comes  from  two 
extensive  publications  by  the  Early  Breast  Cancer  Triallists  Collaboration.  The  first 
publication  reviewed  133  randomised  trials  involving  75,000  women  with  information 
on  follow  up  to  10  years  after  treatment24.  The  second  overview  is  concerned 
primarily  with  the  role  of  tamoxifen  and  is  derived  from  55  randomised  trials 
involving  almost  37,000  women'. 
In  the  first  publication,  significant  reductions  of  17%  (SD  2)  in  the  relative  risk  of 
death  and  annual  rates  of  recurrence  are  seen  for  adjuvant  treatment  with  the  drug 
tamoxifen,  of  25%  (SD  7)  for  ovarian  ablation  for  women  below  age  50  and  of  16% 
(SD  3)  by  polychemotherapy  (chemotherapy  with  more  than  one  drug  for  more  than 
one  month)  but  not  by  ovarian  ablation  at  older  ages  or  by  immunotherapy.  Direct 
comparisons  show  that  for  women  aged  between  50-69  combined  chemotherapy  and 
tamoxifen  is  significantly  better  than  chemotherapy  alone  for  recurrence  and  mortality 
(p<0.00001)  and  for  tamoxifen  alone  for  recurrence  (p<0.000001).  Estimates  suggest 
a  reduction  in  the  risk  of  death  of  around  30%  (SD  4)  for  combined  chemo-endocrine 
therapy  for  women  in  the  50-69  age  group.  The  proportional  risk  reduction  will  be 
about  the  same  for  node  positive  and  node  negative  women  though  the  absolute 
improvement  in  10  year  survival  is  twice  as  high  for  node  positive  women  because  of 
their  relatively  poorer  prognosis. 
For  women  under  50  only  2  treatments  have  clearly  significant  effects.  These  are  a 
27%  reduction  in  the  relative  risk  of  death  following  chemotherapy  (SD  6)  and  a  28% 
reduction  following  ovarian  ablation  (SD  9).  Indirect  comparisons  alone  showed  a 
21 significant  benefit  from  combining  chemotherapy  and  ovarian  ablation.  Both  direct 
and  indirect  randomised  comparisons  showed  polychemotherapy  to  be  significantly 
better  than  single  agent  chemotherapy  at  any  age;  polychemotherapy  has  a  greater 
impact  on  the  risk  of  death  for  younger  women,  a  25%  (SD  5)  reduction  in  the  relative 
risk  of  death  for  women  under  50  compared  with  a  12%  (SD  4)  reduction  in  relative 
risk  for  women  over  50). 
The  effects  of  tamoxifen  appear  to  be  cumulative.  Most  of  the  regimen  included  in  the 
studies  were  for  a  median  of  2  years  for  tamoxifen  and  1  year  for  polychemotherapy 
yet  significant  differences  in  survival  between  treated  and  control  groups  were  found 
at  both  5  and  10  years.  The  collaboration  demonstrated  a  highly  significant  trend 
towards  a  greater  therapeutic  effect  for  longer-term  use  of  tamoxifen  although  the 
directly  randomised  comparisons  of  different  tamoxifen  duration  indicate  only  a  non- 
significant  difference  in  favour  of  long  term  therapy.  These  results  were  confirmed  by 
the  second  overview  which  found  that  in  oestrogen  receptor  women  or  in  those  where 
the  oestrogen  receptor  status  was  unknown  for  women  treated  with  tamoxifen  for  one, 
two  or  five  years  the  reduction  in  the  rate  of  recurrence  was  21%,  29%  and  47% 
respectively.  The  reduction  in  contralateral  tumours  was  13%,  26%  and  47%  and  the 
reduction  in  mortality  was  12%,  17%  and  26%.  The  number  needed  to  treat  (NNT)  to 
prevent  recurrence  for  women  treated  with  tamoxifen  for  five  years  was  eight.  Further 
evidence  also  emerged  in  the  second  overview  on  the  benefits  for  younger  women  of 
about  five  years  of  tamoxifen  adjuvant  therapy  with  an  absolute  reduction  in 
recurrence  rates  as  a  first  event  of  14%. 
It  is  important  also  to  note  in  these  studies  that  the  incidence  of  endometrial  cancer 
was  shown  to  double  after  1-2  years  of  tamoxifen  use  and  to  increase  four  fold  in 
trials  of  five  years  or  more  of  tamoxifen.  The  absolute  reduction  in  the  risk  of 
contralateral  breast  cancer  is  however  about  twice  as  large  as  the  increase  in  the 
incidence  of  endometrial  cancer.  There  was  no  apparent  increase  in  the  incidence  of 
any  other  cancer  although  ascertainment  of  death  was  not  complete.  Overall  there 
was  a  relative  reduction  in  the  risk  of  death  from  all  causes  for  women  in  the 
intervention  group  compared  with  control  (rr=0.99  SD  0.05). 
22 Treatment  of  Advanced  Disease 
There  are  no  standard  therapies  for  second  or  third  line  treatment  for  patients  with 
refractory  disease  or  with  anthracycline  resistant  metastatic  breast  cancer  or  for 
patients  with  high-risk  presentations  of  early  disease.  Yet,  given  the  prevalence  of  the 
condition  and  the  poor  prognosis  for  newly  diagnosed  women  with  extensive  axillary 
node  involvement  and  late  stage  disease  in  general  there  is  a  good  deal  of  interest  in 
developing  new  drugs  to  improve  outcome. 
Claims  are  made  for  the  efficacy  of  some  agents  such  as  docetaxel  (taxotere)  as  a 
unique  agent  in  the  treatment  of  metastatic  breast  cancer  and  use  of  this  drug  is 
increasing.  The  evidence  for  efficacy  of  the  drug  is  mostly  from  case  series  (so  called 
phase  2  studies)  designed  to  test  the  likely  magnitude  of  response  of  the  drug  and  to 
monitor  the  side  effects  and  a  limited  number  of  randomised  controlled  -  phase  3 
drug  trials.  A  review  of  phase  2  studies  report  a  total  of  317  patients  observed  in  8 
different  studies  throughout  Europe,  North  America  and  Japan'-9.  Excluding  the 
Japanese  study  which  had  85  people  entered  and  offered  a  lower  dose  of  docetaxel 
than  in  the  majority  of  the  other  studies,  the  mean  number  of  women  observed  was  33. 
The  range  of  response  to  treatment  in  these  studies  lies  between  39  and  57%  with 
docetaxel  used  as  first  line  therapy  in  four  studies  and  second  line  chemotherapy  in 
three  studies.  Few  patients  achieve  complete  response  in  any  of  the  studies. 
Complete  response  is  defined  as  the  disappearance  of  all  clinical  evidence  of  tumour 
by  physical  examination  or  imaging  studies  for  a  minimum  of  four  weeks.  Most 
reports  are  of  partial  response  defined  as  broadly  a  50%  reduction  in  the  sum  of  the  bi 
-  perpendicular  diameters  of  all  neoplastic  lesions  for  at  least  four  weeks. 
Phase  2  studies  are  not  controlled  studies;  response  rates,  mean  duration  of  response 
and  survival  rates  can  only  be  compared  within  the  study  among  patients  who 
responded  and  those  who  did  not.  Many  of  these  case  series  report  a  high  number  of 
patients  experiencing  significant  side  effects  or  progressive  disease  leading  them  to 
withdraw  from  treatment;  a  large  proportion  of  patients  also  experience  dose 
23 reduction.  The  results  of  the  phase  2  studies  are  broadly  similar  and  a  more  detailed 
examination  of  the  two  most  recent  is  considered  below. 
In  two  Phase  2  studies30'3'  from  North  America  published  in  the  last  three  years 
patients  with  metastatic  breast  disease  treated  with  docetaxel  as  second  and  first  line 
therapy  respectively  achieved  remission  in  53%  and  54%  of  cases.  In  the  patients 
treated  first  line  there  was  complete  response  in  two  (5%)  out  of  the  37  patients 
treated  and  a  partial  response  in  18  (49%)  patients.  The  median  response  duration 
was  26  weeks,  excluding  four  patients  who  withdrew  from  the  study  while  in  response 
in  order  to  receive  high  dose  chemotherapy.  In  the  study  of  second  line  therapy  18 
out  of  35  patients  achieved  a  partial  response.  The  median  response  duration  was  7.5 
months  (30  weeks)  with  an  overall  survival  for  responding  patients  of  13.5  months. 
The  median  overall  survival  rate  was  nine  months  for  all  patients  entered  into  the 
study.  No  information  is  given  in  either  paper  to  compare  the  outcome  with  the 
median  survival  of  patients  treated  on  standard  palliative  therapy 
Of  the  toxicity  reported,  neutropenia  is  the  most  usual  dose-limiting  problem.  In  the 
first  of  the  studies  described  above  31  out  of  35  patients  are  reported  to  have  had 
neutropenia  18  of  which  were  complicated  by  fever  mostly  requiring  intravenous 
antibiotic;  eight  of  these  patients  also  contracted  significant  infections,  one  patient 
died.  In  the  second  study  35  out  of  the  37  patients  experienced  neutropenia  and 
leukopenia  and  there  were  19  episodes  of  febrile  neutropenia.  Infection  was 
documented  in  six  of  these  patients.  One  patient  with  neutropenia  developed 
mucositis  with  gastrointestinal  haemorrhage  and  died.  Myelosuppression  and  alopecia 
are  also  usual  while  nausea  and  vomiting  are  less  so.  A  high  proportion  of  patients  in 
both  studies  (33  out  of  35  and  30  out  of  37  respectively)  experienced  fluid  retention. 
In  the  latter  study  30%  of  patients  withdrew  because  of  this  toxicity.  The  aetiology  of 
fluid  retention  for  patients  taking  this  drug  is  poorly  understood  and  may  limit 
implementation. 
A  randomised  phase  3  trial  completed  on  a  sample  of  392  patients  in  N.  America32 
found  a  significant  improvement  in  response  rate  for  patients  with  anthracycline 
24 resistant  disease  randomised  to  receive  docetaxel  compared  with  those  on  Mitomycin 
C  plus  Vinblastin.  Response  rates  in  the  docetaxel  group  compared  with  standard 
therapy  were  30%  compared  with  11.6%,  time  to  progression  was  19  vs  11  weeks  and 
overall  survival  was  11.4  months  compared  with  8.7  months. 
Costs  involved  in  administering  docetaxel  are  significant  since  a  high  proportion  of 
patients  will  experience  significant  side  effects,  some  of  which  require  in  patient 
hospital  treatment.  Moreover,  anticipated  sensitivity  reactions  are  treated  in  advance 
with  steroids  or  antihistamines.  Treatment  costs  alone  to  achieve  the  three  months 
survival  benefit  rate  reported  in  the  phase  3  randomised  trial  per  patient  benefiting 
would  be  around  £50,000  since  the  data  suggest  an  NNT  of  5.4  and  costs  per  patients 
for  the  drug  alone  are  around  £9,000.32"'  32/2 
Bone  Marrow  and  Peripheral  Blood  Stem  Cell  Transplantation  for  Breast 
Cancer 
The  partial  success  of  adjuvant  chemotherapy  in  the  treatment  of  metastatic  disease 
alongside  evidence  for  a  dose  response  effect  of  chemotherapy  in  both  early  stage 
disease  and  in  patients  with  metastatic  disease  provides  the  clinical  rationale  for 
research  using  intensive  high  dose  therapy  (including  myeloablative  chemo  and 
radiotherapy  treatments  together  with  progenitor  cell  transplantation)  in  patients  with 
high  risk  presentations  of  early  stage  disease.  Moreover,  the  toxicity  associated  with 
high  dose  therapy  has  been  substantial  and  has  constituted  a  considerable  barrier  to  its 
use  for  women  with  breast  cancer.  More  recently,  however,  advances  in  treatment 
have  reduced  the  mortality  (to  below  5%)  and  morbidity  of  treatment  enabling  greater 
experimentation  with  intensive  therapy  and  the  prospect  of  widespread  use  of  active 
treatment  in  advanced  disease.  High  response  rates  have  been  found  in  some  series 
though  the  duration  of  the  effect  has  been  limited. 
To  date  there  have  been  only  three  randomised  trials  of  high  dose  therapy  compared 
with  conventional  chemotherapy  including  a  total  of  197  patients.  One  of  these  trials 
used  high  dose  chemotherapy  with  hematopoetic  rescue  as  a  primary  treatment.  In 
25 the  other  two  trials  initial  chemotherapy  had  been  given  though  in  one  of  these  studies 
only  nine  patients  were  randomised  restricting  meaningful  analysis.  This  latter  small 
study  reported  a  significant  benefit  for  patients  on  conventional  therapy  though 
presented  little  information  on  survival  and  stopped  early  because  of  poor  recruitment. 
The  remaining  trial  found  a  significantly  increased  odds  ratio  for  survival  in  the 
experimental  arm. 
A  review  of  high  dose  therapy33  suggested  that  the  limited  evidence  from  randomised 
trials  is  inconsistent.  The  trial  reporting  a  benefit  when  treating  patients  with  primary 
disease  may  be  confounded  by  tamoxifen  given  as  maintenance  therapy  to  patients 
responding  to  high  dose  regimen.  Patients  receiving  conventional  chemotherapy 
were  less  likely  to  respond  to  treatment  and  so  fewer  also  received  tamoxifen. 
Moreover  patients  in  the  control  arm  had  a  lower  survival  rate  than  expected  by 
comparison  with  other  series.  The  trial  showing  an  advantage  for  patients  on 
conventional  chemotherapy  also  showed  a  significantly  higher  survival  rate  for 
patients  given  high  dose  therapy.  The  results  in  this  case  may  well  have  been  affected 
by  patients  in  the  conventional  arm  crossing  over  to  receive  high  dose  therapy  at  the 
time  of  recurrence.  Clearly  further  studies  are  needed  before  treatments  of  this  kind 
can  have  any  role  in  conventional  care  of  breast  cancer. 
Cost  effectiveness  of  treatment  for  early  breast  cancer 
Few  studies  are  available  to  assess  fully  the  cost  effectiveness  of  current  interventions 
in  breast  cancer.  Results  from  the  overviewsdiscussed  above  were  however  used  to 
estimate  the  comparative  costs  involved  in  following  alternative  treatment  regimes  in 
adjuvant  therapy  for  early  breast  cancer.  The  costs  were  applied  to  the  standard 
cyclophosphamide,  methotrexate  and  flouracil  regimen  (CMF)34  for  chemotherapy 
and  for  antiemetics,  administration  costs,  supplies,  blood  cell  counts  and  medical  time 
and  were  compared  in  relation  to  the  benefits  (numbers  needed  to  treat)  with  the 
addition  of  tamoxifen  for  both  two  and  five  year  regimen.  The  costs  are  based  on 
26 estimates  of  standard  polychemotherapy  and  tamoxifen  and  include  antiemetics,  other 
supplies,  blood  cell  counts  and  doctor  time. 
The  results  for  women  treated  in  the  USA  show  that  systemic  therapy  is  highly  cost 
effective.  The  costs  per  life  saved  at  ten  years  in  early  breast  cancer  ranges  from 
around  $17,000  for  women  at  all  ages  in  the  highest  risk  category  to  over  $50,000  for 
women  at  any  age  at  a  lower  risk  of  death.  Where  the  duration  of  treatment  is 
increased  or  where  combined  therapies  are  used  costs  increase  substantially.  The  cost 
of  treatment  with  tamoxifen  is  less  in  the  UK  now  that  patent  restrictions  no  longer 
apply  to  the  drug.  Costs  of  tamoxifen  in  the  UK  are  around  £30/patient  per  year  and 
of  standard  polychemotherapy  around  £300  for  a  single  cycle  of  treatment. 
The  cost  effectiveness  of  adjuvant  therapy  is  proportional  to  the  individual  risk.  Cost 
per  QALY  estimates  for  women  under  50,  for  example  vary  with  oestrogen  status 
from  $12,000  for  node  negative  oestrogen  receptor  positive  breast  cancer  to  $4000 
and  $6,000  for  node  positive  breast  cancer  in  pre  and  postmenopausal  women 
respectively.  For  postmenopausal  women  with  node  negative  breast  cancer  cost  per 
QALY  estimates  vary  from  $28,000  -  36,00035  The  Early  Breast  Cancer  Triallists 
Collaboration'  concluded  that  the  treatment  of  low  risk  patients  was  as  effective  and 
that  the  addition  of  combined  therapies  offered  moderate  additions  in  life  expectancy. 
Yet  these  strategies  are  unlikely  to  be  as  cost  effective  as  targeting  and  treating 
women  in  higher  risk  categories.  Similar  effects  would  be  seen  with  the  effect  of  dose 
where  increased  or  changed  regimen  may  increase  costs  considerably  for  small 
reductions  in  mortality  or  risk  of  recurrence.  Very  little  information  is  available  on 
the  impact  of  changes  in  quality  of  life  for  alternative  treatment  regimen  in  breast 
cancer  care  yet  this  may  affect  the  balance  of  costs  and  benefits  quite  considerably. 
Most  estimates  of  the  cost  effectiveness  of  treatment  options  are  made  on  the  basis  of 
mortality  reduction  alone. 
27 Quality  of  care 
As  discussed  earlier  the  incidence  of  breast  cancer  in  the  UK  though  high  is 
comparable  to  that  of  other  western  European  countries  yet  the  mortality  rate  has 
remained  consistently  higher.  Studies  in  the  UK  continue  to  show  variations  in  the 
management  of  patients  with  breast  cancer  despite  adjustments  for  case  mix  both  in 
the  North  East  and  South  East  of  England36'3';  variations  in  health  outcome  between 
Health  Authorities  have  also  been  well  documented38.  The  Eurocare  study39  providing 
the  largest  set  of  population  based  estimates  of  cancer  survival  in  12  European 
countries  shows  considerable  variation  in  age  adjusted  survival  for  women  diagnosed 
with  breast  cancer  using  data  from  30  cancer  registries  between  1978  -  1985.  In 
particular  the  study  found  that  women  in  England  and  Wales  faced  lower  prospects 
for  survival  than  women  in  most  other  comparable  countries.  Compared  with  62%  5- 
year  survival  for  women  in  England  and  Wales,  only  2  other  of  the  countries  studied, 
Estonia  and  Poland,  had  poorer  survival  rates.  Survival  in  Scotland  ranked  8th  equal 
with  a  survival  rate  of  around  65%.  The  authors  claim  that  with  implementation  of 
effective  practice  throughout  the  UK  further  reductions  in  mortality  of  at  least  10% 
could  be  achieved. 
Although  guidelines  for  optimal  management  of  breast  cancer  are  now  available""' 
variations  in  management  and  use  of  poorly  evaluated  treatments  persist  across  the 
UK42.  The  average  5-year  relative  survival  rate  for  breast  cancer  in  England  and  Wales 
remains  between  60  and  65%  and  the  median  survival  is  just  over  8  years43.  Data 
from  the  Scottish  cancer  registries  analysing  survival  rates  among  34,107  women  with 
breast  cancer  diagnoses  between  1968  and  1987  did  show  improvements  in  5  year 
survival  rates  particularly  for  women  under  55  (10%)  compared  with  women  aged  55- 
64  and  65-74  (9%  and  6%  respectively)'.  Gillis  and  Hole44  argue  that  this  was  due  to 
a  range  of  therapeutic  advances  including  more  widespread  use  of  chemotherapy  and 
radiotherapy,  the  emergence  of  multidisciplinary  breast  cancer  teams  and  increasing 
specialisation  of  breast  cancer  surgeons  as  well  as  the  introduction  of  tamoxifen. 
28 A  more  recent  audit  from  the  Scottish  Cancer  Therapy  Network  suggest  that 
improvements  in  the  quality  of  care  are  possible  where  patients  have  access  to  breast 
specialists45.  Between  1987  and  1993  the  proportion  of  patients  having  surgery  to  the 
axilla  had  increased  and  the  proportion  of  patients  receiving  systemic  adjuvant 
treatment  had  increased.  The  5-year  survival  was  9%  higher  and  the  10-year  rate  8% 
higher  for  patients  treated  by  specialist  surgeons  than  those  treated  by  general 
surgeons.  When  the  results  were  adjusted  to  account  for  the  case  mix  of  patients  in 
the  different  centres  the  reduction  in  the  risk  of  dying  for  patients  in  specialist  centres 
increased  to  16%.  The  benefits  of  specialist  care  were  found  across  all  subgroups 
examined  including  patient's  age,  the  size  and  stage  of  tumours  and  patients  from 
different  socio-economic  groups16 
Breast  Screening 
The  NHS  Breast  Screening  Programme  (NHS  BSP)  became  fully  operational  in  the 
UK  in  1988  following  publication  of  the  Forrest  Report47.  which  recommended 
routine  mammography  screening  every  3  years  for  women  aged  50-65.  The  policy 
was  adopted  by  the  NHS  and  led  to  the  development  of  99  screening  units  throughout 
the  UK  operating  a  mobile  screening  service  with  a  computerised  call  recall  system 
for  the  relevant  age  group  at  an  estimated  cost  of  £38m.  Women  are  called  via  their 
GP  once  every  3  years;  results  are  usually  posted  within  2  weeks  of  screening. 
Women  with  positive  or  equivocal  results  are  recalled  for  assessment  to  the  breast- 
screening  unit.  Diagnostic  assessment  of  non-palpable  lesions  is  carried  out  using 
triple  assessment:  clinical  examination,  further  mammography  and  core  biopsy  or  fine 
needle  aspiration,  the  latter  is  more  usual  for  palpable  lesions. 
The  rationale  for  the  programme  was  based  on  a  number  of  trials  particularly  those 
published  from  Sweden  which  showed  a  beneficial  effect  of  screening  mammography 
especially  in  the  50-64  age  group°ß.  An  overview  of  the  Swedish  trials49  undertaken  in 
two  counties  and  three  cities  and  including  156,111  women  in  the  invited  group 
compared  with  125,866  in  the  control  group  showed  an  estimated  overall  reduction  in 
mortality  of  24%;  this  was  6%,  28%  and  34%  in  the  age  groups  40-49,50-59  and  60- 
29 69  respectively.  The  cost  effectiveness  estimates  for  the  programme  were  based  on 
single  medio  lateral  oblique  view  mammography  and  a  target  uptake  of  70% 
The  NHS  Breast  Screening  Programme  is  now  in  its  3rd  round.  Uptake  rates  are 
variable  throughout  the  country  though  the  overall  rate  of  72%  uptake  achieved  in 
1990-93  has  been  exceeded  with  uptake  rates  of  77.4%  in  1994-5.  Regionally  the 
uptake  varies  from  just  under  70%  in  the  Thames  Regions  to  over  80%  in  East  Anglia, 
Oxford  and  Wessex50.  The  programme  has  exceeded  the  early  cost  estimates  which 
now  stand  at  nearer  £45m/years'.  Increased  expenditure  will  be  needed  with  the 
demographic  increase  of  women  in  eligible  age  groups. 
Subsequent  trials  of  breast  screening  efficacy  have  however  been  equivocal  in 
supporting  the  early  estimates  of  mortality  reduction  though  an  overview  found  a  30% 
reduction  in  mortality  for  women  in  the  screened  age  groups.  The  cost  of  the 
programme  has  risen  substantially  and  a  full  evaluation  is  urgently  needed  to  tackle 
the  controversy  about  the  value  of  mammography  screening  compared  with 
alternative  means  for  reducing  mortality  from  breast  cancer.  The  impact  of  the 
programme  in  the  UK  is  low  since  screen  detected  cases  still  comprise  around  50%  of 
breast  cancers  detected  in  total  for  women  in  the  screened  age  groups.  As  fewer  than 
40%  of  all  breast  cancers  registered  occur  in  the  eligible  age  range  this  may  limit  the 
impact  of  the  programme  to  the  possible  early  diagnosis  of  only  20%  of  cases". 
Proposals  to  increase  the  impact  of  the  programme  such  as  reducing  the  interval  for 
screening,  extending  the  programme  to  cover  younger  women  or  removing  the  upper 
age  limit  need  to  be  assessed  against  the  impact  of  the  current  programme  on  overall 
mortality53"s4  Changing  or  extending  the  programme  to  target  women  at  high  risk  of 
breast  cancer  because  of  family  history  has  also  been  proposedss 
Many  of  the  criteria  set  out  by  the  WHO56  for  the  validity  of  screening  programmes 
are  met  by  screening  for  breast  cancer:  there  is  an  early  recognisable  stage, 
mammography  is  a  suitable  screening  method  and  appears  to  be  acceptable  to  women, 
facilities  for  diagnosing  and  treating  abnormal  findings  are  available  and  can  be 
monitored.  Breast  cancer  is  an  important  disease  being  responsible  for  a  considerable 
30 number  of  years  of  life  lost  since  it  affects  women  in  middle  age  and  early  detection 
may  lead  to  a  more  favourable  prognosis.  The  natural  history  of  breast  cancer  is  still, 
however,  not  sufficiently  well  understood  and  it  is  possible  that  the  treatment  given  in 
the  early  stage  of  the  disease  is  not  more  effective  than  after  the  clinical  diagnosis  of 
symptomatic  disease.  Early  detection  will  lead  to  an  apparent  improvement  in 
survival  because  of  lead-time  bias  but  may  not  produce  real  reductions  in  mortality. 
The  compelling  public  policy  questions  concerning  the  effectiveness  of  age  based 
mammography  screening  for  breast  cancer  are  whether  the  costs  involved  are  justified 
in  terms  of  reduced  population  morbidity  and  mortality  from  breast  cancer.  Measures 
of  the  effectiveness  of  screening  programmes  should  include  evidence  of  changes  in 
population  mortality  as  well  as  improvements  in  case  survival. 
Published  estimates  of  the  effectiveness  of  breast  cancer  screening  programmes  are 
available  from  nine  randomised  clinical  trials  of  mammography  in  six  countries.  The 
recent  trialsas.  a9.  s7  were  not  significant  though  a  meta  analysis  did  show  a  statistically 
significant  relative  risk  reduction  of  25-30%  in  mortality  due  to  breast  cancer  for 
women  over  50.  "  There  was  no  effect  was  shown  for  women  under  50.  There  is 
considerable  debate  in  the  interpretation  of  this  result  in  terms  of  the  expected 
absolute  benefit  for  women  in  continuing  with  the  screening  programme  and  the  cost 
per  life  saved  in  comparison  with  other  health  care  interventions. 
As  might  be  expected  there  are  a  number  of  differences  in  the  characteristics  of  the 
trials  such  as  the  uptake  rates  and  the  ratio  of  benign  to  malignant  tumours  detected. 
The  policy  of  different  countries  also  varies  with  regard  to  screening  intervals,  follow 
up,  type  of  mammography  used  and  the  weighting  given  to  issues  such  as  costs 
involved  in  further  investigation  and  treatment  and  the  personal  costs  of  travelling  as 
well  as  reduced  availability  for  work  and  incidental  expenses. 
A  recent  editorial  reviewing  all  of  the  published  trials  of  screening  effectiveness 
suggests  that  the  absolute  benefits  of  breast  cancer  screening  are  small  ranging  from 
mortality  reduction  of  0.05  -  0.14p58.  The  number  of  women  who  need  to  be 
31 screened  to  save  one  life  ranges  from  around  7,000  to  63,000  in  the  screening  trials.  A 
number  of  authors'  highlight  that  insufficient  attention  is  given  to  the  problem  of  false 
positives.  About  1  in  20  women  have  a  screening  abnormality  -a  positive  or 
suspicious  result  -but  only  between  1  in  5  and  1  in  14  will  have  cancer.  These 
positive  or  suspicious  lesions  lead  to  considerable  often  quite  invasive  unnecessary 
further  investigation  and  surgery.  Secondly  a  negative  result  does  not  mean  the 
absence  of  cancer  since  10  -15%  of  early  lesions  are  missed  by  screening.  Finally  for 
the  majority  of  women  in  whom  breast  cancer  is  diagnosed  by  screening  the  outcome 
is  unchanged59. 
Other  authors  have  argued  that  screening  is  both  effective  and  cost  effective 
comparing  favourably  with  other  health  care  interventions  such  as  renal  dialysis. 
Estimates  of  the  cost  per  death  prevented  range  from  £25,000  -£100,000  for  UK 
women60.  The  lower  range  depends  on  detection  rates  of  around  0.2%  which  is  higher 
than  the  0.06%  found  for  example  in  the  1985  SNBH  study61.  Based  on  these  studies 
cost  per  year  of  life  saved  is  estimated  to  be  around  £5000;  this  compares  with 
haemodialysis  at  £20,000  per  year  of  life  saved.  Moreover  some  authors  argue  that 
the  rate  of  inappropriate  biopsies  and  other  interventions  in  the  NHS  are  far  lower 
than  might  be  expected  from  an  analysis  of  practice  in  the  USA  where  the  pressure  to 
intervene  leads  to  substantially  higher  average  costs.  The  benign:  malignant  ratio  is 
now  lower  than  the  4:  1  expected  in  the  Forrest  report  with  some  centres  reporting 
1:  462. 
Changing  the  age  range 
Recent  guidance  from  the  NHS  Executive  allowed  women  over  65  to  opt  to  continue 
attending  for  3  yearly  screening  mammography  though  they  will  not  be  included  in 
the  call  recall  system.  The  uptake  among  older  women  is  currently  the  subject  of 
evaluation.  It  has  been  estimated  that  extending  the  age  range  of  the  programme  may 
offer  an  incremental  increase  in  deaths  from  breast  cancer  prevented  at  a  cost,  which 
is,  lower  than  that  implicit  in  the  current  programme63.  The  current  NHS  breast- 
screening  programme  does  not  currently  target  women  at  highest  risk  for  breast  cancer 
32 and  studies  have  shown  an  advantage  for  women  up  to  age  75.  Mortality  from  breast 
cancer  may  well  decline  if  there  is  systematic  screening  of  women  in  older  age  groups 
though  increased  anxiety  could  also  be  a  significant  consequence  of  advancing  the 
lead  time  for  diagnosis  in  this  age  group. 
Incremental  cost  estimates  from  the  current  NHS  BSP  are  £25,142  per  death 
prevented,  or  £2,525  per  life  year  saved.  Extending  the  age  range  to  69  years  offers 
an  incremental  cost  per  death  prevented  of  £21,376  or  £2,990  per  life  year  saved 
whereas  reducing  the  screening  interval  changes  the  incremental  cost  per  death 
prevented  to  £39,431or  cost  per  life  year  saved  £3,545;  both  options  improve  the 
efficiency  of  the  current  breast  screening  programme. 
All  the  arguments  in  favour  of  screening  younger  women  are  derived  indirectly  from 
studies  that  show  no  advantage  in  the  original  analysis.  Only  one  of  the  eight 
randomised-controlled  trials  was  designed  to  study  the  effect  in  pre  -  menopausal 
women'  Meta  analysis  showed  a  non  significant  reduction  of  10-15%  in  women 
under  4065.  In  the  UK,  mortality  from  breast  cancer  in  this  age  group  is  around 
30/100,000  suggesting  that  at  least  1,000  women  would  have  to  be  screened  for  16 
years  before  saving  a  single  life.  Detectability  of  small  lesions  is  more  difficult  in  the 
younger  breast  because  of  the  density  of  the  tissue.  Reduction  in  mortality  for 
increased  cost  are  unlikely  to  compare  favourably  with  that  possible  for  older  women 
although  it  could  be  argued  that  the  increase  in  life  years  gained  would  be 
considerable. 
Targeting  women  who  are  most  at  risk  of  breast  cancer  may  be  the  most  effective  way 
to  improve  the  predictive  value  of  screening  and  to  lower  the  false  positive  rate. 
Between  5  and  20%  of  women  with  breast  cancer  have  an  increased  relative  risk 
because  of  family  history  or  reproductive  factors.  A  proportion  of  these  will  have  the 
highly  penetrant  cancer  susceptibility  gene  such  as  BRCA1  or  a  familial  cancer 
syndrome.  High  risk  women  have  most  to  gain  in  reduced  anxiety  and  earlier 
detection;  this  group  will  experience  higher  absolute  benefit  especially  younger 
women  where  the  potential  years  of  life  saved  are  considerable66 
33 As  discussed  earlier,  an  evaluation  of  the  trends  in  incidence  in  the  UKS  following  the 
development  of  the  screening  programme  show  the  increases  that  were  expected  in  the 
prevalence  round.  From  1979  to  1987  the  rate  of  increase  in  incidence  was 
approximately  2%  per  year  to  86/100,000.  After  the  introduction  of  the  screening 
programme  the  annual  rate  of  increase  more  than  doubled  to  nearly  4.5%  each  year  to 
102/100,000.  The  greatest  increase  is  seen  in  the  screened  age  group  (women  aged 
50-64).  Incidence  rates  rose  and  exceeded  those  seen  in  the  elderly  unscreened 
population  (women  over  65).  As  early  as  1990  incidence  in  60-64  year  olds  exceeded 
that  of  80-84  year  olds.  Incidence  in  age  groups  not  invited  to  the  screening 
programme  fluctuated  only  slightly  throughout  this  period.  Recorded  incidence  is 
expected  to  return  to  pre-screening  levels  in  the  screened  age  group  after  the 
prevalence  round,  except  for  women  in  the  age  group  50  -52  who  will  always  be  in  a 
prevalence  round. 
The  impact  of  the  screening  programme  can  also  be  seen  in  the  proportion  of  tumours 
that  were  small  and  node  negative.  Mortality  has  also  changed  quite  markedly  since 
the  beginning  of  the  screening  programme  though  is  unlikely  to  be  attributable  mainly 
to  it.  For  women  between  55-69  a  steep  rise  in  age  standardised  mortality  after  the  war 
continued  until  the  late  80s  when  it  fell  sharply  until  in  1994  it  was  12%  lower  than  in 
1987.  Any  effect  of  the  screening  programme  on  mortality  is  unlikely  to  be  seen  until 
at  least  7  years  after  the  prevalence  round.  None  of  the  screening  trials  show  a 
reduction  in  mortality  around  the  period  of  the  prevalence  round. 
Further  evaluation  of  the  programme  is  needed  to  address  the  potential  for  reducing 
morbidity  for  patients  with  earlier  diagnosis  of  cancer  prior  to  metastasis  and  the  costs 
of  care  associated  with  earlier  diagnosis.  In  developing  a  true  assessment  of 
population  benefit  the  programme  must  demonstrate  benefits  in  cost  per  life  saved 
which  exceed  those  seen  with  alternative  means  of  reducing  mortality  and  morbidity 
from  breast  cancer.  The  benefits  of  refocusing  the  programme  to  cover  women  at 
highest  risk  including  older  women  and  women  with  risk  factors  due  to  family  history 
or  reproductive  history  are  made  in  comparison  with  the  outcome  from  the  current 
34 programme  though  not  in  terms  of  alternative  means  of  reducing  mortality.  At 
present  estimates  of  the  cost  effectiveness  of  adjuvant  therapy  exceed  those  for  breast 
screening  by  almost  five  fold. 
Risk  of  breast  cancer  and  the  potential  for  primary  prevention. 
Breast  cancer  risk  factors 
Epidemiological  evidence  supports  the  hypothesis  that  ovarian  hormones  are  strongly 
implicated  in  the  aetiology  of  breast  cancer67.  Early  menarche,  late  menopause  and 
nulliparity  are  associated  with  increased  risk.  The  incidence  of  breast  cancer  is 
reduced  by  oophorectomy  or  by  induced  menopause  with  radiation.  Experimental 
evidence  with  mice  shows  that  ovarian  function  or  stimulation  with  oestrogen  is 
required  for  tumour  development68.  The  risk  increases  with  length  of  exposure  -  the 
earlier  the  intervention  to  reduce  ovarian  function  the  greater  the  reduction  in  risk. 
Oestrogen  alone  and  with  progestogen  induces  cell  division  and  is  of  considerable 
interest  in  the  pathogenesis  of  breast  cancer.  Other  endogenous  hormones  such  as 
prolactin  and  androgens  may  also  be  involved  though  further  research  is  needed  to 
fully  elucidate  their  possible  role. 
Family  history  increases  the  probability  of  breast  cancer.  Women  with  an  affected 
first  degree  relative  have  a  2-3  fold  increased  risk  and  those  with  an  affected  second 
degree  relative  have  a  two  fold  increased  risk.  Risks  are  even  further  raised  if  two 
first  degree  relatives  are  involved  or  if  the  first  degree  relative  has  bilateral  breast 
cancer  or  if  the  cancer  was  diagnosed  before  age  4069 
Overall  only  around  5%  of  women  with  a  family  history  of  breast  cancer  have  a  breast 
cancer  gene;  young  age  at  breast  cancer  of  a  first  degree  relative  is  the  strongest 
indicator  of  genetic  susceptibility.  Other  risk  factors  directly  associated  with 
endogenous  oestrogens  include  reproductive  factors.  Late  age  at  first  full  term 
pregnancy  (30  years  of  age  or  more)  and  nulliparity  increase  risk  and  high  parity 
decreases  risk  in  women  aged  over  5070. 
35 Obesity,  which  increases  risk  of  breast  cancer  in  postmenopausal  women,  is  thought 
to  be  linked  to  a  hormonal  mechanism.  Case  series  and  laboratory  studies  have  shown 
that  obese  women  have  higher  levels  of  serum  oestrogen  than  non-obese  women.  This 
is  because  of  greater  metabolisation  of  androstenedione  to  oestrogen  in  adipose  cells70. 
The  extent  to  which  body  mass  is  implicated  as  a  predictor  of  breast  cancer  is 
however  complicated  since  overweight  may  reduce  the  risk  of  breast  cancer  in  pre  - 
menopausal  women  and  the  timing  of  weight  change  as  well  as  the  distribution  of  fat 
may  also  predict  increased  risk  of  breast  cancer".  In  pre-menopausal  women  extended 
breast  feeding  may,  through  suppressing  oestrogen  production,  confer  a  protective 
effect  on  the  risk  of  breast  cancer  but  the  evidence  for  this  is  not  strong72. 
A  meta-analysis  of  27  epidemiological  studies  of  the  effect  of  oral  contraceptives  on 
breast  cancer  risk  suggests  that  risks  may  be  increased  by  about  20%  for  younger, 
nulliparous  women  and  for  long  term  use73.  Likewise,  hormone  replacement  therapy  is 
only  associated  with  an  increased  risk  of  breast  cancer  after  five  years  of  use  and  the 
beneficial  effect  on  the  cardiovascular  system  and  on  a  reduced  risk  of  osteoporosis 
may  also  outweigh  the  adverse  effects  on  breast  cancer  risk74. 
Other  known  risk  factors  which  are  more  amenable  to  change  are  chiefly  associated 
with  diet75  and  exercise76;  alcohol  use  has  also  been  implicated.  A  meta  -  analysis  of 
50  studies  looking  at  the  relationship  between  alcohol  intake  and  breast  cancer  risk 
suggested  a  small  positive  association;  around  a  25%  increase  in  risk  with  the 
equivalent  of  two  drinks  (two  units  of  alcohol)  per  day".  Other  studies78  including  a 
more  recent  review  of  the  literature79  concluded  that  causality  had  by  no  means  been 
demonstrated  and  that  several  factors  modify  the  relationship  including  age,  weight 
and  use  of  exogenous  oestrogen.  There  are  a  number  of  measurement  problems  in 
estimating  alcohol  use,  difficulties  in  detecting  small  relative  risks  and  errors  in 
confounding.  Widespread  changes  in  the  use  of  alcohol  are  unlikely  to  have  a 
significant  effect  on  the  profile  of  breast  cancer  especially  since  the  publication  of 
trials  showing  the  beneficial  effect  of  alcohol  on  HDL  cholesterol  and  the 
corresponding  reduction  in  cardiovascular  risk. 
36 Physical  activity  in  adolescence  and  among  young  adults  has  been  shown  to  reduce 
the  risk  of  breast  cancer  in  premenopausal  and  perimenopausal  women.  Risk 
reductions  may  well  be  hormonally  mediated  since  physical  activity  delays  the  onset 
of  menarche  and  decreases  the  number  of  ovulatory  cycles80.  Studies  suggest  that  the 
effect  of  physical  activity  is  independent  of  body  size  -  though  is  difficult  to  separate 
from  the  effect  of  activity  on  excess  body  masse'. 
A  great  many  studies  have  been  reported  which  seek  to  explore  the  relationship 
between  dietary  fat  and  breast  cancer.  There  is  considerable  debate  about  any 
possible  association  and  the  potential  for  primary  prevention  through  dietary 
intervention.  Consideration  is  given  to  this  in  a  separate  section  below.  A  number  of 
epidemiological  studies  have  suggested  that  carotenoids  in  fruit  and  vegetables  have  a 
protective  effect  on  breast  cancer  risk".  Other  studies  of  specific  nutrients  include 
vitamin  A  from  animal  sources83.  Both  vitamin  A  and  carotenoids  have 
anticarcinogenic  effects  in  laboratory  experiments.  Little  confirmatory  information  is 
available. 
A  great  deal  of  concern  has  been  raised  in  the  literature  about  the  possible  effects  of 
environmental  pollutants  on  breast  cancer  risk84.  Some  authors  have  suggested  that 
women  with  breast  cancer  have  higher  levels  of  organochlorines  in  their  serum  though 
others  have  shown  no  association.  Electromagnetic  fields  and  ionising  radiation  have 
also  been  investigated.  Electromagnetic  fields  are  currently  under  review  though  the 
more  intensive  exposure  through  use  of  electric  blankets  is  not  implicated85.  High 
dose  ionising  radiation  to  the  chest  does  increase  breast  cancer  risk  at  the  level  of  dose 
required  for  radiotherapy86. 
Country  of  birth  has  a  marked  effect  on  risk  of  breast  cancer  and  wide  variations  in 
incidence  rates  suggest  there  is  scope  for  improving  rates  world-wide.  Rates  are 
higher  in  developed  than  in  developing  countries  except  for  Japan  where  the  rates  are 
half  those  of  N.  America  and  N.  Europe  though  they  are  increasing.  Where  women 
migrate,  their  breast  cancer  rates  over  two  or  three  generations  assume  a  pattern  more 
37 similar  to  the  host  country  suggesting  that  the  determinants  of  breast  cancer  risk  are 
more  likely  to  be  environmental  than  genetic87. 
Scope  for  primary  prevention 
For  women  identified  at  high  risk  increased  surveillance  through  screening 
mammography  and  clinical  examination  is  available  for  early  diagnosis.  Bilateral 
mastectomy8°  and  oophorectomy  are  highly  effective  and  may  be  a  practical  option  for 
women  in  high  risk  groups  particularly  those  with  significant  family  history  or 
positive  identification  of  breast  cancer  genes;  doubt  does  remain  however  even  with 
these  radical  procedures  particularly  over  long  term  psychological  sequelae  and  the 
prospect  of  tumours  developing  in  the  chest  wall.  Gene  therapy  may  eventually  be 
possible.  For  women  using  exogenous  hormones  some  modification  of  contraceptive 
method  may  be  possible  after  long  term  use  and  women  taking  HRT  for  longer  than 
five  years  may  wish  to  balance  continued  use  and  the  potential  for  increased  risk  of 
breast  cancer  with  possible  reduced  risk  of  osteoporosis  and  cardiovascular  disease. 
Well  known  risk  factors  explain  a  large  proportion  of  breast  cancer  incidence  yet  there 
are  substantial  gaps  in  knowledge  about  how  they  might  be  modified  to  reduce  the 
risk  of  breast  cancer.  Risk  factors  concerned  with  family  history  are  thought  to  be 
related  to  or  mediated  by  endogenous  hormones  and  so  are  assumed  to  be  not 
amenable  to  change.  Yet  breast  carcinogenesis  and  the  development  of  disease  are 
equally  complex  processes  and  have  been  subject  to  a  great  many  clinical  trials. 
Prevention  trials  have  raised  greater  ethical  concerns. 
In  cancer  prevention  trials  a  great  many  healthy  women  would  need  to  be  involved  to 
detect  an  effect  since  breast  cancer  occurs  at  a  rate  of  between  0.5  and  0.8%  in  the  age 
group  which  is  likely  to  be  targeted  for  prevention.  An  intervention  period  of  several 
years  is  likely  to  be  needed  to  achieve  the  required  endpoint  and  any  trial  would 
involve  considerable  cost  in  order  to  achieve  the  power  needed  to  detect  an  effect. 
Such  considerations  may  have  contributed  to  the  dearth  of  cancer  prevention  trials 
38 though  it  is  surprising  that  even  for  risk  factors  which  could  be  modified  through 
lifestyle  change  such  as  obesity,  changes  in  alcohol  intake  or  contraceptive  use  our 
understanding  of  their  impact  is  almost  entirely  based  on  observational  data  from 
analytical  epidemiology. 
Given  the  impact  of  obesity  on  breast  cancer  risk  it  is  surprising  that  weight  reduction 
in  obese  postmenopausal  women  and  weight  reduction  in  middle  age  is  not  explicitly 
examined  in  health  promotion  trials.  Alternative  means  to  increase  exercise  among 
young  women  may  also  merit  further  research.  A  randomised  controlled  trial  will 
determine  if  dietary  interventions  with  a  vitamin  A  derivative  will  affect  the  rate  of 
recurrence  of  breast  cancer  in  women  with  previously  diagnosed  disease  or  the 
incidence  of  breast  cancer  in  the  contralateral  breast89. 
A  large  randomised  trial  of  dietary  intervention  is  also  underway  in  Canada  and  the 
USA90.  This  will  test  the  impact  of  reduction  of  fat  intake  to  20%  of  calories  from  fat 
and  to  increase  the  intake  of  fruit  and  vegetables  in  postmenopausal  women  aged  50  - 
79.  The  trial  discussed  further  in  the  section  on  diet  below  is  sufficiently  large  to  test 
the  effects  of  vitamin  D  and  calcium  supplements  on  breast  cancer  incidence 
addressing  the  hypothesis  that  the  variation  in  incidence  between  countries  is  in  fact  a 
north  -  south  latitudinal  trend  associated  with  levels  of  solar  radiation. 
Dietary  fat  and  the  risk  of  Breast  Cancer 
The  incidence  of  breast  cancer  varies  about  6  fold  throughout  the  world.  International 
regression  analysis  of  breast  cancer  incidence  in  relation  to  per  capita  fat  intake 
suggests  a  potential  for  reducing  the  relative  risk  of  breast  cancer  by  around  24%9'. 
The  quality  of  data  on  national  per  capita  fat  consumption  has  however  been 
repeatedly  criticised.  At  least  part  of  the  apparent  correlation  may  be  due  to  a  higher 
prevalence  of  reproductive  risk  factors  or  other  environmental  determinants  in 
countries  with  a  high  fat  consumption.  The  results  of  case  control  and  cohort  studies 
on  the  association  between  dietary  fat  and  breast  cancer  are  considered  below. 
39 Cohort  Studies 
A  recent  and  assiduous  review  of  cohort  studies  examining  an  association  between 
dietary  fat  and  breast  cancer  was  undertaken  by  Willett92.  Each  study  included  at  least 
50  incident  cases  of  breast  cancer  and  quantitative  estimates  of  fat  intake  as  a 
proportion  of  total  calories  in  the  diet  were  available  in  six  of  the  studies;  the 
remaining  analysed  intake  of  fat  from  dietary  records.  None  of  the  ten  prospective 
cohort  studies  examined  showed  a  significant  association  between  fat  and  breast 
cancer  comparing  the  highest  category  of  fat  intake  with  the  lowest. 
The  average  relative  risk  among  studies  which  included  a  confidence  interval  (nine 
studies)  was  according  to  Willett  1.01  (95%  CI  0.9-1.13).  This  covered  a  range  from 
a  relative  risk  of  0.62  in  a  10  year  follow  up  study  with  99  incident  cases  identified 
out  of  a  cohort  of  5,485  to  a  relative  risk  estimate  of  1.3  found  in  the  Canadian  breast 
screening  cohort  which  identified  519  cases  of  breast  cancer  among  a  total  cohort  of 
56,837  women93.  Moreover  restricting  the  analysis  of  studies  to  those  concerned  only 
with  post  menopausal  women  -  since  results  from  information  regression  analysis 
suggest  that  an  association  between  fat  and  breast  cancer  may  be  stronger  in  older 
women  -  also  failed  to  show  a  significant  association.  Relative  risk  estimates  in  these 
studies  varied  from  0.79  (95%  CI  0.5-1.09)  to  1.17  (95%  CI  0.79-1.72)94 
In  reviewing  the  biases,  which  may  affect  the  results  of  cohort  studies,  Willett 
concludes  that  none  is  sufficient  to  substantially  alter  his  conclusion  that  there  is  no 
significant  association  between  fat  in  the  diet  and  the  aetiology  of  breast  cancer.  It  has 
been  argued  that  non  differential  misclassification  is  responsible  for  effects  that 
remain  undetected  in  all  epidemiological  analysis95.  This  effect  occurs  where  subjects 
are  incorrectly  assigned  -  in  this  case  -  either  to  high  or  low  dietary  fat  categories.  The 
effect  is  said  to  be  non-differential  where  the  magnitude  of  the  error  for  one  variable 
does  not  vary  according  to  the  actual  value  of  other  variables  i.  e.  the  fact  of  having 
breast  cancer  does  not  alter  the  direction  of  the  bias.  Non  differential 
misclassification  has  the  result  of  attenuating  the  rate  difference  towards  its  null  value 
40 thus  reducing  the  likelihood  of  detecting  a  rate  difference  in  incidence  of  breast  cancer 
between  subjects  in  high  and  low  quintiles  of  fat  intake. 
Discussing  in  particular  the  Nurses  Health  Study,  the  largest  prospective  study 
including  89,494  women  followed  for  eight  years,  Willett  dismisses  the  importance  of 
non  differential  misclassification  of  the  data.  Repeated  assessment  of  dietary  intake  in 
cohort  studies  can  alleviate  the  impact  of  non-  differential  misclassification  yet  is 
rarely  reported  in  studies  of  dietary  fat  and  breast  cancer.  All  of  the  studies  reviewed 
by  Willett  classified  subjects  and  controls  using  a  single  estimate  of  diet.  The  Nurses 
Health  Study  did  however  include  a  validation  exercise  with  detailed  assessment  of 
the  diet  of  a  sub  group  of  173  participants. 
Willett  suggested  that  correcting  for  measurement  error  using  the  increment  of 
24g/day  for  total  fat  intake  which  corresponded  to  the  difference  between  the  10th  and 
90th  percentile  in  relative  risk  assessment  affected  the  relative  risk  only  slightly  from 
1.01  (95%  CI,  0.92  to  1.10)  to  1.00  after  de-attenuation.  While  Willett  has  uniquely 
among  epidemiological  analyses  of  this  kind  sought  to  improve  precision  caused  by 
incorrect  dietary  classification,  such  an  approach  does  not  adequately  account  for 
inappropriate  ascertainment  of  subjects  in  fat  categories.  This  is  particularly  so  where 
a  time  lag  between  exposure  and  effect  may  be  important  or  when  cumulative  effects 
of  diet  are  important.  Willett  does  not  discount  the  possibility  that  fat  intake  earlier  in 
life  or  at  substantially  lower  levels  could  influence  the  rate  of  breast  cancer. 
The  Canadian  Breast  Screening  Study,  96  although  substantially  smaller  than  the 
Nurses  Health  Study  (total  cohort  size  of  56,837  compared  with  89,538)  provides 
comparable  quartile  information  for  assessing  the  relationship  between  breast  cancer 
incidence  and  dietary  fat.  The  study  by  contrast  to  the  Nurses  Health  Study  concludes 
that  there  is  a  likely  association  between  total  fat  intake  and  risk  of  breast  cancer  with 
a  relative  risk  of  1.35  (95%  CI  1-1.82)  for  77g/day  of  fat.  The  association  is  shown  to 
be  independent  of  total  caloric  intake  and  not  due  to  confounding  by  known  breast 
cancer  risk  factors.  This  study  was  unable  to  distinguish  unequivocally  any  difference 
41 in  effects  from  the  major  components  of  fat  neither  did  it  discern  any  increased  effect 
for  postmenopausal  women. 
The  third  relatively  large  cohort  study  to  have  analysed  quantitative  information  in 
reviewing  the  relationship  between  fat  and  breast  cancer  is  the  National  Health  and 
Nutrition  Examination  Survey93.  This  study  is  substantially  smaller  than  the  two 
largest  cohort  studies  discussed  above  having  a  total  size  of  5,485  women  with  99 
incident  cases  of  breast  cancer.  The  study  showed  no  significant  association  between 
fat  and  breast  cancer  with  the  possibility  of  a  negative  association  at  low  levels  of  fat 
intake.  The  study  used  a  measurement  method  of  24-hour  recall,  which  has  been 
shown  to  be  subject  to  considerable  bias.  The  size  of  the  survey  is  too  small  to 
distinguish  effects  for  sub  groups  such  as  for  different  age  of  women  or  different 
components  of  fat  in  the  diet. 
Cohort  studies  while  in  general  being  more  likely  to  demonstrate  an  effect  than  case 
control  or  ecological  studies  are  nevertheless  subject  to  substantial  measurement  error. 
Difficulties  in  assessing  the  dietary  habits  of  individuals  is  well  documented  and  is 
likely  to  give  rise  to  considerable  distortion  and  attenuation  of  relative  risk.  It  can  be 
argued  that  none  of  the  instruments  used  in  assessing  diet  can  be  properly  validated 
since  the  time  period  over  which  diet  may  be  most  relevant  to  cancer  risk  remains 
unknown.  Moreover  the  characteristics  of  individual  cohort  studies  may  have 
different  potential  for  bias  making  a  coherent  review  of  results  problematic. 
In  elucidating  some  of  the  effects  of  likely  errors  Howe94  pointed  out  that  the  recall 
bias,  which  may  occur  if  people  with  breast  cancer  interviewed  after  diagnosis  of 
cancer  report  their  diet  differently  to  control  subjects  may  be  enhanced  among  groups 
such  as  nurses  who  are  more  likely  to  be  aware  of  the  postulated  association  between 
diet  and  disease  risk.  He  highlighted  two  studies,  which  provide  empirical 
information  to  support  this  view.  Relative  risks  derived  from  a  comparison  of 
incidence  of  breast  cancer  in  the  highest  to  lowest  quintile  of  fat  intake  in  the 
Canadian  National  Breast  Screening.  Study  and  the  US  Nurses  Health  Study  were 
assessed  from  both  retrospective  and  prospective  dietary  data.  While  there  is  no 
42 evidence  of  recall  bias  in  the  Canadian  study  -  the  relative  risks  for  total  fat  being  1.12 
(0.76-1.66)  and  1.05  (0.72-1.54)  for  retrospective  and  prospective  data  respectively 
there  does  appear  to  be  an  association  between  fat  and  breast  cancer  with  a  relative 
risk  of  1.43  (0.9-2.27)  based  on  retrospective  data  from  the  nurses  study.  This  result 
is  not  confirmed  by  the  prospective  data  which  has  a  relative  risk  of  0.87. 
Case  Control  Studies 
A  recent  analysis  of  case  control  studies  by  Howe  et  a197  show  a  significant 
association  of  increasing  risk  of  breast  cancer  with  increased  fat  intake  in  post  - 
menopausal  women  which  is  unaffected  after  controlling  for  protein  or  carbohydrate 
intake  or  for  non  dietary  variables.  Relative  risk  was  estimated  per  45g/day  of  fat 
intake  relating  to  consumption  in  a  typical  North  American  diet.  Studies  selected  for 
inclusion  in  the  analysis  had  all  been  completed  by  the  end  of  1986  and  had  used 
quantitative  estimates  of  fat  intake.  From  the  12  studies  included  -  only  2  published 
during  the  relevant  time  period  were  excluded  -  there  were  4,427  cases  and  6,095 
controls.  Dietary  information  was  assessed  by  food  frequency  data  from  the  studies, 
estimates  of  standard  portion  sizes  and  nationally  validated  composition  tables. 
The  strongest  effect  leading  to  an  increased  relative  risk  of  1.46  (95% 
CI=1.23,1.72;  p<0.0001)  for  breast  cancer  was  in  postmenopausal  women  with  an 
increased  intake  of  saturated  fat.  The  relative  risk  for  monounsaturated  fat  was 
similar  at  1.41  (1.19,1.67;  p<0.0001).  The  relative  risk  for  polyunsaturated  fat  was 
lower  at  1.25  (0.9,1.71;  p=0.16).  In  order  to  exclude  the  possibility  that  these  findings 
were  confounded  by  differences  in  the  methodology  or  conduct  of  the  studies,  Howe 
et  al  undertook  a  restricted  analysis  of  studies  showing  lack  of  heterogeneity.  Intake 
of  both  total  fat  and  saturated  fat  in  postmenopausal  women  was  associated  with  an 
increased  risk  of  breast  cancer  with  increased  consumption  and  there  was  a 
statistically  significant  dose  response  relationship.  These  findings  are  unlikely  to  be 
due  to  chance.  Howe  et  al  argue  that  by  removing  inconsistencies  between  studies 
that  may  arise  from  differences  in  coding  and  techniques  for  analysis  and  by  use  of 
43 original  dietary  records  inconsistencies  found  in  comparisons  or  reviews  of  case 
control  studies  have  been  removed. 
Selection  bias  remains  a  substantial  problem  in  case  control  studies.  Non 
participation  by  controls  or  differential  participation  by  controls  following  particular 
dietary  practices  cannot  be  excluded.  Most  of  the  cases  in  the  Howe  study  were 
however  population  based  and  the  refusal  rate  was  low.  Where  the  analysis  was 
restricted  to  population  controls  excluding  hospital  controls  there  were  little  difference 
in  the  results. 
An  association  between  dietary  fat  and  breast  cancer  ? 
Epidemiological  studies  are  inconsistent  in  their  ability  to  detect  a  relationship 
between  fat  and  risk  of  breast  cancer.  A  number  of  authors  have  reviewed  the 
strengths  and  limitations  of  studies  including  cohort,  case,  control  and  regression 
analysis  but  have  continued  to  place  different  emphasis  on  the  conflicting  results. 
In  a  "critical  appraisal"  of  the  evidence  Goodwin  and  Boyd9S  set  out  a  number  of 
criteria  for  assessing  the  quality  of  the  evidence  based  on  the  work  of  Bradford  Hill99. 
They  conclude  that  further  investigation  including  the  possibility  of  an  intervention 
trial  is  needed  to  resolve  the  association.  While  a  number  of  small  studies  show 
positive  results  the  results  from  stronger  designs  are  equivocal.  Time  trends  and 
ecological  studies  are  on  the  whole  consistent  with  a  positive  relationship  between  fat 
consumption  and  breast  cancer.  These  studies  can  however  be  criticised  for  lacking 
precision  in  measurements  of  true  fat  intake  or  make  sufficient  adjustment  for  the 
confounding  effect  of  total  energy  intake. 
In  ecological  studies  the  impact  of  dietary  fat  intake  and  risk  of  breast  cancer  are 
limited  by  the  extent  of  variability  of  fat  intake  in  the  population  (s)  under  review  and 
the  sensitivity  of  the  measurement  instrument  for  detecting  true  differences  in  dietary 
intake.  If  the  heterogeneity  of  fat  intake  within  populations  is lower  than  that  between 
countries,  then  the  potential  for  detecting  an  association  between  fat  and  breast  cancer 
44 from  national  populations  will  be  weaker  than  that  found  in  international  regression 
analysis  and  may  be  impossible  to  detect. 
None  of  the  studies  undertaken  by  the  main  protagonists  in  the  debate  about  a 
plausible  link  between  fat  in  the  diet  and  breast  cancer  can  be  insulated  from  these 
sources  of  error.  Lack  of  heterogeneity  e.  g.  may  well  affect  the  power  of  the  nurses 
health  study  to  show  an  effect.  In  seeking  to  resolve  these  conflicting  results, 
Goodwin  &  Boyd  estimated  the  difference  in  cancer  incidence  that  might  be  found  in 
association  with  fat  intake  within  a  country  if  the  international  data  are  indicative  of  a 
causal  relationship. 
Projecting  onto  a  regression  of  breast  cancer  incidence  and  per  capita  fat  consumption, 
the  range  in  fat  intake  reported  in  the  cohort  study  of  Willet  -  from  44-32%  of  total 
calories  -  they  concluded  that  this  would  be  associated  with  only  a  small  reduction  in 
relative  risk  of  cancer  incidence  of  about  1.4.  This  estimate  would  be  even  smaller 
were  it  associated  with  other  sources  of  measurement  error.  Using  the  validation 
study  of  Willet,  Goodwin  and  Boyd10°  estimate  the  effect  of  misclassification  on 
cancer  risk  associated  with  the  highest  and  lowest  quintiles  of  fat  intake. 
Comparing  the  numbers  of  women  assigned  to  each  quintile  of  fat  intake  according  to 
their  reported  fat  consumption  from  a  semi  quantitative  dietary  questionnaire  or  from 
diet  records  -  an  assumed  gold  standard  more  detailed  record  -  and  projecting  relative 
risk  from  international  regression  analysis  they  estimated  that  misclassification  could 
have  reduced  the  apparent  difference  in  risk  in  the  nurses  health  study  between  the 
highest  and  lowest  quintile  from  an  expected  1.4  to  only  1.16.  This  estimate  is 
plausible  in  comparison  with  the  relative  risk  found  by  Willet  and  is  consistent  with 
the  more  recent  cohort  study  published  by  Howe. 
By  contrast  for  studies  tending  to  show  a  positive  association  insufficient  adjustment 
made  for  the  impact  of  changes  in  overall  energy  intake  when  measuring  fat  in  the 
diet  and  errors  from  selection  bias  and  recall  bias  may  reduce  reported  rate  differences 
substantially. 
45 Moreover,  the  relative  risk  of  1.46  in  the  review  of  case  control  studies  was  reported 
for  a  difference  of  45g  of  saturated  fat/day.  The  validity  of  such  a  reduction  is 
questionable  since  many  women  may  not  be  consuming  such  a  large  amount  of  fat  to 
begin  with92.  Despite  considerable  variation  in  records  of  fat  intake  from  international 
studies  the  average  intake  of  fat  in  the  Nurses  Health  Study  was  25g/day.  Willet 
points  out  that  even  women  who  consume  in  excess  of  45g  of  fat/day  cannot 
realistically  reduce  their  intake  by  this  amount  because  they  cannot  appreciably 
change  their  total  energy  intake.  He  argues  that  even  a  lOg  reduction  in  saturated  fat 
intake  would  be  substantial.  Using  this  incremental  reduction  instead  of  the  45g 
suggested  in  the  Howe  review  would  produce  a  relative  risk  reduction  from  1.46  to 
around  1.1;  recall  bias  may  reduce  this  estimate  still  further. 
Prentice  and  Sheppard9'  have  sought  to  understand  the  discrepancy  between 
observational  epidemiological  studies  in  order  to  shed  some  light  on  the  change  in 
breast  cancer  incidence  which  might  be  expected  from  a  practical  reduction  in  fat 
consumption.  They  argue  that  projected  relative  risk  estimates  from  international 
regression  analysis  correspond  well  with  observational  studies  given  the  limited 
variation  in  fat  intake  categories  in  even  the  best  of  most  recent  studies  and 
acknowledging  random  errors  in  dietary  assessment.  While  this  is  certainly 
reasonable  in  interpreting  those  case  control  studies  which  showed  a  significant 
positive  association  between  daily  grams  of  fat  and  breast  cancer  risk  for 
postmenopausal  women,  the  relative  risks  estimated  from  the  North  American  nurses 
study  are  lower  and  of  borderline  significance  only  when  sampling  variation  and 
measurement  error  are  considered. 
The  results  for  premenopausal  women  are  far  less  consistent.  Indeed  the  trend  for  the 
nurses  study  appears  to  disagree  with  the  international  regression  analysis.  The  cohort 
study  published  subsequently  by  Howe  did  however  show  a  more  consistent 
relationship  between  total  energy  adjusted  fat  consumption  and  breast  cancer  despite 
the  first  quintile  being  at  increased  relative  risk  to  the  second  quartile.  The  results  for 
46 all  women  -  both  pre  and  post  menopausal  were  1.37,1.00,134  and  1.78  again  broadly 
in  line  with  error  adjusted  projections  from  international  regression  analysis. 
Observational  epidemiological  studies  have  an  effect  of  adding  to,  rather  than 
clarifying  the  controversy  surrounding  an  effect  with  such  potential  public  health 
importance  as  a  causal  relationship  between  dietary  fat  and  risk  of  breast  cancer. 
There  are  3  factors  which,  when  combined,  are  likely  to  give  rise  to  severe  attenuation 
of  any  possible  effect.  These  are  the  lack  of  heterogeneity  in  the  studies,  the  potential 
for  non-differential  misclassification  of  data  and  other  measurement  errors  associated 
with  estimating  diet. 
This  review  of  epidemiological  evidence  for  the  relationship  between  diet  and  breast 
cancer  suggests  that  the  better  designed  studies  are  able  to  control  for  family  history 
or  reproductive  risk  factors,  but  none  of  the  studies  has  sufficient  heterogeneity  in  fat 
intake  to  detect  adequately  the  effect  seen  in  international  regression  analysis. 
An  understanding  of  the  biological  plausibility  of  causal  link  between  dietary  fat  and 
breast  cancer  cannot  exclude  the  possible  importance  of  diet  at  key  development 
stages.  In  particular,  the  relationship  with  onset  of  menarche  and  early  adolescence 
where  the  impact  of  diet  on  breast  carcinogenesis  may  be  profound.  A  number  of 
studies  have  demonstrated  a  relationship  between  plasma  oestradiol  and  other 
reproductive  hormones  with  changes  in  fat  intake10..  '°2.  This  effect  may  be  of  major 
importance  in  determining  age  at  onset  of  menarche  and  the  pattern  of  ovulatory 
cycles  setting  the  risk  of  breast  carcinogenesis  well  before  any  potential  mediation  of 
effect  with  diet  in  adult  life.  The  problems  of  a  possible  time  lag  between  dietary 
intake  and  risk  of  breast  cancer  will  also  contribute  to  non-differential 
misclassification  of  subjects  into  fat  categories,  since  early  diet  and  adult  diet  may  not 
coincide. 
The  error  estimates  made  by  Prentice  &  Sheppard,  based  on  the  validation  study  in  the 
nurses  cohort,  arising  from  possible  non  differential  misclassification  of  subjects  was 
based  on  measurement  of  adult  diet.  Revising  this  still  further  to  account  for  early 
47 diet  would  severely  undermine  the  potential  of  the  study  to  show  an  effect.  Other 
measurement  errors  discussed  above  would  further  contribute  to  the  attenuation  of  any 
effect  towards  the  null. 
A  number  of  authors  have  proposed  a  dietary  fat  intervention  trial  to  tackle  the 
controversy  surrounding  the  possibility  of  a  causal  relationship  between  fat  and  breast 
cancer.  The  National  Cancer  Institute  is  now  funding  the  Women's  Health  Initiative"' 
designed  to  determine  the  efficacy  of  low  fat  diet  in  reducing  the  incidence  of  breast 
cancer,  colorectal  cancer  and  coronary  heart  disease  in  middle  aged  women.  The 
study  requires  the  recruitment  of  32,000  women  aged  45-69  and  is  underway  in  20 
centres  in  the  USA.  The  trial  is  set  to  test  the  hypothesis  with  a  statistical  power  of 
80%  that  a  50%  reduction  in  %  of  calories  from  fat  (from  40%  -  20%  of  total  calories) 
will  result  in  a  detectable  reduction  in  breast  cancer  incidence.  The  dietary 
intervention  was  tested  in  a  feasibility  study9°  and  showed  that  dietary  intervention 
can  be  achieved  and  sustained  at  relatively  low  cost.  The  women  will  need  to  be 
followed  for  8.5  years  to  show  an  effect.  While  this  approach  will  overcome  many  of 
the  errors  inherent  in  observational  epidemiology  it  cannot  fully  address  the  question 
of  aetiology  of  breast  cancer  because  it  only  deals  with  adult  diet. 
Another  possible  approach  is  to  consider  a  combined  observational  study  across 
different  countries  which  have  substantial  heterogeneity  in  dietary  practice  and  which 
could  stratify  subjects  according  to  their  fat  intake  at  different  ages  while  still 
controlling  for  increased  risk  due  to  family  history  and  reproductive  factors.  Such  an 
approach  using  a  pooled  cohort  or  case  control  study  would  need  to  be  of  considerable 
time  and  long  duration  to  demonstrate  an  effect.  The  feasibility  may  be  enhanced  by 
the  increasing  reliability  and  availability  of  cancer  registries. 
Deciding  an  appropriate  public  health  strategy  for  primary  prevention  of  breast  cancer 
requires  both  an  understanding  of  the  aetiology  of  disease  and  the  potential  for 
modifying  risk  factors  with  specific  interventions.  A  randomised  controlled  trial  of 
suitable  size  and  duration  to  assess  the  long  term  impact  of  dietary  intervention,  may 
elucidate  the  impact  of  reducing  fat  for  women  at  different  levels  of  risk. 
48 A  pooled  epidemiological  approach  when  corrected  for  both  early  diet  and  established 
risk  factors  would  raise  broader  public  health  questions  concerning  the  social 
determinants  of  diet  during  life  phases  where  risk  of  breast  carcinogenesis  may  be  of 
greatest  importance. 
The  only  means  of  obtaining  aetiologic  information  particularly  where  a  plausible 
hypothesis  includes  a  long  time  lag  between  onset  of  carcinogenesis  and  development 
of  symptoms  is  through  assiduous  observational  epidemiology.  An  appropriate  study 
of  the  impact  of  diet  on  breast  cancer  would  require  a  detailed  review  of  diet  for 
subgroups  of  women  at  substantially  different  levels  of  baseline  risk.  Detailed  dietary 
assessment  would  be  needed,  based  on  repeated  measures  to  validate  the  measurement 
instrument  used  and  to  reduce  the  potential  for  misclassification.  Appropriate  ages  for 
dietary  assessment  would  cover  the  timing  of  main  life  events  where  hormonal 
changes  and  the  potential  carcinogenesis  would  be  greatest:  onset  of  menarche,  early 
adolescence  and  establishment  of  ovulatory  cycles. 
Conclusion 
Summarising  the  evidence  of  benefits  arising  from  alternative  means  of  reducing 
mortality  from  breast  cancer  shows  high  and  comparable  estimates  for  relative  risk 
reduction.  The  early  Breast  Cancer  Triallists  collaboration  have  provided  convincing 
evidence  for  a  45-50%  reduction  in  relative  risk  of  death  for  women  with  early  breast 
cancer  taking  tamoxifen  therapy.  The  screening  trials  have  proposed  a  relative  risk 
reduction  in  mortality  of  around  24%  -  for  screened  women.  The  results  from 
international  regression  analysis  for  the  effect  of  dietary  fat  reduction  on  population 
mortality  from  breast  cancer  also  suggest  a  possible  24%  reduction  with  a  low  fat 
dietary  intervention.  Projections  from  adjuvant  studies  suggested  a  30%  reduction  in 
mortality  for  tamoxifen  chemoprophylaxis  and  results  from  the  NSABP  P-1 
prevention  trial  increased  this  estimate  to  almost  50%  based  on  reduction  in  incidence 
seen  in  the  intervention  group. 
49 For  an  average  district  health  authority  population  of  250,000  people  with  about  100 
deaths  from  breast  cancer  per  year  full  implementation  of  effective  adjuvant  therapy 
may  prevent  around  30-40  deaths,  the  screening  programme  may  prevent  10-15 
deaths.  For  preventive  interventions  the  scope  for  dietary  effects  though  far  from 
proven  may  have  the  potential  of  saving  20-25  deaths;  with  tamoxifen 
chemoprophylaxis  targeted  only  at  say  the  10%  high  risk  women  in  the  population 
would  prevent  only  5-10  deaths.  These  reductions  in  relative  risk  are  of  course 
tempered  by  the  excess  cost  involved  in  each  of  the  programmes,  by  the  proportion  of 
the  population  who  may  be  affected  and  by  the  side  effects  involved.  Screening  for 
example  has  not  yet  been  fully  evaluated  on  a  population  basis  but  clearly  has  the 
limitation  of  being  targeted  only  to  a  small  proportion  of  the  women  at  risk  and 
potentially  carrying  a  high  cost  per  death  prevented.  The  risks  of  both  a  high  false 
positive  and  false  negative  rate  further  increase  the  costs  involved. 
The  range  of  cost  effectiveness  discussed  above  for  alternative  means  of  reducing 
mortality  from  breast  cancer  are  wide  covering  $17-50,000  (£10,625-£62,500)  for 
early  treatment  of  established  disease  to  $40,000-160,000  (£25-100,000)  in  the  breast 
screening  programme.  New  and  innovative  treatments  for  advanced  disease  are  of 
considerable  cost  for  small  benefit  in  terms  of  survival  and  assessments  of  quality  of 
life  for  women  on  high  dose  chemotherapy  are  limited.  Against  this  background  the 
scope  for  chemoprevention  is  wide  though  ought  to  be  targeted  towards  a  cost 
effectiveness  of  less  than  £25,000  per  death  prevented.  34  This  is  a  low  estimate  for  the 
screening  programme  and  a  midpoint  for  effective  treatment  of  breast  cancer  for 
women  in  the  age  group  likely  to  be  eligible  for  chemoprevention. 
Chapter  2  sets  out  the  rationale  for  chemoprevention  of  breast  cancer  with  tamoxifen 
and  addresses  issues  likely  to  impact  on  cost  effectiveness.  The  issues  are  drawn  from 
a  literature  review  of  the  known  adverse  effects  of  tamoxifen  as  well  as  possible 
benefits  associated  with  reduced  risks  of  other  conditions  such  as  heart  disease.  Early 
discussion  is  included  quantifying  the  risks  and  benefits  for  women  who  are  taking 
long  term  tamoxifen  despite  being  asymptomatic  for  breast  cancer  albeit  at  high  risk 
for  the  disease.  Information  on  the  likely  impact  of  long  term  use  of  tamoxifen  on 
50 morbidity  is  supported  in  subsequent  chapters  with  empirical  information  measuring 
changes  in  the  use  of  hospital  services  or  use  of  prescribed  medications  by  women 
taking  tamoxifen  or  control  within  the  International  Breast  Cancer  Intervention  Study. 
These  are  considered  in  Chapters  4  and  5  respectively. 
51 Chapter  Two 
Breast  Cancer  Prevention  with  Tamoxifen:  Prospects  for  Morbidity  and 
Mortality 
Introduction 
This  section  is  concerned  with  the  rationale  for  chemoprevention  of  breast  cancer  and 
in  particular  the  use  of  the  drug  tamoxifen  for  prophylaxis.  Issues  relating  to 
chemoprevention  of  disease  and  the  special  nature  of  prevention  trials  are  considered 
in  the  context  of  the  likely  risks  and  benefits  of  long  term  tamoxifen  use  and  the  trials 
currently  underway  in  the  USA,  Europe  and  Australia.  The  side  effects  of  tamoxifen 
are  discussed  in  order  to  inform  decisions  about  the  costs  of  changes  in  rates  of 
morbidity  and  mortality  for  high  risk  though  asymptomatic  women  wishing  to  take 
prophylactic  tamoxifen  to  reduce  the  risk  of  death  from  breast  cancer.  A  balance 
sheet  of  risks  and  benefits  is  proposed  as  a  basic  design  for  the  cost  effectiveness 
study  of  tamoxifen  chemoprophylaxis  developed  in  later  chapters.  Issues  of  concern 
to  the  economic  analysis  are  also  discussed. 
Chemoprevention  can  be  defined  broadly  as  the  use  of  an  anticancer  substance  - 
including  pharmacological  agents  -  to  enhance  intrinsic  biological  mechanisms  that 
protect  against  the  development  of  malignant  cells.  Such  an  intervention  may  be  an 
appropriate  action  for  individuals  known  to  be  at  high  risk  for  breast  cancer  or  to  have 
had  precursor  lesions  identified  through  screening.  'oa,  105  The  rationale  for 
chemoprevention  of  breast  cancer,  now  under  investigation  in  a  number  of  countries  is 
based  on  the  assumption  that  therapeutic  agents  known  to  be  active  in  suppressing 
tumour  growth  for  women  with  early  and  advanced  breast  cancer  are  likely  to  be 
similarly  effective  in  prevention.  The  expectation  is  that  an  agent  effective  in  reducing 
the  rate  of  development  of  disease  for  women  with  established  breast  cancer  may  be 
successful  in  correcting  or  inhibiting  neoplastic  agents  responsible  for  the  onset  of 
carcinogenesis. 
52 A  number  of  authors  reviewing  the  impact  of  adjuvant  therapies  on  the  development 
of  breast  cancer  have  suggested  that  the  mode  of  action  of  the  drug  tamoxifen  in 
reducing  the  development  of  recurrent  disease  in  women  with  early  breast  cancer 
might  apply  also  to  preventing  the  onset  of  tumour  development  in  healthy 
women"  "06,107,108  Tamoxifen,  a  non-steroidal  antioestrogen  is  used  as  the  front  line 
treatment  for  breast  cancer.  It  is  widely  used  in  both  pre  and  postmenopausal  women 
as  an  adjuvant  treatment  in  early  disease  where  it  has  been  shown  to  delay  recurrence 
and  increase  survival  and  a  recent  review  has  provided  convincing  evidence  of  similar 
value  for  premenopausal  women  as  adjuvant  treatment'. 
There  is  little  doubt  that  oestrogen  is  implicated  in  breast  cancer  carcinogenesis  and 
although  the  precise  mode  of  action  of  tamoxifen  on  the  aetiology  of  breast  cancer  is 
complex  it  is  clear  that  it  blocks  the  tumour  promoting  properties  of  oestrogen1°9. 
Laboratory  studies  suggest  that  it  is  the  amount  of  available  oestrogen  that  is  a  key 
factor  in  the  aetiology  of  breast  cancer1°.  The  amount  of  available  oestrogen  depends 
on  levels  of  sex  hormone  binding  globulin  (SHBG)  and  other  growth  factors.  Sakhai 
and  other  authors  have  reported  that  tamoxifen  raised  levels  of  SHBG"''"`''13. 
Tamoxifen  appears  to  have  a  range  of  effects  acting  as  both  an  oestrogen  agonist  and 
an  oestrogen  antagonist.  The  effect  appears  to  vary  with  menopausal  status.  It  is  more 
likely  to  behave  as  an  antiestrogen  in  premenopausal  women  and  as  an  oestrogen  in 
postmenopausal  women.  Evidence  suggests  that  tamoxifen  is  effective  in  oestrogen 
negative  tumours  though  with  a  stronger  effect  in  oestrogen  dependant  tumours14. 
Tamoxifen  seems  to  be  cytostatic  rather  than  cytocidal  in  laboratory  studies  using 
animal  analogues,  supporting  its  use  in  prevention  as  well  as  in  adjuvant  therapy. 
The  impetus  for  testing  tamoxifen  prophylaxis  in  preventing  breast  cancer  has  been 
strengthened  by  concerns  about  the  lack  of  progress  made  in  reducing  the  burden  of 
the  disease  despite  advances  in  treatment  and  the  development  of  breast  cancer 
screening  programmes.  Moreover  because  of  the  high  incidence  of  breast  cancer  even 
a  small  reduction  in  relative  risk  from  a  preventive  intervention  could  considerably 
reduce  morbidity  and  mortality  and  the  high  costs  of  surgical  and  medical  therapies. 
53 Estimates  of  the  potential  for  tamoxifen  prophylaxis  of  breast  cancer  on  the  burden  of 
disease  in  the  population  have  come  from  long  term  follow  up  in  a  number  of 
adjuvant  trials  testing  the  effectiveness  of  tamoxifen  in  reducing  the  development  of  a 
second  primary  in  the  contralateral  breast1'.  It  is  argued  that  this  may  be  an  effect 
equivalent  to  reducing  the  incidence  of  breast  cancer  in  high  risk women. 
In  the  recent  overview  of  trials  of  the  use  of  adjuvant  tamoxifen  versus  no  adjuvant 
tamoxifen,  the  Early  Breast  Cancer  Triallists  Collaborative  Group  (EBCTCG) 
reported  on  55  trials  that  began  before  1990  and  included  almost  37,000  women.  The 
overview  divided  trials  into  three  categories  of  duration:  one  year,  two  years  and  more 
than  two  years;  the  latter  being  most  usually  five  years  or  more.  For  these  trials  the 
proportional  reductions  in  the  incidence  rate  of  contralateral  breast  cancer  among 
women  allocated  tamoxifen  were  respectively  13%  (SD  13),  26%  (SD  9),  and  47% 
(SD  9).  The  effect  for  one  year  was  not  significant  but  there  was  a  significant  trend 
(chi2  =7.3,  p,  <  0.004)  for  trials  of  tamoxifen  of  two  years  or  more  with  longer  duration 
leading  to  greater  reductions  in  the  incidence  of  contralateral  breast  cancers.  Overall 
the  review  shows  that  approximately  five  years  of  tamoxifen  reduces  the  annual 
incidence  rate  of  contralateral  breast  cancer  by  50%7. 
It  can  be  argued  that  this  effect  is  equivalent  to  the  prevention  of  breast  cancer  in 
healthy  individuals  since  it  is  essentially  suppressing  the  development  of  a  second 
primary  tumour1'.  It  is  possible  however  that  the  effect  is  to  suppress  the  synchronous 
growth  of  tumours  and  that  tamoxifen  has  no  relevance  in  healthy  women1'. 
Moreover,  these  trials  were  concerned  only  with  the  development  of  breast  cancer  in 
postmenopausal  women.  Prevention  is  likely  to  be  focused  towards  large  numbers  of 
healthy  premenopausal  women  where  the  conditions  for  the  development  of  tumours 
in  women  with  risk  factors  for  disease  may  be  quite  different. 
The  results  from  the  EBCTCG  overview  of  therapeutic  interventions  in  breast  cancer 
provides  evidence  that  at  least  two  years  duration  of  tamoxifen  can  prevent  recurrence 
and  reduce  mortality  for  women  with  early  breast  cancer  by  around  50%'-10.  Were 
similar  effects  to  be  available  for  prevention  particularly  to  women  at  high  risk  for 
54 breast  cancer  the  results  could  be  of  considerable  public  health  significance  since  the 
incidence  of  breast  cancer  is  high  and  the  relatively  long  mean  percentage  survival 
relative  to  other  cancers  results  in  a  prevalence  :  incidence  ratio  of  about  10:  1. 
Reducing  the  burden  of  disease  in  the  population  by  around  half  could  have 
considerable  benefits  for  overall  population  mortality  and  result  in  substantial  savings 
on  the  cost  of  health  care. 
Developing  the  concept  of  tamoxifen  chemoprophylaxis  within  the  broader  context  of 
a  population  based  prevention  trial.  does  however  raise  a  number  of  issues1'.  These 
include  the  likely  costs  and  benefits  of  such  an  approach,  the  impact  of  the 
intervention  on  the  burden  of  disease  irrespective  of  the  change  in  carcinogenesis 
found  in  individuals  and  the  precise  impact  of  deleterious  side  effects.  Ethical  support 
for  a  trial  to  test  the  hypothesis  of  chemoprevention  in  breast  cancer  would  rely  on  the 
importance  of  identifying  a  group  of  women  at  relatively  high  risk  for  the  disease  in 
order  to  maximise  benefit  from  a  preventive  intervention  relative  to  possible  harms 
involved1'. 
Net  benefits  of  chemoprevention  would  be  gained  at  a  cost  both  to  the  woman 
involved  and  in  the  resource  use  needed  to  set  up  a  service  for  prevention.  This 
includes  the  means  of  identifying  high  risk  women,  securing  the  compliance  needed  to 
make  such  a  programme  economically  worthwhile,  and  providing  adequate  support 
and  follow  up.  The  prospect  of  routine  screening  for  adverse  events  may  also  need  to 
be  considered.  The  net  effect  of  chemoprevention  can  be  summarised  in  the  balance 
sheet  below: 
Cost  of  active  chemoprevention 
0  the  direct  cost  of  the  preventive  intervention  and  associated  treatment  costs 
(drugs,  staff,  clinic  facilities) 
"  the  differences  in  costs  of  health  services  (including  primary  care  and 
community  health  services)  between  those  receiving  the  preventive 
intervention  and  control  women  (those  at  high  risk  receiving  no  intervention) 
55 "  activity:  number  of  women  eligible  and  taking  up  the  preventive  intervention 
(may  include  costs  of  identifying  women  at  relatively  high  risk) 
"  the  cost  of  "labelling"  women  at  high  risk  creating  anxiety 
Benefits  of  chemoprevention  will  depend  on 
"  the  effectiveness  of  the  intervention  in  reducing  and  delaying  the  development 
of  the  disease 
"  reducing  or  delaying  the  need  for  surgical  or  medical  therapies 
"  improvements  in  quality  of  life 
"  the  uptake  of  the  preventive  intervention 
"  beneficial  effects  on  other  organs 
"  impact  on  the  health  experience  of  women 
How  the  allocation  of  aspects  of  chemoprevention  set  out  in  the  box  above  is  made 
could  make  a  difference  to  the  calculation  of  the  ratio  of  costs  to  benefits  and  to  the 
empirical  results  from  the  study  developed  in  the  analysis  set  out  in  Chapter  7. 
Consistency  ofinethods  in  cost  effectiveness  analysis  is  clearly  important  also  in  the 
ability  to  make  comparisons  across  health  care  programmes  yet  there  appears  to  be 
little  convention  to  guide  the  alicoationo  f  some  of  the  a  ttributes  or  indeed  what 
attaributes  shold  be  included.  Some  of  the  attributes  listed  as  costs  may  arguably  be 
considered  benefits  and  vice  versa.  This  is  of  particular  concern  for  attributes  such  as 
changes  in  the  quality  of  life  or  health  experience  of  the  women  involved  which  are 
not  always  included  in  studies  of  cost  effectiveness. 
In  general  the  use  of  resources  on  health  care  has  been  included  in  the  numerator  and 
the  improvements  in  health  in  the  denominator.  The  direct  costs  of  the  intervention  - 
costs  of  service  delivery  including  treatment  costs  are  identified  as  costs  as  have  the 
differences  in  use  of  health  services  between  women  receiving  the  intervention  and 
those  who  are  not.  The  uptake  of  the  intervention  -  time  spent  by  women  seeking  the 
intervention  or  indeed  receiving  it  and  the  cost  of  targeting  women  are  also  ascribed 
as  costs.  These  activities  use  resources  and  have  no  intrinsic  health  benefit  to  the 
women  involved.  The  possible  costs  of  labelling  women  at  high  risk  and  effects  on 
56 health  experience  such  as  those  associated  with  changing  levels  of  anxiety  are  also 
included  as  costs  though  perhaps  should  more  properly  be  considered  in  the 
denominator  since  they  are  effects  on  health  outcome.  For  this  reason  the  possibility 
of  benefits  associated  with  potential  improvements  in  quality  of  life  arising  directly 
from  use  of  the  intervention  and  the  beneficial  effects  on  other  organs  arising  from  the 
intervention  are  included  in  the  denominator. 
Less  straightforward  is  measuring  the  costs  or  benefits  associated  with  the 
effectiveness  of  the  intervention  and  the  impact  on  reducing  or  delaying  the  need  for 
surgical  or  medical  therapies.  At  this  stage  in  our  understanding  of  the  potential  for 
chemoprophylaxis  of  breast  cancer  it  is  difficult  to  know  whether  delayed  onset  of 
disease  should  be  measured  as  changed  resource  use  for  health  and  personal  costs  of 
care  -  or  as  a  health  benefit.  The  problem  arises  because  of  possible  changes  in  the 
morbidity  experience  of  women  with  a  raised  risk  profile  for  breast  cancer.  Neither 
do  we  know  how  the  intervention  may  affect  future  risks  or  experience  of  life 
threatening  illness  and  eventual  cause  of  death.  The  attributes  have  been  defined  here 
as  benefits  based  on  the  current  evidence  of  changed  health  outcome  from  prevention 
trials  particularly  the  NSABP  Pl  with  6  years  of  follow  up. 
The  issue  will  be  kept  under  review  as  new  information  emerges  to  further  understand 
the  impact  of  changes  in  intervention  related  morbidity  in  years  that  would  have  been 
lived  anyway,  costs  that  would  have  occurred  in  those  years  and  health  care  costs  - 
both  related  and  unrelated  to  the  intervention  -  that  ensue  in  years  that  may  be  added 
-  or  lost  as  a  result  of  the  intervention.  Future  non-health  related  costs  such  as  costs 
of  living  expenditure  during  possible  additional  years  gained  are  not  included. 
Studies  from  continued  follow  up  of  the  women  involved  in  IBIS  will  address  the 
uncertainty  in  the  allocation  of  costs  and  benefits  and  define  more  clearly  how  they 
might  affect  the  calculation  of  costs  effectiveness  of  tamoxifen  chemoprophylaxis  of 
breast  cancer. 
Chemoprevention  -  issues  for  both  research  and  practice 
57 The  special  nature  of  trials  seeking  to  assess  the  efficacy  of  possible  cancer  prevention 
agents  has  been  discussed  by  a  number  of  authors108""8.  Unlike  treatment  trials, 
prevention  trials  set  out  to  recruit  healthy  individuals  and  usually  need  to  be  of  long 
duration  in  order  to  monitor  both  the  relatively  rare  event  of  the  incidence  of  new 
cancers  as  well  as  assessing  the  progress  of  disease  and  the  impact  on  mortality.  In 
IBIS,  for  example,  it  is  estimated  that,  for  a  power  of  95%  to  show  a  significant 
difference  of  40%  between  the  two  arms  of  the  trial  over  ten  years,  8,000  women  are 
needed  based  on  an  average  risk  of  breast  cancer  of  6  per  1,000  in  the  women 
recruited  to  the  trial 
Identifying  a  target  group  for  breast  cancer  prevention  trials  has  most  usually  rested 
on  those  at  high  risk  for  the  condition  under  review.  Trials  for  chemoprevention  in 
breast  cancer  have  sought  to  recruit  women  at  high  risk  since  the  presence  of  risk 
factors  was  thought  more  likely  to  secure  compliance  and  to  reduce  the  expected  trial 
duration  and  size  because  of  the  high  expected  incidence  of  new  tumours2S"19.  In 
resolving  the  ethical  questions  concerning  experimentation  on  healthy  women  it  could 
be  argued  that  recruiting  women  at  high  risk  for  a  disease  is  more  in  line  with 
treatment  trials  where  the  risk  of  mortality  arising  from  the  certain  existence  of  a  life 
limiting  illness  is  balanced  against  the  uncertain  risks  and  benefits  of  the  intervention 
under  review. 
Women  age  50  at  five  or  ten  fold  risk  for  breast  cancer  because  of  family  history  or 
reproductive  factors  have  between  a  30-50%  remaining  absolute  lifetime  risk  of  death 
from  the  disease.  Women  with  elevated  risk  for  breast  cancer  may  find  it  acceptable 
to  balance,  in  favour  of  trial  entry,  their  higher  than  average  lifetime  risk  of  breast 
cancer  with  the  possible  reduction  in  risk  or  prolongation  of  disease  free  life  years  the 
agent  under  review  and  any  likelihood  of  adverse  events.  Providing  that  the  agent 
used  in  chemoprevention  itself  does  not  confer  significant  toxicity,  trial  entry  for 
women  with  increased  risk  of  breast  cancer  may  be  considered  analogous  to  eligibility 
of  women  with  established  disease  in  treatment  trials"'. 
58 There  are  few  medical  alternatives  available  for  women  at  high  risk  of  breast  cancer 
who  seek  active  intervention  in  order  to  reduce  their  risk  of  early  mortality  from 
breast  cancer.  There  is  some  evidence  to  suggest  that  either  frequent  mammography  or 
prophylactic  mastectomy  may  reduce  the  risk  of  mortality  from  breast  cancer  though 
precise  information  on  these  options  is  limited.  Evidence  of  benefit  from  primary 
prevention  as  discussed  earlier  is  scanty  though  studies  are  underway  which  may 
improve  knowledge  in  this  area12'. 
There  are,  however,  reasons  why  results  obtained  from  studying  women  in  high  risk 
groups  may  not  be  generalisable  to  the  general  population.  Evidence  from  studies  of 
hereditary  factors  in  the  case  of  breast  cancer  suggests  that  women  carrying  the 
familial  breast  cancer  gene,  BRCAI  are  more  likely  to  have  hormone  independent 
tumours  than  women  without  this  gene9.  Tamoxifen  used  as  an  as  adjuvant  therapy  for 
women  with  breast  cancer  is  least  effective  with  oestrogen  negative  tumours  and  may 
have  little  preventive  impact  on  women  likely  to  develop  this  kind  of  tumour"'. 
Moreover  the  results  from  chemoprevention  trials  may  be  biased  where  power 
calculations  for  estimating  trial  numbers  needed  to  show  an  effect  are  based  on 
incidence  of  disease  and  not  mortality9.  Close  monitoring  of  the  population  may  result 
in  detection  of  earlier  stage  disease  and  so  reduce  the  perceived  effect. 
Side  effects  from  long  term  use  of  tamoxifen 
Large  numbers  of  healthy  asymptomatic  women  would  need  to  take  the  preventive 
intervention  in  order  to  produce  a  significant  impact  on  population  mortality.  Side 
effects  found  in  adjuvant  treated  patients  may  be  of  greater  concern  in  the  context  of 
prevention  because  of  the  importance  of  justifying  the  risk  of  possible  harm  from  the 
intervention  in  relation  to  the  benefits.  Even  rare  side  effects  could  lead  to  a  large 
number  of  individual  disease  effects  with  considerable  medical  resource  and  social 
implications  and  any  deleterious  effects  on  common  serious  conditions  such  as 
coronary  heart  disease  could  outweigh  the  beneficial  effects  on  breast  cancer.  It  seems 
however  that  the  balance  of  evidence  suggests  that  a  beneficial  effect  on  lipid  profiles 
which  may  reduce  the  risk  of  coronary  heart  disease  in  women  taking  tamoxifen  is 
59 more  likely12'.  There  may  also  be  beneficial  effects  for  the  risk  of  osteoporosis 
although  studies  are  few  and  equivocal"',  "'.  Concerns  remain  about  the  long  term 
metabolic  impact  of  tamoxifen  use  particularly  with  regard  to  risks  associated  with 
endometrial  cancer,  thromboembolism  and  visual  disturbance. 
There  is  little  evidence  other  than  from  the  development  of  hyperplastic  nodules  and 
tumours  in  laboratory  animals  of  an  increased  risk  of  liver  cancer  in  women  treated 
with  tamoxifen  though  ascertainment  of  a  primary  tamoxifen  induced  liver  cancer 
may  be  difficult  in  adjuvant  studies"'.  Liver  cancer  is  a  rare  condition  and  it  is  now 
generally  agreed  that  any  diagnosis  of  liver  cancer  in  women  taking  tamoxifen  is  most 
likely  to  be  due  to  metastatic  spread  of  the  disease.  Cuzick  reports  that  the  available 
evidence  from  trials  has  failed  to  show  an  effect  on  liver  cancer  and  a  large  scale 
epidemiological  cancer  registry  based  study  in  the  United  States  found  no  sign  of  any 
increase  in  liver  cancer  after  the  introduction  of  tamoxifen  in  1977126.  In  the  EBCTCG 
there  were  slightly  fewer  deaths  attributable  to  liver  disease  in  the  tamoxifen  treated 
group  than  in  the  control  group  and  there  was  no  excess  of  liver  cancers  in  the 
tamoxifen  group  even  among  Japanese  women  where  the  incidence  of  liver  cancer  is 
relatively  high  (no  liver  cancers  in  the  tamoxifen  group  versus  three  in  the  control 
group). 
Ocular  toxicity  from  long  term  tamoxifen  treatment  is  uncommon  though  case  reports 
and  case  series  report  clinical  changes  such  as  retinal  deposits,  macular  oedema  and 
corneal  thickening.  A  review  of  tamoxifen  related  eye  disease  documented 
considerable  variability  in  the  presentation  of  these  conditions  which  may  be  due  to 
alternative  explanations  such  as  age  related  eye  disease  or  ocular  changes  caused  by 
other  diagnosis  such  as  diabetes.  There  does  however  seem  to  be  an  increase  in 
severity  of  ocular  findings  and  more  serious  visual  impairment  in  patients  with 
advanced  breast  cancer  on  high  dose  adjuvant  therapy  including  tamoxifen. 
Prospective  data  from  a  review  of  randomised  controlled  clinical  trials  suggests  that 
ocular  complaints  may  be  more  frequent  among  patients  taking  chemotherapy  but  that 
there  is  little  difference  in  symptoms  for  women  on  tamoxifen  alone  compared  with 
control.  Since  there  is,  at  present,  no  clear  evidence  that  long  term  tamoxifen  use 
60 predisposes  to  ocular  degeneration  there  is  little  justification  for  routine  eye  tests  prior 
to  treatment.  Nevertheless  some  authors  have  suggested  that  close  monitoring  might 
be  advised127"128129. 
Evidence  from  published  studies  concerned  with  the  side  effects  from  tamoxifen  that 
are  most  likely  to  influence  the  beneficial  effects  of  tamoxifen  in  chemoprevention  of 
breast  cancer  is  reviewed  below.  This  includes  general  symptoms,  endometrial  cancer, 
thrombolic  events  such  as  deep  vein  thrombosis  (DVT)  and  pulmonary  embolism 
(PE)  and  effects  on  lipid  profiles  and  cardiac  health.  Where  possible  the  information 
has  been  summarised  to  identify  a  rate  which  could  inform  assumptions  about  the 
`cost'  of  side  effects  and  the  impact  they  may  have  on  uptake  of  a  preventive 
intervention  and  long  term  compliance  with  the  treatment  regimen. 
General  symptoms 
Reporting  of  rates  of  symptomatic  side  effects  is  inconsistent  though  numerous  case 
reports  and  observational  studies  document  a  change  in  endometrial  epithelia  with  the 
appearance  of  polyps  in  tamoxifen  treated  women  and  frequent  increase  in 
gynaecological  symptoms  such  as  irregular  menstruation,  hot  flushes  and  vaginal 
discharge8'130.  Some  of  the  reported  side  effects  such  as  hot  flushes  are  clearly 
associated  with  anti-oestrogenic  properties  of  tamoxifen  whereas  vaginal  discharge  or 
bleeding  may  be  associated  with  its  oestrogenic  properties13'. 
Many  authors  concerned  with  the  survival  value  of  adjuvant  tamoxifen  refer  to  the 
relatively  infrequent  reporting  of  symptomatic  side  effects  by  women  taking 
tarnoxifen  in  comparison  with  control  patients132.  A  six  year  follow  up  of  women 
treated  with  tamoxifen  as  a  single  agent  following  surgery,  for  example,  found  that 
only  4%  of  patients  treated  with  tamoxifen  for  two  years  had  side  effects  requiring 
withdrawal  from  the  trial133.  Yet,  many  long-term  studies  do  report  an  increase  in  side 
effects  for  women  on  tamoxifen.  A  large  scale  NSABBP134  study  of  over  3,000 
women  with  oestrogen  receptor  positive  cancers  randomised  to  receive  either 
tamoxifen  (n=1422)  or  placebo  (n=1439)  found  that  the  frequency  of  occurrence  of 
61 many  symptoms  such  as  fluid  retention  and  nausea  was  similar  in  the  two  groups. 
Symptoms  such  as  hot  flushes  and  vaginal  discharge  were  however  higher  in  the 
tamoxifen  treated  group  and  did  cause  women  to  withdraw  from  the  study  though  the 
rate  of  withdrawal  was  not  documented. 
Love  specifically  reported  on  symptoms  associated  with  tamoxifen  in  a  group  of  140 
volunteer  post  menopausal  women  in  the  context  of  a  blinded  randomised  trial1z'. 
They  were  assessed  over  24  months.  All  of  the  women  had  axillary  node  negative 
breast  cancer  in  remission.  He  found  a  significant  level  of  side  effects  for  those  on 
tamoxifen  compared  with  women  on  placebo.  The  study  participants  were 
comparable  for  mean  age,  years  since  menopause,  body  mass  and  prior  hysterectomy 
and  had  comparable  levels  of  the  symptoms  under  review  at  the  beginning  of  the 
study.  None  had  active  radiological,  laboratory  or  clinically  verifiable  breast  cancer  at 
the  time  of  the  study. 
After  the  first  12  months  of  the  study  61.7%  (31/64)  of  women  taking  tamoxifen 
reported  hot  flushes  compared  with  48.4%  (37/60)  on  placebo.  The  significant 
difference  in  rates  appeared  at  the  six  month  visit  and  was  sustained  over  the  study 
period.  Fewer  women  overall  reported  severe  hot  flushes  in  the  first  six  months 
though  there  was  a  significant  increase  for  women  taking  tamoxifen.  13.3%  (8/60)  of 
women  taking  tamoxifen  reported  severe  hot  flushes  compared  with  3.1%  (2/64)  in 
the  placebo  group.  Reporting  of  hot  flushes  of  any  kind  were  equivalent  at  baseline. 
Rates  of  moderate  to  severe  face  flushes  also  increased  significantly  for  the  tamoxifen 
group  after  the  first  three  months.  Powles  found  a  similar  result  of  a  two  fold  increase 
in  the  occurrence  of  hot  flushes  in  tamoxifen  treated  women  though  this  effect  was 
mostly  confined  to  premenopausal  women. 
A  significant  increase  in  general  gynaecologic  symptoms  was  also  reported  in  this 
study.  By  12  months  of  follow  up,  26.7%  of  women  in  the  tamoxifen  arm  reported 
gynaecological  symptoms  compared  with  14.1%  at  baseline.  Gynaecological 
symptoms  also  increased  in  the  placebo  arm  though  to  a  much  lesser  extent  not 
reaching  significance  over  baseline  values.  The  women  in  the  tamoxifen  arm  had  a 
62 higher  proportion  of  gynaecological  symptoms  at  baseline  than  the  women  in  the 
placebo  group  though  this  difference  was  not  significant.  In  the  Powles  pilot  women 
also  reported  a  significant  increase  in  vaginal  discharge  and  in  menstrual 
irregularities.  The  Love  study  found  no  differences  in  a  number  of  symptom  areas 
such  as  in  joint  pain,  fatigue  and  nausea  though  there  was  an  apparent  reduction  in  the 
rate  of  reports  of  headache  in  the  tamoxifen  group.  The  Powles  study  showed  a 
reduction  in  reporting  of  nausea  and  vomiting  in  tamoxifen  treated  women  though  no 
difference  in  headaches  between  the  two  groups. 
In  the  Love  study,  the  apparent  delay  in  the  appearance  of  side  effects  for  some 
women  and  the  fluctuation  in  reporting  over  time  led  the  investigators  to  identify  a 
category  of  persistent  side  effects.  Women  taking  tamoxifen  showed  a  higher  level  of 
overall  toxicity  with  persistent  side  effects  reported  by  48.5%  (16/60)  at  12  months 
compared  with  21.2%  (14/66)  in  the  placebo  group.  Undertaking  an  assessment  of 
well  being  using  a  seven  item  quality  of  life  measure  the  authors  also  found  that 
women  who  experience  symptoms  are  more  likely  to  report  anxiety  about 
involvement  in  the  trial.  They  conclude  that  a  protocol  should  be  devised  for  proper 
evaluation  and  management  of  the  side  effects  and  that  the  decrement  in  quality  of  life 
to  women  on  tamoxifen  be  more  fully  documented 
Endometrial  Cancer 
An  excess  of  endometrial  carcinoma  has  been  identified  from  a  number  of  studies  of 
long-term  follow  up  of  women  on  adjuvant  tamoxifen  and  more  recently  from  the 
results  of  the  NSABP  P-12.  These  studies  suggest  that  the  effect  may  be  related  to  the 
dose  of  tamoxifen  used  and  the  duration  of  use.  The  NSABP  B14  trial  of  tamoxifen 
adjuvant  therapy  in  women  with  breast  cancer  has  now  accumulated  18  cases  of 
endometrial  cancer  out  of  2,638  patients  with  no  cases  reported  in  the  control  group  134. 
This  includes  seven  patients  allocated  to  the  tamoxifen  group  after  the  initial  phase  of 
randomisation  and  two  patients  who  relapsed  in  the  placebo  group  and  were 
subsequently  assigned  to  tamoxifen.  The  median  time  to  development  of  endometrial 
cancer  in  the  11  randomised  cases  was  41  months  (range  4-93  months) 
63 In  the  Stockholm  Adjuvant  Tamoxifen  Trial  13  out  of  931  women  (1.4%)  taking 
tamoxifen  developed  uterine  cancers  compared  with  two  out  of  915  women  (0.2%)in 
the  control  group.  The  stage  of  these  tumours  was  not  uniform  11.  Both  early  and  late 
stage  grades  were  found  challenging  previous  assumptions  that  tamoxifen  induced 
cancers  may  be  of  lower  grade  and  have  a  more  favourable  prognosis  than  those  found 
in  patients  not  taking  tamoxifen16 
Dose  is  clearly  an  important  factor  in  this  trial  since  the  women  were  taking  tamoxifen 
at  40  mg/day  which  is  twice  that  offered  in  most  adjuvant  studies  or  in  prevention 
trials.  It  has  been  estimated  that  the  median  cumulative  dose  of  tamoxifen  needed 
before  increased  risk  of  endometrial  cancer  is  around  29g.  This  level  would  be 
reached  after  four  years  of  treatment  with  a  daily  intake  of  20mg.  Duration  of 
treatment  was  also  important  in  this  study  with  the  number  of  cases  of  endometrial 
cancer  increasing  in  those  treated  for  longer  than  two  years137 
The  Scottish  Adjuvant  Study  13S  by  contrast,  found  no  association  between  endometrial 
cancer  and  tamoxifen  therapy  at  a  dose  of  20mg/day  in  4-10  years  of  follow  up  of 
1,070  randomly  allocated  postmenopausal  women.  The  Danish  Adjuvant  study  139  also 
failed  to  show  a  statistically  significant  increase  in  endometrial  cancer  in  women 
taking  tamoxifen  alone  at  a  dose  of  30mg/day  or  with  radiotherapy  although  there  was 
a  non  significant  trend  towards  an  elevated  risk  in  the  tamoxifen  treated  group.  A 
similar  result  of  a  non  significant  increase  of  uterine  cancer  for  women  on  tamoxifen 
was  shown  in  the  South  Sweden  study  with  719  breast  cancer  patients  randomised  to 
either  radiotherapy  with  tamoxifen,  radiotherapy  alone  or  tamoxifen  alone,  after  nine 
years  of  follow  up140.  The  NATO  study'33  of  20mg  daily  of  tamoxifen  given  to 
postmenopausal  women  with  early  breast  cancer  also  found  no  endometrial  cancer 
after  two  years  of  follow  up. 
A  recent  report  pooling  the  results  of  randomised  studies  on  the  impact  of  tamoxifen 
on  endometrial  cancer  suggests  that  there  is  a  statistically  significant  increase  in 
relative  risk  of  about  4.8  in  the  rate  of  development  of  endometrial  cancer  in  women 
64 with  breast  cancer  treated  with  tamoxifen  compared  with  women  in  the  control  group. 
For  women  receiving  adjuvant  tamoxifen  at  a  dose  of  20mg  per  day  the  relative  risk 
appears  to  be  about  4.08. 
The  results  from  NSABP  P-  l2  show  an  increased  relative  risk  of  endometrial  cancer  of 
2.53  based  on  the  appearance  of  33  cancers  in  the  tamoxifen  treated  group  (out  of 
6,681)  compared  with  14  (out  of  6,707)in  the  control  group.  The  increased  risk  was 
predominantly  in  women  aged  50  or  older  with  an  increased  relative  risk  of  4.01  (95% 
CI=1.7-10.9)  compared  with  a  relative  risk  of  1.21  in  women  aged  49  or  younger 
(95%CI=  0.41-3.60).  The  appearance  of  endometrial  cancer  occurred  early  in  the 
follow  up  period  and  had  an  average  annual  incidence  of  2.3  per  1000  in  the 
tamoxifen  group  compared  with  0.91  in  the  control  group.  The  cumulative  incidence 
was  13  per  1000  women  in  the  tamoxifen  group  at  66  months  of  follow  up  compared 
with  5.4  per  1000  in  the  control  group.  The  estimate  is  lower  than  might  be  expected 
from  adjuvant  studies  though  a  large  proportion  of  the  women  in  the  trial  had 
undergone  hysterectomy.  The  increased  relative  risk  found  in  adjuvant  studies  is 
similar  to  that  seen  in  the  Royal  Marsden  Chemoprevention  pilot.  In  this  study  there 
were  four  endometrial  cancers  reported  after  70  months  of  follow  up  out  of  1238 
women  on  tamoxifen  compared  with  one  woman  with  endometrial  cancer  out  of  1233 
analysed  on  placebo. 
Thromboembolic  effects 
There  is  evidence  of  an  increased  risk  of  thromboembolic  events  in  women  taking 
tamoxifen  though  this  mostly  comes  from  case  reports  and  large  adjuvant  studies  of 
women  with  established  breast  cancer  where  the  causes  of  changes  in  haemostasis 
may  be  complex  and  multifactorial.  There  is  considerable  evidence  of  both  an 
association  between  cancer  in  general  and  risk  of  thromboembolism  and  of  risks 
caused  by  cancer  chemotherapy.  It  is  difficult  to  isolate  the  likely  increased  rate  of 
thromboembolism  which  can  be  attributed  to  tamoxifen  from  these  studies  because 
they  compare  a  variety  of  different  chemotherapeutic  regimen  vs.  Tamoxifen.  Few 
studies  are  available  to  isolate  the  impact  of  tamoxifen  in  comparison  with  placebo. 
65 The  regimen  are  inconsistent  both  in  the  dose  and  duration  of  tamoxifen  and  in  the 
age,  menopausal  and  cancer  status  of  the  women  involved.  Most  of  these  studies  arise 
as  a  secondary  analysis  in  a  design  primarily  seeking  to  assess  the  effect  of  tamoxifen 
on  recurrence  rate  and  survival  rather  than  to  identify  the  precise  rates  of  likely 
thromboembolic  complications.  They  may  not  have  sufficient  power  or  length  of 
follow  up  to  address  questions  of  toxicity.  The  studies  vary  in  the  extent  to  which 
they  record  thromboembolic  complications  in  particular  at  what  level  of  severity 
symptoms  are  included.  Not  all  studies  for  example  include  thrombophlebitis.  Table 
1  summarises  the  rate  of  thromboembolic  complications  for  women  taking  tamoxifen. 
Table  1:  Summary  of  risks  of  Thromboembolic  disease  in  randomised  adjuvant 
studies  (20mg  tamoxifen  daily) 
Study  type  n  follow  up  event  rate  note 
Fisher  -women<70  adjuvant  tamoxifen  , 
double  2644  analysed  4years  Event  rate  0.9%  in  designed  to  study  the 
primary  breast  cancer,  node  blind  placebo  controlled  1326  on  placebo;  1318  on  follow  up  tanwxifen  group,  0.2%  in  recurrence  and  survival 
negative  estrogen  +  temoxifen(but  141  loss  to  placebo  group.  benefit  of  tamoxifee 
f/u) 
66 Saphner  A  review of  7  adjuvant  2673  patients  in  total  3-S  years  follow  up  frequency  of  venous  seeking  estimates  of  the 
studies  (USA)  chemotherapy  vs.  complications  in  frequency  of  venous  and 
chemotherapy  w  tamoxifen  comparisons  including  arterial  thrombo  -embolism 
tamoxifen  vary  from  23-  and  the  contribution  of 
observation,  chemo  or  9.1%  compared  with  0.4%  chemotherapy  with 
ehern  w  tam  for  observation  and  tamoxifen  by  reviewing 
between  3.5  and  3  8%,  for  studies  of  combination 
tamoxifen  vs.  placebo  chemotherapy  in  therapies  and  including 
postmenopausal  women.  patients  on  observation 
chemotherapy  vs  For  premenopausal  women  alone 
observation  range  is  14-4.2%  compared 
with  less  than  I4%for 
chemotherapy  w  tamoxifen  chemotherapy  alone  and  no 
followed  by  radiation  vs.  findings  for  women  under 
observation  observation  alone 
chemotherapy  w  tamoxifen 
followed  by  observation  or 
chemotherapy  with 
tamoxifen  followed  by 
tarnoxifen 
chemotherapy  w  tamoxifen 
vs.  chemotherapy  w  tam 
Fornander  Data  on  intercurent  1846  patients;  931  2  years  with  further  3  years  The  frequency  of  adjuvant  study 
Stockholm  Adjuvant  morbidity  (hospital  tamoxifen.  915  control  with  re  randomisation  admissions  for  thrombotic 
Tarroxifen  Trial  admission)  and  mortality  further  randomisation  by  events  was  2%  in  both  the 
from  an  ret  of  adjuvant  risk status  to  radiation  and  tamoxifen  and  control 
tamoxifen  vs.  no  endocrine  chemotherapy  group 
therapy 
Pritchard  &  Paterson,  141  its  of  tarnoxifen  for  2  years  352  women  receiving  tam  2  years  combination  therapy  led  to 
vs.  tamoxifen  and  chemo  (6  alone.  353  receiving  tam  13.6  %  thromboembolic 
months)  plus  chemo  events  (  with  significantly 
more  serious  grades 
including  3  deaths) 
compared  with  2.6%  in 
women  randomised  to  tam 
alone 
Breast  Cancer  Prevention  ret  of  tamoxifen  vs.  placebo  13,388  women  randomised  median  follow  up  is  3.5  women  taking  tamoxifen  the  absolute  risk  difference 
Trial  for  women  at  high  risk of  to  either  tamoxifen  (6681)  years  1.5%  thromboembolic  between  the  tamoxifen  and 
breast  cancer  or  placebo  (6707)  disease:  pe  (.  25%),  placebo  arte  is  less  than  5 
dvt(.  45%,  cva  (.  5%)  per  1000  women  for  all 
events  (less  than  2  events 
per  1000  women  for  pc 
alone) 
Only  randomised  studies  of  adjuvant  therapy  which  are  able  to  measure  the  incidence 
of  thromboembolic  events  prospectively  and  account  for  possible  confounding  factors 
such  as  the  age  and  menopausal  status  of  the  women  involved  are  included. 
The  study  by  Fisher  et  al  compares  the  incidence  of  thromboembolic  events  in  a 
double  blind  placebo  controlled  trial.  The  rates  of  thromboembolic  events  reported  in 
this  study  are  small  compared  with  other  studies  though  it  was  the  clinically  most 
important  side  effect  occurring  in  0.9%  of  patients  receiving  tamoxifen  compared  with 
67 0.2%  in  the  placebo  group;  a  relative  risk  for  women  taking  tamoxifen  of  4.5.  The 
excess  was  however  mostly  accounted  for  by  thrombophlebitis  and  few  details  are 
given  about  the  specific  conditions  involved  or  the  grade  and  severity  of  the 
complications  experienced. 
Thromboembolic  complications  were  significantly  more  frequent  among  patients 
receiving  adjuvant  therapy  than  those  `observed  only'  following  surgery  in  a  review 
paper  summarising  results  from  seven  consecutive  adjuvant  studies  by  Saphner  et  al 
for  the  Eastern  Co-operative  Oncology  Group14'.  The  paper  seeks  to  subdivide  and 
group  the  studies  in  order  to  make  conclusions  about  the  impact  of  both  hormonal  and 
chemotherapeutic  treatment  alone  or  in  combination  on  the  development  of  arterial  or 
venous  complications  in  both  pre  and  post  menopausal  women. 
Arterial  thrombosis  occurred  in  the  same  frequency  in  both  pre  and  postmenopausal 
women.  Premenopausal  patients  receiving  chemotherapy  and  tamoxifen  developed 
significantly  more  venous  thrombi  than  patients  who  received  chemotherapy  without 
tamoxifen.  Premenopausal  patients  only  developed  arterial  thrombosis  when  on  this 
combined  regime.  Likewise  among  post  menopausal  patients  the  combination  of 
tamoxifen  and  chemotherapy  was  associated  with  a  significantly  higher  frequency  of 
venous  thrombosis  than  tamoxifen  alone.  Postmenopausal  patients  receiving  regimen 
with  tamoxifen  alone  or  in  combination  with  chemotherapy  did  not  experience 
different  levels  of  arterial  thrombosis  in  comparison  with  patients  on  observation  only. 
The  study  lacked  patients  in  sufficient  numbers  with  consistent  regimen  to  fully  assess 
the  impact  of  tamoxifen  alone  although  the  tamoxifen  placebo  controlled  trial 
included  in  the  review  suggests  a  rate  for  post  menopausal  women  of  1.2%  for  arterial 
events  and  2.3%  for  venous  events.  Post  menopausal  women  taking  placebo  in  this 
study  did  however  experience  a  very  high  rate  of  arterial  events  (4.8%)  by 
comparison.  Tamoxifen  appears  in  this  review  to  be  associated  with  only  a  marginally 
increased  risk  of  thrombosis.  The  rate  of  arterial  events  did  not  exceed  2.9%  in  any  of 
the  studies  which  included  tamoxifen.  Venous  events  ranged  from  1.4%  to  10.4% 
though  these  were  all  in  combination  with  chemotherapy. 
68 No  significant  toxic  effects  were  evident  in  a  study  reported  by  Fornander  et  al  of 
hospital  admissions  of  women  involved  in  the  Stockholm  Adjuvant  Tamoxifen  Trial 
though  the  median  follow  up  was  only  4.5  years  and  the  data  are  limited  in  detecting 
complications  that  do  not  result  in  a  hospital  visit.  Thromboembolic  events  were 
reported  in  2%  of  cases  in  both  the  tamoxifen  and  the  placebo  arm. 
The  study  by  Pritchard  and  Paterson  supports  the  finding  emerging  from  the  review 
study  described  above  that  the  major  risk  of  thromboembolism  for  women  with  breast 
cancer  occurs  primarily  with  combination  therapy.  In  a  randomised  trial  of  tamoxifen 
vs.  combination  therapy  the  authors  report  a  strikingly  high  incidence  of 
thromboembolic  events  of  13.6%  among  women  randomised  to  receive  chemotherapy 
with  tamoxifen  while  only  2.6%  of  women  in  the  tamoxifen  arm  experienced 
thromboembolism  of  any  sort.  Most  of  the  complications  including  a  number  of 
severe  effects  and  3  fatalities  occurred  during  chemotherapy.  The  authors  conclude 
that  the  relatively  common  and  serious  impact  of  thromboembolism  in  this  trial  may 
preclude  the  routine  use  of  combination  therapy  for  women  with  breast  cancer. 
Thromboembolism  resulted  in  26  hospitalisations  in  the  combination  arm  and  only 
three  in  the  tamoxifen  arm.  A  broad  definition  of  thrombotic  events  was  however  used 
in  this  study  and  superficial  phlebitis  was  included.  The  trial  used  30mg/day  of 
tamoxifen  which  is  a  high  dose  compared  with  that  used  in  most  other  adjuvant 
studies  and  in  prevention  trials. 
The  Early  Breast  Cancer  Triallists  Collaboration  have  recently  presented  an  updated 
overview  of  randomised  trials  of  adjuvant  tamoxifen  which  increases  substantially  the 
amount  of  information  available  on  long  term  use'.  The  review  reported  one  extra 
death  due  to  thromboembolism  per  5,000  woman  years  of  tamoxifen  use  though  this 
excess  was  not  statistically  significant.  No  thrombolic  events  were  reported  for 
women  under  50,  women  over  70  or  for  those  taking  tamoxifen  for  five  years  of 
treatment  or  more.  No  information  was  collected  on  non  fatal  thromboembolic 
effects. 
69 In  NSABP  P-1  there  was  a  significantly  increased  risk  of  pulmonary  embolism  for 
women  taking  prophylactic  tamoxifen.  Women  randomised  to  the  tamoxifen  group 
experienced  a  greater  number  of  both  pulmonary  embolism  (18  in  the  tamoxifen 
group  compared  with  six  in  the  placebo  group)  and  deep  vein  thrombosis  (35  versus 
22  cases)  compared  with  women  in  the  placebo  arm.  This  included  two  episodes  of 
fatal  pulmonary  embolism  in  women  randomised  to  taking  tamoxifen.  This  excess 
risk  occurred  primarily  in  women  aged  50  and  over.  The  increased  relative  risk  of 
pulmonary  embolism  was  almost  three  fold  for  women  on  tamoxifen  though  the 
absolute  risk  difference  for  all  thromboembolic  disease  reported  in  the  study  between 
the  control  and  intervention  ann  is  less  than  5  per  1000  women.  This  includes  both 
stroke  (34  cases  for  women  on  tamoxifen  and  24  in  the  control  arm)  and  transient 
ischaemic  attack  (TIA)  (18  for  women  on  tamoxifen  and  21  for  women  in  the  control 
arm)  with  99  events  in  total  for  women  on  tamoxifen  compared  with  70  in  the  placebo 
group. 
The  overall  relative  risk  of  thromboembolic  disease  was  less  than  two  for  women  on 
tamoxifen  compared  with  women  on  control.  The  result  is  similar  taking  deep  vein 
thrombosis  and  pulmonary  embolism  together  excluding  cerebrovascular  disease  and 
when  the  incidence  of  stroke  and  TIA  is  included.  A  similar  result  was  found  in 
findings  from  the  Royal  Marsden  study  144  with  a  relatively  low  incidence  of 
thromboembolic  events  but  an  increased  relative  risk  of  1.7  for  deep  vein  thrombosis 
and  pulmonary  embolism  in  the  tamoxifen  arm  compared  with  women  on  placebo. 
A  number  of  studies  have  sought  to  assess  the  biochemical  effects  of  tamoxifen  on  the 
haemostatic  system.  Decreases  in  antithrombin  III  -  which  inhibits  thrombin  and 
other  activated  clotting  factors  have  been  reported  in  patients  treated  with  tamoxifen 
for  advanced  disease  145  or  as  an  adjuvant  therapy  in  node  positive  breast  cancer 
although  these  have  not  been  recorded  to  the  levels  which  might  be  expected  to 
increase  the  frequency  of  blood  clotting.  Manucci  et  al  in  the  Italian  prevention  study 
146  published  results  of  heamostasis  and  lipid  measurements  on  the  first  68  consecutive 
women  enrolled  in  the  study  at  one,  two,  three  and  six  months  after  entry.  Tamoxifen 
induced  a  modest  non  significant  decrease  in  anticoagulant  proteins  though  there  were 
70 no  signs  of  activation  of  fibrinolysis  or  protein  markers  of  coagulation.  Other  studies 
have  also  demonstrated  a  decrease  in  levels  of  antithrombin  III  though  few  have  found 
changes  which  would  appear  to  have  clinical  significance 
Jones  and  Powles147  found  no  increase  in  fibrinogen  levels  which  would  be  associated 
with  an  increased  risk  of  thromboembolism  in  healthy  women  participating  in  the 
randomised  double  blind  prevention  trial  underway  at  the  Royal  Marsden  up  to  36 
months  after  recruitment  though  any  history  of  venous  thrombosis  or  pulmonary 
embolism  are  significant  exclusion  criteria  for  the  trial.  In  fact  for  both  pre  and  post 
menopausal  women  there  was  a  sustained,  significant  reduction  in  fibrinogen  levels 
over  the  first  year  of  follow  up.  There  was  no  reduction  in  antithrombin  III  for 
premenopausal  women  and  only  a  small  reduction  (less  than  10%)  in  postmenopausal 
women.  In  the  absence  of  positive  results  with  fibrinogen  and  antithrombin  III  the 
authors  measured  other  molecular  derivatives  involved  in  blood  coagulation, 
principally  Protein  C  and  Protein  S.  Inherited  deficiency  in  these  proteins  is 
associated  with  an  increased  incidence  of  deep  vein  thrombosis. 
The  study  found  a  marginal  reduction  in  Protein  S  at  six  months  though  not  at 
clinically  significant  levels  and  no  change  in  Protein  C.  The  authors  speculate  that  the 
increased  risk  of  thrombotic  events  associated  with  tamoxifen  use  may  be  due  to  an 
14s  inherited  tendency  in  patients  at  risk  of  breast  cancer  or  with  diagnosed  disease,  ýas 
The  increased  risk  for  women  taking  tamoxifen  as  adjuvant  therapy  may  be 
considered  acceptable  because  it  is  outweighed  by  the  beneficial  effect  of  tamoxifen 
on  disease  free  survival.  Further  research  is  needed  to  establish  whether  prior 
screening  for  congenital  clotting  disorders  is  likely  to  be  feasible  and  effective  for 
women  seeking  tamoxifen  prophylaxis,  especially  given  the  low  incidence.  In  any 
event  eligibility  criteria  should  continue  to  exclude  women  with  previous  history  of 
thromboembolic  disease. 
By  contrast  there  is  convincing  evidence  for  a  beneficial  effect  of  tamoxifen  on  risk 
factors  associated  with  cardiac  health.  In  general,  studies  conclude  that  the  favourable 
71 impact  of  tamoxifen  on  lipid  profiles  is  likely  to  translate  into  reduced  risk  of  both 
death  from  coronary  heart  disease  and  cardiac  morbidity  requiring  hospitalisation  or 
long  term  drug  treatment  149,150  This  relationship  has  however  been  more  thoroughly 
investigated  in  men  than  in  women.  Clinical  reports  and  case  studies  suggest  that  the 
change  in  lipid  profiles  for  women  taking  tamoxifen  may  be  mediated  by  the  drug's 
oestrogenic  effect  producing  a  reduction  in  total  serum  cholesterol  principally  due  to  a 
lowering  of  low  density  lipoprotein.  Follow  up  of  patients  mostly  in  studies  of 
adjuvant  tamoxifen  for  women  with  breast  cancer  suggest  that  the  reduction  in  mean 
total  serum  cholesterol  might  be  around  12%  with  a  lowering  of  LDL  cholesterol  of 
20%'5'  Such  an  effect  if  sustained  could  lead  to  an  anticipated  reduction  in  risk  of 
coronary  heart  disease  which  might  be  as  much  as  20%'S2. 
Lipids 
In  a  double  blind  randomised  trial  of  140  postmenopausal  women  who  were  disease 
free  after  primary  treatment  for  node  negative  breast  cancer,  Love"'  reported  a 
significant  decrease  of  12%  in  total  cholesterol,  largely  due  to  a  16%  reduction  in 
LDL  cholesterol  at  three,  six  and  12  months  of  follow  up.  There  was  a  also  a  small 
but  significant  reduction  in  HDL  cholesterol  which  might  be  expected  with  a 
reduction  in  total  cholesterol.  Powles  et  a!  "9  in  early  reports  from  the  UK 
chemoprevention  pilot  found  significant  reductions  of  around  15%  in  total  cholesterol 
and  reductions  in  LDL  cholesterol  in  both  pre  and  post  menopausal  women  after  two 
years  of  follow  up.  These  findings  were  confirmed  in  further  follow  up"  with  a  total 
of  400  women  with  the  addition  of  a  significant  reduction  in  apolipoprotein  B  in 
postmenopausal  women.  There  was  no  effect  on  HDL  cholesterol.  A  subgroup 
analysis  from  this  study152  found  a  13%  reduction  in  total  cholesterol  in  a  small  group 
of  women  who  were  also  taking  hormone  replacement  therapy. 
Studies  of  the  impact  of  lipid  lowering  on  coronary  heart  disease  suggest  that  the 
effect  is  related  to  both  the  extent  of  lipid  lowering  and  the  duration  of  the  effect.  The 
effect  appears  to  increase  with  duration  of  taking  tamoxifen  although  published 
reports  from  such  sub  group  analysis  is  limited""  54 
72 Few  studies  are  available  however  to  quantify  the  impact  of  tamoxifen  on  death  from 
coronary  heart  disease  or  on  cardiac  morbidity.  In  the  first  report  from  the  Early 
Breast  Cancer  Triallists  Collaboration  overview  of  adjuvant  trials  tamoxifen  was 
associated  with  reductions  of  25%  (SD13.2p=0.06)  in  deaths  from  vascular  causes24. 
Results  from  the  more  recent  longer  term  follow  up  of  these  randomised  trials'  were 
consistent  with  these  findings  though  the  difference  for  vascular  causes  was  not 
significant.  There  was  no  significant  difference  in  deaths  from  myocardial  infarction 
between  the  two  arms  of  the  trial.  Likewise  tamoxifen  administration  did  not  alter  the 
average  annual  rate  of  ischaemic  heart  disease  in  the  NSABP  P-12.  The  number  of 
women  who  had  a  myocardial  infarction  was  28  in  the  placebo  group  and  31  in  the 
tamoxifen  group.  There  was  no  significant  difference  in  fatality  between  the  placebo 
and  tamoxifen  group  with  7  and  8  deaths  respectively.  There  was  also  no  significant 
difference  in  reporting  of  cardiac  morbidity  between  the  two  groups  including  angina 
and  acute  ischaemic  syndrome. 
A  significant  reduction  (p<0.005)  in  the  incidence  of  fatal  myocardial  infarction  was 
also  demonstrated  in  the  Scottish  Adjuvant  Tamoxifen  Trial  although  there  was  no 
significant  difference  in  the  incidence  of  other  fatal  vascular  events  in  the  two  arms  of 
the  trial'55.  Of  200  deaths  in  the  tamoxifen  arm  (n=539)  ten  were  due  to  myocardial 
infarction  compared  with  25  out  of  251  deaths  in  the  control  arm  (n=531)  of  the  trial. 
This  38%  reduction  in  relative  risk  of  death  from  myocardial  infarction  was  measured 
after  a  mean  duration  of  29  months  (9-93)  with  tamoxifen  taken  at  a  dose  of  20  mg 
daily.  The  results  may  underestimate  the  effect  since  the  non  intervention  arm  of  the 
study  included  some  women  who  crossed  over  to  taking  tamoxifen  on  relapse. 
Further  follow  up  of  this  trial  population  using  record  linkage  with  the  inpatient 
record  scheme  at  the  Scottish  Home  and  Health  Department  found  statistically 
significant  differences  between  the  rate  of  admission  to  hospital  for  women  taking 
tamoxifen  and  those  in  the  control  arm  of  the  trial  with  a  hazard  ratio  2.03  (1.05  - 
3.92,  p=0.033)  for  myocardial  infarction.  The  effect  was  greatest  in  current  users  of 
tamoxifen  suggesting  that  the  protective  effect  may  diminish  once  treatment  stops'56 
73 These  results  are  consistent  with  studies  showing  that  the  reduction  in  serum 
cholesterol  and  LDL  cholesterol  is  greatest  in  current  users  than  in  former  and  non 
users  of  tamoxifen'sa  Some  non  significant  reduction  in  the  incidence  of  other  cardiac 
ischaemic  episodes  was  also  seen  in  this  study. 
A  significant  reduction  in  overall  cardiac  morbidity  in  women  taking  a  daily  40mg 
dose  of  tamoxifen  as  adjuvant  therapy  was  shown  by  the  Stockholm  Breast  Cancer 
Study  Group15'.  The  confidence  intervals  are  too  wide  to  offer  a  convincing  effect  for 
specific  cardiac  causes;  there  is  a  significant  reduction  in  relative  hazard  of 
admissions  for  MI  (0.68  0.48-0.97)  and  a  trend  towards  reduction  for  angina  pectoris 
as  well  as  other  forms  of  ischaemic  heart  disease  such  as  congestive  heart  failure  and 
myocardial  ischaemia.  This  study  did  however  show  a  statistically  significant  benefit 
in  terms  of  cardiac  morbidity  for  longer  duration  of  treatment  with  patients  treated  for 
five  rather  than  two  years.  There  was  a  significant  decrease  of  admissions  due  to  any 
cardiac  disease  in  the  five  year  group  (relative  hazard,  0.37,0.15-0.92  p=0.03).  The 
authors  conclude  that  longer  follow  up  is  needed  to  determine  whether  this  benefit 
will  be  translated  into  a  significant  reduction  in  cardiac  mortality. 
In  the  context  of  chemoprevention  of  breast  cancer  for  women  at  high  risk  the  impact 
of  tamoxifen  on  mortality  from  coronary  heart  disease  may  be  at  least  as  important  as 
the  reduction  in  risk  from  breast  cancer'  12  5'  Among  women  at  high  risk  for  breast 
cancer  the  probability  of  death  from  breast  cancer  relative  to  death  from  other  causes 
decreases  with  time;  mortality  from  coronary  heart  disease  particularly  ischaemic 
heart  disease  becomes  of  far  greater  significance. 
Bones 
Because  of  its  oestrogenic  properties  it  is  assumed  that  tamoxifen  may  have  a 
beneficial  effect  on  the  rate  of  bone  loss  in  post  menopausal  women.  Studies  in 
postmenopausal  women  taking  tamoxifen  have  found  positive  changes  in  bone 
activity  markers  and  in  general  a  significant  increase  in  bone  mineral  density  (BMD). 
The  clinical  significance  of  these  changes  in  terms  of  reduced  fracture  risk  or 
74 mortality  is  less  clear  though,  it  is  unlikely  from  present  evidence  that  the  effect  will 
be  deleterious.  The  NSABP  P-1  recorded  fracture  rate  and  reported  a  significant 
reduction  in  hip  fractures  for  women  taking  prophylactic  tamoxifen.  The  effects  of 
tamoxifen  on  premenopausal  women  is  more  difficult  to  discern  because  the  numbers 
of  younger  women  included  in  studies  is  small.  Some  authors  have  expressed  concern 
that  tamoxifen  may  antagonise  oestrogen  in  premenopausal  women  leading  to  bone 
loss15'. 
A  number  of  adjuvant  studies  have  included  an  assessment  of  the  impact  of  tamoxifen 
treatment  on  bone  mineral  density.  In  general,  even  where  studies  have  been  unable 
to  demonstrate  a  reduction  in  the  rate  of  bone  loss  in  postmenopausal  women  the 
effect  has  been  one  of  no  difference  in  comparison  with  women  in  control  groups 
rather  than  of  an  acceleration  in  bone  loss160"161162.  A  study  of  the  interaction  between 
HRT  use  and  tamoxifen  use  also  concluded  that  there  were  no  adverse  effects  in 
postmenopausal  women.  152 
Larger  and  better  controlled  studies  have  on  the  whole  shown  an  increase  in  bone 
mineral  density  in  postmenopausal  women  taking  tamoxifen  of  the  order  of  1.5%  per 
year  compared  with  -  as  expected  -a  loss  of  bone  mineral  density  in  control  groups. 
In  a  randomised  study  of  140  postmenopausal  women  with  breast  cancer  taking  either 
20mg  daily  of  tamoxifen  or  placebo,  Love  et  al  found  strong  evidence  for  a  significant 
reduction  in  the  rate  of  bone  loss  in  the  lumbar  spine  in  tamoxifen  treated  women"'. 
There  was  no  similar  effect  in  comparison  with  the  placebo  group  on  radial  bone; 
bone  mineral  density  in  both  the  tamoxifen  and  placebo  group  declined  over  the  two 
years  of  measurement.  Assessments  of  bone  mineral  density  in  the  femur  were  not 
made  and  there  was  no  assessment  of  the  impact  on  long  term  fracture  rate.  The 
authors  conclude  that  tamoxifen  is  an  anti  -  resorptive  agent  affecting  those  bone  sites 
normally  affected  by  oestrogen.  The  3%  increase  -  in  bone  mineral  density,  over  the 
two  year  follow  up,  found  in  this  study  -  even  after  correcting  for  menopausal  status 
at  the  time  of  diagnosis  of  breast  cancer  in  the  lumbar  spine,  is  within  the  range  seen 
with  agents  commonly  prescribed  for  oestrogen  replacement  therapy. 
75 Results  from  a  40  month  follow  up  of  women  enrolled  in  the  Marsden  tamoxifen 
prophylaxis  pilot  found  no  effect  on  bone  mineral  density  in  the  forearm  for  women  in 
the  tamoxifen  arm  of  the  study  even  where  postmenopausal  women  only  were 
considered14°.  Results  of  BMD  in  the  lumbar  spine  and  hip  did  however  show  an 
effect  of  tamoxifen  and  are  discussed  below.  The  same  effect  from  forearm 
measurement  was  found  in  75  women  enrolled  in  the  Swedish  tamoxifen  trial  after 
either  two  or  five  year  follow  up"'.  Forearm  measurement  of  bone  mineral  density 
showed  no  significant  differences  for  women  randomised  to  tamoxifen  in  the 
treatment  arm  compared  with  control  even  at  the  high  dose  of  40mg  daily. 
Evidence  on  the  longer  term  impact  of  tamoxifen  is  available  from  a  five  year 
assessment  of  62  of  the  original  subjects  by  Love  et  al165.  This  study  confirmed  the 
increase  in  bone  mineral  density  in  post  menopausal  women  taking  tamoxifen  though 
with  no  significant  further  increase  from  the  two  year  level.  Further  assessment  of 
longer  term  effects  are  reported  by  Cuzick  and  Baum142  reviewing  a  wide  range  of 
biological  markers  including  measures  of  bone  mineral  density  in  the  spine  and 
trochanter  of  both  current  and  ex  -  users  of  tamoxifen.  73  ex  -  users  were  compared 
with  60  controls;  the  median  follow  up  was  seven  years.  Bone  mineral  density  was 
about  11%  higher  among  current  users  compared  with  both  ex  -  users  and  controls  and 
the  effect  was  greater  in  postmenopausal  women.  None  of  the  differences  achieved 
significance  though  the  consistent  difference  between  current  users  compared  with 
both  ex  -  users  and  control  suggests  that  the  effect  of  tamoxifen  may  be  lost  with 
cessation  of  use.  Measurements  were  not  made  on  21  of  the  women  in  this  study  and 
the  number  of  premenopausal  women  included  was  too  small  for  subgroup  analysis. 
Significant  results  were  found  in  an  analysis  of  bone  mineral  density  made  in  the 
lumbar  spine  and  femur  over  three  years  for  women  enrolled  in  the  Royal  Marsden 
Prevention  pilot  as  discussed  earlier144.  In  premenopausal  women,  BMD  in  the  lumbar 
spine  decreased  progressively  and  was  significantly  lower  than  pre-treatment  values  at 
year  one  (n=49),  year  two  (n=32)  and  year  three  (n=19).  Overall,  there  was  a  loss  of 
BMD  in  the  lumbar  spine  of  1.44%  per  year  for  women  in  the  tamoxifen  group 
compared  with  a  small  gain  of  0.24%  per  year  for  premenopausal  women  on  placebo. 
76 At  the  hip  there  was  a  significant  loss  of  BMD  in  premenopausal  women  in  the 
tamoxifen  group  compared  with  baseline  values  by  the  third  year  and  compared  with 
the  placebo  group  by  the  second  and  third  years.  For  postmenopausal  women  taking 
tamoxifen  compared  with  placebo  there  was  a  significant  increase  in  BMD  at  both  the 
hip  (average  annual  increase  of  1.71  %)  and  the  lumbar  spine  (average  annual  increase 
of  1.17%)  mostly  occurring  in  the  first  year  of  treatment.  Larger  studies  are  needed  to 
confirm  the  results  for  premenopausal  women.  For  postmenopausal  women  taking 
tamoxifen  there  appears  to  be  a  consistent  effect  increasing  bone  mineral  density  by 
an  annual  average  of  1.5%  though  the  long  term  duration  of  this  effect  and  its  clinical 
significance  are  not  properly  understood. 
Quantifying  risks  and  benefits  of  chemoprophylaxis 
Few  authors  have  been  able  to  quantify  the  health  benefits  and  costs  of 
chemoprevention  for  breast  cancer  in  terms  of  life  expectancy  or  in  terms  of  costs  in 
relation  to  life  years  gained  because  of  the  lack  of  information  on  efficacy  or  costing 
from  randomised  controlled  trials  or  observational  studies.  Broad  theoretical 
estimates  derived  from  the  rationale  for  the  NSABP  P-1  trial  have  been  attempted  by 
Nease  and  Ross'2.  Based  on  a  50  year  old  woman  with  a  breast  cancer  risk  twice  that 
of  the  average  woman  her  age  they  argue  that  prophylaxis  with  tamoxifen  offers  an 
increase  in  life  expectancy  of  about  nine  days.  This  estimate  is  based  on  decision 
analysis  which  accounts  for  increased  relative  risks  of  non  fatal  endometrial  cancer 
and  of  death  from  thromboembolism  of  2.4  and  3.5  respectively  -  and  beneficial 
effects  on  risk  of  death  from  myocardial  infarction  and  hip  fracture  of  0.2  and  0.25. 
Risk  of  mortality  from  breast  cancer  is  estimated  to  reduce  by  35%.  These  results  are 
in  line  with  findings  from  Cuzick126  who  estimated  a  slightly  higher  result  of  40% 
reduction  in  breast  cancer  incidence,  the  same  level  as  for  ischaemic  heart  disease  risk 
with  slightly  greater  benefits  on  bone  (reduction  of  spinal  fractures  by  33%)  with  a 
lower  adverse  effect  on  thromboembolic  disease  (approximately  two  fold  increase). 
Such  a  modest  net  improvement  in  health  is  clearly  dependant  on  the  estimates  used 
for  comparative  relative  risks  between  detrimental  and  beneficial  effects  and  widely 
77 differing  conclusions  arise  from  relatively  small  changes  in  the  assumptions.  No 
account  is  taken  in  this  model  of  changes  in  quality  of  life  or  other  non  life  threatening 
conditions  or  of  the  weight  to  be  attached  to  changes  in  risk  of  death  from  different 
causes.  The  changes  discussed  in  this  study  include  changes  in  mortality  from 
myocardial  infarction,  thromboembolic  causes,  hip  fracture  and  breast  cancer  and 
nonfatal  changes  in  risk  of  endometrial  cancer.  Estimates  of  reduction  in  risk  of 
mortality  from  ischaemic  heart  disease  are  inferred  from  a  number  of  authors  who 
report  beneficial  effects  of  tamoxifen  on  lipid  profiles.  The  findings  from  the 
Scottish  Adjuvant  Trial  discussed  above  suggest  a  reduction  in  risk  of  myocardial 
infarction  of  20%. 
They  use  weaker  evidence  to  derive  estimates  of  changes  in  hip  fracture  mortality. 
Assumptions  are  based  on  studies  of  changes  in  the  bone  mineral  density  of  women 
on  tamoxifen  though  no  studies  have  found  any  conclusive  evidence  of  a  direct  impact 
of  tamoxifen  on  fracture  risk  let  alone  mortality.  Nease  and  Ross  also  assume  that 
tamoxifen  will  be  at  least  as  half  as  effective  as  oestrogen  in  relation  to  hip  fracture 
risk  in  postmenopausal  women  though  present  little  evidence  for  this  view.  Since  the 
relationship  between  oestrogen  use,  hip  fracture  risk  and  mortality  from  hip  fracture  is 
extremely  unclear  the  assumption  of  a  reduction  in  fracture  risk  of  25%  for  all  women 
on  tamoxifen  is  unsupported. 
The  significance  of  the  change  in  risk  of  death  from  endometrial  cancer  may  be 
regarded  as  of  less  importance  in  relation  to  beneficial  effects  on  breast  cancer  risk 
since  the  absolute  risk  of  death  from  endometrial  cancer  is  low.  Increased  risk  of 
thromboembolic  disease  are  well  documented  in  women  taking  tamoxifen  and  Nease 
and  Ross  take  their  estimate  from  published  studies  showing  an  increase  in  the  range 
of  3-4  fold  relative  risk.  Estimates  of  reduction  in  risk  of  breast  cancer  mortality  of 
35%  are  taken  from  the  early  work  of  the  Early  Breast  Cancer  Triallists  Collaboration 
and  from  the  projections  set  out  in  the  rationale  for  the  NSABP  P-1  Breast  Cancer 
Prevention  Trial.  This  is  in  line  with  some  of  the  early  findings  from  breast  cancer 
chemoprevention  studies. 
78 The  analysis  from  Nease  and  Ross  highlights  the  importance  of  baseline  risk  of  breast 
cancer,  the  effects  of  tamoxifen  on  breast  cancer  mortality  and  the  effects  of 
tamoxifen  on  cardiovascular  mortality  in  determining  cost  effectiveness  of 
chemoprevention.  The  importance  of  the  effect  on  cardiovascular  mortality  can  be 
further  illustrated  by  reference  to  an  English  health  district  population.  Prevention 
trials  in  general  target  women  at  increased  relative  risk  of  breast  cancer.  For  a 
hypothetical  population  of  400,000  women  say  between  the  ages  of  35  and  69  around 
10%  might  be  expected  to  be  at  3  or  4  fold  relative  risk  of  breast  cancer  with  an 
absolute  lifetime  risk  of  between  20  and  30%.  This  would  give  rise  to  between  800 
and  1200  cases  of  breast  cancer.  If  the  impact  of  tamoxifen  prophylaxis  were  to 
reduce  the  risk  of  breast  cancer  by  30  to  50%  a  range  of  266  to  600  cases  might  be 
prevented.  Any  adverse  impact  of  tamoxifen  on  serum  lipids  however  would  have  to 
be  only  relatively  small  to  offset  this  benefit.  The  average  50  year  old  women  has  a 
lifetime  risk  of  coronary  heart  disease  of  about  45% 
. 
Increasing  the  absolute  lifetime 
risk  by  1%  for  the  high  risk  group  would  result  in  an  additional  400  cases  of  coronary 
heart  disease.  An  increase  of  2%  would  considerably  outweigh  the  numbers  of  breast 
cancer  cases  prevented.  It  has  been  argued  that  the  latitude  over  cardiovascular 
disease  effects  is  small  and  that  even  a  change  in  relative  risk  from  1  to  1.03  would  be 
sufficient  to  abolish  any  beneficial  effects  of  tamoxifen149. 
Nevertheless,  it  seems  clear  that  tamoxifen  reduces  the  hazard  of  cardiovascular 
events.  A  number  of  authors  have  shown  that  effects  on  lipid  profiles  occur  within  2 
weeks  of  first  taking  tamoxifen  and  although  the  levels  appear  to  return  to  normal 
after  stopping  the  benefits  may  persist15'.  Cuzick  et  al'45  point  out  that  as 
cardiovascular  benefit  is  cumulative  any  period  of  lowered  cholesterol  may  translate 
into  long  term  benefits  on  risks  of  cardiovascular  events.  The  feasibility  of 
chemoprevention  for  breast  cancer  relies  on  a  neutral  or  beneficial  impact  on 
cardiovascular  risk  for  any  potential  pharmacological  agent.  Subgroup  analysis  is  also 
clearly  important  in  this  regard  since  women  taking  HRT  and  women  at  different 
menopausal  status  may  experience  different  effects  of  an  oestrogen  agonist  on  lipid 
profiles. 
79 Economics  of  tamoxifen  chemoprophylaxis 
In  an  economic  analysis  of  chemoprevention  in  Australia,  Butler"  uses  the  estimates 
from  the  Nease  and  Ross  model  described  above  to  derive  possible  values  for  the  cost 
per  life  year  gained  for  tamoxifen  prophylaxis.  Leaving  discounting  aside  and  basing 
his  calculations  only  on  costs  for  tamoxifen  over  five  years,  costs  of  treating  an 
increased  incidence  of  endometrial  cancer  and  savings  from  both  a  reduced  incidence 
of  breast  cancer  and  myocardial  infarction  and  from  discontinuation  of  HRT  -a 
requirement  of  the  USA  trial  -  Butler  concludes  that  the  net  cost  of  treatment  over  five 
years  is  around  $2,500  of  which  the  cost  of  tamoxifen  has  the  greatest  impact  on 
overall  cost.  The  most  significant  savings  in  the  Butler  analysis  come  from 
discontinuation  of  HRT  by  women  taking  tamoxifen.  The  estimates  for  expected 
change  in  the  resource  intensive  outcomes  reviewed  come  from  the  NSABP  P-1. 
Taking  an  18  day  gain  in  life  expectancy  from  the  study  set  out  by  Nease  and  Ross  but 
not  including  the  prospect  of  being  randomised  to  a  non  tamoxifen  arm,  Butler  goes 
on  to  conclude  that  the  cost  per  life  year  saved  is  over  $50,000  (£31,250).  If  the 
higher  USA  costs  of  tamoxifen  are  included  then  the  overall  cost  per  year  of  life 
gained  rises  to  over  $100,000  (£62,500).  Increasing  the  relative  risk  of  women 
exposed  to  the  preventive  intervention  reduces  the  cost  per  year  of  life  saved.  For  a  50 
year  old  women  at  5x  average  risk,  for  example,  the  estimate  falls  to  around  $43,000 
(£26,875)  per  year  of  life  gained. 
Different  assumptions  underpin  IBIS.  Firstly  the  costs  of  tamoxifen  in  the  UK  and  the 
rest  of  Europe  is  considerably  lower  than  in  the  USA  since  patent  restrictions  on 
pricing  no  longer  apply.  Secondly  discontinuation  of  HRT  is  not  a  requirement  in  the 
UK  study  and  so  the  substantial  savings  estimated  for  the  NSABP  P-1  are  not 
relevant.  Finally  estimates  for  both  the  incidence  of  endometrial  cancer  and  the  cost 
of  treatment  are  high  in  relation  to  the  change  in  event  rate  of  breast  cancer  and  the 
associated  costs. 
80 Broad  costs  of  chemoprevention  for  breast  cancer  looking  solely  at  the  cost  of 
tamoxifen  in  the  UK  study  are  around  £  120  over  5  years  or  £24  per  women  per  year 
taken  at  a  dose  of  20mg/day.  If  the  2%  absolute  risk  reduction  in  incidence  of  breast 
cancer  found  in  the  NSABP  P-1  applies  to  the  women  recruited  to  IBIS  then  the  cost 
per  tumour  prevented  is  around  £6,000.  The  costs  in  this  simple  calculation  are  based 
solely  on  the  costs  of  tamoxifen.  They  illustrate  that  the  cost  of  chemoprevention  will 
be  affected  by  the  costs  of  delivering  the  preventive  agent  to  the  number  of  women 
who  need  to  be  treated  in  order  to  prevent  one  breast  cancer  (NNT)  and  the  cost  of 
treating  side  effects  in  relation  to  the  unit  of  effect  for  those  who  do  benefit. 
More  precise  estimates  at  the  cost  of  morbidity  due  to  long  term  tamoxifen  use  are 
developed  in  Chapters  4  and  5.  Morbidity  of  women  enrolled  in  IBIS  is  measured  in 
terms  of  changes  in  use  of  hospital  services  or  prescribed  medications  respectively  for 
women  in  the  2  arms  of  the  trial  (taking  tamoxifen  or  control). 
The  following  chapter  makes  conclusions  about  the  likely  range  of  costs  involved  in 
delivering  a  service  for  tamoxifen  chemoprophylaxis.  These  are  based  on  estimates  of 
the  costs  of  running  clinics  for  women  enrolled  in  IBIS.  Directly  related  research  costs 
are  not  included. 
Summary  and  Conclusions 
The  rationale  for  tamoxifen  chemoprophylaxis  comes  from  the  mode  of  action  of 
tamoxifen  both  as  an  antioestrogen  in  suppressing  carcinogenesis  but  also  a  possible 
effect  on  preventing  the  development  of  neoplastic  agents.  Clinical  adjuvant  studies 
have  shown  a  reduction  in  the  incidence  of  new  contralateral  breast  cancers  with 
apparently  low  overall  toxicity  from  the  drug. 
Tamoxifen  has  been  seen  as  the  front  line  treatment  for  breast  cancer  since  the  early 
1970s  and  a  number  of  important  studies  are  available  to  assess  long  term  outcome 
including  time  to  recurrence  and  5  year  survival.  Many  of  these  studies  have  reported 
on  serious  side  effects  of  the  drug  such  as  deep  vein  thrombosis  &  pulmonary 
81 embolism  and  endometrial  cancer.  As  a  result  long  term  breast  cancer  adjuvant 
studies  are  useful  in  providing  information  on  the  safety  of  trials  for  tamoxifen 
prophylaxis  but  more  detailed  studies  are  needed  to  assess  the  effect  of  long  term 
exposure  to  tamoxifen  for  chemoprevention  of  breast  cancer  in  healthy  asymptomatic 
women. 
Evidence  for  the  impact  of  tamoxifen  on  levels  of  morbidity  which  may  have 
consequences  for  use  of  health  services  is  scanty  both  in  adjuvant  studies  and 
prevention  trials.  Yet,  the  impact  of  tamoxifen  on  general  health  and  well  being  may 
be  the  key  factor  in  deciding  its  use  for  prophylaxis  once  efficacy  has  been 
established.  Moreover  detailed  information  on  the  resource  implication  for  the  health 
service  is  needed  prior  to  the  introduction  of  an  intervention  which  may  have 
widespread  use. 
Acute  toxicity  of  tamoxifen  is  low  and  prolonged  exposure  in  adjuvant  studies  does 
not  appear  to  result  in  adverse  effects  on  coronary  heart  disease  or  bone  mineral 
density  despite  its  anti  -  oestrogenic  properties.  In  fact,  where  serum  levels  of  lipids 
and  lipoproteins  have  been  monitored  tamoxifen  appears  to  have  an  oestrogenic  effect 
improving  the  lipid  profile.  Various  oestrogen  -  like  effects  of  tamoxifen  do  however 
appear  to  produce  premature  or  recurrent  menopausal  symptoms. 
Evidence  from  adjuvant  studies  suggests  that  the  increase  in  persistent  general 
gynaecological  effects  from  long  term  tamoxifen  use  may  be  around  a  25%  increase  in 
symptoms  sufficient  to  have  an  impact  on  psychological  well  being.  Symptoms  may 
well  be  underreported  in  adjuvant  studies  or  more  likely  to  be  tolerated  by  patients 
than  might  be  expected  in  a  healthy  population. 
There  are  concerns  about  an  increase  in  the  relative  risk  of  endometrial  cancer  for 
women  taking  adjuvant  tamoxifen.  This  effect  appears  to  be  dose  and  duration 
dependant.  For  women  receiving  adjuvant  tamoxifen  at  a  dose  of  20mg  per  day  the 
relative  risk  appears  to  be  between  two  and  three  fold.  Estimates  from 
chemoprevention  studies  are  now  as  high  as  a  five  fold  increase  though  the  former 
82 may  be  explained  by  the  high  number  of  hysterectomies  at  baseline  for  women 
enrolled  in  the  NSABP  P-1.  The  median  cumulative  dose  of  tamoxifen  needed  before 
diagnosis  of  endometrial  cancer  estimated  from  the  Stockholm  Trial  was  29g.  This 
level  would  be  reached  after  four  years  of  treatment  with  a  daily  intake  of  20mg. 
There  is  both  clinical  and  biochemical  evidence  of  an  increased  risk  of 
thromboembolic  events  in  women  taking  tamoxifen.  The  effect  is  clearly  complex 
and  multifactorial  influenced  also  in  adjuvant  studies  by  the  presence  of  disease  and 
the  impact  of  chemotherapy.  The  relative  risk  for  women  taking  tamoxifen  alone 
either  as  an  adjuvant  therapy  or  for  prophylaxis  may  be  between  three  and  five  fold 
although  was  less  than  two  for  all  thromboembolic  disease  in  the  NSABP  P-1.  The 
relative  risk  appears  to  increase  when  tamoxifen  is  taken  in  combination  with 
chemotherapy  with  implications  for  treatment  options;  the  effect  is  greater  in 
postmenopausal  women. 
In  terms  of  benefits  of  tamoxifen  chemoprophylaxis,  the  impact  of  long  term  exposure 
to  tamoxifen  on  cardiac  health  may  be  at  least  as  important  as  the  end  point  of  primary 
breast  cancer  reduction.  Consistent  findings  of  an  effect  on  lipid  lowering  may  give 
rise  to  a  relative  protective  effect  of  tamoxifen  on  mortality  from  myocardial 
infarction  of  around  2.0  though  the  recent  updated  overview  of  randomised  trials  of 
adjuvant  therapy  among  women  with  early  breast  cancer  showed  no  significant 
difference  in  the  aggregate  of  all  cardiac  or  vascular  deaths  after  about  five  years  of 
tamoxifen.  The  long  term  impact  on  cardiac  morbidity  in  general  is  unclear  and  will 
require  further  research  to  establish  fully.  The  precise  duration  of  the  effect  after 
cessation  of  tamoxifen  treatment  is  also  uncertain. 
The  impact  of  tamoxifen  on  bone  mineral  density  in  postmenopausal  women  seems  to 
be  an  increase  primarily  in  the  lumbar  spine  and  hip  by  an  annual  increment  of  around 
1.5%  though  this  increase  appears  to  occur  only  during  the  early  years  of  tamoxifen 
use.  Some  evidence  also  suggests  that  the  protective  effect  on  BMD  may  be  lost  after 
cessation  of  use  and  similar  effects  on  radial  bones  appear  doubtful.  Larger  studies 
are  needed  to  confirm  the  reduction  in  bone  mineral  density  in  premenopausal  women 
83 suggested  in  results  from  the  Royal  Marsden  prevention  pilot  and  to  assess  both  the 
duration  of  this  effect  and  the  clinical  significance. 
Estimates  of  the  likely  reduction  in  risk  of  death  from  breast  cancer  with 
chemoprevention  have  been  predicted  from  adjuvant  studies  where  a  review  of  long 
term  follow  up  has  shown  a  consistent  improvement  of  around  50%  in  ten  year 
survival  with  use  of  tamoxifen  after  surgical  resection  of  disease.  Consistent  with  this 
finding,  NSABP  P-1  found  a  49%  reduction  in  risk  of  invasive  breast  cancer  in 
healthy  women  taking  tamoxifen.  This  has  not  been  confirmed  by  the  publication  of 
two  further  preliminary  reports  from  chemoprevention  studies.  Differences  in  the 
study  populations  may  may  be  responsible  for  these  contrary  findings. 
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Cost  of  delivering  tamoxifen  chemoprophylaxis  (using  the  pattern  of  work  and 
models  of  service  delivery  in  IBIS  centres). 
Introduction 
This  section  sets  out  a  range  of  likely  costs  for  delivering  a  service  for 
chemoprevention  of  breast  cancer  with  tamoxifen.  The  costs  are  based  on  the  process 
for  care  established  within  the  International  Breast  Cancer  Intervention  Study.  (IBIS)' 
A  distinction  is  made  between  those  costs,  which  should  be  primarily  attributed  to 
service  delivery  within  the  NHS  and  those  which  derive  primarily  from  the  research 
protocol.  These  issues  are  discussed  with  conclusions  drawn  about  possible 
alternative  models  for  service  delivery  should  tamoxifen  prophylaxis  prove  to  be 
effective  in  reducing  incidence  and  mortality  from  breast  cancer. 
Method 
A  number  of  models  of  care  have  emerged  in  establishing  IBIS  within  existing  routine 
breast  care  services.  These  probably  represent  the  range  of  options  for  any  future 
development  of  preventive  care  for  women  at  high  risk  for  breast  cancer  though  the 
structure  and  function  of  the  IBIS  centres  has  arisen  largely  from  expedience  in  each 
of  the  host  services  -  fitting  a  research  trial  alongside  busy  breast  care  services  - 
rather  than  with  the  economic  aim  of  aim  of  maximising  the  efficiency  of  service 
provision.  Information  about  costs  are  derived  both  from  a  survey  sent  to  each  of  the 
centres  and  followed  up  through  telephone  discussion  as  well  as  direct  observation  on 
10  occasions  in  4  centres.  Additional  information  was  obtained  from  the  IBIS  co- 
ordinator. 
Costing  information  is  derived  from  national  pay  scales  and  standard  costs  for  drugs 
and  tests.  Comparisons  are  made  between  the  different  possible  models  of  care  for 
delivering  tamoxifen  chemoprophylaxis  based  on  approaches  used  in  IBIS  centres. 
85 Centres  and  settings  for  IBIS 
At  1  April  1997,  there  were  in  the  UK  16  centres  involved  in  the  IBIS  trial  with  a  total 
accrual  of  1,917  women.  The  rate  of  women  attending  the  centres  who  are  not 
subsequently  randomised  into  the  trial  is  low  although  considerable  time  can  be  spent 
by  discussing  the  trial  with  women  who  choose  not  to  be  randomised. 
Table  1  shows  the  number  of  sessions  per  week  run  in  each  of  the  centres  and  the 
setting  in  which  women  recruited  to  the  trial  are  seen. 
Table  1  Sessions  /week  and  settings  of  IBIS  Centres 
Centres  Sessions  per  week  setting 
Aberdeen  I  ibis* 
Belfast  0.25  th** 
B'mingham  I  fig 
Bristol  3  g.  brst***/th 
Cardiff  3  g.  brst/fh 
Chelmsford  I  ibis 
Edinburg'  I  ibis 
Glasgow  I  ibis 
Guys  3  ibis 
H'dersfield  I  ibis 
Leeds  I  g.  brst 
Leicester  I  fh 
Manchester  I  th 
Newcastle  I  fh 
Nottingham  I  fh 
S'hampton  I  ibis 
Total  21.25 
Mean/week  1.33 
*  refers  to  standalone  clinic 
**  refers  to  IBIS  clinic  integrated  into  the  family  history  clinic 
***refers  to  IBIS  clinic  integrates  with  general  breast  outpatient  clinic 
86 In  general  centres  run  one  IBIS  session  per  week  though  there  are  three  possible 
sessions  in  Bristol,  Cardiff  and  at  Guys  with  one  each  month  in  Belfast.  In  at  least  six 
out  of  the  16  IBIS  centres  women  recruited  to  the  trial  are  seen  within  family  history 
clinics  (fh);  in  Cardiff  and  Bristol  two  further  sessions  are  held  alongside  general 
breast  care  clinics(g,  brst).  In  the  remaining  six  centres  IBIS  clinics  have  been 
established  as  standalone  sessions  though  working  closely  with  and  receiving  referrals 
from  the  main  breast  care  clinics.  In  Aberdeen  and  Chelmsford  the  IBIS  clinics  are 
sited  within  the  breast  screening  unit. 
A  broad  range  of  staff  are  involved  in  running  IBIS  clinics.  Doctors  involved  are 
usually  surgeons  involved  in  examining  women  prior  to  their  recruitment  to  the  trial. 
Consultant  radiologists  and  geneticists  are  also  closely  involved.  A  number  of  the 
centres  have  the  close  involvement  of  clinical  assistants  or  associate  specialists  who 
may  also  be  involved  in  supporting  clinics  in  other  parts  of  the  breast  care  service 
particularly  family  history  clinics.  Nurses  working  in  IBIS  are  for  the  most  part  F  or 
G  grade  nurses  usually  with  a  breast  care  qualification.  A  number  of  the  nurses 
involved  are  also  qualified  in  research.  IBIS  sessions  in  general  run  with  a  1:  1  doctor 
to  nurse  ratio  with  other  specialist  advice  available  where  needed. 
The  rate  of  recruitment  was  lower  than  anticipated  in  all  of  the  centres  with  the 
possible  exception  of  Bristol  which  has  the  highest  total  number  of  women  enrolled 
into  IBIS  and  the  highest  rate  of  accrual  of  new  recruits.  Table  2  shows  the  average 
number  of  new  women  recruited  to  each  of  the  centres  and  the  average  number  of 
women  attending  for  follow  up  visits  per  week. 
Table  2:  Numbers  of  new  and  follow  up  attendance's/week  in  IBIS  Centres 
Centres 
Aberdeen  2.2  8 
Belfast  1.5  1.5 
Birmingham  3  6.5 
Bristol  2.5  8.5 
Cardiff  2  6 
Chelmsford  1  1.5 
Edinburgh  1.5  5 
87 Glasgow  3  3 
Guys  2.5  12 
Huddersfield  0.5  3.5 
Leeds  I  1 
Leicester  0.25 
Manchester  1.5  13.5 
Newcastle  0.25  3.5 
Nottingham  1  3 
Southampton  2.5  6.5 
Total  26.2  84 
Mean/week  1.64  5.25 
An  average  of  around  1.6  new  women  are  seen  per  week  with  a  range  of  0.25-2.5 
depending  on  the  size  of  the  clinic.  Although  the  time  involved  in  seeing  women  for 
follow  up  visits  is  considerably  less  than  that  for  new  recruits  the  follow  up  visits 
represent  a  considerable  workload  for  the  centres  because  of  the  numbers  and  total 
amount  of  time  involved.  The  average  number  of  follow  up  visits  per  week  is  5.25 
with  a  range  of  1-13.5  depending  on  how  long  the  centre  has  been  running. 
Women  are  seen  2x  per  year  according  to  the  schedule  set  out  in  the  IBIS  protocol. 
The  time  spent  with  new  recruits  varies  between  the  centres  though  is  on  average 
about  3x  higher  for  new  visits  than  for  follow  up  visits.  Table  3  shows  the  estimated 
mean  time  spent  with  women  on  the  first  and  subsequent  visits  across  all  centres. 
Table  3:  Time  (mins)  spent  with  patients  (mean  (std  dev)) 
New  Visits  Follow  up  visits 
Dr  23(16)  5(4) 
Nurse  36(28)  14(9) 
Total  59(44)  19(13) 
At  the  initial  visit  the  trial  is  discussed  with  the  woman  and  any  questions  answered  in 
detail  either  by  the  nurse  or  the  doctor  depending  on  the  usual  practice  in  the  centre. 
In  most  centres  initial  enquiries  about  the  trial  are  made  outwith  the  clinic  session  and 
the  time  involved  is  not  included  here  since  it  does  not  relate  directly  to  service 
88 delivery.  Once  the  women  have  consented  to  participate  in  the  trial  a  randomisation 
number  is  obtained  from  the  IBIS  office  at  the  Imperial  Cancer  Research  Fund  (ICRF) 
and  the  recruitment  process  takes  place.  A  complete  clinical  history  is  taken  along 
with  measurements  of  height,  weight  and  blood  pressure  according  to  the  IBIS 
protocol.  Women  have  a  mammogram  at  the  initial  visit  unless  they  have  had  one 
within  the  last  12  months. 
A  blood  test  is  also  taken  at  this  visit  which  the  nurse  spins  and  sends  to  St  Mary's 
NHS  Trust  for  analysis  for  cholesterol  levels;  no  other  test  is  made  though  the  bloods 
are  stored  for  subsequent  review  of  compliance  or  further  tests  should  they  be  needed. 
The  women  are  provided  with  supplies  of  tablets  (tamoxifen  or  placebo)  according  to 
randomisation  and  future  appointments  are  made.  Written  information  is  given  to  all 
patients  with  a  telephone  number  for  queries  or  concerns.  Supplies  of  tamoxifen  or 
placebo  are  counted,  prepared  and  stored  either  by  the  IBIS  nurse  or  co-ordinator 
though  in  some  centres  the  pharmacy  department  take  responsibility  themselves  for 
storing  and  dispensing. 
Most  of  the  activities  undertaken  for  the  initial  visit  within  IBIS  would  be  the  same 
within  routine  service  delivery.  Activities  such  as  randomisation  and  discussion  of 
the  aims  and  objectives  of  the  trial  would  not  of  course  take  place  in  an  NHS  clinic. 
The  former  is  however  a  small  part  of  the  overall  time  taken  at  the  initial  visit  and  the 
latter  would  be  equivalent  if  adopted  in  routine  practice  to  time  spent  describing  the 
evidence  on  which  the  prophylaxis  was  being  offered. 
Staff  Costs 
Table  4  shows  the  estimated  staff  costs  per  new  patient  visit  per  centre.  The  costs  are 
based  on  the  number  of  new  patient  visits  and  incremental  costs  of  staffing  the 
sessions  assuming  £300  per  consultant  sessions,  £100  per  clinical  assistant  session 
and  £50  per  nurse  session.  The  length  of  each  session  is  taken  as  3  hours.  The 
secretarial/administrative  costs  are  not  included  at  this  stage  since  they  vary 
considerably  between  the  centres.  Moreover  many  of  the  tasks  involved  in  advertising 
89 the  trial  and  recruiting  women  are  not  included  here  since  they  relate  to  the  running  of 
IBIS  and  are  not  relevant  to  routine  service  delivery. 
Table  4:  New  Recruits  -  Staff  Costs 
IBIS  Doctor 
Centre  Specialty  mean  tim 
(m) 
e  number  new  Dr  cost  Nurse  time  spent  nurse  Total  staff"  cost 
per  woman  women/week  *  grade  by  nurse(m)  cost#  er  new  recruit 
1  rad/altsurg/onc  45.00  2.20  162.36  d  5.00  1.21  74.35 
2  surg  10.00  2.00  32.80  h  20.00  12.30  22.55 
3  scmo  25.00  3.00  41.25  h  10.00  12.30  17.85 
4  scmo/surg  2.00  2.50  8.20  g  15.00  11.63  7.93 
5  surg  30.00  2.00  98.40  f  120.00  50.40  74.40 
6  surg  5.00  1.00  8.20  f  15.00  3.15  11.35 
7  genetics  35.00  1.50  86.10  f  45.00  20.93  71.35 
8  surg  10.00  3.00  49.20  h  40.00  37.20  28.80 
9  surg  40.00  2.50  164.00  g  45.00  34.88  79.55 
10  surg  0.50  0.50  0.41  g  30.00  4.65  10.12 
11  surg  20.00  1.00  32.80  f  60.00  18.60  51.40 
I2  ass  spec  10.00  0.25  1.38  f  20.00  1.05  9.70 
13  oncol/gen  15.00  1.50  36.90  f  20.00  6.30  28.80 
14  gp/surg  30.00  0.25  4.13  f  45.00  2.36  25.95 
15  sr/clin  asst/surg  50.00  1.00  27.50  g  50.00  15.50  43.00 
16  clin  asst  40.00  2.50  55.00  2xg  40.00  62.00  46.80 
Total  367.50  26.70  808.62  294.45  41.31 
mean  22.97  1.67  50.54  0.00  18.40  41.31 
td  dev  16.10  0.93  52.32  27.60  18.45  76.28 
*at  £300/consultant  session 
#at  £50/Nurse  session 
**Dr  and  nurse  only 
The  mean  costs  per  new  patient  are  just  under  £42 
,  the  range  is  from  £8  in  centre  4  to 
almost  £80  in  centre  9.  The  variation  in  costs  per  new  patient  are  explained  by  the 
difference  in  doctor  time  spent  with  new  patients  . 
Costs  are  directly  proportional  to 
the  amount  of  time  spent  by  doctors  irrespective  of  the  differences  in  costs  of  doctor 
time  between  grades.  Lower  costs  are  found  in  centres  where  nurse  involvement 
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90 occupies  the  greatest  proportion  of  time  spent  by  clinical  staff.  In  centres  such  as 
Guys,  Aberdeen,  Cardiff  and  Edinburgh  where  doctors  spend  relatively  more  time 
explaining  the  trial  and  the  process  of  care  for  women  involved  costs  are  higher. 
The  process  of  care  in  IBIS  is  well  illustrated  by  the  centre  with  the  highest  rate  of 
recruitment  to  the  trial.  This  centre  also  has  the  lowest  cost  per  patient.  Until  recently 
this  centre  was  based  only  in  the  family  history  clinic.  The  nurse  discusses  the  trial 
with  women  referred  from  either  the  family  history  clinic  or  from  general 
practitioners.  She  also  completes.  the  history  for  entry  to  the  trial,  takes  blood  and 
secures  referral  for  mammography.  The  doctor  examines  the  patient  between  routine 
consultations  within  the  general  clinic.  On  occasions  staff  in  training  grades  are 
available  to  support  this  process  and  may  be  able  to  examine  women  recruited  for 
IBIS.  In  general  the  surgeon's  time  is  not  much  reduced  by  this  process  since  queries 
can  take  a  good  deal  of  time  and  trainees  are  likely  to  see  far  fewer  women  than  the 
consultant.  More  recently  a  clinical  assistant  has  been  recruited  to  support  the  general 
clinic  and  is  available  to  see  IBIS  women.  Again,  in  general  the  clinical  assistant  sees 
fewer  women  than  the  consultant  and  takes  longer.  Queries  are  discussed  with  the 
consultant.  Routine  ultrasound  is  offered  to  women  in  this  clinic  yet  the  costs  in 
terms  of  doctor  time  are  not  affected.  Follow  up  costs  in  terms  of  clinical  staff  time 
are  shown  in  table  5  below: 
Table  5.  Follow  up  staff  costs  per  woman 
IBIS  number  Cost  Total  cost 
Centre  Vu  per  week  nurse  t(m)  Cost  Nu  t(£)  Dr  t  (m)  Dr  time  Dr&Nu  (£) 
1  8.00  17.50  15.40  2.00  26  42 
2  1.50  20.00  12.30  2.00  5  17 
3  6.50  1.00  2.67  5.00  18  21 
4  8.50  15.00  39.53  5.00  70  109 
5  6.00  25.00  31.50  2.00  20  51 
6  1.50  10.00  3.15  2.00  5  8 
7  5.00  15.00  15.75  15.00  123  139 
8  3.00  20.00  24.60  2.00  10  34 
9  12.00  10.00  37.20  10.00  197  234 
10  3.50  10.00  10.85  0.50  3  14 
11  1.00  15.00  3.15  10.00  16  20 
12  1.00  0.00  0.00  10.00  6  6 
91 13  13.50  25.00  70.88  1.00  22  93 
14  3.50  12.50  9.19  5.00  29  38 
15  3.00  30.00  27.90  3.50  17  45 
16  6.50  15.00  60.45  2.00  21  82 
Total  84  365  77  587  952 
Mean  5  23  5  37  59 
Std  dev  4  21  4  52  61 
Overall  the  follow  up  visits  during  the  week  increase  the  total  cost  per  new  recruit  per 
week  by  a  factor  of  about  1.5.  The  numbers  of  follow  up  visits  quickly  accrue 
particularly  in  centres  with  a  high  rate  of  recruitment.  The  time  spent  with  women 
during  follow  up  visits  by  both  the  doctor  and  nurse  is  however  considerably  less  than 
with  women  new  to  the  study.  The  amount  of  time  spent  with  the  doctor  is  still  the 
main  factor  explaining  the  cost  differences  between  the  centres.  The  centres  with  the 
highest  follow  up  costs  are  those  where  medical  staff  spend  a  large  proportion  of  the 
total  time  of  the  visit  with  the  patient.  Where  doctor  time  is  also  relatively  higher  in 
centres  such  as  11  and  12  with  lower  overall  costs  this  is  because  of  the  lower  grade 
of  the  doctor  involved.  Clinical  assistants  and  associate  specialists  are  responsible  for 
IBIS  patients  in  five  of  the  centres. 
This  analysis  has  focussed  on  costs  most  likely  to  influence  the  cost  effectiveness 
rates  for  tamoxifen  chemoprophylaxis.  Where  breast  cancer  chemoprevention  was  to 
be  introduced  into  routine  services  fixed  costs  would  need  to  be  considered.  This 
study  demonstrates  however  only  a  small  increase  in  the  proportion  of  women  seen 
compared  with  the  overall  numbers  attending  breast  services.  Moreover  where  service 
delivery  was  offering  in  general  practice  changes  in  fixed  costs  to  women  attending 
for  chemoprevention  would  be  negligible. 
There  are  a  number  of  hidden  costs  involving  staff  time  which  could  be  attributed  to 
IBIS  because  they  may  bear  on  the  overall  costs  of  the  trial;  they  are  less  likely 
however  to  play  a  significant  role  in  service  delivery.  These  include  the  time  spent 
discussing  the  trial  with  potential  new  recruits  in  settings  other  than  those  designated 
for  the  study.  In  some  hospitals  the  trial  is  discussed  extensively  with  eligible  women 
92 attending  genetics  clinics,  particularly  those  under  50;  one  centre  estimates  that  only 
1  in  8  women  decide  to  become  involved  in  the  study  though  about  3-5  eligible 
women  are  seen  per  week  and  a  substantial  amount  of  time  is  spent  with  them. 
Another  centre  based  in  a  screening  unit  asks  women  if  they  have  a  family  history  of 
breast  cancer  in  order  to  assess  eligibility  for  IBIS.  Where  eligible  women  are 
identified  they  are  referred  to  the  IBIS  clinic  but  only  via  a  referral  to  the  genetic 
clinic.  Direct  costs  which  can  be  attributed  to  IBIS  from  general  practice  emerge  in 
one  centre  where  women  are  routinely  referred  back  to  their  GPs  for  breast 
examination. 
In  most  centres  the  hospital  pharmacy  has  been  helpful  in  storing,  counting  and 
dispensing  tablets  though  there  have  been  concerns  about  funds  available  to  support 
this  work.  Where  pharmacy  has  been  unwilling  or  unable  to  store  and  process 
supplies  the  centre  co-ordinator  or  nurse  has  taken  on  this  task. 
A  considerable  amount  of  time  is  spent  in  writing  to  or  phoning  women  who  have 
expressed  an  interest  in  the  study,  or  those  who  have  missed  an  appointment  or  have  a 
particular  problem.  Most  centres  also  contact  women  prior  to  appointments  or  to 
follow  up  an  initial  discussion  since  this  is  thought  to  be  an  efficient  means  of 
screening  out  those  women  who  are  unlikely  to  pursue  the  study  and  to  reduce  the  rate 
of  missed  appointments.  Centre  co-ordinators  also  spend  time  working  through  the 
press  or  within  local  networks  seeking  to  publicise  the  study  and  to  encourage  new 
recruits.  A  range  of  estimates  are  reported  from  centres  on  the  time  spent  on  these 
activities  although  all  report  the  need  to  increase  the  time  available  for  recruitment.  In 
general  it  might  be  expected  that  an  additional  three-hour  session  of  clerical  time  may 
be  needed.  This  would  increase  the  cost  by  around  £13/new  patient  visit.  This  cost  is 
excluded  from  the  analysis  since  it  is  a  research  cost  rather  than  directly  attributable 
to  service  delivery. 
Costs  of  tests  and  drug  supplies 
Additional  costs  (see  table  6)  include  an  annual  mammogram  at  around  £56,  blood 
tests  taken  at  the  beginning  and  end  of  the  study  costed  at  £10  in  total  and  drug 
93 costs16'.  Other  consumables  including  equipment  used  during  in  examination  and  set 
up  costs  for  the  clinic  are  omitted  since  they  are  unlikely  to  add  substantially  to  the 
cost  of  clinic  visits.  Tamoxifen  is  a  relatively  inexpensive  drug  and  at  around  £30  per 
year  will  represent  a  small  proportion  of  the  total  overall  costs.  The  cost  for  each  new 
patient  visit  is  around  £81.  The  average  cost  for  follow  up  visits  is  around  £33.8. 
Table  6:  Costs  of  Tests  and  Drug  Supplies  (£) 
For  women  in  IBIS 
Visit  Mammography  Blood  Drugs  Total  (new) 
1  56  10  15 
Total  new  56  10  15  81 
Follow  up  month 
6  0  0  15 
12  0  10  15 
18  56  0  15 
24  0  0  15 
30  0  0  15 
36  56 
42  0 
48  0 
54  56 
P 
60  0 
total  f/u  168  338 
£/per  fu 
visit 
16.8  15  33.8 
Costs  per  woman  per  five  year  recruitment 
The  staff  time  costs  set  out  above  together  with  the  costs  of  drugs  investigations  and 
mammography  outlined  above  are  used  to  derive  an  estimate  of  the  overall  cost  for 
delivering  tamoxifen  chemoprophylaxis  per  woman.  This  is  set  out  in  the  table  6. 
Estimated  cost  per  woman  recruited  to  IBIS 
Item  £/episode  over  5  years  % 
Mean  staff  cost  (new  recruit)  42.00  42.00  4% 
Mean  staff  cost(  follow  up  visit)  59.00  590.00  53% 
Tests,  investigations  (new  recruits)  66.00  66.00  6% 
Tamoxifen  prescriptions(new  recruits)  15.00  15.00  1% 
Test,  investigation  (follow  up)  18.80  188.00  17% 
Tamoxifen(follow  up)  15.00  150.00  13% 
94 Administration  cost/woman/year  13  65.00  6% 
1  Total  1116.00  100% 
The  overall  cost  per  woman  over  the  5-year  period  of  taking  tamoxifen  is  around 
£1000  per  woman.  The  cost  of  recruitment  (4%)  is  a  relatively  small  proportion  of  the 
overall  cost  of  offering  tamoxifen  chemoprophylaxis.  Staff  costs  for  time  involved  in 
follow  up  visits  accounts  for  by  far  the  greatest  proportion  of  the  overall  cost  (53%). 
The  costs  of  prescription  and  investigations(mammography  and  blood  tests)  account 
for  a  similar  proportion  (around  15%  and  17%  respectively) 
Discussion 
The  costs  discussed  here  based  on  the  amount  of  time  spent  by  staff  involved  in 
delivering  tamoxifen  prophylaxis  together  with  the  costs  of  mammography  and 
routine  blood  tests.  Only  costs,  which  are  clearly  associated  with  service  delivery,  are 
included.  Costs  attributable  to  the  context  of  a  research  trial  are  excluded.  These 
include  the  time  spent  outwith  clinic  sessions  discussing  the  trial  with  potential 
recruits,  time  spent  in  talking  with  women's  groups  or  press  activity.  The  time  spent 
in  randomisation  is  likely  to  be  small  in  terms  of  the  overall  time  spent  recruiting 
women.  Discussion  about  the  trial,  which  takes  place  within  the  clinic  session,  may 
be  assigned  as  a  research  cost  but  would  be  equivalent  to  time  spent  discussing  the 
rationale  and  evidence  for  prophylaxis  with  women  in  a  service  context. 
Fixed  costs  are  not  included  since  they  would  be  likely  to  vary  considerably  between 
centres  irrespective  of  the  model  of  care  for  IBIS.  The  overall  cost  of  service  delivery 
at  less  than  £200  per  new  women  per  year  recruited  is  relatively  low  in  comparison 
with  many  other  areas  of  health  care.  This  level  of  cost  might  be  considered 
equivalent  to  outpatient  costs  for  some  medical  specialties  where  there  are  few 
expensive  investigations  and  the  costs  of  medical  therapies  are  low.  The  difference 
between  the  cost  of  routine  service  delivery  and  the  research  protocol  is  likely  to  be 
small  since  there  are  relatively  few  investigations  for  women  recruited  to  IBIS  other 
than  annual  mammography.  Blood  tests  are  taken  only  at  the  beginning  and  end  of 
the  recruitment  period.  Routine  endometrial  screening  and  other  tests  undertaken  in 
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between  the  research  and  the  clinical  setting,  are  not  included  in  the  IBIS  protocol. 
It  is  possible  however  that  in  the  context  of  a  clinical  trial  more  frequent  follow  up 
and  investigation  might  be  considered  necessary  than  for  routine  service  provision. 
Women  involved  in  chemoprevention  of  breast  cancer  may  potentially  require 
minimal  investigation.  Even  annual  mammography  for  example  required  within  the 
trial  protocol  may  be  inappropriate  within  the  context  of  service  delivery.  The 
evidence  for  improved  health  outcomes  with  frequent  mammography  screening  for 
women  under  50  is  poor  and  women  over  age  50  would  have  access  to  mammography 
as  part  of  the  NHS  Breast  Screening  Programme  (every  3  years  until  age  65).  Such  an 
approach  would  also  reduce  overall  costs  and  the  pressure  on  mammography  services. 
The  amount  of  time  spent  by  specialist  breast  surgeons  either  in  breast  examination  or 
in  providing  information  to  women  about  the  risk  and  benefits  of  tamoxifen 
prophylaxis  accounts  for  the  greatest  proportion  of  staff  cost.  If  this  task  were 
appropriate  to  be  performed  by  a  nurse  with  specialist  support  staff  costs  could  be 
much  reduced.  Such  an  approach  is  within  the  range  of  models  of  service  delivery 
currently  used  within  the  IBIS  trial  protocol  and  might  be  adopted  with  minimal 
additional  training  for  nursing  staff  within  the  umbrella  of  breast  care  services  in  the 
UK.  Where  the  service  is  led  by  nurse  practitioners  minimal  input  from  a  consultant 
surgeon  may  be  reduced  to  a  single  session  to  discuss  the  risks  and  benefits  of 
tamoxifen  prophylaxis  in  terms  of  individual  level  of  risk  of  breast  cancer.  Such  an 
approach  with  nurse  only  follow  up  visits  and  mammography  reduced  to  3  times  over 
the  course  of  the  5  year  period  of  active  prevention  would  reduce  costs  per  woman  to 
around  £535  over  the  5  year  period.  The  burden  of  cost  likely  to  fall  on  breast  units 
adopting  this  approach  would  depend  on  the  numbers  of  additional  women  eligible  for 
prophylaxis  and  willing  to  comply  with  long  term  drug  treatment  -  and  the  marginal 
increase  in  numbers  of  women  within  the  breast  service  likely  to  increase  the  demand 
for  additional  members  of  clinical  staff  and  clinic  sessions. 
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to  most  hospital  care  possibly  with  referral  for  specialist  support  should  problems  or 
anxieties  arise.  In  practice  symptoms  or  signs  emerging  during  the  course  of 
prophylaxis  are  likely  to  be  dealt  with  in  primary  care  or  referred  on  by  GPs  to 
appropriate  specialists.  Evidence  from  other  areas  of  health  care  suggests  that  there  is 
little  value  in  routine  follow  up  visits  to  specialist  centres.  Where  general  practice 
were  to  be  considered  a  more  appropriate  setting  particularly  for  follow  up  visits  costs 
may  reduce  to  around  £410  per  woman  over  the  5  year  period  assuming  as  in  the 
nurse  led  model  a  single  visit  to  a  specialist  breast  surgeon  and  5  annual  visits  to  a 
GP.  Most  GPs  would  expect  to  see  only  2  or  3  women  per  year  with  the  eligibility  for 
tamoxifen  prophylaxis  and  the  motivation  to  undertake  long  term  drug  therapy. 
These  issues  are  discussed  further  in  Chapter  7  where  a  consolidated  estimate  for  cost 
effectiveness  is  modelled  from  the  costs  set  out  in  this  and  subsequent  chapters.  The 
baseline  estimate  for  the  cost  of  service  delivery  used  in  the  model  is  of  a  hospital 
based  service  led  by  consultant  breast  specialists  though  with  significant  involvement 
of  specialist  nurses  (£535/woman)  as  described  above.  Sensitivity  analysis  does 
however  include  other  estimates  including  the  possibility  of  a  service  delivered 
through  general  practice  at  £410/woman  and  with  the  lower  estimates  of  £200/woman 
underpinning  the  budgets  available  to  centres  within  IBIS 
Summary  and  Conclusions 
Costs  for  service  delivery  are  based  on  a  direct  observation  and  a  telephone  survey  of 
workload,  staffing  and  the  clinical  protocol  used  in  IBIS  centres.  Costings  are  based 
on  bottom  up  assessment  of  the  time  spent  by  staff  with  IBIS  recruits  using  national 
pay  scales.  Mammography  is  costed  at  £56,  blood  tests  at  £10  in  total  and  the  cost  of 
20  mg  tamoxifen  daily  is  taken  as  £15  per  year  from  the  National  Drug  Tariff.  The 
overall  cost  for  delivering  tamoxifen  prophylaxis  within  the  context  of  the  trial  is 
£1116  per  woman  per  5  years.  The  largest  proportion  of  cost  (57%)  is  in  staff  time. 
The  cost  of  doctor  time  is  the  largest  element;  the  amount  of  time  spent  by  the  doctor 
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for  a  further  23%  of  the  cost  and  provision  of  the  drug  tamoxifen  for  14%  of  the  cost. 
Costs  of  administration  make  up  the  remainder  of  the  cost  (6%) 
Hidden  costs  are  discussed  and  include  the  time  spent  discussing  the  trial  by  other 
health  professionals  particularly  geneticists  running  family  history  clinics  and  GP 
time.  In  one  centre  for  example  the  physical  examination  is  carried  out  by  the  GP. 
The  review  illustrates  that  there  is  little  specialist  input  to  the  provision  of  tamoxifen 
prophylaxis  and  that  the  main  time  element  is  in  discussing  the  concept  to  the  women 
and  the  protocol  for  consent  to  enter  the  trial.  While  the  time  element  in  `consenting' 
woman  may  translate  into  time  spent  discussing  the  evidence  base  and  side  effects  of 
tamoxifen  prophylaxis  if  the  approach  was  adopted  in  routine  practice  some  savings 
could  be  made. 
Leaving  aside  the  research  costs  included  in  the  overall  estimate  and  reducing  the  time 
spent  by  women  in  the  clinic  as  well  as  some  of  the  investigation  two  scenarios  for 
service  delivery  are  proposed.  These  are  £535  for  a  nurse  led  hospital  service  or  £410 
for  a  service  run  in  general  practice.  The  hospital  service  is  used  as  the  baseline 
approach  for  the  model  developed  in  chapter  7  and  the  GP  run  service  is  explored 
through  the  sensitivity  analysis.  Both  approaches  would  rely  on  minimal  input  from  a 
consultant  surgeon  or  equivalent  with  only  1  visit  included  for  the  5-year  period.  The 
frequency  of  mammography  would  reduce  to  a  maximum  of  3  times  in  the  5-year 
period.  Both  scenarios  exclude  the  costs  attributable  to  the  research  trial  particularly 
the  need  for  annual  mammography,  the  taking  and  processing  of  blood  and  time  spent 
recruiting  women  to  the  study. 
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Morbidity  and  Resource  Use: 
Use  of  Hospital  Services 
Introduction 
Following  the  review  of  literature  about  the  risks  and  benefits  for  women  taking  the 
drug  tamoxifen  in  Chapter  2,  this  and  the  following  chapter  derive  more  precise 
estimates  of  the  likely  impact  of  morbidity  on  the  cost  effectiveness  of  tamoxifen 
chemoprophylaxis.  This  chapter  is  concerned  with  the  prospect  of  changes  in  the  use 
of  hospital  visits  for  symptoms  associated  with  long  term  tamoxifen  use  and  Chapter 
5  measures  changes  in  the  rate  of  use  of  prescribed  medications.  The  analysis  is  based 
on  measurements  of  differences  in  the  morbidity  experience  of  women  in  the 
tamoxifen  or  control  arm  of  the  International  Breast  Cancer  Intervention  Study  (IBIS). 
Small  changes  in  the  use  of  hospital  services  or  prescribed  medications  for  the  age 
group  targeted  in  prevention  trials  could  have  a  significant  impact  on  overall  cost  if 
large  numbers  of  women  were  affected.  Yet,  there  have  been  few  studies  published  on 
the  effect  of  tamoxifen  on  morbidity  as  measured  through  changes  in  hospitalisation 
rates  or  use  of  medications.  As  discussed  earlier  there  have  been  great  many  studies  of 
the  effects  of  tamoxifen  when  used  as  adjuvant  therapy. 
Most  prevention  studies  have  been  primarily  concerned  with  the  effects  of  tamoxifen 
on  adverse  outcomes  such  as  thromboembolism  or  endometrial  cancer.  Primary 
endpoints  in  NSABP  P-12  and  in  the  Powles8  and  Veronesi'  l  studies  all  include 
incidence  and  mortality  from  histologically  confirmed  breast  cancer.  Other  incident 
cancers  including  endometrial  cancer  are  also  recorded  and  all  causes  of  death  during 
the  trial  verified.  Secondary  endpoints  include  ischaemic  heart  disease  events,  other 
vascular  events  and  fractures.  `Other  disease'  and  medical  problems  are  sometimes 
recorded  at  each  visit  yet  there  has  been  no  systematic  reporting  of  morbidity  from 
these  studies. 
Fornander  et  al142  considered  the  impact  of  adjuvant  tamoxifen  on  the  intercurrent 
morbidity  and  mortality  of  women  involved  in  the  Stockholm  Adjuvant  Trial  using 
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reported  the  detailed  pattern  of  hospital  use  by  women  involved  in  prevention  studies 
or  their  use  of  prescribed  medications  for  conditions  relevant  to  known  side  effects  of 
tamoxifen  or  for  their  health  in  general. 
Women  may  experience  symptoms  arising  directly  from  the  use  of  tamoxifen 
necessitating  a  hospital  referral  or  the  use  of  a  drug  or  by  contrast  they  may 
experience  a  reduction  in  the  frequency  of  morbidity  because  of  a  protective  effect  of 
prophylaxis.  Changes  in  the  pattern  of  morbidity  may  also  arise  indirectly  from 
different  health  behaviour  elicited  by  involvement  with  a  preventive  intervention. 
Women  taking  long  term  preventive  therapy  may  be  more  likely  to  seek  medical 
advice  as  a  result  of  heightened  awareness  of  their  risk  of  disease;  greater  personal 
awareness  of  health  and  illness  may  reduce  their  threshold  for  consultation  about 
relatively  minor  symptoms.  Alternatively  they  may  feel  more  reassured  by  the  fact  of 
the  preventive  intervention  and  reduce  their  use  of  health  services.  Women  recruited 
to  IBIS  for  example  may  make  use  of  routine  consultations  with  health  care 
professionals  at  IBIS  clinics  for  discussion  of  broader  health  issues  and  as  a 
consequence  reduce  their  use  of  other  health  facilities. 
Quite  apart  from  the  relatively  rare  adverse  outcomes  from  tamoxifen  therapy  there 
are  common  side  effects  which  may  have  consequences  for  the  pattern  of  morbidity  in 
patients  treated  with  tamoxifen  over  a  long  period  of  time.  These  side  effects  may 
affect  both  compliance  with  prophylaxis  in  healthy  women  who  are  otherwise 
asymptomatic  for  breast  cancer  or  related  diseases  and  if  translated  into  use  of  health 
services  or  the  rate  of  prescribing  may  influence  the  relative  cost  effectiveness  of 
chemoprevention.  Information  from  women  recruited  into  IBIS  is  used  in  this  section 
to  identify  and  quantify  this  effect  through  measuring  changes  in  the  use  of  hospital 
services  by  women  recruited  to  IBIS. 
Method 
The  information  presented  below  is  collected  from  self-reports  of  hospital  visits  made 
by  women  recruited  into  IBIS.  Women  are  asked  at  recruitment,  at  the  first  follow  up 
visit  at  6  months  and  at  each  of  the  subsequent  visits  at  6  monthly  intervals  over  the  5- 
100 year  duration  of  the  trial  about  any  hospital  visit.  A  brief  outline  is  requested  on  the 
data  collection  form  and  the  study  co-ordinators  in  each  centre  are  asked  to  forward 
details  on  an  illness  report  form  together  with  any  confirmatory  information  including 
pathology  reports  or  copies  of  correspondence  between  GPs  and  hospital  consultants. 
Information  on  the  use  of  hospital  services  since  the  previous  visit  is  also  occasionally 
recorded  on  the  section  of  the  follow  up  form  requiring  details  of  side  effects.  This 
covers  a  range  of  usual  symptoms  and  includes  a  request  for  details  of  `other' 
symptoms  where  information  about  hospital  use  is  sometimes  entered.  All 
information  on  hospital  visits  from  the  follow  up  forms  is  entered  into  an  oracle 
database  by  data  entry  clerks. 
The  information  selected  to  assess  the  hospital  resource  use  included  all  women 
recruited  to  IBIS  who  had  a  hospital  visit  by  the  end  of  December  1997. 
Completeness  and  accuracy  of  the  follow  up  entries  for  the  women  was  checked 
through  hand  searching  of  the  patient  records.  A  great  many  incomplete  records  were 
found  necessitating  validation  and  completion  of  the  information  by  reference  to  the 
woman's  original  notes  or  through  discussions  with  the  study  centre  co-ordinators. 
The  data  were  downloaded  to  an  Excel  spreadsheet  for  each  of  the  women  reporting 
hospital  use  and  then  summarised  to  produce  where  possible  a  diagnosis  using  3  digit 
codes  from  the  International  Classification  of  Diseases  9th  series  (ICD9)  and  main 
ICD9  chapter  headings  for  the  diagnosis  given  on  the  form. 
Since  the  main  aim  of  the  study  was  to  assess  any  change  in  use  of  health  services  by 
women  taking  tamoxifen  for  breast  cancer  prophylaxis  it  was  important  to  quantify 
the  use  of  health  care  resources  arising  from  hospital  visits.  This  was  done  by 
assigning  each  of  the  procedures  recorded  in  the  notes  to  a  health  care  resource  group 
(HRG)  15'  The  HRGs  are  readily  costed  with  standard  prices  from  the  District 
General  Hospital  Accounting  System  used  within  the  National  Health  Service 
(NHS)  166  HRGs  were  developed  by  the  National  Case  Mix  Office  funded  by  the 
NHS.  They  aim  to  provide  a  straightforward  means  of  assigning  hospital  admissions 
including  both  day  case  and  inpatient  episodes  into  clinically  meaningful  groups 
representing  similar  levels  of  health  care  resource  consumption.  The  main  value  of 
HRGs  is  that  they  include  case  mix  information  and  so  can  provide  appropriate 
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Case  mix  adjustments  include  the  age  of  the  patient  and  the  presence  of  comorbidities 
or  secondary  diagnosis  in  relation  to  the  main  condition  under  review.  The  use  of 
HRGs  in  this  study  is  to  derive  a  likely  cost  for  each  hospital  visit  that  is  based  on 
more  detailed  information  than  diagnosis  or  procedure  code  alone.  Costs  can  vary 
considerably  depending  on  the  severity  of  the  condition,  the  age  and  general  health  of 
the  patient.  A  number  of  studies  have  use  of  HRGs  in  predicting  cost  differences 
between  hospitals  and  they  have  been  adopted  as  the  main  means  for  costing  health 
care  contracts  in  the  NHS.  167,168,169,170 
Hospital  visits  involving  any  clinical  procedure  in  the  6  months  prior  to  each  IBIS 
follow  up  visit  had  an  HRG  assigned  to  them  where  possible  using  the  primary 
diagnosis  from  the  information  given  on  the  women's  record,  the  procedure  and  the 
age  of  the  woman.  Each  assignment  was  checked  by  a  general  practitioner  advisor  to 
the  National  Case  Mix  Office  and  a  reference  set  of  HRGs  established  for  the  most 
frequent  symptoms  and  information  found  within  the  records.  In  the  main  the  final 
set  of  HRGs  included  in  the  analysis  presented  here  include  only  those  which  would 
normally  be  classified  in  the  routine  information  from  the  NHS  as  `inpatients'  or  `day 
cases'.  Out  patient  visits  do  however  increasingly  result  in  the  use  of  procedures  such 
as  endoscopy  or  breast  biopsy  and  where  possible  an  HRG  has  been  assigned  to  them. 
The  information  included  under  the  heading  of  outpatient  activity  therefore  includes 
only  those  cases  where  no  specific  procedure  was  reported  for  example  where  the 
woman  may  have  been  offered  advice,  given  a  test  result  (recorded  at  a  previous  visit) 
or  referred  back  to  her  general  practitioner.  These  `outpatient  episodes'  have  been 
costed  using  GP  Fundholders  price  tariffs  from  the  specialty  reported  on  the  record  or 
that  most  usually  associated  with  the  diagnosis  or  procedure166. 
In  order  to  preserve  the  blinded  nature  of  the  IBIS  trial  the  data  have  been  separated 
into  2  groups:  A  and  B  for  women  taking  either  tamoxifen  or  placebo;  the  2  groups 
are  anonymised  and  do  not  label  the  same  arm  of  the  trial  throughout  this  analysis.  It 
was  not  possible  to  assign  an  ICD  9  Chapter  to  68  of  the  visits  reported,  33  in  group  A 
and  35  in  group  B.  For  9  women  -5  in  group  A  and  4  in  group  B  it  was  unclear 
whether  a  procedure  had  taken  place  as  a  result  or  their  visit  to  hospital.  For  these 
women  hospital  expenditure  of  £100  was  assumed  since  it  was  clear  from  the  record 
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the  reason  for  the  hospital  visit.  Since  pregnancy  is  unlikely  to  have  been  affected  by 
tamoxifen  chemoprophylaxis  but  immediately  excludes  the  woman  from  further 
participation  in  the  study  they  have  been  excluded  from  the  final  analysis. 
Statistical  analysis 
For  all  women  recruited  to  the  trial  descriptive  information  on  the  use  of  hospital 
services  is  grouped  and  ranked  according  to  the  number  and  proportion  of  visits  by 
main  reason  for  visit  within  main  ICD9  chapter  heading,  for  specific  diagnosis 
associated  with  3  digit  codes)  and  by  main  procedure  undertaken  (HRG).  The  number 
of  visits  per  woman  is  also  calculated  overall  and  per  follow  up  visit.  A  frequency 
distribution  of  the  cost  of  hospital  visits  is  used  as  the  most  suitable  means  to 
demonstrate  the  shape  of  the  cost  distribution. 
Differences  in  the  rates  of  use  of  hospital  both  by  diagnosis  category  and  for 
procedures  undertaken  are  calculated  as  odds  ratios  with  confidence  intervals 
calculated  by  the  standard  method  of  Cornfield.  Comparisons  of  the  mean  cost  per 
visit  overall  in  each  of  the  2  series  is  calculated  with  Fishers  exact  test  using  a  normal 
approximation.  The  size  of  the  sample  and  the  shape  of  the  distribution  may  affect 
the  significance  of  the  finding  between  the  2  series.  Once  a  larger  sample  is  available 
consideration  may  be  given  to  a  Wilcoxon  Sum  test  to  account  for  the  non  normal 
shape  of  the  distribution  of  costs  to  women  although  as  the  sample  size  increases  the 
conditions  for  assuming  a  normal  distribution  increase.  Applying  the  test  at  this  stage 
would  have  discerned  no  further  information.  A  student's  t  test  was  used  to  compare 
the  distribution  of  costs  per  women  within  each  of  the  disease  categories.  A  non 
parametric  test  on  ranked  data  may  have  been  more  appropriate  although  the 
distribution  of  costs  per  women  within  disease  categories  more  greatly  approximates  a 
normal  distribution  than  seen  in  the  overall  costs. 
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Women  recruited  to  IBIS:  broad  patterns  of  hospital  use 
Out  of  the  2531  women  recruited  to  the  study  with  a  total  of  6696  IBIS  follow  up 
visits  at  the  time  of  analysis  a  total  of  825  (32.32%)  women  reported  1321  hospital 
visits  since  their  previous  assessment  at  an  IBIS  clinic;  a  rate  of  1.6  visits  per  woman. 
There  were  814  outpatient  visits  where  no  procedure  was  undertaken  and  507  visits 
made  by  429  women  (16.9%)  included  procedures  which  could  be  assigned  to  an 
HRG.  By  comparison,  the  rate  of  admission  either  for  a  day  case  or  an  ordinary  in- 
patient  admission  to  an  NHS  hospital  in  1994/5  was  around  17.8%  of  women  aged 
45-64  (see  fig  1)  167. 
Fig  1.  The  rate  of  admissions  to  NHS  hospitals  (ordinary  and  day  cases)  for  all 
women  in  England.  The  rate  of  all  admissions  is  shown  (rate)  and  the  rate  for 
genitourinary  (genito)  conditions  only. 
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Age 
Women  in  the  45-64  age  group  most  likely  to  be  targeted  for  breast  cancer 
prophylaxis  are  relatively  high  users  of  hospital  and  other  health  services  for 
104 conditions  associated  with  breast  care  and  genitourinary  problems  though  they  have  a 
lower  overall  rate  of  admission  than  both  older  and  younger  adult  women.  The  higher 
rate  of  admission  to  hospital  for  all  conditions  in  younger  women  (aged  15-44)  is  due 
to  pregnancy  and  childbirth.  Older  women  in  the  age  groups  65-74  and  75+  have  the 
highest  rates  of  admission  for  all  causes,  these  are  principally  due  to  cardiovascular 
conditions,  cancer  and  other  chronic  diseases  such  as  respiratory  problems  and 
diabetes. 
The  mean  age  of  women  recruited  to  the  study  overall  is  49.5  years  compared  with  a 
mean  of  49.8  years  in  series  A  and  49.1  years  in  series  B.  The  median  time  of  follow 
up  was  18  months.  Table  1  shows  the  main  reasons  for  attending  hospital  by  all 
women  reporting  a  hospital  visit.  In  the  table  all  diagnosis  are  grouped  for  all  women 
under  the  main  ICD9  chapter  headings  since  it  is  expected  that  tamoxifen  may  have 
similar  effects  in  similar  body  systems.  Also,  there  are  small  numbers  in  some  of  the 
specific  disease  categories  and  review  of  broader  groupings  may  allow  more 
meaningful  statistical  analysis.  Some  analysis  of  specific  diagnosis  at  the  level  of 
ICD9  3-digit  code  has  been  possible  for  the  more  common  diagnosis  and  is  discussed 
below. 
Table  1.  Numbers  and  %  of  Visits  in  each  ICD9  Main  Disease  Chapter 
Disease  Chapter  Number  of  Visits  %  of  total  Cumulative  % 
Genitourinary(X)  429  32.48%  3248% 
Musculoskeletal(XIII)  195  14.76%  47.24% 
Digestive(IX)  137  10.37%  57.61% 
Vascular(VII)  92  6.96%  64.57% 
Nervous  and  sense  organs(VI)  77  5.83%  70.40% 
Endocrine  and  Metabolic((III)  74  5.60%  76.00% 
Neoplasms(II)  61  4.62%  80.62% 
Injury  and  Poisoning((XVII)  61  4.62%  85.24% 
Respiratory  System((VIII)  57  4.31%  89.55% 
Skin(XII)  31  2.35%  91.90% 
Infectious(I)  17  1.29%  93.19% 
Mental  disorders(V)  14  1.06%  94.25% 
Blood(IV)  5  0.38%  94.63% 
Unassigned  71  5.37%  100.00% 
Total  1321  100.00% 
Number  of  women  825 
Mean  age  of  women  49.  Syears 
Median  follow  up  18  months 
105 Overall,  the  main  reason  for  hospital  visits  accounting  for  over  a  third  of  the  total 
(32.4%)  fall  into  Disease  Chapter  10  -  diseases  of  the  genitourinary  system  covering 
disorders  of  the  female  genital  tract,  urinary  tract  and  breast  diseases.  Musculoskeletal 
disorders  including  fractures  form  the  second  major  category  of  reasons  for  visits 
(14.7%).  Diseases  of  the  digestive  system  account  for  10.3%  of  the  total  visits  and 
diseases  of  the  circulatory  system  covering  cardiological  and  vascular  disease  account 
for  6.9%  of  visits.  Diseases  of  the  endocrine  and  metabolic  system,  the  nervous 
system  including  sense  organs,  injury  and  poisoning  including  fractures  and  the 
respiratory  system  each  account  for  less  than  6%  of  the  reasons  for  visits  and  5%  were 
unclassified;  4.6%  of  the  women  had  visits  due  to  neoplasms. 
The  distribution  of  hospital  visits  by  main  ICD9  Disease  Chapters  for  women 
recruited  to  IBIS  overall  is  similar  to  that  found  in  the  NHS  routine  admissions  data 
(ordinary  and  day  cases)  although  the  NHS  routine  data  do  not  include  outpatient 
visits  (Table  2). 
Table  2:  Number  and  %  of  Admissions  (Ordinary  and  Day  Cases)  to  NHS 
Hospitals  in  England  (1994/5)  by  main  ICD9  Disease  chapter  for  Women  aged 
45-64. 
Admissions 
Disease  Chapter  ordinary  and  day  cases 
Numbers  % 
Neoplasms  160534  15.58% 
Genitourinary  156835  15.22% 
Musculoskeletal  and  injury  142393  13.82% 
Digestive  125722  12.20% 
Vascular  96426  9.36% 
Nervous  and  sense  organs  56512  5.48% 
Respiratory  41248  4.00% 
Mental  disorders  28145  2.73% 
Skin  25144  2.44% 
Endocrine  and  metabolic  18412  1.79% 
Blood  11584  1.12% 
Infectious  6968  0.68% 
Other  160775  15.60% 
TOTAL  1030698  100.00% 
106 The  largest  category  in  the  NHS  admissions  data  is  women  admitted  for  neoplasm  - 
these  women  would  be  ineligible  for  recruitment  to  IBIS.  Apart  from  this  category  the 
ranking  of  reasons  for  hospital  attendance  is  broadly  the  same  by  main  ICD9  chapters 
for  both  women  reporting  hospital  visits  in  IBIS  and  women  in  routine  NHS  data. 
The  proportions  in  the  2  series  are  not  directly  comparable.  NHS  data  are  based  on 
hospital  episodes  rather  than  individual  visits.  The  routine  NHS  data  do  not  include 
information  on  outpatients  although  they  do  cover  a  rather  broader  range  of  reasons 
for  admission  than  is  seen  for  women  in  IBIS.  Nevertheless  it  is  interesting  to  note 
that  women  enrolled  in  IBIS  appear  to  report  the  use  of  hospital  services  for 
genitourinary  conditions  at  a  higher  rate  than  seen  for  women  in  the  NHS  data  set. 
238  women  out  of  the  2,531  women  recruited  to  IBIS  (9.4%)  reported  a  visit  to 
hospital  including  a  procedure  categorised  within  an  HRG  in  the  disease  chapter 
concerned  with  genitourinary  conditions  compared  with  a  consultation  rate  seen  in  the 
NHS  for  these  conditions  (see  fig  1)  of  2.71%.  By  contrast  the  reported  rate  of 
consultation  for  musculoskeletal  conditions,  the  second  highest  reason  for  hospital  use 
by  women  in  IBIS  was  similar  to  that  seen  in  the  NHS  data  set.  There  were  62 
women  out  of  the  2,531  reporting  a  visit  involving  a  procedure  in  this  group,  a  rate  of 
2.4%.  This  compares  with  around  2%  in  the  NHS  data  set  (113,612  admissions 
including  ordinary  and  day  cases  out  of  a  population  of  562,4364  in  the  relevant  age 
group).  The  comparison  is  imprecise  since  the  2  data  sets  are  not  directly  comparable 
though  the  indication  of  an  increased  rate  of  consultation  by  women  recruited  to  IBIS 
merits  further  investigation. 
Comparison  between  the  use  of  hospital  services  by  women  in  IBIS  and  the  pattern  of 
admissions  for  women  in  England  does  offer  face  validity  to  the  IBIS  data  set.  The 
range  and  ranking  of  hospital  visits seen  for  women  enrolled  into  IBIS  are  as  might  be 
expected  from  routine  sources. 
Main  diagnosis  within  disease  chapters 
The  tables  below  show  the  specific  diagnosis  based  on  the  3  digit  ICD9  code  which 
contribute  the  greatest  overall  proportion  of  hospital  visits  for  each  of  the  main 
chapter  headings. 
107 Diseases  of  the  Genitourinary  System 
For  diseases  of  the  genitourinary  system,  the  most  frequent  cause  of  any  hospital  visit, 
almost  a  third  of  hospital  visits  are  due  to  disorders  of  menstruation  and  other 
abnormal  bleeding  from  the  genital  tract.  Slightly  more  than  half  is  for  diagnostic 
procedures  such  as  hysteroscopy  -  or  for  hysterectomy.  A  further  20%  of  visits  are 
due  to  disorders  of  the  breast  including  fibroadenoma,  cysts  and  benign  lumps  as  well 
as  inflammatory  disease  of  the  uterus  (615)  such  as  fibroids  or  secretory  changes  in 
the  endometrium  and  inflammatory  disease  in  the  cervix,  vagina  or  vulva.  The 
remaining  causes  include  problems  of  pelvic  floor,  abnormalities  resulting  from 
prolapse  (618)  and  other  symptoms  such  as  pain  and  urethritis. 
Table  3:  Hospital  visits  made  by  women  recruited  to  IBIS:  Diseases  of  the 
Genitourinary  System  by  main  cause. 
Main  primary  diagnosis  for  diseases  of  the  genitourinary 
system 
Numbers  %  Cumulative  % 
Disorders  of  menstruation  (626)  129  30.07%  30.07% 
Disorders  of  the  breast(611)  87  20.28%  50.35% 
Inflammatory  diseases  of  the  uterus(615)  47  10.96%  61.31% 
Inflammatory  diseases  of  the  cervix,  vagina,  vulva(616)  34  7.93%  69.23% 
Genital  prolapse(618)  24  5.59%  74.83% 
other  108  25.17%  100.00% 
Total  429  100% 
Diseases  of  the  Musculoskeletal  system 
The  main  diagnosis  for  women  with  musculoskeletal  conditions  is  shown  in  Table  4. 
Back  problems  account  for  the  highest  proportion  of  visits.  Other  arthropathies 
account  for  a  further  10%.  Osteoarthritis  and  other  joint  disorders  make  up  around 
8%  each. 
108 Table  4:  Hospital  visits  made  by  women  recruited  to  IBIS:  Diseases  of  the 
Musculoskeletal  System 
3  digit  code  Diagnosis  Numbers  % 
724  Disorders  of  the  back  41  21.03% 
716  Arthropathies  20  10.26% 
715  Osteoarthritis  and  allied  disorders  17  8.72% 
717  Internal  derangement  of  knee  17  8.72% 
727  Disorders  of  tendon  and  synovium  16  8.21% 
714  Rheumatoid  arthritis  15  7.69% 
722  Intervertebral  disc  disorders  14  7.18% 
Other  1  -1  55  J  28.21% 
Total  --T  1 
195 
Diseases  of  the  Digestive  System 
Table  5  shows  the  main  reasons  for  attending  hospital  with  digestive  disorders. 
Cholelithiasis  is  the  main  specific  diagnosis  accounting  for  around  20%  of  the  reasons 
for  visits  in  this  group.  Other  less  specific  diagnosis  have  been  classified  under  537 
for  disorders  of  the  stomach  and  duodenum  including  hiatus  hernia  and  celiac  disease 
or  under  564  covering  pain  and  other  symptoms  in  the  lower  abdomen.  Together 
these  2  diagnoses  make  up  about  35%  of  the  total.  Other  conditions  reported  include, 
for  example,  7  women  with  diverticulitis,  4  women  having  6  visits  due  to 
gastrointestinal  haemorrhage  and  4  women  admitted  with  acute  appendicitis. 
Table  5:  Hospital  visits  made  by  women  recruited  to  IBIS:  Diseases  of  the 
Digestive  System 
3  digit  code  Diagnosis  Numbers  of  visits  % 
564  Digestive  disorders  33  24.09% 
574  Cholelithiasis  28  20.44% 
537  Disorders  of  stomach  and  duodenum  15  10.95% 
530  Disorders  of  oesophagus  7  5.11% 
562  Diverticula  of  intestine  7  5.11% 
520  wisdom  tooth  problems  6  4.38% 
578  Gastrointestinal  haemorrhage  6  4.38% 
577  Disease  of  the  pancreas  5  3.65% 
Other  29  21.17% 
outpatient  1  0.73% 
Total  137  100.00% 
109 Diseases  of  the  Vascular  System 
The  largest  proportion  of  visits  for  vascular  conditions  are  for  varicose  veins(25%) 
(see  Table  6).  There  were  also  13  visits  for  angina  and  11  for  hypertension.  Other 
forms  of  heart  disease  and  heart  failure  account  for  a  further  15%  of  the  visits.  A  total 
of  6  visits  were  recorded  for  venous  embolism  and  venous  thrombosis  with  a  further  2 
visits  for  thrombophlebitis  and  2  for  peripheral  vascular  disease.  There  was  1 
subarachnoid  haemorrhage  and  3  women  with  transient  cerebral  ischaemia;  there  were 
2  visits  for  acute  myocardial  infarction. 
Table  6:  Hospital  visits  made  by  women  recruited  to  IBIS:  Diseases  of  the 
Vascular  System 
3  digit  code  Diagnosis  Number  of  visits  % 
454  Varicose  veins  22  23.91% 
413  Angina  13  14.13% 
401  Hypertension  11  11.96% 
427  Cardiac  dysrhythmias  7  7.61% 
429  Complications  of  heart  disease  6  6.52% 
453  Venous  embolism/thrombosis  6  6.52% 
428  Heart  failure  3  3.26% 
435  Transient  Cerebral  ischaemia  3  3.26% 
410  Acute  myocardial  infarction  2  2.17% 
443  Peripheral  vascular  disease  2  2.17% 
448  Disease  of  capillaries  2  2.17% 
451  Phlebitis  2  2.17% 
396  Disease  of  aortic  /  mitral  valve  1  1.09% 
402  hypertensive  heart  disease  1  1.09% 
414  Chronic  ischaemic  heart  disease  1  1.09% 
426  Conduction  disorders  1  1.09% 
430  Subarachnoid  haemorrhage  1  1.09% 
444  Arterial  embolism  1  1.09% 
447  Other  disorders  of  arteries  1  1.09% 
344  Other  1  1.09% 
Outpatient  5  5.43% 
Total  92  100.00% 
110 Diseases  of  the  Nervous  System  and  Sense  organs 
The  majority  of  conditions  listed  under  diseases  of  the  nervous  system  and  sense 
organs  in  Table  7  below,  are  concerned  with  either  visual  disturbances  (25%)  or 
disorders  of  the  eye  (7.7%).  19  women  experienced  visual  disturbance  requiring  a 
visit  to  an  ophthalmologist.  Other  conditions  included  here  are  5  visits  by  4  women 
for  epilepsy  (345)  and  8  women  with  9  visits  for  vertigo  (386). 
Table  7:  Hospital  visits  made  by  women  recruited  to  IBIS:  Diseases  of  the 
Nervous  System  and  Sense  Organs. 
3  digit  code  Diagnosis  Number  of  visits  % 
368  Visual  disturbances  19  24.68% 
386  Vertigo  8  10.39% 
375  Lacrimal  disorders  6  7.79% 
345  Epilepsy  5  6.49% 
361  Retinal  detachment  4  5.19% 
365  Glaucoma  4  5.19% 
369  Low  vision  3  3.90% 
389  deafness  3  3.90% 
Other  diagnosis  23  29.87% 
Undefined  2  2.60% 
Total  77  100.00% 
Diseases  of  the  Endocrine  and  Metabolic  System 
Endocrine,  nutritional  metabolic  diseases  and  immunity  disorders  are  shown  in  Table 
8.  Diabetes  accounts  for  a  large  proportion  of  the  visits  in  this  group  (9  women  with 
12  visits)  with  thyroid  disorders  in  general  being  the  most  frequent.  11  women  in  this 
group  made  13  visits  for  mineral  disorders.  There  were  4  visits  for  disorders  of  the 
immune  system,  7  for  ovarian  dysfunction  and  3  for  thyrotoxicosis. 
Table  8:  Diseases  of  the  Endocrine,  Metabolic  and  Immune  System 
3  digit  code  Diagnosis  Numbers  of  visits  % 
246  Thyroid  disorders  18  24.32% 
250  Diabetes  mellitus  12  16.22% 
275  Mineral  disorders  13  17.57% 
256  Ovarian  dysfunction  7  9.46% 
111 279  Immune  disorders  4  5.41% 
242  Thyrotoxicosis  3  4.05% 
244  Hypothyroidism  3  4.05% 
272  Disorders  of  lipid  metabolism  3  4.05% 
240  Simple  goitre  2  2.70% 
252  Parathyroid  disorders  2  2.70% 
253  Disorders  of  pituitary  2  2.70% 
251  Pancreatic  disorders  1  1.35% 
266  Vitamin  B  deficiency  1  1.35% 
271  Carbohydrate  transport  disorder  1  1.35% 
274  Gout  1  1.35% 
276  Fluid  imbalance  1  1.35% 
Total  74  100.00% 
Procedures  undertaken  during  visits  to  hospital  by  women  recruited  to  IBIS 
There  were  507  hospital  visits  where  an  HRG  was  reported  out  of  1321  total  visits 
reported  (see  Table  9).  The  proportion  of  HRGs  reported  at  each  of  the  IBIS  follow 
up  visits  is  around  8%  on  each  of  the  visits  apart  from  at  6  months  where  it  is  only 
slightly  lower  at  6.7%.  Overall  there  is  no  indication  of  an  increase  in  the  rate  of 
hospital  use  requiring  a  procedure  by  women  in  IBIS  with  increasing  time  on  the  trial. 
Table  9:  Number  and  proportion  of  hospital  visits  including  a  procedure 
assigned  to  an  HRG  and  %  of  all  follow  up  visits  including  a  procedure. 
(Ordinary  outpatient  visits  defined  as  those  without  procedures  undertaken.  ) 
Month  MONTH06  MONTHI2  MONTHI8  MONTH24  MONTH30  MONTH36  MONTH42  MONTH48  Grand  Total 
HRG  132  123  96  65  39  24  18  10  507 
Outpatient  221  166  148  103  90  50  21  11  810 
not  known  2  1  1  0  0  0  0  0  4 
Total  355  290  245  168  129  74  39  21  1321 
All IBIS  visits  1966  1545  1160  851  480  262  110  21  6395 
%  HRG  6.7%  7.96%  8.27%  7.63%  8.12%  9.16%  na  na  7.92% 
The  numbers  and  causes  of  hospital  procedures,  which  are  assigned  an  HRG  reported 
by  women  in  the  study,  are  shown  in  Table  10.  The  HRGs  are  given  for  all  major  or 
minor  causes  of  hospital  admission  and  day  cases;  breast  biopsy  and  other  diagnostic 
procedures  such  as  those  for  investigation  of  the  digestive  system  are  included. 
112 Table  10:  Women  recruited  to  IBIS  undergoing  Procedures  (assigned  to  Health 
Care  Resource  Groups  -  HRGs)  during  hospital  visits. 
Hospital  visits  made  by  women  In  IBIS  by  procedure  and 
Health  care  Resource  Groups  (HRGs). 
HRG  Procedures  Number 
Ophthalmic  procedures 
b04  operation  on  eyelid 
b05  corneal  graft 
b06  cataract  2 
b07  detached  retina,  vitreous  detachment  and  tear  duct  operation  3 
Cancer 
BRCA  breast  cancer  18 
CABLA  bladder  cancer  I 
CACOL  colon  cancer 
OVCA  ovarian  cancer  2 
d02  lobectomy  (lung  cancer) 
Ear,  nose  and  throat  procedures 
c04  wisdom  tooth  extraction  5 
c22&c32  surgery  to  nasal  passages  &  sinus  operations  4 
c24  mouth  or  throat  procedures  including  throat  biopsy  and  treatment  for 
vocal  cords 
5 
c34  operation  on  salivary  gland 
Respiratory 
p04  pneumonia  9 
d07  bronchoscopy 
d14  atypical  viral  pneumonia 
d22  asthma  3 
Vascular 
e12  acute  myocardial  infarction  2 
e21  deep  vein  thrombosis  7 
a06  subarachnoid  haemorrhage 
ql  1  varicose  veins  19 
Digestive  system 
fl6&f35  endoscopyor  sigmoidoscopy  34 
f12  surgery  to  stomach  or  duodenum(very  major) 
f32  surgery  to  large  intestine  (very  major)  1 
f47  other  general  abdominal  disorders  3 
f65  gastrointestinal  bleed 
f71  abdominal  hernia(w  cc) 
f82  appendectomy  5 
f95  haemorrhoidectomy  4 
Liver  or  biliary 
g05  l  iver  biopsy  1 
g08  polycystic  disease 
g12  c  holecystectomy  11 
113 g15  residual  gallstones  1 
Musculoskeletal 
h02  primary  hip  replacement  2 
h04  primary  knee  replacement  4 
h07  shoulder,  ankle  or  elbow  replacement  2 
h09  ant  cruciate  ligament  reconstruction  1 
h  l0  arthroscopy  7 
hl  M12  12  foot  operations,  amputation  of  toe  I1 
h13&h  l4  operations  for  carpal  tunnel  syndrome  and  other  hand  procedures  7 
h  l7  soft  tissue  or  other  bone  procedures 
h22  musculoskeletal  (minor)  procedures  1 
h26  Inflammatory  spine  joint  or  connective  tissue  1 
h37  fractures  of  ankle  heel  or  other  lower  limb  5 
h40  shoulder,  elbow,  wrist  and  other  upper  limb  fractures  13 
h44  Major  cranial  visceral  or  blood  vessel  injury 
h52  removal  of  fixation  device 
101  minor  spinal  procedures 
r02  surgery  for  degenerative  spinal  disorders  4 
r04  vertebral  column  injury  w  decompression  or  fluid  I 
Breast  and  skin  care 
j02&j03  major  breast  surgery  inc.  plastics  9 
j05&j07  minor  and  intermediate  breast  surgery  including  breast  biopsy,  fna, 
cyst  aspiration  and  removal  of  lump  breast  surgery 
71 
j37  minor  skin  procedures  9 
j39  major  dermatological 
j42  major  skin  infections  I 
j43  major  skin  tumours  II 
j44  benign  tumours  or  dermatological  conditions  3 
Thyroidectomy 
kOl  partial  thyroidectomy  I 
k02  thyroidectomy 
k08  fluid  or  electrolyte  disorders 
Kidney  or  urinary  tract  infection 
110  kidney  infection  1 
119  bladders  tones  and  bladder  polypectomy  3 
123  bladder  or  urinary  mechanical  problems  3 
126  bladder  neck  procedure 
130  endoscopy(bladder)  1 
153  r  enal  stones  and  renal  colic  4 
154  i  ntravenous  pyelogram 
T 
Genital  tract 
mOl&mo2&mo3  c  olposcopy,  plus  vault  smear,  D&C  30 
m05  h  ysteroscopy  70 
m06  s  terilisation  7 
m07  h  ysterectomy  4  9 
Other 
n12  p  regnancy  2 
114 q07  surgery  for  Raynauds  syndrome  1 
q  10  procedures  on  the  lymphatic  system  I 
a25  transverse  myelitis  1 
a30  epilepsy 
s04  coagulation  disorders  I 
s13  pyrexia  of  unknown  origin  1 
s14  other  viral  illness  2 
s16  poisoning  or  overdose  2 
s25  other  admissions  I 
t07  depression  w/o  section  I 
Total  (HRGs)  507 
O  outpatient  814 
Grand  Total  1321 
The  2  most  frequent  reasons  for  admission  to  hospital  among  women  experiencing  a 
hospital  visit  were  either  minor  or  intermediate  gynaecological  procedures,  principally 
m05  -  hysteroscopy  or  j07  -  breast  interventions  such  as  breast  biopsy,  fine  needle 
aspiration  of  suspicious  breast  lump 
,  removal  of  benign  lump  or  cyst  aspiration.  The 
gynaecological  procedures  shown  in  the  table  as  m05  (hysteroscopy  or  other  minor 
procedures  in  the  upper  genital  tract),  m07  (hysterectomy  and  other  more  major 
procedures  in  the  upper  genital  tract)  and  m03  (procedures  such  as  D&C  or 
colposcopy  in  the  lower  genital  tract  together  account  for  over  a  quarter  of  all 
procedures.  Including  mOl  and  m02  (minor  and  intermediate  procedures  in  the  lower 
genital  tract  ),  gynaecological  procedures  are  a  third  of  all  procedures  experienced  by 
this  group  of  women. 
Of  breast  care  excluding  breast  cancer,  which  is  discussed  separately  below, 
procedures  included  under  j07  together  with  j05  (minor  and  intermediate  breast 
surgery  account  for  some  13%  of  all  procedures.  Major  breast  procedures  - 
principally  prophylactic  mastectomy  -  account  for  only  an  additional  2%  of  the  cases. 
None  of  the  women  undergoing  procedures  in  these  categories  had  a  diagnosis  of 
breast  cancer,  most  were  classified  under  Disease  Chapter  10  for  disorders  of  the 
genital  tract  including  `other  disorders  of  the  breast'.  The  reason  for  prophylactic 
mastectomy  was  in  most  cases  given  as  due  to  concern  about  family  history  from 
breast  or  ovarian  cancer  though  in  one  case  cancer  phobia  was  the  stated  reason. 
115 There  were  18  breast  cancer  cases  identified  in  this  group  of  women.  None  have  been 
assigned  to  an  HRG  since  women  leave  the  study  once  a  breast  cancer  diagnosis  has 
been  made;  no  treatment  details  are  available.  An  average  cost  for  the  treatment  of 
breast  cancer  of  £6000  has  been  assigned  to  these  cases.  Other  cases  of  cancer 
identified  in  this  group  of  women  are  one  case  each  of  gastric  cancer,  cancer  of  the 
colon,  lung,  bladder  and  2  cases  of  cancer  of  the  ovary.  HRGs  were  assigned  to  2  of 
these  cases  since  the  women  remained  in  the  study.  These  were  d02  for  lobectomy  of 
the  lung  and  f12,  for  major  gastric  surgery. 
Eleven  women  have  a  procedure  code  for  skin  tumours  (j43).  This  includes  2  women 
with  malignant  melanoma  and  9  with  other  skin  neoplasms  such  as  rodent  ulcer  or 
basal  cell  carcinoma;  a  further  2  women  had  benign  tumours  removed  (j44). 
Admissions  to  hospital  for  disorders  of  the  digestive  system  are  also  common  in  this 
group.  Most  (f16  and  f35)  are  for  endoscopy  or  colonoscopy  (including 
sigmoidoscopy).  A  small  proportion  of  women  had  haemorrhoidectomy  and  2  cases 
of  major  surgery  either  of  the  stomach  or  large  intestine  (including  the  case  of  gastric 
cancer  described  above. 
Any  impact  of  tamoxifen  on  osteoporosis  or  musculoskeletal  system  in  general  is 
likely  to  be  slow  to  progress.  There  were  only  18  fractures  requiring  a  hospital 
procedure  recorded  among  this  group  of  women,  these  were  mainly  in  the  wrist  or 
other  upper  limb  region  (shoulder  and  elbow)  with  only  5  fractures  in  the  ankle  or 
lower  limb.  A  small  number  of  11  women  experienced  orthopaedic  operations  due  to 
arthritis  mainly  foot  operations  with  4  for  carpal  tunnel  syndrome.  There  were  7 
arthroscopies. 
Other  than  the  cancer  cases  described  above,  very  few  procedures  of  concern  to 
women  taking  tamoxifen  have  been  recorded  in  those  reporting  hospital  visits. 
There  have  been  7  reports  of  thrombosis  (pulmonary  embolism  or  deep  vein 
thrombosis)  and  no  reports  of  endometrial  cancer  in  this  group.  7  women  reported 
hospital  procedures  involving  ophthalmic  problems:  problems  of  detached  retina  and 
vitreous  humour,  cataract,  corneal  graft  and  an  operation  on  an  eyelid.  Visual 
disturbances,  in  general,  are  more  likely  to  be  seen  as  outpatients. 
116 Distribution  of  cost 
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A  frequency  distribution  of  the  total  costs  including  all  ordinary  outpatient  visits  and 
those  assigned  an  HRG  is  shown  below. 
Fig  2.  Frequency  distribution  of  the  cost  of  hospital  visits  per  woman  recruited  to 
IBIS. 
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cost  (£) 
Of  women  reporting  a  hospital  visit  the  mean  cost  per  hospital  visit  is  £945.80.  The 
median  cost  of  hospital  visits  for  all  women  reporting  a  visit  is  less  at  £507  suggesting 
that  most  of  the  resource  use  is  in  the  early  part  of  the  distribution.  Although  only  the 
reported  visits  are  shown  in  the  histogram,  the  total  distribution  of  costs  of  hospital 
visits  for  all  women  recruited  to  IBIS  is  in  fact  non  normal  having  a  long  left  hand  tail 
117 since  most  women  (over  60%)  have  not  had  a  visit  to  hospital.  The  range  of  costs  for 
those  reporting  a  hospital  visit  is  £74  -  £7793  for  823  women. 
Figure  3.  shows  how  the  total  resource  use  on  hospital  visits  by  women  in  IBIS  is 
distributed  among  the  major  ICD9  Disease  Chapters. 
Fig  3:  Costs  of  visits  to  hospital  by  women  in  IBIS  by  main  ICD9  disease  chapter. 
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so  Cost 
In  line  with  the  distribution  of  numbers  of  visits  the  greatest  costs  are  seen  in  the 
disease  chapter  concerned  with  gynaecological  and  breast  symptoms.  The  second 
major  category  of  costs  is  however  in  the  group  containing  malignancies.  Visits 
concerned  with  musculoskeletal  disease  account  for  the  next  largest  category  of  cost 
followed  by  diseases  of  the  digestive  system  including  biliary  disease  and  diseases  of 
the  vascular  system. 
118 Differences  in  the  pattern  of  hospital  visits  for  women  taking  tamoxifen  or 
placebo 
Method  of  Analysis 
The  data  were  separated  into  tables  comprising  women  taking  tamoxifen  or  placebo. 
The  two  groups  are  labelled  A  and  B  though  may  not  represent  the  same  arm  of  the 
trial  throughout  the  analysis.  Adverse  disease  end  points  and  such  as  serious 
malignancies  or  pulmonary  embolism  are  not  reported  separately  in  the  2  groups.  The 
costs  associated  with  these  endpoints  are  aggregated  under  main  disease  headings  or 
within  the  HRGs.  The  main  aim  here  is  to  assess  the  likely  level  of  morbidity 
associated  with  women  in  each  of  2  arms  of  the  trial  as  measured  through  visits  to 
hospital. 
Results 
The  number  of  women  reporting  a  hospital  visit  in  each  of  the  2  groups  A  and  B  is 
remarkably  similar.  By  December  1997  -  the  cut  off  taken  for  this  analysis  -  there 
were  1988  women  enrolled  in  IBIS,  1000  in  group  A  and  988  in  group  B.  Of  these 
women,  407  in  group  A  (40.7%)  and  418  in  group  B  (42.3%)  had  reported  a  hospital 
visit.  The  total  number  of  follow  up  IBIS  visits  made  by  all  of  the  women  recruited  to 
the  study  was  6471  a  mean  of  3  IBIS  follow  up  visits  for  each  women  recruited 
consistent  with  a  median  of  18  months  follow  up.  There  were  664  visits  to  hospital  by 
women  in  group  A,  a  total  of  1.63  visits  per  woman  compared  with  657  visits  made 
by  women  allocated  to  group  B,  a  total  of  1.57  visits  per  woman. 
Reasons  for  hospital  visits  by  main  disease  chapter 
The  rate  of  reporting  of  hospital  visits  is  the  same  in  each  of  the  two  groups  A  and  B 
as  for  all  women.  In  Table  11,  the  ranking  of  the  disease  chapters  in  terms  of  the 
number  and  proportion  of  total  visits  in  each  series  is  similar  in  both  series  to  that 
seen  in  the  total  of  hospital  visits  presented  earlier. 
119 Table  11:  Number  and  %  of  Hospital  visits  made  by  women  in  either  A  or  B  by 
main  ICD  9  Disease  Chapter. 
Disease  Chapter 
In  order  of% 
Series  A  %  of  Total 
In  Series  A 
Disease  Chapter 
In  order  of  Series  A 
Series  a  %  of  Total 
in 
in  Series  B 
Genitourinary  226  32.90%  Genitourinary  203  32.02% 
Musculoskeletal  114  16.59%  Musculoskeletal  81  12.78% 
Digestive  62  9.02%  Digestive  75  11.83% 
Vascular  47  6.84%  Vascular  45  7.10% 
Endocrine  and  metabolic  38  5.53%  Endocrine  36  5.68% 
Respiratory  system  33  4.80%  Respiratory  24  3.79% 
Nervous/sense  organs  32  4.66%  Nervous  system  45  7.10% 
Neoplasm  32  4.66%  Neoplasms  29  4.57% 
Injury  and  poisoning  29  4.22%  Injury  32  0  5.05% 
Skin  13  1.89%  Skin  18  2.84% 
Infectious  disease  12  1.75%  Infectious  5  0.79% 
Mental  disorders  9  1.31%  Mental  5  0.79% 
Pregnancy  3  0.44%  Pregnancy  0  0.00% 
Blood  2  0.29%  Blood  3  0.47% 
Unassigned  35  5.09%  Unassigned  33  5.21  % 
Total  687  100.00°h  Total  634  100.00°/. 
Most  women  attended  hospital  for  reasons  associated  with  principally  Disease 
Chapters  10,13,9  and  7:  diseases  of  the  genitourinary  system  (  both  breast  diseases 
and  reasons  associated  with  the  genital  organs  such  as  menstrual  disorders), 
musculoskeletal  disorders,  digestive  and  cardiovascular  problems  respectively. 
There  are  no  obvious  differences  in  the  rate  of  hospital  use  between  the  2  series  of 
women  (Table  12).  For  the  most  part  the  width  of  the  95%  confidence  intervals  for 
the  odds  ratio  between  the  2  series  reflects  the  small  sample  size  for  most  of  the 
disease  categories.  There  may  be  a  statistical  association  in  the  rate  of  visits  for 
vascular  causes  between  series  A  and  B  with  an  odds  ratio  of  1.06  (CI:  1.04-1.07). 
For  neoplasms  the  odds  ratio  is1.12  (CI:  1.06-1.1).  In  the  largest  category  -  that  of 
genitourinary  diseases  -  the  odds  ratio  is  1.13  but  the  confidence  interval  includes  1.0 
suggesting  that  the  result  is  not  significant  for  p=0.05.  Likewise  for  musculoskeletal 
conditions  the  odds  ratio  suggests  an  effect  though  the  confidence  interval  is  wide  and 
includes  the  null  value  suggesting  that  there  is  no  statistical  significance  at  this  level. 
120 Overall  the  odds  ratio  of  1.1  between  series  A  and  B  for  all  hospital  visits  also  has  a 
confidence  interval  that  includes  1.0  (CI:  1.00-1.21). 
Table  12:  Hospital  Visits  for  Series  A  and  B  in  each  main  Disease  Chapter 
Disease  chapter  Total  (A&B)  Total  (A)  Total  (B)  Odds  ratio  Confidence 
interval 
(95%) 
Genitourinary  429  226  203  1.13  1.0-1.29 
Musculoskeletal  195  114  81  1.43  0.59  -  3.44* 
Digestive  137  62  75  0.84  0.69-1.01 
Vascular  92  47  45  1.06  1.04-1.07 
Endocrine  and  metabolic  74  38  36  1.07  1.05-  1.09 
Respiratory  system  57  33  24  1.39  0,89-2.19 
Nervous  system  and  sense  organs  77  32  45  0.72  0.44-1.19 
Neoplasm  61  32  29  1.12  1.06-1.18 
Injury  and  poisoning  61  29  32  0.92  0.89-95 
Skin  31  13  18  0.73  0.54-0.98 
Infectious  disease  17  12  5  2.43  0.44-13.54 
Mental  disorders  14  9  5  1.83  0.87-3.82 
Other  8  5  3 
Unassigned  68  35  33  1.08  1.05-1.10 
Grand  Total  1321  687  634  1.1  1.00-1.21 
"signlflcant(p<0.05) 
Procedures  undertaken  by  women  taking  tamoxifen  or  placebo  during  hospital 
visits. 
Table  13  shows  the  differences  between  the  2  series  in  use  of  all  of  the  procedures 
categorised  as  HRGs.  The  list  contains  only  those  procedures  where  visits  occur  in 
sufficient  numbers  to  allow  meaningful  analysis  and  for  conditions  or  disease  areas, 
which  might  be  affected  by  tamoxifen.  Conditions  such  as  multiple  sclerosis,  asthma 
and  eczema  are  not  included  in  this  part  of  the  analysis  since  they  occur  in  this  series 
in  extremely  small  numbers  and  there  is  no  evidence  that  they  are  affected  by 
tamoxifen. 
121 The  following  analysis  includes  HRGs  in  main  ICD9  Disease  Chapter  : 
"  10:  including  2  main  categories  of  procedures  for  either  breast  disease  or  the 
female  genital  tract.  These  are  j02  &  j03  covering  major  breast  surgery  including 
plastics,  j05  &  j07  covering  minor  and  intermediate  breast  surgery  including 
breast  biopsy,  fine  needle  aspiration,  cyst  aspiration  and  surgery  for  removal  of 
lump  and  mOl,  m02,  m03  covering  colposcopy,  vault  smear  and  D&C  or  m05  for 
hysteroscopy,  m06  for  sterilisation  or  m07  for  hysterectomy 
"  13:  principally  separating  the  fractures  which  are  all  included  in  this  disease 
chapter  (both  of  lower  limb(h37)  and  upper  limb(h40))  from  other  procedures 
mostly  associated  with  arthritis  including  h02  (primary  hip  replacement),  h04 
(primary  knee  replacement),  h07  (shoulder,  ankle  or  elbow  replacement), 
arthroscopy  (h  10),  operations  for  carpal  tunnel  syndrome  and  other  hand 
procedures  (h13  and  h14)  and  h52  (removal  of  fixation  device)  following  hip 
replacement 
"  9:  there  are  2  main  categories  covering  either  the  digestive  tract  or  biliary 
conditions.  The  former  include  the  diagnostic  procedures  of  endoscopy  & 
sigmoidoscopy  (fl6&f35),  surgery  to  stomach  or  duodenum  (fl2)  surgery  to  large 
intestine  (f32),  other  general  abdominal  disorders  (f47),  gastrointestinal  bleed 
(f65),  abdominal  hernia  (f71)  appendectomy  (f82),  haemorrhoidectomy  (05). 
Biliary  conditions  in  this  chapter  include  g05  (liver  biopsy),  g08  (polycystic 
disease),  g12  (cholecystectomy)  and  g15  (gallstones) 
"  7;  vascular  conditions  have  been  grouped.  These  include:  acute  myocardial 
infarction  (e12),  deep  vein  thrombosis  (e21),  subarachnoid  haemorrhage  (a06)  and 
varicose  veins  (q  11) 
"  6;  ocular  conditions  have  also  been  grouped.  These  include  bo7  (detached  retina 
(vitreous  detachment  and  tear  duct  operation),  b04  (operation  on  eyelid)  b05 
(corneal  graft),  b06(cataract). 
The  major  disease  chapter  responsible  for  the  largest  numbers  of  procedures  in  both 
groups  of  women  is  for  genitourinary  disorders  (See  Table  13).  This  disease  chapter 
includes  procedures  for  genitourinary  conditions  concerned  with  breast  disease  and 
with  the  genital  tract  as  listed  in  the  bullet  points  above. 
122 Table  13:  Numbers  of  Procedures  (HRGs)  in  the  most  frequent  disease  areas  for 
women  taking  tamoxifen  or  placebo  (Groups) 
Groups 
A  B  OR  CI  (95%) 
Musculoskeletal 
Fractures  10  12  0.85  0.79-0.91 
Other  19  20  0.96  0.96-0.97 
Total  29  32  0.92  0.89-0.95 
Genitourinary 
Breast  49  31  1.6  0.56-4.59 
Genital  85  63  1.37  0.74-2.53 
Total  134  94  1.45  0.53-3.93 
Circulatory 
Vascular  15  14  1.09  1.06-1.11 
Digestive 
Biliary  9  5  1.83  0.87-3.82 
Renal  2  9  0.23  0.01-7.37 
Other  25  23  1.1  1.06-1.14 
Total  36  37  0.93  0.91-0.95 
Ocular  5  3  2.54  0.76-8.46 
The  odds  ratio  between  groups  A  and  B  is  indicative  of  a  difference  between  the  two 
groups  for  diseases  of  the  breast  and  genitourinary  system  though  the  result  is  not 
significant.  The  confidence  intervals  are  wide  and  include  1.0.  This  result  does  merit 
follow  up  in  a  larger  series  of  women.  Renal  procedures  do  also  show  apparent  excess 
in  1  group  over  the  other  although  the  numbers  are  small  and  the  difference  is  not 
significant  (p<0.05).  For  other  main  procedures  there  are  no  significant  differences  in 
the  observed  numbers  of  procedures  for  women  in  each  of  the  two  series. 
Cost 
There  is  no  significant  difference  (p=0.241)  between  the  overall  cost  in  series  A  and  B 
(see  Table  14). 
123 Table  14:  Mean,  median  and  range  of  costs  for  all  hospital  visits  in  series  A  and 
B. 
Mean  Median  and  range  of  overall  cost  for  women  in  series  A  and  B 
f  series  A  series  B 
mean  990  890 
median  553  451 
range  74-6374  1-7793 
n  418  407 
sum  413,892  362,612 
The  mean  total  cost  of  visits  in  series  A  is  £990  (standard  error,  £61.41)  and  median  is 
£553 
. 
The  mean  in  series  B  is  slightly  lower  at  £890  (standard  error,  £61.41)  and  the 
median  is  £451.  The  histograms  in  fig  4  and  fig  5  present  the  distribution  of  cost  for 
all  hospital  visits  in  each  of  the  2  series  A  and  B. 
Distribution  of  resource  use 
Looking  at  the  cumulative  distribution  of  cost  for  each  of  the  2  series  A  and  B  it 
seems  that  a  large  proportion  of  the  total  cost  of  hospital  visits  is  accounted  for  by  a 
small  number  of  women. 
Figure  4:  Cumulative  distribution  of  resource  use  by  women  in  series  A 
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124 
1  27  53  79  105  131  157  183  209  235  261  287  313  339  365  391 Figure  5.  Cumulative  resource  use  distribution  for  all  hospital  visits  by  women  in 
series  B. 
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Number  of  women 
The  lower  part  of  the  distribution  in  series  A  shows  that  203  women  (50%)  account 
for  only  15%  of  the  total  cost  (£53,369).  By  contrast,  at  the  other  end  of  the 
distribution,  11  women  (3%)  account  for  15%  of  the  cost. 
Differences  between  women  taking  tamoxifen  or  placebo  for  the  cost  per  hospital 
visit  in  each  main  disease  chapter 
Table  15  shows  the  total  cost  by  chapter  and  the  cost  per  visit  within  each  chapter  for 
the  2  groups  A  and  B.  The  mean  cost  per  visit  for  each  of  the  main  disease  chapters  is 
very  similar  between  the  2  groups  at  £540.82  for  group  A  and  £540.94  in  group  B. 
There  are  however  interesting  differences  between  the  rank  order  for  cost  across 
disease  chapters  compared  with  simply  ranking  the  numbers  of  visits  in  each  chapter. 
Moreover  the  differences  in  cost  between  chapters  indicates  that  small  changes  in  the 
disease  profile  for  a  group  of  women  may  affect  health  services  costs  quite 
considerably. 
125 Table  15:  Cost  per  hospital  visit  within  each  disease  chapter  for  women  taking 
tamoxifen  or  placebo  (groups) 
DISEASE  CHAPTER  Group  A  Group  B 
Total  Cost  Visits  Mean  cost  pe 
visit 
r  Total  Cost  Visits  Mean  cost  per 
visit 
NEOPLASMS  93,964.00  32  2,936.38  59950  29  2,067.24 
GENITOURINARY  127,107.00  226  562.42  128223  203  631.64 
INJURY  15,854.00  29  546.69  17688  32  552.75 
MUSCULOSKELETAL  58,617.00  114  514.18  46476  81  573.78 
VASCULAR  23,924.00  47  509.02  29270  45  650.44 
RESPIRATORY  16,612.00  33  503.39  15141  24  630.88 
MENTAL  3,988.00  9  443.11  3452  5  690.4 
DIGESTIVE  25,240.00  62  407.1  40929  75  545.72 
INFECTIOUS  4,633.00  12  386.08  2096  5  419.2 
ENDOCRINE  12,742.00  38  335.32  11560  36  321.11 
NERVOUS  6,744.00  32  210.75  10853  45  241.18 
BLOOD  400  2  200  1215  3  405 
SKIN  2,336.00  13  179.69  3802  18  211.22 
PREGNANCY  204  3  68  0  0 
UNASSIGNED  7,756.00  25  310.24  5728  33  173.58 
MEAN  540.82  540.94 
MEDIAN  407.1  545.72 
The  table  shows  clearly  how  the  costs  of  neoplasms  is  considerable;  this  chapter  has 
by  far  the  highest  cost  per  visit  despite  a  relatively  low  number  of  cases.  Most  of  the 
women  presenting  with  a  malignant  neoplasm  left  the  study  and  so  the  costs  in  this 
category  cover  the  total  cost  of  care  whereas  costs  in  other  categories  of  disease  are 
restricted  to  specific  procedures  recorded  during  the  visit. 
The  high  costs  of  other  categories  of  disease  such  as  injury  and  poisoning  and  mental 
disorders  are  also  apparent  in  the  order  of  costs.  The  mean  cost  per  patient  for  injury 
makes  this  the  third  highest  cost  category  after  the  cost  per  patient  for  genitourinary 
disorders  -  the  most  frequent  reason  for  attending  hospital.  In  group  B  the  cost  per 
patient  for  mental  disorders  is  also  relatively  high  at  £630.88  compared  with  an 
average  of  £540.9  overall.  The  difference  is  not  significant  (p<0.05).  The  cost  per 
patient  for  vascular  conditions  is  high  in  group  B  (£650.44  per  visit)  suggesting  that 
the  case  mix  is  more  complex  compared  with  group  A  (£509.02  per  visit)  despite 
126 there  being  a  similar  number  of  patients  in  the  2  groups:  47  in  group  A  and  45  in 
group  B. 
The  costs  per  patient  are  lowest  in  those  specialities  where  patients  are  most  likely  to 
be  seen  in  the  outpatient  setting.  These  include  endocrine,  metabolic  or  immunity 
disorders  in  ICD9  Chapter  3  with  a  mean  cost  per  patient  of  £335.32  in  group  A  and 
£321.11  in  group  B.  This  chapter  includes  diabetes.  Diseases  of  the  blood  in  chapter 
4  with  a  mean  cost  of  £200  per  patient  in  group  A  and  £405  in  group  B  includes 
common  conditions  such  as  atrial  fibrillation  which  is  treated  through  anticoagulation 
clinics  usually  in  outpatient  settings.  For  diseases  of  the  sense  organs  in  chapter  6  the 
mean  cost  per  patient  is  £210.75  in  group  A  and  £241.18  in  group  B.  This  includes 
routine  visits  for  eye  conditions  and  diseases  of  the  central  nervous  system  such  as 
epilepsy  also  treated  in  outpatient  settings. 
The  cost  per  patient  for  genitourinary  conditions  is  higher  in  group  B  than  in  group  A 
with  a  higher  overall  cost  despite  a  smaller  number  of  patients  in  this  group.  The 
series  clearly  includes  patients  having  a  greater  severity  of  disease  requiring  more 
costly  intervention. 
Cost  of  main  procedure  (assigned  to  an  HRG)  undertaken  during  hospital  visits 
for  women  taking  tamoxifen  or  placebo. 
Table  16  sets  out  the  costs  per  HRG  for  the  most  frequent  procedures  undertaken 
during  hospital  visits.  Costs  are  similar  for  women  in  the  two  arms  of  the  trial. 
However  in  reviewing  specific  procedures  it  seems  that  the  costs  involved  per 
procedure  can  vary  within  disease  areas.  Fractures,  for  example,  are  clearly  a  smaller 
part  of  the  overall  cost  of  musculoskeletal  disorders  than  other  conditions  grouped 
under  this  heading.  This  difference  is  more  apparent  in  group  B. 
Case  mix  differences  between  the  series  are  also  clear.  Procedures  concerned  with  the 
breast  and  genital  organs  for  example,  though  more  frequent  in  A  have  a  higher  cost 
per  case  than  found  in  those  in  B. 
127 Table  16:  Cost  per  HRG  for  women  taking  tamoxifen  or  placebo  (groups) 
Group  A 
Main  HRGs  Nos.  of  HRGs  Cost  of  HRGs  %  of  total  cost 
in  group  A 
Mean  cost  per 
procedure 
Genital  organs  85  82305  53.00%  968.29 
Breast  49  31867  55.00%  650.35 
Musculoskeletal  19  24030  41.00%  1264.74 
Digestive  25  17321  66.00%  692.84 
Biliary  9  12253  68.00%  1361.44 
Vascular  15  11910  44.00%  794 
Fractures  10  10990  56.00%  1099 
Ocular  5  4863  76.00%  972.6 
Renal  2  400  11.00%  200 
Total  219  195939 
Mean  Cost  Per  HRG  889.25 
Group  B 
Main  HRGs  Nos.  of  HRGs  Cost  of  HRGs  %of  total  cost  in 
series  B 
Mean  cost  per 
procedure 
Genital  organs  63  73979  47.00%  1174.27 
Musculoskeletal  20  34570  59.00%  1728.5 
Breast  31  25642  45.00%  827.16 
Vascular  14  15173  56.00%  1083.79 
Digestive  23  8865  34.00%  385.43 
Fractures  12  8508  44.00%  709 
Biliary  5  5702  32.00%  1140.4 
Renal  9  3051  89.00%  339 
Ocular  2  1550  24.00%  775 
Total  179  177040 
Mean  Cost  per  HRG  906.95 
Discussion 
Comparison  of  the  rate  of  hospital  use  by  the  women  in  IBIS  with  routine  information 
from  the  NHS  admissions  data  supports  the  validity  of  the  information  collected  here 
since  the  rate  of  hospital  use  is  broadly  that  which  might  be  expected  for  women  in 
the  age  group.  Moreover  the  reasons  for  hospital  visits  are  similarly  distributed 
amongst  disease  groups  within  the  IBIS  women  and  the  NHS  admissions  data. 
Comparing  the  rate  of  admission  to  hospital  (for  both  ordinary  admissions  and  day 
cases)  for  women  in  the  general  population  in  England  (aged  45-64)  161  with  the  use  of 
128 hospital  services  by  women  recruited  into  IBIS  for  specific  causes,  does  however 
seem  to  suggest  a  higher  consultation  rate  for  genitourinary  conditions  among  women 
recruited  to  IBIS.  Further  investigation  of  this  estimate  would  require  more  detailed 
information  from  NHS  routine  sources  than  is  generally  available  and  it  is  important 
to  note  that  the  IBIS  data  set  is  not  strictly  comparable  with  routine  data  collected 
from  the  NHS  returns.  This  is  because  the  NHS  data  set  counts  consultant  episodes 
rather  than  individual  women  and  because  of  the  eligibility  criteria  for  IBIS  that 
excludes  women  who  are  likely  to  have  a  high  rate  of  illness  168.  In  particular  women 
with  a  history  of  neoplasm  or  some  vascular  conditions  such  as  deep  vein  thrombosis 
are  ineligible  for  recruitment  to  the  trial.  This  finding  does  however  merit  further 
review  once  recruitment  is  completed  and  analysis  of  hospital  visits  can  be  completed 
on  a  larger  sample  over  a  longer  time  period. 
The  pattern  of  reported  morbidity  in  terms  of  the  kinds  of  conditions  presented  is 
consistent  with  that  seen  in  the  NHS  hospital  admissions  data  with  the  exception  of 
the  rate  of  admissions  for  neoplasms  -  the  commonest  reason  for  admission  in  the 
NHS  for  women  in  this  age  group.  Women  recruited  to  IBIS  are  most  likely  to  use 
hospital  services  for  conditions  associated  with  the  breast  or  due  to  genital  disorders 
such  as  fibroids  or  abnormal  bleeding.  Other  frequent  causes  of  hospital  use  are,  for 
musculoskeletal  disorders,  digestive  disease  and  vascular  disease.  These  causes  of 
admission  are  seen  in  the  same  rank  order  for  women  in  IBIS  and  in  the  NHS  data  set 
for  the  general  population. 
There  are  few  differences  in  overall  reported  hospital  morbidity  for  women  in  the  2 
arms  of  the  trial  in  terms  of  the  numbers  of  visits  for  all  causes.  There  do  however 
appear  to  be  some  differences  emerging  for  women  in  the  two  groups  for  disease 
associated  with  the  breast  and  for  genital  conditions.  This  finding  does  indicate  the 
need  for  further  study  in  this  area.  In  particular  it  will  be  important  to  discern  -  once 
the  trial  is  completed  -  whether  the  difference  between  the  2  groups  is  an  increase  in 
the  frequency  of  symptoms  in  these  2  disease  areas  for  women  taking  tamoxifen  or 
whether  it  is  a  protective  effect. 
Looking  at  the  analysis  of  procedures  undertaken  during  hospital  visits  (assigned  to  an 
HRG)  it  is  apparent  that  small  differences  in  cost  may  have  a  large  impact  overall 
129 considering  the  potentially  large  numbers  of  women  who  might  wish  to  be  involved  in 
taking  tamoxifen  prophylaxis.  For  breast  symptoms,  for  example  the  difference  in  the 
cost  per  visit  per  HRG  for  women  taking  tamoxifen  or  placebo  is  £177  per  woman 
with  an  odds  ratio  of  1.6  for  women  undergoing  a  procedure  for  breast  symptoms 
between  the  two  groups.  Should  this  represent  a  saving  on  the  cost  of  benign  breast 
disease  to  the  health  service  for  women  taking  tamoxifen  prophylaxis  the  impact  may 
be  substantial. 
By  contrast,  an  increase  in  the  numbers  of  procedures  needed  to  treat  a  possible 
increase  in  gynaecological  symptoms  in  the  intervention  group  by  say  one  third  of 
women  -  the  difference  seen  between  group  A  and  B  here  -  with  the  cost  difference 
between  the  2  groups  of  around  £200  as  found  between  A  and  B  may  give  rise  to  a  net 
cost  of  health  care  due  to  women  taking  tamoxifen  prophylaxis.  The  direction  of  the 
effect  found  in  breast  and  gynaecological  procedures  is  unknown  at  this  stage  but  the 
possible  impact  on  the  cost  effectiveness  of  chemoprophylaxis  will  be  tested  in  the 
sensitivity  analysis  presented  in  the  subsequent  chapter. 
The  distribution  of  cost  for  women  in  each  of  the  2  arms  of  the  trial  show  that  a  high 
proportion  of  overall  cost  of  hospital  visits  is  due  to  a  small  number  of  women.  This 
suggests  that  it  is  the  outcome  in  terms  of  high  cost  adverse  events  particularly 
neoplasms  which  will  determine  the  balance  of  cost  effectiveness  for  tamoxifen 
prophylaxis  of  breast  cancer. 
The  methodology  used  in  this  analysis  of  categorising  the  diagnosis  into  major  ICD9 
disease  chapters  is  broad  enough  to  allow  comparison  across  major  disease  areas 
between  women  in  the  2  arms  of  the  trial.  Costing  the  procedures  undertaken  by  the 
women  during  hospital  visits  using  HRGs  takes  account  of  possible  differences  in 
case  mix  between  the  women  which  may  affect  the  costs  of  health  care.  This  method 
of  costing  has  been  well  validated  within  the  NHS.  It  would  not  have  been  possible 
because  of  the  small  numbers  involved  to  compare  specific  diagnosis  between  the  2 
series  of  women  or  to  assess  in  more  detail  the  individual  costs  of  care. 
The  analysis  is limited  at  this  stage  because  of  the  need  for  longer  term  follow  up  and 
the  importance  of  retaining  the  blinded  nature  of  the  study.  It  is  also  important  to  note 
130 that  a  number  of  biases  are  possible  at  this  stage  which  may  underestimate  aspects  of 
morbidity  particularly  those  likely  to  have  a  lag  time  or  latency  period  before 
symptoms  develop.  These  will  arise  firstly  because  the  period  of  time  over  which  the 
sample  was  taken  will  underestimate  longer  term  effects.  Secondly,  it  is  possible  that 
women  most  likely  to  develop  adverse  symptomatology  in  relation  to  recruitment  to 
the  trial  may  have  a  greater  tendency  to  withdraw  than  those  for  whom  any  effects  of 
long  term  tamoxifen  use  are  benign  or  beneficial.  The  nature  of  the  randomised  trial 
design  with  complete  randomisation  of  subjects  should  be  sufficient  to  address  biases 
concerned  with  the  latter  effect  though  further  follow  up  is  needed  to  fully  understand 
the  potential  for  changes  in  morbidity  of  women  taking  long  term  tamoxifen  on 
resource  use  associated  with  health  services. 
More  detailed  assessment  of  the  hospital  visits  made  by  the  women  will  be  possible 
once  the  trial  is  complete  and  a  full  unrestricted  analysis  can  take  place.  At  this  stage 
it  appears  that  in  general  no  substantial  deficits  or  improvements  in  morbidity  seem  to 
occur  for  women  recruited  to  IBIS  or  between  the  2  arms  of  the  trial.  There  are  no 
differences  in  the  pattern  of  morbidity  in  comparison  with  that  of  the  general 
population. 
Summary 
The  costs  of  changes  in  morbidity  which  might  be  attributable  to  long  term  use  of 
tamoxifen  is  assessed  through  review  of  the  use  of  hospital  services  by  all  women 
recruited  to  IBIS  at  the  end  of  December  1997  (1988  women).  Small  changes  in  the 
use  of  hospital  services  or  prescribed  medications  for  the  age  group  targeted  in 
prevention  trials  could  have  a  significant  impact  on  overall  cost  if  morbidity  worsened 
or  indeed  improved  for  large  numbers  of  the  women  involved.  Yet,  there  have  been 
few  studies  published  on  the  effect  of  tamoxifen  on  morbidity  as  measured  through 
changes  in  hospitalisation  rates  or  use  of  medications.  Prevention  trials  have 
published  endpoints  other  than  the  incidence  and  mortality  from  breast  cancer  though 
have  mostly  been  concerned  with  ischaemic  heart  disease  and  vascular  events  or  with 
thromboembolism.  There  has  been  a  great  deal  of  concern  about  endometrial  cancer. 
131 The  morbidity  reported  here  is  derived  from  information  given  by  women  recruited  to 
IBIS  during  the  first  and  all  subsequent  follow  up  visits.  The  diagnosis  are  recorded 
and  assigned  to  an  ICD  9  diagnosis  code  and  by  Health  Care  Resource  Groups 
(HRGs)  in  order  to  quantify  and  cost  them.  The  main  value  of  HRGs  is  to  provide  a 
validated  method  for  producing  case  mix  adjusted  information  with  which  to  compare 
the  morbidity  patterns  for  both  arms  of  IBIS.  No  previous  studies  have  reported  the 
use  of  HRGs  to  describe  changes  in  morbidity  patterns  in  this  context. 
The  information  is  aggregated  to  compare  the  numbers  and  reason  for  hospital  visits 
looking  at  both  diagnosis  and  treatment  in  the  two  arms  of  the  trial.  The  approach  has 
face  validity  from  a  comparison  of  the  proportion  of  visits  in  each  main  lCD  9 
grouping  with  the  routine  data  available  for  women  of  the  same  age  in  the  NHS 
hospital  episode  system.  Although  not  a  directly  comparable  data  set  the  proportion 
and  magnitude  of  women  in  each  category  is  similar. 
The  highest  proportion  of  visits  for  women  recruited  to  IBIS  were  for  disease  of  the 
genitourinary  system  (32.4%)  including  diseases  of  the  female  genital  tract,  urinary 
system  and  breast  diseases  followed  by  diseases  of  the  musculoskeletal  system 
(14.7%)  including  fractures,  the  digestive  system  (10.3%)  and  diseases  of  circulation 
including  cardiological  conditions  and  vascular  causes  (6.9%). 
Of  the  diagnosis  for  genitourinary  problems  over  50%  were  for  abnormalities  of 
menstruation  and  abnormal  bleeding  resulting  in  procedures  such  as  hysteroscopy  or 
hysterectomy.  An  additional  20%  were  for  breast  diseases  including  fibroadenoma  or 
benign  breast  disease  and  treated  with  fine  needle  aspiration  or  cyst  aspiration.  There 
were  a  number  of  fractures  in  the  musculoskeletal  category  (18)  mostly  of  the  wrist  or 
upper  limb  though  most  reports  in  this  group  were  of  back  problems  (21%). 
Procedures  reported  included  carpal  tunnel  syndrome  and  arthropathies. 
Cholelithiasis  was  the  most  commonly  reported  diagnosis  in  the  digestive  disease 
category  (20%).  Procedures  most  often  reported  were  endoscopy  or  colonoscopy. 
Among  diseases  of  the  circulatory  system  a  large  proportion  of  the  procedures  were 
for  varicose  veins  (25%)  with  a  smaller  number  for  angina  and  hypertension. 
132 Major  adverse  events  in  this  series  were  breast  cancers,  and  a  number  of  other  cancers 
including  colon,  lung  bladder  and  2  cases  of  cancer  of  the  ovary.  There  were  a 
number  of  skin  tumours  reported. 
Separating  the  series  into  A  and  B  according  to  the  2  arms  of  the  trial,  there  were 
407(42.3%)  women  reporting  a  hospital  visit  in  group  A  and  418(40.7%)  in  group  B. 
The  mean  costs  for  hospital  visits  were  £889.25  in  series  A  and  £906.95  in  series  B. 
There  were  no  significant  differences  between  the  2  arms  of  the  trial.  The  odds  ratio 
for  disease  of  the  breast  and  genital  organs  does  indicate  a  difference  between  the  2 
groups  though  the  confidence  intervals  are  wide.  This  trend  will  need  to  be  pursued 
further  with  greater  accrual.  Likewise  some  case  mix  differences  do  appear  between 
the  2  arms  of  the  study  such  that  the  procedures  for  breast  disease  and  disorders  of  the 
female  genital  tract  do  seem  to  be  more  costly  in  group  A  than  in  group  B.  In  terms 
of  the  distribution  of  cost  a  small  number  of  women  do  account  for  a  large  proportion 
of  the  overall  costs.  This  finding  suggests  that  it  will  be  the  impact  of  tamoxifen 
chemoprophylaxis  on  increasing  or  reducing  the  incidence  of  high  cost  procedure  that 
determines  the  cost  impact  from  morbidity.  The  findings  presented  here  suggest  that 
there  are  no  major  differences  in  morbidity  for  women  taking  tamoxifen  or  control 
though  the  results  may  warrant  further  investigation  particularly  for  disease  of  the 
genitourinary  system.  The  method  of  quantifying  the  data  with  HRGs  is  a  useful 
means  of  categorising  and  costing  data  of  this  kind. 
Consequently  in  the  model  of  cost  effectiveness  of  tamoxifen  chemoprophylaxis 
developed  in  Chapter  7  the  baseline  case  does  not  include  the  cost  of  morbidity  for 
women  taking  tamoxifen  although  the  likely  increased  risk  of  endometrial  cancer  is 
included.  In  constructing  the  sensitivity  analysis  for  cost  effectiveness  in  Chapter  7 
however,  it  did  however  seem  reasonable  to  include  a  possible  effect  of  long  term 
tamoxifen  use  of  hospital  visits  for  benign  breast  disease.  Further  work  pending 
continued  recruitment  to  IBIS  will  clarify  this  issue.  Including  morbidity  within  the 
sensitivity  analysis  provides  information  on  the  impact  of  possible  changes  in 
morbidity  within  a  range  of  estimates. 
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Morbidity  and  Resource  Use: 
Use  of  Medication 
Introduction 
As  discussed  earlier,  this  chapter  builds  on  information  set  out  in  Chapters  2  and  4 
seeking  to  define  a  cost  estimate  for  the  likely  impact  of  changes  in  morbidity  of 
women  taking  tamoxifen  chemoprophylaxis.  In  this  chapter  measures  of  morbidity  are 
made  from  changes  in  the  use  of  prescribed  medications  for  women  recruited  to  either 
the  tamoxifen  or  the  control  arm  of  the  International  Breast  Cancer  Intervention  Study 
(IBIS). 
Analysis  of  the  reported  use  of  medications  by  women  enrolled  into  IBIS  provides  an 
independent  means  of  understanding  possible  morbidity  of  tamoxifen  prophylaxis  and 
the  costs  (or  savings)  associated  with  it.  This  section  presents  information  on  the 
medications  taken  by  a  series  of  women  enrolled  in  IBIS  during  each  of  their  routine 
six  monthly  visits  over  a  maximum  of  48  months.  Only  those  drugs  thought  to 
interact  with  or  be  affected  by  tamoxifen,  as  discussed  in  Chapter  2,  have  been 
reviewed  in  detail.  Most  of  the  drugs  included  in  the  main  analysis  are  available  on 
prescription  only  with  the  exception  of  evening  primrose  oil  which  is  purchased  as  an 
over  the  counter  medication  for  the  relief  of  breast  pain  and  other  menstrual  or 
menopausal  symptoms. 
Method 
The  sequence  of  visits,  for  women  enrolled  into  IBIS,  to  the  study  centres  has  been 
described  earlier  (Chapter  3).  The  information  on  use  of  medications  is  collected  in 
the  same  way  as  for  hospital  visits.  Women  are  asked  at  each  six  monthly  visit  about 
medications  prescribed  in  the  previous  six-month  period.  The  name  of  the  drug  and 
the  dose  are  recorded  on  the  follow  up  form. 
134 This  information  was  downloaded  onto  an  Excel  spreadsheet  for  all  women  enrolled 
up  until  the  end  of  December  1997.  The  information  was  first  reviewed  to  ensure 
completeness  of  data  collection  particularly  to  ensure  correct  labelling  for  drug  names 
to  avoid  confusion  when  assigning  to  generic  categories  using  the  British  National 
Formulary  (BNF)16.  Drugs  unlikely  to  be  associated  with  tamoxifen  use  were  then 
removed  from  the  data  set.  These  included  antibiotics,  antimalarials,  asthma  drugs 
and  inhalers,  analgesics  other  than  for  breast  pain  or  migraine,  vitamins  and  food 
supplements  such  as  iron,  calcium  and  cod  liver  oil. 
It  is  of  course  possible  that  the  numbers  of  drugs  taken  by  women  in  the  study  is  a 
measure  of  their  overall  health  and  well  being  and  that  this  may  be  affected  in  some 
general  way  by  tamoxifen  prophylaxis.  It  was  not  however  considered  possible  to 
make  general  conclusions  about  this  issue  by  studying  all  categories  of  drugs 
irrespective  of  their  likely  interaction  with  tamoxifen.  Changes  in  use  of  a  wide 
variety  of  different  drugs  would  not  be  comparable  and  the  small  number  of  drugs  in 
each  of  the  excluded  categories  as  well  as  the  wide  spectrum  of  indications  for  their 
use  would  make  subcategorisation  difficult  to  interpret.  Antibiotics  for  example,  are 
widely  prescribed  for  a  range  of  conditions  with  well-known  differences  in  the 
threshold  of  symptomatology  preceding  a  decision  to  prescribe.  Changes  in  the  use  of 
antibiotics  by  women  recruited  to  IBIS  could  have  a  variety  of  interpretations  with  no 
clear  relevance  to  tamoxifen  prophylaxis. 
The  remaining  drugs,  those  used  for  the  treatment  of  symptoms  in  three  main  systems: 
for  cardiovascular  disease,  for  abnormalities  of  the  endocrine  system,  and  for 
symptoms  associated  with  the  central  nervous  system  -  mostly  psychiatric  drugs  for 
the  treatment  of  depression  are  set  out  in  Table  1.  Drugs  for  migraine  and  the  specific 
drug  thyroxine  are  included  separately.  The  numbers  of  women  reporting  taking  each 
one  of  these  drugs  is  included  in  the  table.  The  two  largest  categories  of  drugs:  those 
associated  with  cardiovascular  or  psychiatric  treatment  have  been  further  subdivided. 
Medical  advice  was  sought  to  support  the  assignment  of  drugs  according  to  usual 
prescribing  practice.  Disaggregation  only  down  to  the  level  of  major  sub  categories 
was  favoured  since  local  variations  in  prescribing  practice  would  reduce  the  value  of 
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headings  described  above. 
Comparisons  between  the  rates  of  use  of  drugs  for  women  in  IBIS  with  those  in  the 
general  population  are  made  using  data  from  a  single  General  Practice  and  by 
reference  to  the  National  Morbidity  Survey1'.  Routine  information  on  drug  use  by 
age  is  not  collected  nationally.  The  GP  research  database  administered  by  the 
Department  of  Health  contains  information  on  GPs  prescribing,  but  this  is  not 
routinely  broken  down  into  age  categories  relevant  to  women  enrolled  into  IBIS. 
Moreover  the  reasons  for  prescribing  a  particular  drug  may  overlap  and  indeed  many 
different  drugs  are  prescribed  for  the  same  condition.  An  example  relevant  to  this 
study  is  the  use  of  the  beta-blocker,  propranolol,  which  can  be  used  either  as  a 
migraine  prophylaxis  or  as  an  antihypertensive  agent. 
The  main  aim  of  this  study  was  to  gain  an  understanding  of  the  likely  differences  in 
morbidity  and  costs  between  the  two  arms  of  IBIS  as  measured  by  differences  in 
prescribed  medicines  for  women  taking  tamoxifen  and  those  on  placebo.  Also,  the 
results  could  highlight  areas  where  further  study  of  prescribing  patterns  for  women 
taking  tamoxifen  prophylaxis  may  be  productive. 
Once  the  drugs  to  be  studied  were  separated  from  all  other  reported  medications, 
tables  were  obtained  for  women  in  the  two  arms  of  IBIS.  In  the  same  way  as  for  the 
hospital  visit  data,  these  remain  anonymised  pending  completion  of  the  trial.  The 
results  are  set  out  below.  A  further  analysis  was  undertaken  to  review  differences  for 
women  who  were  prescribed  new  medications  after  they  were  recruited  to  IBIS. 
Results 
Main  categories  of  drugs  reported 
Over  the  time  period  reviewed,  1279  women  out  of  2531  women  recruited  to  the 
study  during  the  time  period  (50.5%)  reported  having  taken  3054  drugs  since  their  last 
IBIS  visit  as  discussed  above.  Large  proportions  of  these  drugs  (79.7%)  are  not 
136 included  in  the  final  analysis  because  they  are  unlikely  to  have  any  relevance  in 
relation  to  tamoxifen.  Table  1  below  shows  the  remaining  687  women  (27.1%  of 
those  recruited)  who  reported  taking  prescribed  medications  in  the  categories  thought 
most  likely  to  indicate  morbidity  associated  with  tamoxifen  chemoprophylaxis.  The 
proportion  of  drugs  in  each  of  main  categories  and  the  rate  of  use  of  drugs  in  each 
category  by  women  recruited  to  the  trial  is  also  given. 
Table  1.  Self  reported  use  of  medications  by  women  recruited  to  IBIS  in  main 
BNF  categories. 
Main  Categories  of  Drugs  (BNF) 
Cardiovascular  Psychiatric  Endocrine  Migraine  Thyroxine  Total 
(without  propranotol) 
Number  of  women  302  174  84  48  79  687 
%  in  category  43.9  25.3  12.2  6.9  11.5  !  00% 
rate  of  use  11.9  6.87  3.32  1.89  3.1  27.1 
The  main  categories  include  drugs  associated  with  the  cardiovascular  system  (43.9%), 
the  endocrine  system  including  thyroxine  (11.5%)  as  well  as  drugs  prescribed  for 
breast  pain  and  associated  symptoms  (12.2%),  and  finally  the  central  nervous  system 
including  the  psychiatric  drugs  (25.3%)  -  tricyclics  and  SSRIs  for  the  treatment  of 
depression,  hypnotics  -  sleeping  tablets  -  and  anxiolytics,  for  the  treatment  of  anxiety 
as  well  as  analgesics  for  migraine  (6.9%). 
Drugs  associated  with  the  cardiovascular  system 
302  women  report  taking  at  least  one  of  the  drugs  listed  in  Table  2  prescribed  for 
cardiovascular  symptoms.  The  numbers  below  each  of  the  subheadings  for 
cardiovascular  drugs  show  how  many  drugs  were  reported  in  each  category.  67 
women  report  taking  more  than  one  drug  and  a  small  number  of  women  (7)  report 
taking  three  prescribed  medications. 
137 Table  2.  Cardiovascular  drugs  reported  by  women  recruited  to  IBIS:  numbers 
in  each  subcategory.  Specific  drugs  are  also  listed. 
Beta  Diuretics  Lipid  Calcium  ACE  Glycosides  Alpha  Arrhythmia  Nitrates 
Blockers  lowering  Blockers  Inhibitors  Blockers 
Atenolol  Bendrofluazide  Bezafibrate  Diltiazem  Captopril  Digoxin  Doxazosi 
n 
Flecanide  GTN 
Bisoprolol  Frusemide  Cholestyramin 
e 
Lacidipine  Enalapril  lsosorbide 
Metoprolol  Indapamide  Clofibrate  Nicardipin 
e 
Lisinopril  Nitrates 
Oxprenolol  Spironolactone  Pravastatin  Nicorandil 
Propranolol  Triamterene  Simvasatin  Nifedipine  Perindopril 
Sotalol  Atorvastatin  Verapamil  Ramipril 
Timolol  Fluvastatin  Trandolapril 
131  109  36  52  57  2  3  2  7 
Beta  blockers  and  calcium  blockers  together  account  for  the  highest  proportion  of 
prescribed  medications  in  this  category  (45.8%  of  the  total  drugs  prescribed)  and  are 
used  primarily  for  angina  and  hypertension.  Diuretics,  ace  inhibitors  and  glycosides 
(42%  of  the  total  number  of  drugs),  form  the  second  largest  group  and  are  prescribed 
primarily  for  heart  failure  though  there  is increasing  cross  over  in  prescribing  between 
these  sub  categories  of  drugs. 
Lipid  lowering  drugs  accounting  for  just  less  than  10%  of  the  total  prescribed  drugs 
are  used  for  secondary  prevention  of  myocardial  infarction  though  are  being 
increasingly  used  in  primary  prevention  for  people  with  a  high  cardiovascular  risk 
profile.  Women  taking  more  than  two  drugs  are  most  likely  to  be  hypertensive 
prescribed  a  diuretic  and  either  a  beta  blocker  (11  women),  or  a  calcium  blocker  (13 
women),  or  an  ACE  inhibitor  (15  women).  Other  combinations  (28)  include  beta 
blockers  and  lipid  lowering  drugs  most  likely  to  be  given  after  myocardial  infarction 
for  secondary  prevention  or  beta  blockers  and  ace  inhibitors  for  prevention  of  heart 
failure. 
138 Drugs  associated  with  the  endocrine  system 
There  were  84  women  reporting  use  of  four  drugs  concerned  with  the  endocrine 
system  taken  for  the  treatment  of  breast  pain  and  associated  symptoms  (see  Table  3). 
These  drugs  are  collectively  referred  to  as  Epos.  Evening  primrose  oil  was  most 
commonly  reported  (68%).  This  is  the  only  medication  in  the  data  set,  which  is 
purchased  rather  than  prescribed.  A  small  number  of  women  reported  taking  two 
drugs. 
Table  3.  Endocrine  system:  Drugs  reported  by  women  recruited  to  IBIS  for 
treatment  of  breast  pain  and  menstrual  symptoms 
Drug  Number  reported 
Efamast  14 
Epogam  14 
Evening  Primrose  Oil  61 
Efamol  1 
Total  90 
In  addition,  thyroxine  was  reported  by  79  women.  This  drug  is  taken  for  an 
underactive  thyroid  gland  causing  symptoms  of  persistent  tiredness,  lethargy  and 
weight  gain. 
Drugs  associated  with  psychiatric  symptoms 
There  were  174  women  reporting  taking  drugs  for  psychiatric  morbidity  (see  Table  4). 
Most  are  taking  only  one  drug  most  likely  to  be  an  antidepressant  -  either  Tricyclics  or 
Selective  Serotonin  Re-uptake  Inhibitors  (SSRIs),  together  these  account  for  85%  of 
the  total.  Hypnotics  (sleeping  tablets)  and  anxiolytics  for  anxiety  are  each  less  than 
10%  of  the  total.  A  small  number  of  women  are  taking  two  drugs  usually  an 
antidepressant  in  the  SSRI  category  and  a  hypnotic  to  aid  sleeping. 
139 Table  4.  Psychiatric  drugs:  numbers  reported  in  each  subcategory.  Specific 
drugs  are  also  listed 
Hypnotics  Anxiolytics  Tricyclics  SSRIs  Total 
Zoplicone  Diazepam  Amitryptyline  Venflexane 
Temazepam  Buspirone  Dothiepin  Sertraline 
Nitrazepem  Nortyptyline  Paroxetine 
Lofepramine  Fluoxetine 
Imipramine  Paroxetine 
Clomimpramine 
18  11  97  67  193 
Analgesics  and  prophylaxis  for  migraine  are  set  out  in  Table  5.  The  drug  Propranolol 
is  included  in  this  table  since  it  can  be  used  both  for  the  treatment  of  migraine  or as  an 
antihypertensive  agent 
Table  5.  Drugs  reported  by  women  recruited  to  IBIS  for  Migraine. 
Specific  drug  Number 
Propranolol  25 
Pizotifen  3 
Paramax  2 
Migril  1 
Migraleve  4 
Migraine  Tabs  2 
Imigran  21 
Ergotamine  I 
Clonidine  16 
Inderal  14 
Total  89 
80  women  reported  taking  89  drugs  in  this  category.  Omitting  propranolol  there  were 
48  women  taking  51  drugs. 
140 Differences  in  prescribed  medication  between  those  taking  tamoxifen  or 
placebo 
The  tables  below  are  the  results  of  separating  the  data  for  women  in  each  of  the  2  arms 
of  IBIS.  The  identity  of  each  arm  remains  anonymised  pending  the  completion  of  the 
trial.  The  first  section  is  concerned  with  all  women  reporting  use  of  drugs  in  the 
series.  Table  8  deals  with  woman  reporting  drugs  newly  prescribed  subsequent  to 
their  recruitment  to  IBIS. 
Cardiovascular  drugs 
The  odds  ratios  for  each  of  the  categories  of  cardiovascular  drugs  shown  in  Table  6 
suggest  that  there  is  no  significant  difference  between  the  2  arms  of  the  trial  for  ace 
inhibitors  or  diuretics  for  p=0.05.  For  beta  blockers,  calcium  blockers  and  lipid 
lowering  drugs  the  confidence  intervals  are  wide  including  1.0  in  each  case  suggesting 
that  while  there  may  be  an  effect  between  the  two  arms  of  the  trial  the  sample  size  is 
too  small  at  this  stage  for  meaningful  analysis. 
Table  6.  Differences  in  the  use  of  Cardiovascular  drugs  by  women  taking 
tamoxifen  or  placebo  (groups) 
Cardiovascular  drugs 
(number  of  women) 
Ace  Beta  Diuretics  Lipid  Calcium  Others 
Groups  Inhibitors  Blockers  Lowering  Blockers 
A  27  81  57  23  22  7 
B  30  50  52  13  30  7 
Odds  ratio  0.9  1.66  1.1  1.78  0.73 
Cl  0.86-0.94  0.40-6.87  1.05-1.16  0.67-4.73  0.51-1.04 
Psychiatric  drugs 
Table  7  shows  the  drugs  prescribed  for  anxiety  and  depression  separated  into  two 
groups  A  and  C  corresponding  to  the  two  arms  of  IBIS.  There  may  be  an  association 
141 between  chemoprophylaxis  and  use  of  antidepressants  although  the  strength  of  the 
effect  for  SSRIs  seems  greater  than  for  women  on  tricyclics  and  grouping  these  two 
categories  reduces  the  effect.  There  are  too  few  women  taking  hypnotics  and 
anxiolytics  to  demonstrate  an  effect  between  the  two  arms  of  the  trial. 
Table  7.  Differences  in  the  use  of  drugs  by  women  taking  tamoxifen  or  placebo 
(groups) 
Psychiatric  drugs 
Tricyclics  SSRIs  Hypnotic  Anxiolytics 
Groups 
C  50  29  7  7 
D  47  37  10  3 
Odds  ratio  1.07  0.78  0.7  2.34 
95%CI  1.05-1.09  0.61-1.00  0.54-0.91  0.8-6.9 
Endocrine  system 
Of  the  84  women  reporting  taking  drugs  in  this  category,  38  were  in  one  arm  of  the 
trial  and  46  in  the  second.  The  odds  ratio  is 0.82  (95%CI  =0.69-0.98)  indicating  that 
there  might  be  a  small  effect  for  this  category  of  drugs. 
Migraine 
For  the  migraine  drugs  including  propranolol  the  women  separated  into  the  two  arms 
of  the  trial  with  43  in  on  group  and  37  in  the  second  group.  The  odds  ratio  is  1.17 
(95%CI=1.3-1.05)  suggesting  a  small  but  potentially  interesting  difference  between 
the  two  groups. 
Drugs  initiated  while  on  the  study 
Table  8  below  shows  the  numbers  of  women  whose  first  report  of  a  prescribed  drug 
began  on  the  first  or  subsequent  follow  up  visits  i.  e.  women  whose  report  of 
142 prescribed  medications  began  after  recruitment  to  the  trial.  These  are  separated  into 
the  main  categories  described  above  and  to  each  of  two  groups  corresponding  to  either 
the  tamoxifen  or  placebo  arm. 
Table  8.  Differences  in  reports  of  drugs  newly  prescribed  subsequent  to 
recruitment  to  IBIS  for  women  on  tamoxifen  or  placebo  (groups) 
Drugs  initiated  while  on  the  study 
Group 
Drugs  E  F  Odds  ratio  95%  Cl 
Migraine  10  14  0.71  0.54-0.94 
Migraine 
(inc. 
Propranolol) 
17  21  0.81  0.70-0.93 
Epos'  30  31  0.97  0.96-0.97 
Thyroxine  10  17  0.59  0.28-1.21 
Cardiovascular  Drugs 
Beta 
blockers 
31  46  0.67  0.33-1.35 
Lipid 
lowering 
drugs 
9  18  0.5  0.15-1.68 
Calcium 
blockers 
20  23  0.87  0.81-0.93 
Ace 
inhibitors 
13  18  0.72  0.54-0.97 
Others  3  7  0.43  0.15-1.25 
Psychiatric  drugs 
Hypnotics  4  5  0.8  0.74-0.86 
Anxiolytics  2  5  0.4  0.14-1.13 
Tricyclics  31  32  0.97  0.96-0.97 
SSRIs  21  30  0.7  0.44-1.10 
There  does  appear  to  be  a  difference  between  the  two  groups  for  migraine  both  where 
Propanolol  is  excluded  (OR=0.71,95%CI=0.54-0.94)  or  included  (OR=0.81, 
95%CI=0.7-0.93)  in  the  sample  although  both  include  confidence  intervals 
approaching  1.0  suggesting  that  the  effect  is  unlikely  to  be  significant.  For 
cardiovascular  disease  the  odds  ratio  for  beta  blockers  and  lipid  lowering  drugs  are 
0.67  and  0.50  respectively  though  the  confidence  intervals  are  wide  and  in  both  cases 
include  1.0  suggesting  that  the  effect  is  not  significant  for  p=0.05. 
143 For  women  taking  antidepressants  the  main  difference  again  appears  to  be  a  higher 
number  of  women  taking  SSRIs  though  again  there  are  only  small  numbers  involved 
and  the  difference  is  not  significant.  For  medications  in  other  categories  more  women 
initiated  thyroxine  in  one  arm  compared  with  the  other;  the  difference  is  not 
significant. 
Discussion 
Analysing  the  use  of  drugs  by  women  in  IBIS  is  limited  by  the  quality  of  the  data 
collection.  A  great  deal  of  time  was  spent  in  validating  the  records  entered  into  the 
system  and  establishing  the  identity  of  the  drugs  recorded,  moreover  it  is  difficult  to 
assess  the  completeness  of  the  data  collection.  In  particular  it  was  not  possible  to 
assess  dose  from  the  records  since  this  was  not  recorded  consistently.  It  is  likely  also 
that  there  may  be  some  error  in  assignment  of  drugs  to  causes.  Nevertheless  it  is 
clear  that  a  large  proportion  of  the  drugs  listed  are  unlikely  to  have  any  association 
with  tamoxifen  chemoprophylaxis.  Only  a  small  proportion  of  the  drugs  excluded 
from  the  analysis  indicate  any  major  illness  or  morbidity  for  women  recruited  to  IBIS. 
Of  those  excluded  the  use  of  an  anti-inflammatory  drug  is  probably  the  most 
important  category  suggesting  morbidity  from  musculoskeletal  disorders  primarily 
osteoarthritis.  Other  drug  usage  suggest  relatively  minor  and  probably  self  limiting 
illnesses  such  as  chest  infections,  chronic  disease  such  as  asthma  or  diabetes  or  use  of 
food  supplements  such  as  vitamins  and  minerals. 
Just  under  a  third  of  all  women  recruited  to  IBIS  during  the  time  period  reviewed  in 
this  sample  are  taking  -  mostly  -  prescribed  medications  for  morbidity  which  is 
associated  with  tamoxifen  chemoprophylaxis.  The  highest  proportion  of  drug  use 
(43.9%)  reported  by  almost  12%  of  women  recruited  to  IBIS  is  for  cardiovascular 
disease.  The  second  largest  category  -  psychiatric  drugs  accounting  for  just  over  a 
quarter  (25.3%)  of  the  total  reported  are  taken  at  a  rate  of  nearly  7%  per  women 
recruited  to  IBIS. 
144 Coronary  heart  disease  and  mental  illness  particularly  depression  are  common  reasons 
for  attendance  in  General  Practice.  There  are  few  routine  sources  of  information  with 
which  to  compare  these  results.  PACT  data  are  available  for  monitoring  prescribing 
in  general  practice  though  are  not  based  on  individual  patients  and  are  not  published 
routinely.  Findings  from  the  review  of  activity  in  general  practice  published  as 
Morbidity  Statistics  from  General  Practice1'  is  relevant  though  rarely  relates 
consultations  in  general  practice  to  specific  drugs.  For  this  reason  information  was 
requested  from  a  general  practitioner14  covering  a  large  practice  population(10,000) 
on  the  rate  of  use  of  the  specific  categories  of  drugs  reported  by  women  in  IBIS.  On 
the  whole  this  information  suggested  that  prescription  rates  are  comparable  for 
coronary  heart  disease  though  may  be  high  for  antidepressants.  Over  an  annual  period, 
14.5%  of  women  aged  45-64  in  the  General  Practice  were  taking  drugs  for 
cardiovascular  disease  in  the  BNF  categories  described  above  (compared  with  12%  of 
women  in  IBIS)  whereas  only  4%  were  taking  drugs  for  depression  (compared  with 
nearly  7%  of  women  in  IBIS)  18'  It  is  possible  to  speculate  that  women  who  perceive 
themselves  to  be  at  increased  risk  of  breast  cancer  are  likely  to  have  a  higher  rate  of 
use  of  antidepressants  than  the  general  population.  Alternatively,  involvement  in  the 
IBIS  trial  may  reduce  depression.  There  are  few  reports  to  suggest  that  tamoxifen 
itself  leads  to  low  mood  although  the  known  side  effect  of  symptoms  such  as  hot 
flushes  and  headaches  may  give  rise  to  mood  swings. 
Comparing  the  results  with  the  most  recent  findings  from  Morbidity  Statistics  from 
General  Practice  (fourth  national  study)"'  supports  these  conclusions  with 
consultations  for  coronary  heart  disease  of  the  order  of  15%  for  women  aged  45-64 
and  for  depression  around  7%.  Since  not  all  of  these  consultations  would  have 
resulted  in  the  provision  of  a  prescription  the  results  are  not  directly  comparable. 
They  do  however  lend  validity  to  the  estimates  given  above  for  the  overall  morbidity 
of  women  in  IBIS. 
For  specific  drugs  5.6%  of  the  General  Practice  population  in  the  age  group  45-64 
were  taking  betablockers  compared  with  5.2%  for  women  recruited  to  IBIS.  Only 
3.3%  of  women  in  IBIS  report  taking  the  category  of  drugs  labelled  Epos  (12.2%  of 
145 the  total  drugs  reported)  for  the  relief  of  breast  pain  and  other  gynaecological 
symptoms.  It  is  not  possible  to  compare  this  drug  directly  with  reports  from  general 
practice  since  many  women  take  Evening  Primrose  Oil  for  the  relief  of  gynaecological 
symptoms,  which  can  be  purchased  over  the  counter.  About  3%  of  women  in  IBIS 
report  the  use  of  thyroxine,  which  is  similar  to  the  rate  reported  in  the  General 
Practice  population  (3.7%).  Acquired  hypothyroidism  is  the  reason  for  prescription  of 
thyroxine  and  this  was  reported  at  a  rate  of  0.87%  for  women  aged  45-64  in  the 
Morbidity  survey.  Migraine  was  reported  at  a  rate  of  1.89%  of  women  in  IBIS 
compared  with  I%  in  the  General  Practice  population. 
Differences  between  the  two  arms  of  the  trial  in  the  frequency  of  use  of  drugs  reported 
here  cannot  be  fully  evaluated  because  of  the  small  numbers  involved.  Nevertheless, 
there  does  appear  to  be  an  indication  from  the  data  of  a  potentially  interesting 
difference  in  the  two  groups  in  the  use  of  beta  blockers.  The  potentially  beneficial 
effect  of  tamoxifen  on  cardiovascular  health  has  been  discussed  earlier  though  it  is 
equally  likely  that  women  taking  tamoxifen  are  prescribed  betablockers  to  counteract 
vascular  symptoms  such  as  hot  flushes.  Since  the  two  arms  of  the  trial  are  not 
unblinded  at  this  stage  it  is  not  possible  to  assess  whether  the  women  more  likely  to 
be  taking  drugs  for  cardiovascular  disease  are  those  randomised  to  the  control  or  to 
the  tamoxifen  arm.  At  this  stage  the  significance  of  any  differences  in  the  use  of 
drugs  for  vascular  symptoms  in  terms  of  cost  appears  to  be  small. 
Broad  cost  implications  might  be  estimated  by  taking  the  rate  of  use  of  beta  blockers 
by  women  aged  45-64  in  the  general  practice  population  discussed  above  (5.6%)  and 
assuming  that  there  may  be  a  relative  risk  of  1.63  or  0.61  in  the  intervention  group 
from  IBIS  data.  For  1000  women  assuming  prescription  of  the  drug  Atenolol  -a 
commonly  used  betablocker  at  a  cost  of  £1/month  (50mg/day)  the  cost  for  560  women 
at  10  years  would  be  £67,200.  Using  the  assumption  of  an  increased  relative  risk  of 
1.63  the  additional  cost  would  be  £42,240  (352  women)  for  10  years  -  around  £4  per 
woman  per  year.  For  a  reduction  in  relative  risk  of  0.62  the  savings  would  be  £26,280 
(219  women)  over  10  years  -  around  £2  per  woman  per  year. 
146 Summary 
Analysis  of  the  medications  taken  by  women  enrolled  into  IBIS  is  used  to  assess 
changes  in  the  morbidity  of  women  taking  tamoxifen  chemoprophylaxis  for  breast 
cancer.  The  information  was  collected  from  reports  by  the  women  themselves  during 
routine  (6  monthly)  visits  to  IBIS  centres.  Information  was  validated  and  then 
categorised  using  groups  from  the  British  national  formulary  (BNF).  Data  on  1279 
women  out  of  the  2531  recruited  to  the  study  in  total  (50.5%)  reporting  use  of  one  or 
more  drugs  were  included  initially  although  the  report  is  based  on  around  on  third  of 
women  (27%)  of  those  recruited  once  inclusion  criteria  were  applied. 
Medications  were  excluded  where  there  was  thought  to  be  no  association  with 
tamoxifen  or  where  a  precise  reason  for  prescription  would  be  difficult  to  obtain. 
Criteria  were  based  on  the  literature  review  reported  in  Chapter  2  and  independent 
medical  advice  was  taken.  Drugs  excluded  were,  for  example,  antibiotics  for  self 
limiting  illness  such  as  chest  infections,  antimalarials  and  medications  for  chronic 
diseases  such  as  diabetes  or  asthma  as  well  as  food  supplements  and  analgesics  for 
inappropriate  causes  such  as  bee  stings. 
The  remaining  medications  were  primarily  concerned  with  cardiovascular  symptoms 
(43.9%),  for  abnormalities  of  the  endocrine  system  (12.2%)  and  for  symptoms 
associated  with  the  central  nervous  system  (25.3%)  -  mostly  for  the  treatment  of 
depression.  Drugs  for  migraine  (6.9%)  and  the  drug  thyroxine  (11.5%)  were 
categorised  separately. 
Betablockers  and  calcium  blockers  account  for  the  highest  proportion  of  drugs 
prescribed  for  cardiovascular  symptoms;  these  are  used  primarily  for  angina  and 
hypertension.  Lipid  lowering  drugs  accounting  for  around  10%  are  primarily  used  for 
secondary  prevention  of  heart  disease  though  there  is  increasing  use  for  primary 
prevention  Of  the  4  drugs  used  for  the  relief  of  breast  pain  evening  primrose  oil  -  the 
only  non  prescribed  medication  included  -  was  the  most  frequent  comprising  68%  of 
147 reports  in  the  endocrine  category.  Thyroxine  use  was  reported  by  79  women.  This 
drug  is  taken  for  underactive  thyroid  and  for  the  relief  of  symptoms  such  as  tiredness 
and  lethargy.  174  women  reported  use  of  an  antidepressant  accounting  for  85%  of 
drugs  for  psychiatric  symptoms.  Migraine  drugs  were  used  by  80  women  (though 
excluding  Propanolol  which  can  also  be  used  for  hypertension  the  number  was  48 
women). 
Comparison  of  the  rates  of  use  of  medications  for  women  recruited  to  IBIS  with  that 
found  in  a  large  general  practice  (8,000  registered  patients)  provides  face  validity  for 
the  data  set  since  the  rates  of  use  are  comparable  across  all  categories  and  for  a 
number  of  specific  drugs  such  as  betablockers.  For  example,  around  14.5%  of  women 
aged  45-64  were  prescribed  drugs  for  cardiovascular  symptoms  in  general  practice 
compared  with  12%  of  women  in  IBIS  and  around  4%  of  women  are  prescribed 
drugs  for  depression  in  the  general  practice  compared  with  7%  of  women  in  IBIS. 
The  results  are  also  comparable  to  those  reported  in  the  National  Morbidity  survey. 
There  are  no  significant  differences  between  the  2  arms  of  the  trial  for  any  of  the 
major  categories  of  drugs  or  for  any  sub  category  although  this  may  be  due  to  the 
small  numbers  involved.  Further  recruitment  is  needed  to  fully  elucidate  any 
differences,  which  may  exist.  In  particular  there  is  a  trend  towards  a  difference  in  the 
use  of  betablockers  between  the  2  arms  of  the  study;  a  sub  group  of  drugs  used  for  the 
relief  of  vascular  symptoms  such  as  hot  flushes.  The  additional  cost  (or  saving)  in  the 
use  of  betablockers  is  estimated  at  around  £4  per  woman  per  year. 
This  estimate  is  included  in  the  sensitivity  analysis  for  the  model  of  cost  effectiveness 
developed  in  Chapter  7.  No  morbidity  estimate  is  included  in  the  baseline  case  for  the 
model  because  of  the  lack  of  sufficient  evidence  of  either  a  difference  in  the  use  of 
prescribed  medications  or  in  the  use  of  hospital  visits  (discussed  in  the  previous 
Chapter)  between  women  in  the  2  arms  of  IBIS.  Including  an  estimate  for  morbidity 
in  the  sensitivity  analysis  does  however  identify  the  range  within  which  any  impact  on 
morbidity  would  bear  on  the  cost  effectiveness  ratio.  Prior  to  the  development  of  the 
model  for  cost  effectiveness,  the  following  Chapter  assesses  any  costs  which  might 
148 accrue  to  the  women  themselves  when  taking  chemoprophylaxis.  An  analysis  of  any 
impact  on  quality  of  life  for  women  taking  long  term  tamoxifen  is  also  considered. 
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Indirect  Costs  of  Tamoxifen  Chemoprophylaxis 
Women  in  IBIS:  Personal  Costs  and  Quality  of  Life. 
Introduction 
This  chapter  sets  out  to  assess  the  effect  of  tamoxifen  chemoprophylaxis  on  the 
women  themselves.  Two  main  issues  are  considered.  These  are  the  impact  on  personal 
costs  such  as  taking  time  off  work  and  travel  costs  to  health  facilities  for  women 
taking  tamoxifen  chemoprophylaxis  and  the  impact  on  quality  of  life.  The  former 
analysis  identifies  a  range  of  estimates  for  personal  costs,  which  are  included  in  the 
sensitivity  analysis  for  the  cost  effectiveness  model  in  Chapter  7.  A  decrease  or  an 
increase  in  cost  due  to  changes  in  quality  of  life  is  included  neither  in  the  baseline 
model  or  in  the  sensitivity  analysis  since  there  is  no  evidence  in  the  analysis  set  out 
below  to  suggest  that  women  taking  long  term  tamoxifen  experience  any  change  in 
quality  of  life. 
The  cost  effectiveness  of  breast  cancer  chemoprophylaxis  will  depend  on  its  efficacy 
in  preventing  incidence  and  mortality  from  breast  cancer.  The  acceptability  of  long 
term  drug  taking  will  however  bear  considerably  on  the  success  of  the  intervention  in 
routine  health  care.  Few  studies  have  addressed  the  indirect  costs  or  benefits 
associated  with  changes  in  quality  of  life  or  the  compromises  made  by  the  women 
themselves  in  terms  of  personal  costs  of  chemoprevention.  This  trade-off  between 
benefit  from  life  years  gained  and  the  costs  of  potentially  lowered  quality  of  life  for 
the  women  themselves  is  explored  further  in  this  section.  Costs  are  examined  in  terms 
of  the  personal  costs  of  travel  and  time  spent  attending  clinic  visits.  The  results  are 
discussed  in  terms  of  the  potential  reduced  value  of  breast  cancer  chemoprophylaxis. 
History  of  some  previous  illnesses  particularly  thrombosis  or  neoplasm  renders 
women  ineligible  for  taking  long  term  tamoxifen.  The  physical  health  of  women 
recruited  to  IBIS  and  indeed  of  all  women  likely  to  be  eligible  for  tamoxifen 
prophylaxis  is  therefore  likely  to  be  equivalent  to  or  better  than  women  of  the  same 
150 age  and  socio-economic  status  in  the  general  population.  It  is  possible  however  that 
there  is  some  psychological  morbidity  associated  with  being  at  high  risk  for  breast 
cancer  though  it  is  difficult  to  discern  how  this  might  be  affected  by  tamoxifen 
prophylaxis.  Fallowfield15  has  suggested  that  the  effects  may  be  bipolar  with 
women's  anxiety  state  being  either  ameliorated  or  exacerbated  by  inclusion  in  a  trial 
depending  on  factors  such  as  level  of  internal  locus  of  control,  personality  and  recent 
history  of  stressful  life  experiences  such  as  bereavement. 
Information  on  these  issues  was  obtained  by  means  of  a  questionnaire  sent  to  a  sample 
of  women  recruited  to  IBIS.  The  questionnaire  had  three  parts,  firstly  using  a 
standard  health  status  instrument  to  assess  quality  of  life,  secondly  a  set  of  questions 
concerned  with  the  personal  cost  of  tamoxifen  prophylaxis  asking  about  the  cost  of 
travel,  the  cost  of  time  off  work  and  other  costs  associated  with  attending  clinics  and 
finally  a  set  of  questions  concerned  with  how  women  perceive  issues  concerning 
breast  care  and  breast  examination  in  particular.  The  third  group  of  questions  was 
included  by  the  IBIS  co-ordinator  to  assess  the  impact  of  the  study  on  the  women's 
approach  to  personal  breast  care  and  are  not  discussed  here. 
Personal  costs 
Questions  cover  the  cost  and  time  of  travel  and  any  specific  costs  incurred  because  of 
attendance  at  the  clinic  such  as  childcare  costs  and  time  off  work.  The  aim  is  to 
estimate  the  range  and  significance  of  personal  cost  in  the  overall  cost  of  breast  cancer 
chemoprophylaxis. 
This  set  of  questions  was  also  used  to  assess  the  value  women  place  on  the  possibility 
of  taking  tamoxifen  for  breast  cancer  prophylaxis  in  relation  to  the  benefit  they 
perceive  from  it.  Two  linked  questions  were  asked:  Firstly,  about  the  level  of  efficacy 
-  in  terms  of  breast  cancers  prevented  -  at  which  they  would  be  prepared  to  take 
tamoxifen.  Secondly,  the  personal  costs  they  might  be  prepared  to  incur  (in  terms  of 
distance  travelled)  in  order  to  receive  the  service.  These  questions  are  indicative  of  the 
women's  perception  of  risk  and  benefit  from  tamoxifen  prophylaxis.  They  provide  a 
151 basis  for  quantifying  the  cost  women  would  be  willing  to  bear  in  order  to  receive 
tamoxifen  prophylaxis. 
Quality  of  Life 
The  quality  of  life  questionnaire  is  intended  to  inform  the  economic  analysis  about 
any  possible  decrement  or  increment  in  health  status  that  may  represent  a  cost  for 
women  taking  tamoxifen  chemoprophylaxis.  Quality  of  life  information  is  also  of 
value  in  understanding  issues  such  as  compliance  since  changes  in  health  status 
because  of  tamoxifen  use  may  affect  the  willingness  of  otherwise  asymptomatic 
women  to  comply  with  a  long  term  daily  drug  regimen. 
After  careful  consideration,  information  on  quality  of  life  was  sought  using  the  SF36  - 
a  generic  health  related  quality  of  life  instrument"'.  This  instrument  met  a  number  of 
requirements.  Firstly  it  was  considered  important  to  use  a  measure  which  had 
demonstrated  sensitivity  to  detecting  small  variation  in  the  health  status  of  normal 
healthy  individuals.  Women  recruited  into  IBIS  are  drawn  from  the  general  population 
and  are  expected  to  be  as  healthy.  Moreover  the  objective  of  treatment  with  tamoxifen 
in  this  context  is  to  maintain  health. 
Secondly  the  SF36  has  been  shown  to  be  better  at  detecting  low  levels  of  ill  health 
than  other  quality  of  life  instruments  such  as  the  Nottingham  Health  Profile  172 
. 
Thirdly  the  reliability,  validity,  responsiveness  and  acceptability  of  the  SF36  has  been 
demonstrated  in  a  number  of  settings  with  both  healthy  and  disease  specific 
populations  13.  Normative  data  for  the  SF36  are  available  by  age  and  gender  for  the 
UK  population  which  will  allow  comparison  for  women  recruited  into  IBIS  with  the 
general  population14. 
Finally,  since  a  battery  of  other  questions  were  to  be  included  in  the  questionnaire  it 
was  essential  that  the  quality  of  life  instrument  be  short  and  acceptable.  Many  other 
quality  of  life  measures  were  found  to  be  too  long  or  not  to  have  been  validated  in 
large  samples1'.  The  SF36  was  designed  as  a  self-administered  questionnaire16.  It 
152 contains  36  items  and  is  intended  to  take  about  5  minutes  to  complete.  It  measures 
health  across  3  main  health  attributes  on  eight  multi-item  dimensions.  The  attributes 
are:  functional  status  -  including  dimensions  about  physical  functioning,  social 
functioning  and  role  limitations  attributed  to  either  physical  or  emotional  problems, 
well  being  -  covering  mental  health,  energy  (or  fatigue)  and  pain,  and  finally  an 
overall  evaluation  of  health.  This  structure  allows  an  assessment  of  the  impact  of 
tamoxifen  chemoprophylaxis  across  all  aspects  of  health.  In  6  of  the  8  dimensions 
respondents  are  asked  to  rate  their  responses  on  3  or  6  point  scales  rather  than  as  yes 
or  no  as  in  other  questionnaires.  For  each  dimension  items  are  scored,  coded  and 
summed  on  a  scale  from  worst  health  (0)  to  best  health  (100). 
Method 
The  3  sets  of  questions  were  piloted  with  a  group  of  women  in  the  study  to  assess 
acceptability  and  ease  of  response.  While  the  women  selected  are  a  highly  motivated 
group  being  representatives  from  each  centre  there  was  a  100%  response  rate  from  the 
20  questionnaires  sent  out.  Subsequent  discussions  at  a  meeting  with  the  women 
suggested  that  they  had  experienced  few  problems  completing  the  questionnaire  and 
had  welcomed  the  opportunity  to  address  questions  about  general  health  and  personal 
costs  involved.  Information  was  sought  in  particular  on  the  understanding  of  the 
question  about  the  level  of  effectiveness  at  which  they  would  be  willing  to  take 
tamoxifen  and  again  understanding  was  high.  None  of  the  questions  had  been  missed 
and  most  women  had  spent  less  than  20  minutes  overall  in  completing  the  forms. 
The  final  version  of  the  questionnaire  including  the  3  sets  of  questions  described 
above  comprised:  the  quality  of  life  instrument  including  36  questions,  a  set  of  13 
questions  concerned  with  feelings  about  breast  cancer  and  breast  care  including  the 
question  about  the  level  of  effectiveness  of  tamoxifen  prophylaxis  at  which  women 
might  be  willing  to  participate  in  the  programme  and  5  questions  concerning  the 
personal  cost  of  IBIS.  A  question  was  also  added  to  elicit  information  about  the 
socio-economic  status  of  the  women  using  occupational  status  from  the  General 
Household  Survey.  Information  on  age  of  the  women  and  other  characteristics  could 
153 be  cross  matched  from  their  general  IBIS  record  since  the  women  were  also  asked  to 
include  their  name  and  study  number.  The  3  sets  of  questions  were  put  together  into  a 
booklet  and  sent  to  all  women  recruited  to  UK  centres.  A  total  of  2,380 
questionnaires  were  mailed  to  all  women  recruited  to  the  study  using  the  address 
database  correct  at  January  1s`  1998  along  with  a  newsletter  and  other  information 
relating  to  IBIS.  Most  questionnaires  were  sent  on  July  10`h  1998;  a  further  274  were 
forwarded  to  women  three  weeks  later.  A  reminder  was  sent  to  all  women  alongside 
mailing  of  an  information  sheet  at  the  beginning  of  September. 
The  covering  letter  sent  with  the  questionnaire  explained  the  context  for  the  three  sets 
of  questions  and  stressed  2  main  points.  Firstly  that  the  women  should  offer  her 
immediate  response  to  the  questions  not  spending  over  long  completing  the 
questionnaire  and  secondly  that  there  was  no  expectation  at  all  that  the  health  of 
women  in  IBIS  was  likely  to  be  at  all  different  from  the  general  population. 
A  form  was  devised  from  the  questionnaire  so  that  the  responses  could  be  entered 
onto  a  database  in  oracle  and  the  analysed  using  STATA.  For  analysis  requiring 
knowledge  of  the  randomisation  status  of  the  women  the  data  was  separated  into  2 
tables  Q  and  L  according  to  the  2  arms  of  the  trial. 
Results 
The  analysis  is  based  on  1,557  questionnaires.  This  is  an  estimated  response  rate  of 
68.2%  returned  questionnaires.  An  error  with  the  mailing  machine  resulted  in  the  loss 
of  around  10%  of  the  questionnaires.  The  response  rate  is  based  on  2,380 
questionnaires  known  to  have  been  mailed  and  1,624  returned.  Of  those  returned 
1,577  were  completed  and  entered.  47  questionnaires  were  returned  though  not 
completed.  The  proportion  of  questionnaires  returned  and  entered  is  66.3%. 
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Costs  to  the  women  themselves  arising  from  the  cost  of  travelling  to  a  clinic  for 
chemoprevention;  the  costs  of  time  off  work  and  other  costs  involved  such  as 
childcare  or  maintenance  are  set  out  in  the  tables  below. 
1.  Mode  of  transport 
921  women  (59%),  travel  to  an  IBIS  centre  using  their  own  means  of  transport  (see 
Table  1).  An  additional  9%  of  women  use  their  own  transport  in  combination  with 
public  transport,  a  friend's  vehicle  and  either  walking  or  using  a  taxi.  23%  of  the 
women  use  public  transport  alone  with  an  additional  7%  using  either  their  own 
vehicle,  a  friend's  vehicle,  a  taxi  or  walking  as  well.  At  least  6%  of  women  rely 
solely  on  a  friend  to  transport  them  to  the  centre.  Around  11%  of  women  use  two  or 
more  forms  of  transport. 
Table  1.  Mode  of  transport  to  IBIS  Centres 
Type  of  Transport  Frequency  % 
Own  921  59% 
Public  353  23% 
Friend  92  6% 
P&O  60  4% 
O&F  26  2% 
P&W  19  1% 
Walk  17  1% 
P&T  18  1% 
P&F  15  1% 
POW  8  1% 
O&W  7  0% 
Taxi  4  0% 
F&T  2  0% 
F&W  2  0% 
POF  2  0% 
PFT  2  0% 
PFW  1  0% 
OTW  1  0% 
PTW  1  0% 
missing  6  0% 
Total  1557  100% 
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Table  2  shows  that  the  median  frequency  for  travel  time  is  between  30-60  minutes. 
Almost  75%  of  the  women  spend  longer  than  30  minutes  in  travelling  and  half  of 
those  spend  over  an  hour  travelling  to  the  centre. 
Table  2.  Travel  time  (m)  to  IBIS  centres 
Time  Frequency  % 
<30  minutes  385  25% 
30-60  minutes  573  37% 
>60  minutes  592  38% 
missing  1  7  0% 
Total  1557  100% 
3.  Cost  (£)  of  travel  to  the  clinic 
The  cost  women  incur  in  travelling  to  IBIS  centres  are  detailed  in  the  Table  3.  Over 
half  of  the  women  (58%)  travel  solely  by  car;  a  further  7%  use  the  car  supplemented 
by  some  other  means  of  transport  as  well  either  public  transport  (3.5%),  other  (2.6%), 
public  transport  and  taxi,  (1%)  or  public  transport  and  other,  (1%).  The  mean  cost  of 
transport  by  car  accounting  for  the  use  of  petrol  only  was  estimated  at  £5  per  woman. 
Public  transport  only  was  used  by  379  (24%)  of  the  women  and  by  a  further  100 
alongside  the  car  (3.5%),  taxi  (1.6%),  other  (,  1%),  car  and  taxi,  (1%),  car  and  other 
(<I%),  taxi  and  other,  (1%)  and  car,  taxi  and  other  (<I%).  The  mean  cost  of  public 
transport  was  estimated  at  £7.1.  Taxis  were  used  by  43(3%)  of  the  women  but  only  9 
used  taxis  alone.  Almost  10%  of  women  used  2  or  more  means  of  transport.  Most  of 
these  used  public  transport  and  car  or  car  and  taxi  or  car  and  other;  16  women  used  3 
means  of  transport  and  1  woman  used  4  means  of  transport.  106  women  did  not 
complete  this  section.  The  mean  costs  overall  from  the  estimates  given  by  the  women 
themselves  were  £6.1.  The  costs  ranged  from  60p  to  £200,  the  latter  for  travel  by  air 
for  1  woman  in  the  study.  The  range  of  costs  represents  the  low  geographic  spread 
of  centres  available  for  recruitment  to  IBIS  and  the  willingness  of  some  women  to 
incur  considerable  travel  cost  in  order  to  have  the  opportunity  to  participate  in  the 
trial. 
156 Table  3.  Costs  of  travel  by  mode  of  transport  (£) 
Mode  of 
transport 
number  Sum  cost 
(£) 
Mean  cost  (£) 
Public(P)  379  2697.2  7.12 
Car  (C)  906  4543.4  5.0 
Taxi  (T)  9  73.5  8.2 
Other(O)  14  40.5  2.9 
P&C  55  804.1  14.6 
P&T  26  378.5  14.6 
P&O  3  54  18.0 
C&O  41  503.8  12.3 
T&O  1  175  175.0 
P,  C&T  5  75.9  15.2 
P,  C&O  10  153.8  15.4 
P,  T&O  1  11.0  11.0 
P,  C,  T&O  1  0  0.0 
missing  106  0  0.0 
Total  1557  9510.6 
Mean  cost  6.1 
4.  Time  (m)  spent  at  the  clinic:  first  visit 
It  is  clear  that  over  half  of  the  women  in  the  sample  (58%)  spend  over  41  minutes 
with  almost  a  third  spending  longer  than  60  minutes  in  the  centre;  around  a  third  of 
women  spend  between  21  and  40  minutes  in  the  centre.  The  median  frequency  is 
between  41  and  60  minutes.  The  5%  of  women  who  spend  less  than  20  minutes  on 
their  first  visit  are  most  likely  to  have  reported  on  their  initial  discussion  pending 
recruitment  to  IBIS  rather  than  their  first  full  IBIS  visit.  The  initial  recruitment  visit 
requires  sufficient  time  for  full  discussion  of  the  implications  of  the  trial  as  well  as  the 
history  taking,  physical  examination,  blood  test  and  mammography  described  earlier. 
Some  IBIS  centres  explain  a  good  deal  about  the  trial  process  including  issues 
concerning  randomisation  and  the  background  to  the  study  prior  to  the  woman 
deciding  to  enrol  in  the  study.  5%  of  women  did  not  complete  this  section. 
157 Table  4.  Time  (m)  spent  at  first  visit. 
Time(minutes)  frequency  % 
U=20  77  5% 
21-40  496  32% 
41-60  488  31% 
>60  425  27% 
missing  71  5% 
Total  1557  100% 
5.  Time  (m)  spent  in  follow  up  visits. 
The  median  time  spent  in  follow  up  visits  is  between  21-40  minutes  with  63% 
spending  less  than  40  minutes  in  the  centre  during  follow  up  visits;  a  fifth  spend  less 
than  20  minutes.  14%  of  women  did  not  complete  this  section. 
Table  5.  Time  (m)  for  follow  up  visits 
Time  Frequency  % 
</=20minutes  326  21% 
21-40  647  42% 
41-60  252  16% 
61+  115  7% 
Missing  217  14% 
Total  1557  100% 
6.  Other  costs 
The  women  were  asked  to  specify  other  costs  involved  in  attending  an  IBIS  centre. 
The  costs  listed  are  for  childcare  or  for  loss  of  earnings  including  taking  time  from 
holiday  entitlement  in  order  to  attend  an  IBIS  centre.  The  other  category  includes 
expenditure  on  maintenance  such  as  meals  and  snacks.  1,106  women  recorded  that  no 
additional  costs  other  than  travel  were  incurred. 
158 Table  6.  Additional  costs  (£)  incurred  by  women  recruited  to  IBIS 
Type  of  cost  (freq)  %  Sum  cost  (£)  Mean  cost  (C) 
Child  care(C)  3  0%  35.3  11.8 
Lost  pay(LP)  94  6%  2620.6  27.9 
Holiday(H)  91  6%  2944.9  32.4 
Other(O)  128  8%  773.2  6.0 
None(N)  1106  71%  0  0 
C&LP  4  0%  128.5  32.1 
C&H  3  0%  177.0  59.0 
C&O  3  0%  37.0  12.3 
LP&H  3  0%  267.0  89.0 
LP&O  8  1%  467.3  58.4 
H&O  4  0%  119.8  30.0 
C&LP&O  1  0%  15.0  15.0 
LP&H&O  1  0%  114.0  114.0 
Missing  108  7%  7699.5 
Total  1557 
I 
Mean  cost(E)  4.94 
_  __ 
I 
i 
Only  343(22%)  women  reported  incurring  additional  costs  other  than  travel  when 
attending  IBIS  centres.  The  largest  group  -  128  women  (8%)  record  `other'  costs 
which  relate  mostly  to  food  and  drink  purchased  while  travelling  to  or  attending  IBIS 
centres.  The  mean  cost  was  estimated  by  these  women  as  £6.0  per  women.  For  the 
106(7%)  of  women  who  recorded  loss  of  earnings  through  attending  the  clinic  the 
mean  cost  is  £27.9  for  lost  pay  alone;  12  women  record  additional  costs  either  through 
taking  holiday  entitlement  as  well  (3),  other  costs  (8)  or  holiday  entitlement  and  other 
costs(1).  For  the  91  women  (6%)  who  take  holiday  entitlement  in  order  to  attend 
clinics  the  mean  cost  estimated  by  them  is  £27.9.  A  very  small  number  of  woman 
(1%)  incur  childcare  costs  which  reflects  the  age  range  of  women  recruited  to  IBIS; 
most  are  unlikely  to  have  pre-school  age  children. 
159 7.  Main  Occupation 
Table  7  shows  that  a  large  proportion  of  the  women  (62%)  are  employed  either  full  or 
part-time;  a  further  8%  are  self-employed.  14%  of  the  women  describe  themselves  as 
retired  and  13%  record  that  they  work  mainly  in  the  home.  Very  few  (2%)  describe 
their  main  occupation  as  undertaking  charity  work  and  only  2%  are  unemployed. 
Table  7.  Main  Occupation 
Occupation  Frequency  % 
Employed  full  time  545  35% 
Employed  part  time  414  27% 
Retired  223  14% 
Work  mainly  in  the  home  199  13% 
Self  employed  117  8% 
Do  charity  work  28  2% 
Unemployed  25  2% 
Missing  6  0% 
Total  1557  100% 
8.  How  women  value  tamoxifen  prophylaxis 
Responses  to  the  questions  concerning  the  value  women  place  on  tamoxifen 
prophylaxis  (Tables  8&9)  suggest  that  the  women  recruited  to  IBIS  are  highly 
motivated  and  willing  to  travel  some  considerable  distance  to  receive  the  service. 
All  of  the  women  who  returned  questionnaires  completed  the  section  designed  to 
assess  the  value  women  place  on  taking  tamoxifen  prophylaxis  in  relation  to  the 
numbers  of  deaths  likely  to  be  prevented  per  year.  Table  8  shows  that  60%  would  be 
willing  to  take  tamoxifen  prophylaxis  at  a  relatively  low  level  of  absolute  risk 
reduction  with  1  death  prevented  per  year.  A  further  17%  of  women  expressed  a 
willingness  to  take  tamoxifen  at  the  highest  stated  level  of  risk  reduction  (preventing  5 
deaths  per  year)  with  the  remaining  responses  ranged  in  the  middle  of  the  distribution. 
160 Table  8.  Willingness  to  take  tamoxifen  prophylaxis  in  relation  to  numbers  of 
deaths  prevented  per  year. 
Deaths  prevented  Frequency  % 
>1  933  60% 
>2  123  8% 
>3  163  10% 
>4  44  3% 
>5  264  17% 
Missing  30  2% 
Total  1557  100% 
Table  9  shows  how  far  women  would  be  prepared  to  travel  to  receive  tamoxifen 
prophylaxis  at  the  level  of  risk  reduction  expressed  above. 
Table  9.  Willingness  to  travel  to  receive  Tamoxifen  prophylaxis 
Travel  to:  Frequency  % 
Local  GP  14  1% 
Local  hospital  219  14% 
Specialist  centre  1311  84% 
Missing  13  1% 
Total  1557  100% 
The  responses  show  a  very  clear  willingness  to  travel  to  specialist  centres  at  least  5 
miles  away. 
9.  Total  time  and  travel  costs  involved  in  attending  IBIS  centres. 
Table  10  is  set  out  as  a  summary  of  the  per  woman  personal  costs  associated  with 
recruitment  to  IBIS.  The  costs  are  based  on  the  estimates  of  travel  time  and  time  spent 
at  the  clinic  both  for  the  first  and  subsequent  visits  described  earlier.  The  travel  time 
and  time  spent  at  the  clinic  has  been  costed  at  average  hourly  earnings  for  all  women. 
Including  the  wage  cost  of  time  spent  is  in  line  with  the  employment  status  of  the 
161 women  in  the  study;  very  few  (2%)  report  themselves  as  unemployed  compared  with 
62%  who  report  being  in  full  or  part  time  paid  employment.  The  national  earnings 
survey  was  used  to  cost  time  for  women  in  the  age  groups  recruited  to  IBIS  and 
childcare  costs  were  taken  as  an  average  of  estimates  available  from  the  study  of 
Employers  and  Childcare  published  by  Incomes  Data  Services.  The  costs  of  journeys 
to  and  from  the  IBIS  centres  are  taken  from  the  cost  estimates  given  by  the  women 
themselves  with  the  addition  of  4%  non  fuel  variable  costs  for  travel.  Using  a 
reimbursement  cost  per  mile  travelled  was  considered.  This  would  be  extremely 
difficult  to  apply  since  the  kinds.  of  cars  used  by  the  women  were  not  known. 
Weighting  the  cost  in  terms  of  the  loss  of  time  involved  valued  at  average  earnings 
provides  an  estimate  of  the  willingness  of  these  women  to  participate  in  a  trial  with 
the  opportunity  to  take  tamoxifen  prophylaxis.  This  can  be  compared  with  the 
sensitivity  analysis  also  included  in  the  table  which  values  travel  times  at  zero.  The 
costs  of  loss  of  pay  are  also  taken  from  the  estimates  given  by  the  women  themselves. 
A  sensitivity  analysis  included  in  the  table  values  the  loss  of  pay  at  average  earnings 
and  loss  of  holiday  entitlement  at  half-average  earnings. 
Table  10.  Estimates  of  personal  costs  for  women  recruited  to  IBIS  using  time 
costed  at  zero  or  alternatively  at  average  hourly  earnings. 
Average  Costing 
earnings  Time@0 
per  visit  per  5  years  Cost(£8.7/hr)' 
Median  time  spent  in  travel  to  the  centre  (50m)  100  1000  145  0 
Median  time  spent  per  woman  per  1st  visit  50  50  7.25  0 
Time  spent  per  woman  per  follow  up  visit  30  270  39.15  0 
Total  time  1320  191.4  0 
Mean  cost  of  travel(E)per  woman  +4%  non  fuel  variable 
cost 
£12.69  126.9  18.3976  18.3976 
Other  expenditure  per  woman  "  £4.94  49.4  7.163  7.163 
Total  cost  (E)per  5  years  216.9606  25.5606 
Total  cost  per  woman  per  year  43.39212  5.11212 
162 *Cost  of  travel  estimated  by  the  women  in  IBIS  plus  4%  non  fuel  variable  costs 
*Average  hourly  earnings  for  women  aged  40-59  in  full  time  work.  Taken  from  the 
New  Earnings  Survey.  Part  A.  ONS  published  by  HMSO.  April  1998 
**Average  childcare  costs.  Taken  from  Employers  and  Childcare.  Study  no  633 
published  by  Incomes  Data  Services  in  September  1997 
^  Including  loss  of  pay  as  loss  of  average  earnings  and  loss  of  holiday  entitlement  as 
loss  of  half  pay  assuming  4  hours  taken  in  total  changes  this  estimate  to  £5.5 
The  amount  of  time  spent  travelling  to  or  attending  clinics  over  5  years  of  taking 
tamoxifen  prophylaxis  is  estimated  as  4.4  hours  per  year.  Including  the  costs  of  this 
time  using  the  average  earnings  for  women  in  this  age  group  along  with  the  reported 
costs  of  travel  and  other  costs  involved  in  attending  IBIS  clinics  gives  an  estimated 
cost  per  woman  per  year  of  £43.4.  The  cost  assumptions  are  changed  in  the 
sensitivity  analysis.  Firstly  assuming  that  the  costs  of  time  are  not  included  (i.  e. 
costed  at  zero)  reduces  the  costs  per  woman  per  year  to  £5.  Secondly,  the  costs  of 
loss  of  earnings  or  loss  of  holiday  entitlement  is  included  at  average  annual  earnings 
rather  than  at  the  level  of  lost  pay  reported  by  the  women.  This  changes  the  overall 
analysis  very  little  since  there  is  little  difference  in  the  costs  reported  by  the  women 
and  those  taken  from  Incomes  Data  Services.  The  cost  per  woman  per  year  is 
estimated  at  around  £43  or  £215  over  5  years. 
10.  Visits  to  GP 
601(39%)  report  having  visited  their  GP  in  the  last  4  weeks;  956(61%)  had  not.  Of 
those  who  had,  the  outcome  of  the  visit  is  listed  in  Table  12.  For  63%  of  the  women 
the  visit  resulted  in  a  prescription.  For  284(46%)  this  was  for  a  prescription  alone,  39 
(6%)  report  receiving  a  referral  and  a  prescription  and  a  further  29  (5%)  received  a 
referral  to  the  practice  nurse  or  other  member  of  the  primary  health  care  team  and  a 
prescription.  A  small  proportion  of  women  (3%)  reported  a  referral  to  hospital  and  to 
the  practice  nurse  as  well  as  receiving  a  prescription.  For  76(12%)  the  visit  had 
resulted  in  a  referral  to  hospital  and  89(14%)  had  a  consultation  only  with  the  doctor 
163 resulting  in  neither  referral  nor  prescription.  41(7%)  of  the  women  had  a  referral  to 
the  practice  nurse  or other  member  of  the  primary  care  team  with  an  additional  4(1  %) 
being  referred  to  hospital  and  to  the  practice  nurse  or  other  member  of  the  primary 
health  care  team.  12  women  (2%)  did  not  complete  this  section  though  they  did  state 
they  had  seen  their  GP  in  the  last  4  weeks.  16  women  stated  that  they  had  not  visited 
their  GP  in  the  last  4  weeks  but  completed  the  section  on  the  outcome  of  the  visit:  13 
reported  receiving  a  prescription  only,  1  also  visited  the  practice  nurse,  1  received  a 
referral  to  hospital  1  had  a  consultation  with  the  GP  only. 
Table  12  Outcome  of  visits  to  GP 
Outcome  from  GP  visit  frequency  % 
Consultation  only  (C)  89  14% 
Referral  to  hospital  (R)  76  12% 
Prescription  only  (P)  284  46% 
Appointment  with  nurse  (V)  41  7% 
GP  and  practice  nurse  10  2% 
Referral  and  prescription  39  6% 
Referral  and  practice  nurse  4  1% 
Prescription  and  practice  nurse  29  5% 
CRP  4  1% 
CPV  12  2% 
RPV  16  3% 
CRPV  2  0% 
Missing  data  12  2% 
Total  618  100% 
Of  the  women  who  visited  their  GP  in  the  last  4  weeks  a  computation  was  made  of 
which  study  arm  they  had  been  randomised  to.  This  was  only  possible  for  the  352 
women  (65%)  who  also  declared  their  study  number  on  the  survey  sheet.  The  results 
were  that  169/352  (48%)  were  on  treatment  A  and  183/352  (52%)  were  on  treatment 
B.  There  is  no  significant  difference  between  the  two  treatment  arms. 
Quality  of  Life 
Table  13  below  shows  the  results  for  scores  on  each  of  the  dimensions  of  the  SF36 
including  the  missing  data  in  each  case.  In  general  proportion  of  missing  data  was 
164 low.  Instructions  for  the  SF36  were  followed  for  dealing  with  the  missing  items.  This 
was  as  follows: 
"  Physical  Functioning  is  scored  from  a  10  item  question  with  missing  data 
calculated  from  the  answered  items;  for  11  scores  no  average  could  be  calculated. 
"  Social  Functioning  is  scored  from  2,  two  item  questions.  Where  scores  were 
missing  the  missed  score  is  assumed  to  be  equal  to  the  answered  item;  there  were 
5  missing  scores  where  neither  item  had  been  answered. 
"  Role  Limitation  (physical)  is  scored  from  1,  four  item  question;  missing  responses 
were  calculated  as  the  average  of  answered  items 
"  Role  Limitation  (emotional)  is  calculated  from  1,  three  item  question;  missing 
responses  are  calculated  as  an  average  of  answered  items 
"  Pain  is  taken  from  2,  two  item  questions;  missing  scores  are  assumed  to  be  equal 
to  answered  items.  There  were  12  questions  where  both  items  were  omitted 
"  Mental  health  was  scored  from  5  items  of  a  single  question;  missing  data  were 
calculated  as  the  average  of  completed  items;  there  were  11  uncompleted 
responses  where  calculating  an  average  was  not  possible 
"  Energy  is  calculated  from  4  items  of  a  single  question,  averages  are  taken  to 
calculate  missing  scores;  there  were  10  responses  were  an  average  could  not  be 
calculated 
"  General  Health  Perception  was  calculated  from  4  items  of  a  question  and  a  second 
question  as  a5  item  score.  Averages  across  completed  items  were  taken  for 
missing  items  where  possible;  there  were  4  completely  missing  scores 
9  Change  in  health  status  compared  with  a  year  ago  is  scored  from  a  single  question; 
there  were  14  missing  responses 
Table  13.  Summary  scores  for  the  SF36  for  IBIS  women  compared  with  results 
from  a  study  of  the  general  population. 
Attribute  Physical 
functioning 
Social 
functioning 
Role 
Limitation 
Role 
Limitation 
Pain  Mental 
Health 
Energy 
Fatigue 
General 
Health 
IBIS  women  (physical)  (emotional)  Perception 
N  1546  1552  1557  1557  1545  1546  1547  1553 
missing  data  11  5  0  0  12  11  10  4 
Mean  83  84  80  80  76  74  59  73 
165 Standard  deviation  21.8  22.9  34.7  34.7  24.6  17.1  21  20.1 
Rank  2  1  33  5  6  8  7 
GP  Sample(women  aged 
45-54)174 
85  87  82  81  77  73  59  73 
N  917  973  960  965  950  957  965  950 
Rank  2  1  34  5  6  8  6 
In  general  the  distribution  of  scores  shows  that  the  women  perceive  themselves  to  be 
healthy  across  the  range  of  dimensions  particularly  for  physical  functioning,  social 
functioning,  role  functioning  (physical)  and  role  functioning  (emotional).  The 
perception  of  general  health  is  also  high.  The  scores  for  mental  health  are  more 
widely  distributed  with  a  mean  of  74.  For  pain,  a  significant  proportion  of  women 
perceives  themselves  as  having  some  bodily  pain  reducing  the  mean  score  to  76. 
Women  recruited  into  IBIS  perceive  energy  and  fatigue  as  the  lowest  scoring  health 
dimension;  the  mean  score  is  59. 
A  comparison  with  results  from  a  population  survey  reporting  `norms'  for  health 
status  is  included  in  the  table  (in  bold).  The  results  included  are  for  women  aged  45- 
64  from  a  postal  survey  based  on  a  random  sample  taken  from  the  computerised 
family  health  service  register  in  4  health  districts1'.  The  comparison  suggests  that  the 
health  of  women  recruited  to  IBIS  does  not  differ  from  that  of  women  of  the  same 
age  in  the  general  population.  The  ranking  of  scores  for  the  IBIS  group  and  for  the 
general  population  sample  is  similar.  Physical  and  social  functioning  rank  highest  in 
both  the  general  population  sample  and  the  IBIS  group  with  mental  health  pain  scores 
and  scores  for  general  health  lower.  Energy  and  fatigue  is  the  lowest  ranked  score  in 
both  groups. 
A  final  question  asked  within  the  SF36  is  concerned  with  change  in  health  status  over 
the  last  12  months.  Scores  are  much  lower  in  this  section  because  a  score  of  100% 
would  mean  much  better  health  and  of  0%  would  be  much  worse  health.  The  mean 
score  was  51.9  %  (SD=14.8)  which  suggests  that  women  recruited  to  IBIS  report  the 
same  or  improved  health  compared  with  the  previous  year. 
166 Differences  in  the  2  arms  of  the  trial 
Table  14  below  shows  the  means  and  standard  deviations  from  the  SF36  for  each  of 
the  health  dimensions  separated  for  women  in  the  2  arms  of  the  trial  notionally 
referred  to  as  Q  and  L.  The  results  from  t  tests  for  each  health  dimension  are  also 
included. 
Table  14.  SF36  summary  scores  and  t-test  for  women  allocated  to  either  Q  or  L 
representing  the  2  arms  of  the  trial. 
Q  L 
Physical  functioning  mean(n)  83.7(511)  85.1(471) 
std  dev  21.1  20.1 
t  -1.082 
pt  0.279 
Social  functioning  mean(n)  83.8(513)  85.5(474) 
std  dev  23  22.3 
t  -1.157 
pt  0.2472 
Role  Limitation  mean(n)  81.9(513)  82.7(478) 
(physical)  std  dev  33.7  32.9 
t  -0.409 
pt  0.682 
Role  Limitation  mean(n)  81.3(513)  81.4(478) 
(social)  std  dev  33.9  33.6 
t  -0.763 
pt  0.9392 
Pain  mean(n)  75.9(512)  77.9(475) 
std  dev  23.9  24.4 
t  -1.302 
pt  0.193 
Mental 
health 
mean(n)  74.1(511)  75.5(473) 
std  dev  17.2  17 
t  -1.285 
pt  0.198 
Energy  mean(n)  58.9(513)  60.7(473) 
std  dev  21.3  21.4 
t  -1.278 
pt  0.201 
General  Health  mean(n)  72.4(513)  73.7(475) 
std  dev  20.2  20.4 
t  -0.951 
pt  0.342 
Change  from  mean(n)  52.0(512)  51.6(468) 
1  year  ago  s  td  dev  1  4.5  1  4 
It  0  . 432 
p  >t  0  . 
6658 
167 None  of  the  results  suggest  that  women  in  the  2  arms  of  the  trial  are  different  in 
respect  of  any  aspect  of  health  status.  There  are  clearly  no  adverse  effects  on  general 
quality  of  life  for  women  taking  tamoxifen  prophylaxis.  Neither  do  women  in  one  arm 
or  the  other  consider  their  health  to  have  deteriorated  over  the  last  year. 
Discussion 
The  personal  costs  for  women  in  IBIS  range  from  £20  to  £30  per  year  of  recruitment 
depending  on  whether  time  spent  travelling  to  or  during  clinic  visits  is  included  at 
zero  base  or  costed  at  average  hourly  earnings  for  women  in  this  age  group.  The 
impact  of  these  costs  on  the  overall  cost  effectiveness  of  tamoxifen  chemoprophylaxis 
is  discussed  in  Chapter  7. 
Responses  from  the  questionnaire  show  that  a  high  proportion  of  women  recruited  to 
IBIS  are  car  owners  who  spend  between  £5-7  on  their  journeys  to  IBIS  centres.  Most 
of  the  women  have  either  full  or  part  time  employment  although  only  14%  of  the 
women  claim  to  lose  money  through  attending  an  IBIS  clinic.  There  may  be  some 
underestimation  of  these  costs  since  women  may  disregard  there  own  personal 
expenditure  when  undertaking  health  care.  In  particular,  women  recruited  to  IBIS 
are  self  selected  and  the  motivation  to  seek  recruitment  to  a  trial  may  lead  them  to 
place  relatively  low  value  on  the  cost  of  time  spent,  travel  or  other  incidental 
expenditure. 
Less  than  1%  of  the  women  say  they  have  responsibilities  for  children  that  would 
cause  them  to  incur  additional  cost  while  they  are  attending  the  centre.  The  wide 
range  of  travel  costs  reported  includes  over  75%  of  journeys  lasting  30-60m  or  more 
than  60  minutes;  10%  of  women  use  2  or  3  different  forms  of  transport.  This  finding 
of  a  willingness  to  travel  to  distant  sites  in  order  to  participate  in  a  trial  with  the 
chance  of  receiving  tamoxifen  is  supported  by  the  responses  showing  a  high  value 
placed  on  receiving  tamoxifen  even  at  the  lowest  stated  level  of  absolute  risk 
reduction  despite  the  need  to  travel  to  specialist  centres. 
168 The  extent  to  which  travel  costs  including  the  time  spent  travelling  would  be  incurred 
outside  the  trial  setting  will  depend  on  the  terms  of  any  possible  extension  given  to 
the  license  for  use  of  tamoxifen  following  completion  of  the  UK  trial.  If  licensing  is 
extended  to  include  prophylactic  use  then  access  through  GP  practices  might  be 
possible  which  would  reduce  travel  time  and  personal  costs  for  women  seeking  this 
service.  Under  such  a  model  of  care  it  is  possible  that  time  spent  in  follow  up  would 
reduce  though  an  initial  referral  to  a  specialist  breast  unit  may  continue  to  be  needed 
to  secure  eligibility  for  long  term  treatment  with  tamoxifen.  Time  spent  during  visits 
to  IBIS  is  higher  on  the  first  than  on  subsequent  visits  with  a  mean  of  40-60  minutes 
for  the  first  appointment  compared  with  20-40  minutes  for  follow  up. 
The  impact  of  quality  of  life  effects  from  tamoxifen  prophylaxis  has  been  recognised 
by  study  investigators  for  both  the  UK  and  USA  trials  though  to  date  there  are  no 
published  reports  available  from  these  studies.  The  economic  consequences  of 
changes  in  health  status  are  likely  to  be  threefold.  Anxiety  among  women  at  high  risk 
for  breast  cancer  may  have  consequences  for  counselling  needs  which  should  be 
addressed  within  the  health  service.  This  would  be  particularly  important  if  there  was 
a  profound  increase  in  anxiety  among  women  taking  tamoxifen  prophylaxis.  Changed 
anxiety  or  other  effects  of  tamoxifen  prophylaxis  on  quality  of  life  may  also  affect 
compliance  with  the  drug  regimen  and  with  appointment  keeping. 
The  similar  ranking  and  level  of  scores  for  most  of  the  health  dimensions  for  the  SF36 
Quality  of  Life  instrument  in  the  IBIS  population  in  comparison  with  a  general 
population  sample  does  however  suggest  that  there  is  little  or  no  effect  on  quality  of 
life  for  women  recruited  to  IBIS.  Low  scores  for  pain  recorded  in  both  IBIS  women 
and  the  general  population  sample  have  also  been  observed  in  other  general  health 
surveys  for  women  of  this  age.  The  high  ranking  of  mental  health  scores  for  women 
in  IBIS  compared  with  the  general  population  is  interesting.  While  this  result  is  not 
significant  it  does  suggest  that  recruitment  to  the  trial  does  not  have  an  adverse  effect. 
Fallowfield  has  suggested  that  for  women  at  high  risk  for  breast  cancer  the  possibility 
of  participation  in  a  prevention  trial  may  improve  their  quality  of  life  by  raising  their 
locus  of  control  and  reducing  anxiety. 
169 The  results  for  t-tests  between  the  2  arms  of  the  trial  shows  that  no  adverse  effects  of 
quality  of  life  occur  for  women  taking  tamoxifen,  neither  has  health  changed  over  the 
last  year  for  women  taking  tamoxifen  or  for  those  in  the  control  arm.  These  results 
may  be  biased  by  a  possible  tendency  of  women  likely  to  have  a  high  quality  of  life 
and  health  status  being  most  willing  to  put  themselves  forward  for  trial  entry.  It  is 
noticeable  that  the  score  for  physical  health  for  women  in  the  study  remains  high 
suggesting  no  adverse  effects  of  symptoms  or  side  effects  from  taking  tamoxifen 
affect  these  women.  Mental  health  remains  close  to  the  scores  for  the  general 
population  shown  in  Table  13  for  women  in  both  arms  of  the  study  suggesting  no 
adverse  effects  on  mental  health  for  women  in  either  group.  Indeed  women's  health  in 
both  groups  is  no  different  than  for  women  of  a  similar  age  in  the  general  population. 
Costs  in  terms  of  any  possible  decrement  on  quality  of  life  for  women  taking 
tamoxifen  are  minimal  These  results  suggest  that  no  adjustment  would  be  needed  to 
calculate  quality  adjusted  life  years  gained  for  women  willing  to  undertake  this  kind 
of  treatment. 
Other  issues  concerning  biases  in  this  study  should  be  considered.  The  response  rate 
to  the  questionnaire  was  less  than  70%.  This  may  have  been  a  low  estimate  since  the 
precise  number  of  questionnaires  mailed  was  unknown  due  to  an  error  with  the 
mailing  machine.  It  does  however  raise  questions  about  the  possible  characteristics  of 
women  failing  to  complete  or  not  receiving  the  form.  An  undertaking  was  given  to  the 
women  both  in  the  covering  letter  forwarded  with  the  questionnaire  and  the  reminder 
letter  that  completion  was  entirely  voluntary.  In  the  interests  of  meeting  this 
commitment  and  not  compromising  possible  continuance  of  any  women  with  the 
study  it  was  not  possible  to  seek  further  information  from  the  women  failing  to 
respond. 
Biases  associated  with  volunteers  are  also  relevant  in  this  context  and  may  result  in  a 
more  positive  health  report  among  those  responding.  Volunteer  bias  documented  for 
example  in  screening  programmes  suggests  that  people  who  choose  to  participate  are 
likely  to  differ  from  the  general  population  in  a  number  of  ways  that  may  affect 
170 reported  health.  In  general  volunteers  tend  to  have  better  health  and  lower  mortality 
rates  than  the  general  population  and  are  more  likely  to  adhere  to  prescribed  regimen. 
On  the  other  hand  those  who  volunteer  for  IBIS  may  have  an  increased  risk  of 
mortality  or  morbidity  than  the  general  population.  Such  individuals  may  be  more 
likely  to  score  lower  for  aspects  of  quality  of  life  than  the  general  population.  The 
direction  and  magnitude  of  this  bias  is  difficult  to  predict  though  will  be  considered  in 
further  follow  up. 
In  more  general  terms,  it  could  be  argued  that  asymmetry  may  also  exist  in  the  sample 
because  of  a  differential  drop  out  rate  between  the  2  arms  of  the  trial.  Those  women 
most  likely  to  suffer  adverse  consequences  on  quality  of  life  as  a  result  of  taking 
tamoxifen  may  be  more  likely  to  drop  out  of  the  study  than  those  experiencing  no 
effects  or  indeed  net  benefits.  As  a  consequence,  decrements  in  general  health  and 
well  being  will  have  been  underrepresented  in  the  sample  taken.  In  addition  the 
results  presented  here  do  not,  of  course,  include  longer  term  effects.  Further  research 
is  needed  to  assess  the  extent  to  which  women  involved  in  the  trial  are  representative 
of  all  those  who  may  be  eligible  for  tamoxifen  prophylaxis. 
Summary  and  Conclusions 
Costs  to  the  women  themselves  are  measured  in  order  to  assess  any  possible  reduction 
in  the  value  of  breast  cancer  chemoprophylaxis  caused  by  unreasonable  personal  costs 
for  the  women  involved.  This  includes  both  the  cost  of  work  lost  due  to  clinic  visits, 
costs  of  travel  to  the  clinics  or  other  costs  associated  with  clinic  visits  and  possible 
decrements  in  quality  of  life  for  women  taking  tamoxifen  prophylaxis. 
Due  to  the  eligibility  criteria  for  IBIS  the  women  recruited  might  be  expected  to  be  as 
healthy  if  not  healthier  than  women  of  the  same  age  in  the  general  population  with  the 
possible  exception  of  possible  psychological  morbidity  due  to  being  at  high  risk  for 
breast  cancer.  Compliance  with  a  long  term  drug  regimen  will  rely  on  the  trade  off 
women  are  prepared  to  make  balancing  a  possible  future  benefit  against  possible  side 
effects  or  reduced  quality  of  life. 
171 Personal  costs  and  quality  of  life  were  assessed  by  means  of  a  questionnaire  piloted 
and  then  sent  to  all  women  in  the  study  (as  at  January  1S`  1998).  Two  main  sets  of 
questions  were  included.  The  first  set  dealt  with  travel  cost,  the  cost  of  time  lost, 
work  lost  and  other  specific  costs  such  as  the  cost  of  childcare.  The  second  set 
concerned  with  quality  of  life  and  health  status  used  the  SF  36,  a  specific  instrument 
validated  in  populations  with  low  levels  of  ill  health.  Normative  data  have  been 
published  for  the  SF36  and  it  is  a  short  and  acceptable  form  to  complete.  The  response 
rate  was  68%  though  not  all  forms  were  completed;  the  analysis  is  based  on  66%  of 
the  forms. 
A  large  proportion  of  women  recruited  to  IBIS  report  themselves  to  be  in  part  time  or 
full  time  work  (62%)  although  few  women  report  loss  of  earnings  due  to  an  IBIS  visit 
(7%).  Personal  car  use  is  the  most  frequent  form  of  transport  to  the  centre  involving 
over  70%  of  journeys  and  75%  of  journeys  are  longer  than  30  minutes  with  half  of 
these  being  over  1  hour. 
The  women  are  characterised  by  their  willingness  to  travel.  A  question  concerning 
the  value  they  place  of  tamoxifen  prophylaxis  suggests  that  over  60  %  would  wish  to 
take  it  at  a  low  level  of  absolute  benefit  (1  death  prevented  per  year)  and  that  84%  of 
women  would  be  happy  to  travel  to  a  specialist  centre  to  receive  tamoxifen.  The  costs 
used  for  travel  are  those  reported  by  the  women  themselves  with  a  4%  non-fuel 
variable  cost.  The  National  Earnings  Survey  was  used  to  cost  time  off  work. 
Sensitivity  analysis  included  time  lost,  costed  at  average  earnings  and  at  zero  cost. 
The  costs  of  travel  range  from  60p  to  £200;  the  mean  costs  of  travel  are  £6.1.  The 
total  mean  cost  summarised  across  all  costs  including  the  cost  of  travel,  time  spent 
and  other  costs  is  an  estimated  £217/  5  woman  years  when  time  is  included  at  average 
earnings  and  £25.56/  5  woman  years  when  time  is  costed  at  zero. 
A  question  was  included  about  recent  visits  to  the  GP  in  order  to  assess  any 
differences  between  the  2  arms  of  the  trial  in  use  of  primary  care.  39%  of  the  women 
overall  reported  a  visit  to  the  GP  in  the  last  4  weeks;  63%  of  these  visits  had  resulted 
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between  the  2  arms  of  the  trial. 
Responses  to  the  SF36  show  that  women  recruited  to  IBIS  have  the  same  pattern  of 
health  as  women  in  the  general  population  across  all  of  the  health  dimensions 
including  physical  functioning,  role  limitation  (includes  both  physical  and  emotional), 
social  functioning,  pain,  mental  health  energy/fatigue  and  general  health  perception. 
Energy  and  fatigue  has  the  lowest  score  for  both  groups.  There  is  also  no  significant 
difference  in  any  of  the  health  dimensions  between  the  2  arms  of  the  trial.  There 
appear  to  be  no  adverse  effects  on  quality  of  life  for  women  taking  long  team 
tamoxifen  prophylaxis  and  no  adjustment  for  quality  of  life  is  needed  in  assessing  cost 
effectiveness. 
The  impact  of  personal  costs  to  the  women  themselves  on  cost  effectiveness  of 
tamoxifen  chemoprophylaxis  are  discussed  further  in  Chapter  7.  The  estimates 
derived  from  the  analysis  discussed  above  are  included  in  the  sensitivity  analysis  for 
cost  effectiveness.  The  range  of  estimates  used  identifies  the  level  at  which  personal 
costs  begin  to  bear  adversely  on  the  cost  effectiveness  ratio. 
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173 Chapter  Seven 
Economics  of  Tamoxifen  Chemoprophylaxis  for  Reducing  Mortality  and 
Morbidity  from  Breast  Cancer. 
The  following  section  sets  out  a  population  based  cost  effectiveness  analysis  for 
prophylaxis  of  breast  cancer  with  the  drug  tamoxifen.  The  data  were  collected  from 
women  enrolled  in  the  International  Breast  Cancer  Intervention  Study  (IBIS);  costs 
directly  related  to  research  in  the  trial  are  not  included.  The  design  is  based  on  a 
decision  model  assessing  the  health  and  economic  outcomes  of  chemoprophylaxis  for 
women  at  different  levels  of  risk  for  breast  cancer  compared  with  no 
chemoprophylaxis. 
Assumptions  used  in  both  the  baseline  model  and  in  the  sensitivity  analysis  are  based 
on  the  data  presented  in  previous  chapters.  This  includes  summary  data  from  the 
analysis  of  service  delivery  for  tamoxifen  chemoprophylaxis  reported  in  chapter  3,  the 
possible  range  of  costs  associated  with  changes  in  morbidity  reported  in  chapter  4  for 
the  rate  of  use  of  hospital  visits  by  women  in  the  2  arms  of  the  trial  and  in  chapter  5 
for  the  use  of  medications.  A  range  of  assumptions  for  costs  associated  with  travel  to 
the  centres  and  the  loss  of  earnings  for  the  women  themselves  are  included  based  on 
the  analysis  presented  in  chapter  6.  Costs  associated  with  changes  in  quality  of  life  are 
not  included  since  the  analysis  also  shown  in  chapter  6  found  no  evidence  of 
differences  in  health  status  and  quality  of  life  between  women  in  the  2  arms  of  IBIS. 
Cost  associated  with  the  risk  of  adverse  events  includes  only  the  increased  risk  of 
endometrial  cancer  since  information  based  on  the  literature  review  in  Chapter  2 
minimises  the  likelihood  of  other  major  mortality  risks.  The  estimate  for  the  cost  of 
breast  cancer  included  in  the  model  is  taken  from  the  analysis  developed  below. 
The  determinants  for  cost  effectiveness  are  derived  from  modelling  the  impact  of 
tamoxifen  chemoprophylaxis  on  a  district  health  authority  population.  The  outcome  - 
cost  per  breast  cancer  prevented  -  is  assessed  against  alternative  assumptions  for  cost 
and  for  efficacy  of  chemoprophylaxis.  More  detailed  analysis  for  the  cost  per  life 
year  gained  for  women  taking  tamoxifen  chemoprophylaxis  is  modelled  on  a  cohort 
of  women  at  high  risk  (an  incidence  of  breast  cancer  of  6.76/1000)  with  estimates  for 
174 risk  reduction  taken  from  the  NSABP  P-1  study2.  This  model  includes  estimates  for 
cost  effectiveness  with  different  assumptions  about  the  duration  of  the  protective 
effect  of  tamoxifen  in  reducing  the  risk  of  breast  cancer.  This  approach  is  further 
developed  to  produce  an  estimate  of  the  likely  extreme  difference  in  cost  per  life  year 
gained  depending  on  the  lowest  or  highest  assumptions  associated  with  the  costs  of 
service  delivery,  costs  associated  with  morbidity  and  with  the  women's  personal 
costs. 
Core  Assumptions 
In  the  baseline  case,  a  decision  model  is  prepared  to  compare  the  health  and  economic 
outcomes  of  breast  cancer  chemoprophylaxis  for  women  in  an  average  district  health 
authority  with  a  population  of  one  million.  The  average  population  risk  of  breast 
cancer  is  used  to  set  the  predicted  numbers  of  cases.  It  is  estimated  that  7%  of  the 
women  in  each  of  four,  five  year  age  bands  (45  -  64)  have  at  least  a  two  fold  increased 
risk  of  breast  cancer  (this  risk  is  distributed  as  5%  at  two  fold  relative  risk,  1%  at  five 
fold  relative  risk  and  1%  at  10  fold  relative  risk)  and  would  be  eligible  for  tamoxifen 
chemoprophylaxis.  The  baseline  incidence  in  the  population  for  each  age  band  in  the 
model  is  taken  from  the  Public  Health  Common  Data  Set  for  England  and  Wales. 
Efficacy  is  estimated  at  50%  reduction  in  incidence  of  breast  cancer  for  women  taking 
tamoxifen  chemoprophylaxis  based  on  the  finding  from  the  North  American  NSABP 
P-12,  though  the  impact  of  a  lower  estimate  of  efficacy  on  the  cost  effectiveness  ratio 
is  determined  in  the  sensitivity  analysis.  The  efficacy  of  prophylaxis  is  assumed  to  be 
equivalent  for  women  across  all  levels  of  risk.  Core  assumptions  about  the  model  of 
service  delivery  is  of  specialist  hospital  based  care  with  significant  involvement  of 
specialist  nurses.  Other  models  of  care  considered  in  the  sensitivity  analysis  are  a 
service  based  in  primary  care;  the  impact  on  cost  effectiveness  of  assumptions  about 
the  costs  of  service  delivery  included  in  IBIS  is  also  assessed. 
Outcome  estimates  for  the  analysis  set  out  below  are  made  from  the  predicted 
endpoints  for  women  involved  in  IBIS  and  for  changes  in  breast  cancer  incidence 
from  those  reported  in  the  NSABP  P-I  chemoprevention  trial  referred  to  earlier.  The 
potential  impact  of  tamoxifen  chemoprophylaxis  on  morbidity  is  discussed  even 
though  there  were  no  significant  findings  from  the  blinded  subgroup  analysis  of 
175 reported  morbidity  in  the  2  arms  of  IBIS  presented  earlier  (Chapters  4  and  5). 
Specifically  there  are  2  scenarios  that  seem  feasible  based  on  current  evidence.  These 
are  the  costs  associated  with  the  use  of  betablockers  and  the  costs  associated  with 
changes  in  the  rate  of  hospital  visits  for  benign  breast  disease. 
Breast  cancer  treatment  costs  are  derived  from  an  audit  of  diagnosis  and  management 
of  1,779  breast  cancer  cases  from  17  different  hospital  Trusts  carried  out  by  the 
Thames  Cancer  Registry  (TCR)  17.  This  is  described  in  detail  below.  The  17  Trusts 
included  in  the  TCR  breast  cancer  audit  database  all  provide  complete  and 
comparable  data.  The  patients  represent  48%  of  the  total  of  North  Thames  Region's 
activity  of  3039  new  cases  of  breast  cancer  diagnosed  between  January  1St  1996  and 
December  30  1996  7. 
In  the  model,  the  marginal  cost  of  chemoprophylaxis  compared  with  no 
chemoprophylaxis  is  expressed  as  the  cost  per  breast  cancer  prevented  and  per  year  of 
life  gained.  Projections  are  also  included  about  the  potential  for  years  of  life  gained 
based  on  survival  estimates.  The  marginal  cost  effectiveness  is  the  additional  cost  of 
prophylaxis  minus  any  cost  savings  due  to  the  use  of  prophylaxis  (savings  from  breast 
cancers  prevented  and  any  other  beneficial  health  effects)  divided  by  the  number  of 
cases  of  breast  cancer  (under  65)  averted.  Cost  per  life  year  gained  is  based  on 
average  expectations  of  survival  for  women  in  each  age  band.  Economic  outcomes  are 
the  cost  of  prophylaxis  and  the  changed  cost  of  treating  breast  cancer.  Estimates  with 
discounting  of  both  costs  and  benefits  are  included. 
Costs  of  breast  cancer 
The  cost  of  breast  cancer  averted  is  taken  from  the  Thames  Cancer  Registry  Audit  of 
New  Cases  of  Breast  Cancer.  The  audit  was  used  because  it  is  more  likely  to  provide 
estimates  of  the  true  cost  of  breast  cancer  treatment  than  a  protocol  based  cost  study. 
A  number  of  studies  have  shown  that  there  are  wide  variations  in  the  quality  of  care  in 
relation  to  published  standards.  The  audit  was  however  carried  out  at  a  time  when 
there  was  widespread  discussion  in  the  medical  press  about  the  importance  of 
implementing  an  agreed  protocol  for  management  of  breast  cancer  and  nationally 
agreed  guidelines  had  been  published.  It  is  likely  therefore  that  the  variations  in 
176 estimate  of  £200  per  woman  available  to  clinics  participating  in  IBIS.  Developments 
in  the  model  also  look  at  the  potential  impact  of  costs  or  savings  which  may  arise 
from  changes  in  the  morbidity  experience  for  women  taking  long  term  tamoxifen 
particularly  the  cost  of  treatment  for  symptoms  of  benign  breast  disease  or  for  changes 
in  the  cost  of  beta  blockers  prescribed  for  the  vascular  symptoms  such  as  hot  flushes 
which  are  commonly  associated  with  tamoxifen.  Variations  are  also  proposed  in  the 
numbers  of  women  eligible  for  prophylaxis  including  targeting  only  women  at  very 
high  risk  of  breast  cancer  and  the  possibility  that  all  women  over  55  might  be  eligible. 
Finally,  the  impact  of  the  costs  to  the  women  themselves  is  included  by  using  two 
different  assumptions  about  the  value  of  the  time  spent  by  women  in  travelling  to  and 
attending  clinics.  These  are  time  valued  at  average  hourly  earnings  for  women  of  the 
same  age  or  with  time  valued  at  zero.  Other  personal  costs  such  as  childcare  are 
reviewed. 
Cost  of  breast  cancer 
The  frequency  of  each  of  the  procedures  for  women  diagnosed  with  breast  cancer 
noted  during  the  TCR  audit  and  the  costs  based  on  charges  is  set  out  in  Table  1.  The 
procedures  appearing  with  the  highest  frequency  in  the  audit  are  for  clinical 
assessment  (91%),  mammography  (74%)  and  cytology  (80%).  This  is  in  line  with 
NHS  guidance  from  the  Clinical  Outcomes  Group40  which  states  that  a  definitive 
diagnosis  on  the  majority  of  women  presenting  with  a  breast  lump  (95%)  should  be 
made  on  the  basis  of  triple  assessment  by  clinical  assessment,  breast  imaging  and 
cytology  by  fine  needle  aspiration  or  core  biopsy.  In  general  the  use  of  frozen  section 
histology  should  only  be  needed  in  a  small  proportion  of  cases.  Trucut  biopsy  was 
used  in  23%  of  cases  in  the  TCR  sample.  This  is  likely  to  have  been  used  in  addition 
to  cytology  by  fine  needle  aspiration  in  some  cases. 
The  use  of  mammography  seems  rather  low.  In  general,  patients  receive  full  blood 
count,  urea  and  electrolytes,  liver  function  tests  and  chest  X  ray  as  a  baseline  to 
surgery.  Blood  counts,  urea  and  electrolytes  are  not  listed  in  the  TCR  sample  though 
are  assumed  to  be  included  in  the  charges  associated  with  surgery.  The  use  of  liver 
function  tests  and  chest  X-ray  does  seem  to  be  low  in  the  sample  given  that  80%  of 
178 women  receive  surgery.  This  may  be  due  to  variations  in  the  local  protocol  for  care 
among  the  different  hospitals  included  or  in  underreporting.  The  cost  of  these 
interventions  is  small  in  relation  to  the  overall  cost  and  variations  in  practice  are 
unlikely  to  affect  the  overall  cost  of  care.  Other  tests  such  as  bone  scan  and  liver 
ultrasound  are  not  routinely  indicated  since  they  do  not  have  a  high  yield  in 
asymptomatic  patients  with  operable  breast  cancer  and  there  is  no  evidence  that  there 
use  improves  survival  or  quality  of  life1.  84 
The  radiotherapy  regimen  proposed  by  the  Royal  College  of  Radiologists  suggests  a 
rather  higher  frequency  of  use  than  the  50%  recorded  in  the  TCR  audit.  The 
difference  may  well  be  explained  by  variations  in  mastectomy  rates  around  the  North 
Thames  Region  and  the  local  policy  in  relation  to  radiotherapy.  Although 
radiotherapy  has  been  shown  to  reduce  local  recurrence  in  patients  undergoing  local 
excision  of  a  breast  lump,  there  is  still  no  conclusive  evidence  on  the  value  of 
radiotherapy  in  improving  local  control  following  mastectomy.  Current  conclusions 
from  overviews  of  randomised  trials  suggest  that  there  is  no  survival  benefit  from 
radiotherapy  and  that  deaths  from  other  causes  may  increase  with  radiotherapy 
following  mastectomy180'  186.  An  ongoing  trial  (START)  presently  still  recruiting 
patients  will  provide  more  detailed  information  to  resolve  this  issue.  Until  the 
completion  of  the  START  trial,  rates  of  radiotherapy  are  likely  to  vary  according  to 
local  policy.  At  just  under  £1500  per  patient  the  overall  cost  of  radiotherapy  is  24%  of 
the  total  charges  for  breast  cancer  care  -a  surprising  proportion  considering  the 
paucity  of  research  evidence  to  guide  practice.  It  is  interesting  to  note  also  that  the 
cost  of  treating  advanced  disease  with  high  cost  chemotherapy  amounts  to  a  small 
proportion  of  the  total  cost  (<0.6%)  while  these  treatments  remain  accessible  to  only  a 
small  proportion  of  the  population. 
179 Table  1.  Charges  for  breast  cancer  care 
Costs  of  new  cases  of  breast  cancer 
Procedure  Price  %  Cost(f)  Note 
clinical  assessment  147  91  133.77  1 
mammogram  28  74  20.72  1 
ultrasound  30  30  9  1 
cytology  8  80  6.4  1 
trucut  biopsy  20  23  4.6  1 
chest  X  ray  12  38  4.56  1 
bone  scan  138  19  26.22  1 
liver  ultrasound  30  20  6  1 
liver  function  tests  5  28  1.4  1 
women  undergoing  surgery  80  0 
excision  biopsy  562  19  106.78  2 
wide  local  excision  661  45  297.45  3 
repeat  excision  562  4  22.48  2 
mastectomy  1472  28  412.16  4 
cavity  wall  biopsy  562  3  16.86  2 
reconstruction  1,472  3  44.16  5 
women  prescribed  tamoxifen  120  77  92.4  6 
ovarian  ablation  1914  2  38.28  7 
chemotherapy  754  21  158.34  8 
lymphoedema  147  2  2.94  9 
Radiotherapy  48  10  4.8  10 
following  lumpectomy  3000  80(45%)  1080 
f  ollowing  mastectomy  2250  60(45%)  378 
Advanced  Disease  0 
5  year  follow  up  3540  8  02  832  11 
%  advanced  disease  1  20 
%non  anthracyclines  1  60  3  4 
.8 
%  anthracyclines  1  648  7 
.. 
5  1  23.544 
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Notes 
1  Hospital  outpatient  cost  of  test 
2  HRG (j07)'59 
3  HRG  (j04) 
4  HRG(j02) 
5  HRG  (j02) 
6  Non  proprietary  cost  of  prescribing  tamoxifen(20mg 
tabs)  16 
@  £2.95  for  30  tabs)/yr 
17  HRG  (m03) 
Cost  of  triple  combination  of  cyclophosphamide16 
methotrexate  and  5-flouracil(CMF)8  cycles. 
General  surgery  outpatient  cost  for  management  of  lymphoedema's 
110  Radiotherapy  costs  taken  from  Mount  Vernon  Cancer  Centre 
11  1  Mytomycin  C:  dosc  of  12mg/m2,  doxorubicin:  dose  of  65mg/m2,  paclitaxel: 
dose  of16 
Costs  of  10  outpatient  oncology  visits  also  included 
12  Cost  of  palliative  care/patient 
12 
Costs  for  endometrial  cancer 
The  estimated  increase  in  the  incidence  of  endometrial  cancer  for  women  taking  long 
term  tamoxifen  is  taken  from  the  relative  risk  for  women  taking  tamoxifen  found  in 
the  NSABP  P-1  chemoprevention  trial.  An  overall  annual  average  rate  of  2.3  per 
1000  women  in  the  tamoxifen  arm  compared  with  0.91  in  the  placebo  group  this  is  a 
relative  risk  of  2.53  (95%  CI  =  1.53  -  4.97).  This  information  is  used  in  the  model  to 
estimate  the  expected  increase  in  the  incidence  of  endometrial  cancer  for  the  baseline 
case  and  for  varying  assumptions  about  the  efficacy  of  treatment.  The  baseline  rates 
for  endometrial  cancer  are  estimated  at  3  per  10,000  for  women  in  England  and 
181 Wales.  Background  rates  in  the  USA  are  considerably  higher.  The  cost  of 
endometrial  cancer  is  estimated  as  £2,261  per  woman. 
Baseline  case  (core  assumptions) 
The  cost  effectiveness  of  tarnoxifen  chemoprophylaxis  is  based  on  information 
presented  in  Tables  2  and  3.  Table  2,  presents  the  baseline  model  for  the  estimated 
numbers  and  cost  of  breast  cancer  in  an  average  English  District  Health  Authority 
with  a  million  population  including  a  total  of  120,140  women  in  the  eligible  age  group 
for  tamoxifen  prophylaxis  (45  -  64).  The  expected  incidence  of  breast  cancer  for 
these  women  is  shown  by  age  group.  Seven  percent  of  the  women  in  this  population 
(8,410)  are  estimated  as  having  at  least  a  two  fold  relative  risk  of  breast  cancer 
because  of  family  history  and  to  be  eligible  to  receive  prophylaxis.  The  table 
approximates  the  number  of  cases  per  year  likely  both  for  women  at  average 
population  risk  (188)  and  for  those  at  increased  risk  (28).  The  cost  of  breast  cancer 
care  for  the  total  number  of  new  cases  (216.49)  is  just  over  a  million  pounds 
(£1,320,994)  per  year. 
Table  2.  The  expected  number  (and  cost)  of  cases  of  breast  cancer  for  a  health 
district  (population  of  1,000,0000  with  120,000  women  aged  45-64) 
Women  at  least  2  fold  risk  cost  of 
Incidence  increased  risk  2Xrr  baseline  risk  total  breast  cancer 
(£) 
Age  Number  Rate/100,00 
0 
number  (7%)  Incidence  cases/year  cases/year  cases/year  6102 
45-49  35,100  125  2457  250  6.14  40.80  46.95  286,466 
50-54  34,240  134  2396.8  268  6.42  42.67  49.09  299,567 
55-59  26,060  185.5  1824.2  371  6.77  44.96  51.73  315,627 
60-64  24,740  259.6  1731.8  519.2  8.99  59.73  68.72  419,334 
Total  120,140  8,409.8  1,408.2  28.33  188.16  216.49  1,320,994 
182 In  the  baseline  case  for  tamoxifen  chemoprophylaxis,  shown  in  the  first  column  of 
Table  3,  it  is  assumed  that  efficacy  is  a  50%  reduction  in  breast  cancer  incidence  per 
year  for  the  5  years  duration  of  tamoxifen  use  for  women  with  at  least  a  two  fold  risk 
of  breast  cancer.  It  is  assumed  that  all  women  at  high  risk  (8,410)  comply  with  a 
regimen  of  daily  tamoxifen  for  five  years.  The  estimated  cost  effectiveness  is  £57,558 
per  breast  cancer  prevented. 
Sensitivity  Analysis 
1.  Changes  in  assumptions  about  efficacy  and  eligibility 
Table  3  compares  the  results  for  the  cost  per  breast  cancer  prevented  in  the  baseline 
case  with  results  for  changes  in  assumptions  about  efficacy  of  tamoxifen 
chemoprophylaxis  and  for  a  scenario  where  all  women  over  age  55  are  eligible  for 
chemoprevention  with  50%  uptake. 
Table  3.  Cost  per  breast  cancer  prevented  in  the  baseline  case  (Risk  Reduction 
(RR)  =0.50)  and  with  a  series  of  alternative  assumptions  about  Risk  Reduction. 
Risk  Reduction  (RR) 
Baseline  case 
RR=0.50  n  RR=0.45  In  RR=0.33  In  RR=0.5  n 
Cost  of  chemoprevention  50%55+ 
Cost  of  delivery  £4,499,243  8409.8  £4,499,243  8,409.8  £4,499,243  8409.8  £1,713,7013  32031.8 
Cost  of  adverse  events  £8,727.7  3.9  £8727.7  3.9  £8,727.7  3.9  £54964.9  24.3 
Total(cost)  £4,507,970.7  £4,507,970.7  £4,507,970.7  £17191977.9 
Savings  from 
chemoprevention 
Breast  cancers 
prevented/year 
£86,420.2  14.2  £77,778.2  12.7  £57,728.7  9.5  £247314.1  40.5 
Breast  cancers  prevented  (5 
years) 
£432,101.1  70.8  £388,891.0  63.7  £288,643.5  47.3  £1236570.3  202.7 
I  Total(savings)  £432101.1  £388891.0  £288643.5  £1236570.3 
Cost  per  breast 
cancer  prevented 
£57,558.2  £64,631.5  £89,197.7  £78,733.8 
183 The  cost  of  delivering  a  service  for  tamoxifen  chemoprophylaxis  using  the  estimate  of 
£535  per  woman  in  a  specialist  hospital  based  service  (from  Chapter  3)  for  8,410 
eligible  women  is  £4,499.243.  This  cost  remains  the  same  when  varying  the 
assumption  about  efficacy  since  the  same  numbers  of  women  are  treated  in  each  case. 
For  the  scenario  where  women  can  opt  into  the  programme  once  over  age  55,  the  cost 
of  delivering  chemoprevention  increases  by  around  3  fold  in  order  to  treat  around 
32,000  women  in  addition  to  those  at  high  risk  for  reasons  other  than  age.  The  cost  of 
treating  the  21  additional  cases  of  endometrial  cancer  which  might  be  expected  to 
arise  with  such  a  large  number  of  additional  women  taking  prophylactic  tamoxifen 
outweighs  the  savings  in  cost  terms  from  the  26  additional  breast  cancers  prevented. 
Estimates  for  the  cost  effectiveness  (cost  per  breast  cancer  prevented)  of  tamoxifen 
prophylaxis  shown  in  Table  3  increases  by  over  50%  when  efficacy  is  estimated  at 
only  0.33  reduction  in  risk  of  breast  cancer.  The  cost  effectiveness  does  not  improve 
when  increasing  the  numbers  of  women  taking  tamoxifen  with  eligibility  determined 
by  age  since  the  cost  of  service  delivery  rises  at  a  greater  rate  than  the  numbers  of 
breast  cancers  prevented.  In  the  same  way,  the  impact  of  adverse  events  on  overall 
costs  remains  the  same.  Despite  a  relatively  low  unit  cost  for  service  provision  in 
comparison  with  many  other  health  care  interventions  the  overall  costs  are  high.  This 
is  because  a  large  number  of  women  must  be  treated  in  order  to  prevent  one  breast 
cancer.  The  absolute  risk  reduction  in  this  Health  Authority  population  model  is 
0.007.  The  numbers  of  women  who  would  need  to  receive  tamoxifen  in  order  to 
prevent  one  breast  cancer  is  142. 
2.  Alternative  means  of  service  delivery:  Model  based  on  the  budget  available  to 
participating  centres  in  the  International  Breast  cancer  Intervention  Study  (IBIS) 
Table  4  sets  out  the  estimates  for  tamoxifen  prophylaxis  based  on  the  expenditure 
assumptions  used  in  IBIS.  The  expenditure  is  set  at  £200  per  woman  recruited.  The 
cost  per  breast  cancer  prevented  is  £17,773.4  for  the  baseline  case  with  an  assumed 
relative  risk  reduction  of  0.5.  This  estimate  rises  to  £29,639.6  for  the  lowest 
assumption  of  relative  risk  reduction  at  0.33  and  is  £20,426.2  at  0.45. 
184 Table  4.  Cost  effectiveness  (Cost  per  breast  cancer  prevented)  of 
chemoprevention  based  on  the  expenditure  assumptions  in  IBIS  with  a  series  of 
assumptions  of  relative  risk  reduction. 
Risk  Reduction  (RR) 
RR=0.50  n  RR=0.45  n  RR=0.33  n  RR=0.5  n 
Cost  of  chemoprevention  50%55+ 
Cost  of  delivery  £1,681,960.0  8,410  £1,681,960  8,410  JE1,681,960.0 
0  8,410 
JE6,406,360.  32,031.8 
Cost  of  adverse  events  £8,727.7  3.9  £8727.7  3.86  £8727.7 
3.86 
£54,964.9  24.3 
Total(cost)  £1,690,687.7  £1,690,688  £1,690,687.7  £6,461,324.9 
Savings  from 
chemoprevention 
Breast  cancers  preventedlyear  £86,420.2  14.2  £77778.2  12.75  £57728.7  9.46  £247,314.1  40.5 
Breast  cancers  prevented  (5 
years) 
£432,101.1  70.8  £388891.0  63.7  J  E288643.5  47.30  J 
31 
E1236570.3-  202.7 
Total(savings)  £432,101.1  £388891.0  £288643.5  £1236570.3 
Cost  per  breast  cancer 
prevented 
£17,773.4  £20,426.2  £29,639.6  £25,782.2 
Table  5  shows  the  equivalent  data  for  the  service  delivery  option  of  offering 
tamoxifen  prophylaxis  in  primary  care.  The  most  cost  effective  option  of  £42,713.1 
per  breast  cancer  prevented  is  seen  with  a  risk  reduction  of  50%  for  a  service  based  in 
primary  care.  This  model  would  include  consultation  with  specialists  only  at  the  first 
and  final  visits. 
Table  5.  Cost  effectiveness  of  chemoprevention  based  on  the  expenditure 
assumptions  in  a  GP  led  model  in  a  primary  care  setting  with  a  series  of 
assumptions  of  relative  risk  reduction. 
Risk  Reduction  (RR) 
RR=0.50  n  RR=0.45  n  RR=0.33  n  RR=0.5  n 
Cost  of  chemoprevention  50%55+ 
Cost  of  delivery  £3,448,018  8409.8  £3,448,018  8409.8  £3,448,018  8409. 
8 
£1,313,3038  £32,031.8 
Cost  of  adverse  events  £8727.7  3.9  £8727.7  3.9  £8727.7  3.9  £54964.9  24.3 
Total(cost)  £3,456,745.7  £3,456,745.7  £3,456,745.7  £13,188,002.9 
185 Savings  from 
chemoprevention 
Breast  cancers  £86,420.2  14.2  £77,778.2  12.7  £57,728.7  9.5  £24,7314.1  40.5 
prevented/year 
1 
Breast  cancers  prevented  £432101.1  70.8  £388891.0  63.7  £288643.5  47.3  £1236570.3  202.7 
(5  years) 
Total(savings)  £432,101.1  £388,891.0  £288,643.5  £1,236,570.3 
Cost  per  breast  cancer  £42,713.1  £48,137.0  £66,974.5  £58,975.7 
prevented 
Impact  of  risk 
Table  6  uses  a  simple  model  to  illustrate  the  impact  of  risk  in  the  population  on  cost 
effectiveness  of  prophylaxis  (Cost  per  breast  cancer  prevented).  Using  the  same 
parameters  as  for  the  model  above  in  the  tables  above,  changes  in  cost  effectiveness 
are  calculated  for  a  population  of  1,000  women  at  three  different  levels  of  risk  of 
breast  cancer  (two  fold,  five  fold  and  ten  fold  of  baseline  risk)  with  the  three  different 
estimates  for  efficacy  described  above  (risk  reduction  of  0.33,0.45  and  0.5). 
Table  6.  Impact  on  cost  effectiveness  (cost  per  breast  cancer  prevented)  of  the 
relative  risk  of  breast  cancer  in  the  targeted  population 
Cost  per  breast  cancer  prevented  (£) 
Relative  risk 
Risk  reduction  Vold  5foid  10foid 
0.33  89,197.7  36,899.5  17,839.5 
0.45  64,631.54  27,073.0  12,926.3 
0.5  57,558.2  24,243.7  11,511.6 
The  cost  effectiveness  estimate  ranges  from  £89,197.7  to  £  11,511.6  for  women  at  two 
fold  increased  risk with  a  reduction  in  the  incidence  of  breast  cancer  of  0.33  to  women 
at  ten  fold  increased  risk  with  a  reduction  in  risk  of  0.5  respectively.  The  costs  are  . 
primarily  determined  by  the  numbers  of  women  receiving  tamoxifen.  The  cost 
effectiveness  is  lowest  for  groups  of  women  at  very  high  risk  for  breast  cancer  as 
increasing  numbers  of  breast  cancers  are  prevented. 
186 3.  Impact  of  changes  in  morbidity 
The  possible  impact  of  changes  in  morbidity  for  women  taking  tamoxifen  included 
here  are  based  on  results  from  women  enrolled  in  IBIS  discussed  earlier.  Although,  in 
general,  there  were  few  apparent  differences  in  hospital  visits  or  in  use  of  prescribed 
medications  -  the  proxy  measures  used  for  morbidity  -  for  women  in  either  of  the  two 
arms  of  the  trial,  the  results  did  suggest  a  need  for  continued  review  with  increasing 
accrual  to  the  trial.  In  particular  from  the  hospital  visit  data  there  was  a  non 
significant  trend  indicating  the  possibility  of  changes  in  symptoms  of  benign  breast 
disease  requiring  specialist  advice  and/or  hospital  treatment  and  from  the  medications 
data,  changes  in  the  use  of  beta  blockers. 
The  relative  risk  reduction  for  benign  breast  disease  for  women  taking  tamoxifen  was 
calculated  for  women  enrolled  in  IBIS  using  the  hospital  visits  data  which  suggested 
that  there  was  a  non  significant  difference  of  about  5%  in  the  numbers  of  women 
having  hospital  visits  resulting  in  a  procedure,  between  the  2  arms  of  the  trial. 
Moreover  the  visits  in  one  arm  of  the  trial  tend  to  be  lower  cost  than  in  the  other  arm 
(a  mean  of  £650.35  compared  with  £827.16).  The  baseline  rate  of  hospital  visits  by 
women  in  the  relevant  age  group  was  taken  as  around  17%  from  the  NHS  hospital 
episode  system  per  yeart67.  For  the  baseline  District  Health  Authority  model  where 
8,410  women  are  receiving  tamoxifen  this  might  result  in  a  difference  in  the  cost  of 
hospital  visits  of  £32-£4l  per  woman  per  year  receiving  tamoxifen.  Since  the  trial  has 
not  yet  concluded  it  is  necessary  to  assess  these  effects  as  a  difference  between  the 
two  arms  of  the  trial.  This  is  a  cost  -  or  a  saving  -  on  the  overall  cost  of  delivering 
tamoxifen  chemoprophylaxis  per  woman  of  between  30  and  38%. 
For  possible  changes  in  the  use  of  betablockers  the  impact  is  smaller.  The  rate  of  use 
of  betablockers  in  the  general  population  was  estimated  as  5.6%  of  a  general  practice 
population  aged  45-64  (87/1,565).  The  relative  risk  between  the  2  anus  of  the  trial 
was  0.67.  Assuming  that  the  frequently  used  drug,  Atenolol,  is  prescribed  at  50 
mg/day  at  a  cost  of  £1/month  the  cost  or  saving  from  tamoxifen  prophylaxis  would  be 
an  estimated  £7  per  woman.  This  is  less  than  0.2%  of  the  total  cost  of  tamoxifen 
chemoprophylaxis.. 
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breast  cancer  prevented)  in  Table  8. 
4.  Impact  of  personal  costs  to  the  women  themselves 
The  analysis  in  Chapter  6  found  a  range  of  personal  costs  per  woman  per  year  from  £5 
to  £43  depending  on  whether  or  not  the  time  spent  by  women  in  travelling  to  and 
attending  clinics  is  included  at  average  earnings  or  at  zero.  Table  7  shows  the  effect 
on  the  cost  per  breast  cancer  prevented  for  the  baseline  case  in  the  District  Health 
Authority  model  with  an  assumption  of  0.50  reduction  in  incidence  of  breast  cancer 
based  on  a  population  where  women  at  2  fold  increased  risk  of  breast  cancer  are 
eligible  to  take  tamoxifen.  Table  7  shows  both  personal  cost  estimates. 
Table  7.  Cost  effectiveness  (Cost  per  breast  cancer  prevented)  of  tamoxifen 
chemoprophylaxis  including  two  assumptions  about  the  women's  personal  costs 
Risk 
reduction=0.5 
0 
n 
Cost  of  chemoprevention  £ 
Cost  of  delivery  4,499,243.00  8,410 
Cost  of  adverse  events  8,727.68  3.8600982 
Women's  personal 
costs 
@  £5  42,049.00 
@  £43  361,621.40 
Total(cost)  @  £5  4,550,019.68 
£43  4,869,592.08 
Savings  from  chemoprevention 
Breast  cancers  prevented/year  86,420.22  14.16 
Breast  cancers  prevented  (5  years)  432,101.10  70.8 
1  Total(savings)  432,101.10 
Cost  per  breast  cancer  prevented  ©£5  58,151.99 
Cost  per  breast  cancer  prevented  @  £43  62,664.89 
The  cost  per  breast  cancer  prevented  increases  by  between  1%  and  8%  compared  with 
the  baseline  estimate  of  £57,558.2  shown  in  Table  3. 
188 5.  Consolidated  estimate  for  cost  per  breast  cancer  prevented 
Table  8  sets  out  a  summary  cost  effectiveness  for  tamoxifen  chemoprophylaxis  for 
breast  cancer  based  on  the  analysis  in  Table  12.  In  this  summary  it  is  assumed  that  the 
protective  effect  of  tamoxifen  endures  only  during  the  period  of  active  intervention. 
Estimates  for  cost  effectiveness  would  of  course  improve  were  there  to  be  a  longer 
term  protective  effect.  Alternative  estimates  for  the  impact  of  findings  for  morbidity 
and  for  personal  costs  to  the  women  themselves  are  included.  For  the  latter,  both 
estimates  of  £5  and  £43  per  woman  per  year  in  the  nurse  led  and  IBIS  model  are 
included.  In  the  GP  model  of  service  delivery  the  personal  costs  are  included  either  as 
£5  or  at  zero  cost.  This  latter  assumption  is  based  on  the  expectation  that  most  care 
will  take  place  in  the  GP  practice  with  minimal  cost  to  the  woman  herself.  Under  this 
model,  a  single  visit  to  the  specialist  centre  may  occur  once  during  the  5  year  period 
and  the  £5  personal  cost  assumption  represents  a  high  estimate  for  the  cost  women 
may  have  to  bear  for  a  hospital  visit. 
The  table  shows  that  the  highest  estimate  for  cost  per  breast  cancer  prevented  is 
£40,645  in  a  nurse  led  service  when  the  highest  estimate  of  personal  cost  for  the 
women  and  themselves  is  included  and  when  assuming  that  costs  accrue  because  of 
tamoxifen  use  due  to  increased  incidence  of  benign  breast  disease  and  increased  use 
of  beta  blockers.  In  the  scenario  with  costs  for  beta  blockers  accruing  to 
chemoprophylaxis  but  with  a  reduction  in  the  rate  of  benign  breast  disease  the  cost  per 
breast  cancer  prevented  is  £14,423.5.  The  lowest  cost  per  breast  cancer  prevented  is 
obtained  where  the  cost  of  service  delivery  approximates  to  the  budget  available  to 
participating  IBIS  centres  of  £200  per  woman  and  where  personal  costs  to  the  women 
are  set  at  £5  per  woman. 
In  the  GP  led  service  which,  based  on  available  information  may  be  a  feasible 
approach  a  negative  value  for  cost  effectiveness  of  -  £3990.83  is  obtained  where 
tamoxifen  use  is  considered  to  reduce  the  rate  of  benign  breast  disease  and  increase 
the  use  of  beta  blockers.  This  suggests  that  benefits  exceed  costs  and  arises  partly 
because  it  is  assumed  in  the  GP  led  service  that  there  will  be  no  or  few  personal  costs 
to  the  women  themselves.  The  cost  effectiveness  is  £12,426.19  when  both  aspects  of 
189 morbidity  accrue  as  costs.  These  results  demonstrate  the  impact  of  both  personal 
costs  and  the  possible  impact  of  morbidity  on  overall  cost  effectiveness. 
Table  8.  Summary  estimates  for  cost  effectiveness  of  tamoxifen  prophylaxis  for 
breast  cancer  for  hospital  based,  GP  led  or  IBIS  cost  for  service  delivery 
including  or  excluding  estimates  of  impact  of  morbidity  (benign  breast  disease  or 
use  of  beta  blockers)  and  personal  costs  for  women  at  £5  or  £43  per  woman  for 
the  nurse  led  and  IBIS  service  models  and  £5  or  £0  personal  cost  for  woman  in 
the  GP  model  of  service. 
Service  delivery  &  personal  cost  Morbidity  Assumptions 
assumptions 
plus  benign  minus  benign  plus  benign  minus  benign 
breast  disease  breast  disease  breast  disease  breast  disease 
plus  beta  minus  beta  minus  beta  plus  beta 
blockers  blockers  blockers  blockers 
Cost  effectiveness  for  nurse  led  40,644.60  24,083.64  40,534.93  24,193.31 
service(£535twoman)  assuming  £43 
personal  cost  per  woman. 
Cost  effectiveness  for  nurse  led  30,874.78  14,313.82  30,765.10  14,423.49 
service(£535/woman)  assuming  £5 
personal  cost  per  woman. 
Cost  effectiveness  for  GP  led  12,426.19  (4,100.51)  12,350.78  (3,990.83) 
service(£410/woman) 
assuming  £0  personal  cost  per  woman. 
Cost  effectiveness  for  GP  led  service  24,468.13  7,919.95  24,371.24  8,029.63 
(£4101woman)  assuming  £5  personal  cost 
per  woman. 
Cost  effectiveness  for  IBIS  model  23,474.78  6,948.09  23,399.38  7,057.76 
(£200/woman) 
assuming  £43  personal  cost  per  woman. 
Cost  effectiveness  assuming  IBIS  12,681.94  (  3,844.75)  12,606.54  (  3,735.08) 
costs  (£200) 
and  £5  personal  cost  per  woman 
190 6.  Cost  per  life  years  gained 
Table  9  shows  the  years  of  life  gained  for  women  taking  tamoxifen  prophylaxis.  The 
model  in  this  case  is  based  on  the  annual  incidence  of  breast  cancer  found  in  the 
NSABP  P-1  Breast  Cancer  Prevention  Trial.  The  results  were  monitored  over  six 
years.  Mortality  from  all  causes  of  324.6  per  100,000  is  taken  from  age  specific 
mortality  for  women  aged  35-64  in  England  and  Wales  included  in  the  Public  Health 
Common  Data  set  for  1998  based  on  data  for  1995-7.  Women  in  the  placebo  arm  of 
the  trial  had  an  average  incidence  of  breast  cancer  of  6.76  per  1000  for  women. 
The  model  assumes  that  there  is  no  further  protection  from  tamoxifen  beyond  the  6 
year  monitoring  period  and  the  incidence  of  breast  cancer  reverts  to  that  of  the  control 
population.  In  Table  8  different  assumptions  for  the  length  of  the  protective  effect  are 
included.  Under  three  different  possible  outcomes  of  an  additional  5,10  or  15  years 
continuous  protective  effect  it  is  assumed  that  women  in  the  tamoxifen  arm  retain  a 
relative  risk  of  reduction  in  incidence  of  breast  cancer  of  0.5. 
Table  9.  Net  reduction  in  incidence  of  breast  cancer.  The  core  assumption  in 
this  table  is  of  no  further  protective  effect  beyond  year  6.  The  average  rate  of 
breast  cancer  is  6.76/1000.  Deaths  from  all  causes  are  assumed  to  be  an  average 
mortality  rate  of  324  per  100,000  woman  years. 
Year  Breast  cancer  Incidence  Deaths 
from  all 
causes 
Breast  cancer  free 
population  surviving 
Net 
reduction 
in 
incidence 
control  tam  RR  multiplier  control  tam  control  tam 
0.0067  0.00324  100,000  100,000  0 
1  670  448.9  0.33  0.67  324  324  99,006.0  99,227.1  221 
2  663.3  298.5  0.55  0.45  320.8  320.8  98,021.9  98,607.8  365 
3  656.7  400.6  0.39  0.61  317.6  317.6  97,047.5  97,889.6  256 
4  650.2  331.6  0.49  0.51  314.4  314.4  96,082.9  97,243.6  319 
5  643.8  199.6  669  0.31  311.3  311.3  95,127.8  96,732.7  444 
6  637.4  286.8  0.55  0.45  308.2  308.2  94,182.3  96,137.7  351 
191 7  631.0  305.2  93,246.1  631 
8  624.7  302.1  92,319.2  625 
9  618.5  299.1  91,401.6  619 
10  612.4  296.1  90,493.0  612 
11  606.3  293.2  89,593.5  606 
12  600.3  290.3  88,703.0  600 
13  594.3  287.4  87,821.3  594 
14  588.4  284.5  86,948.3  588 
15  582.6  281.7  86,084.1  583 
16  576.8  278.9  85,228.4  577 
17  571.0  276.1  84,381.2  571 
18  565.4  273.4  83,542.5  565 
19  559.7  270.7  82,712.0  560 
20  554.2  268.0  81,889.9  554 
21  548.7  265.3  81,075.9  549 
Total  12755.7  Total  10,790 
Net  1966.0 
reduction 
in 
incidence 
The  result  for  the  assumption  of  no  further  protection  beyond  year  6  is  a  net  reduction 
of  breast  cancer  incidence  of  1966  at  year  21,15.4%  of  the  total  number  of  cases  of 
breast  cancer  (12,755.7)  overall  in  this  high  risk  population  during  the  time  period. 
Using  the  same  approach  the  results  for  three  alternative  assumptions  in  the  duration 
of  the  effect,  an  additional  5,10  or  15  years  of  protection,  yields  a  reduction  of  3,513, 
4,984  and  6,383  cases  of  breast  cancer  respectively.  These  estimates  are  used  in 
Table  10  to  assess  the  impact  of  the  duration  of  the  protective  effect  on  the  marginal 
cost  effectiveness. 
Table  10.  Cost  per  breast  cancer  prevented  and  per  additional  breast  cancer  free 
life  year  gained  with  a  series  of  assumptions  about  the  duration  of  the  protective 
effect  of  chemoprevention  for  100,000  women  at  high  risk  (6.76  per  1000)  for 
breast  cancer.  The  table  is  based  on  hospital  based  service  delivery  (£535/woman). 
Protective  effect  (duration  in  years)  beyond  year  6 
Cost  0  5  10  15 
Cost  of  delivery  at  £535  per 
woman 
£53,500,000. 
0 
Cost  of  adverse  events  £103,779.9 
192 For  each  possible  outcome  of  an  additional  5,10  or  15  years  in  the  duration  of  the 
protective  effect,  Table  10  shows  the  cost  effectiveness  of  tamoxifen 
chemoprophylaxis.  For  an  additional  5  years  gained  the  estimate  for  cost  per  breast 
cancer  prevented  decreases  by  over  60%  to  £9,156.7.  Gaining  an  additional  10  or  15 
years  of  protection  results  in  a  cost  per  breast  cancer  prevented  of  £4,653.2  and 
£2,295.9  respectively. 
The  calculation  of  cost  per  life  year  gained  also  shown  in  Table  10,  assumes  that 
women  with  no  protective  effect  beyond  year  6  have  gained  5  years  of  life  during  the 
first  protective  phase.  Women  who  gain  an  additional  5,10  or  15  years  have  a  net 
gain  of  10,15  and  20  years  respectively.  The  cost  per  life  year  gained  is  £4,235.5.  for 
the  base  case  with  no  additional  years  gained  beyond  year  6.  Cost  effectiveness 
estimates  range  from  £915.7  to  £114.8  per  life  year  gained  for  gains  of  10  to  20  years 
duration  of  the  protective  effect. 
Discounted  cost  effectiveness  is  shown  in  Table  11.  Costs  and  benefits  are  discounted 
to  net  present  value  at  5%  per  year  using  the  public  sector  discount  rate.  Costs  are 
discounted  at  5%  over  5  years  and  the  benefits  are  discounted  at  5%  over  5,10,15 
and  20  years  according  to  the  additional  years  of  the  protective  effect  (0,5,10,15  years 
respectively).  Thus  a  breast  cancer  prevented  was  valued  more  highly  in  year  1  than  in 
later  years  and  the  costs  of  tamoxifen  prophylaxis  are  considered  more  expensive  in 
the  early  than  later  years.  Results  in  Table  9  are  shown  for  the  hospital  based  model  of 
service  delivery  at  £535  per  woman.  Results  for  a  GP  led  model  at  £410  per  woman 
are  summarised  in  Italics. 
193 Table  11.  Discounted  cost  per  breast  cancer  prevented  and  per  additional  life 
year  gained  with  a  series  of  assumptions  about  the  duration  of  the  protective 
effect  of  chemoprevention  for  100,000  women  at  high  risk  (6.76  per  1000)  for 
breast  cancer.  Costs  are  discounted  at  5%  over  5  years  and  savings  are  discounted  at 
5%  over  5,10,15and  20  years  respectively  according  to  the  years  of  protective  effect 
(0,5,10,  and  15years  respectively).  The  table  is  based  on  hospital  based  service 
delivery  at  £535/woman.  Results  for  a  primary  care  led  service  at  £410  per  woman  are 
included  in  italics. 
Additional  Protective  Effect  (years) 
Costs  0  5  10  15 
Cost  of  delivery  at  £535  £53,500,000  £41,917,250.0  £41,917,250.0  E41,917,250.0  £41,917,250.0 
.0 
J 
Cost  of  adverse  events  £103,779.9  £81,311.6  £81,311.6  £81,311.6  £81,311.6 
Total  cost  £53,603,779  £41,998,561.6  £41,998,561.6  £41,998,561.6  £41,998,561.6 
.9 
Savings  from  breast  cancer  £9,394,501.9  £13,159,760.5  £14,628,349.0  £14,679,903.0 
Net  reduction  in  breast  1540.4  2156.6  2397.3  2405.8 
cancer  (discounted) 
Cost  per  breast  cancer  £21,166.5  £13,372.2  £11,417.1  £11,355.6 
prevented  (14,808.4)  (8,831.0)  (7,331.8)  (7,284.4) 
Life  years  gained  7697.9  21566.3  35959.6  48115.1 
Cost  per  life  years  gained  £4,235.5  £1,337.2  £761.1  £567.8 
(specialist  based  service 
delivery) 
Cost  per  life  years  gained  £2,963.2  £883.1  £488.8  £364.2 
(primary  care  led  service 
delivery) 
The  (discounted)  marginal  cost  per  breast  cancer  prevented  is  £13,372.2  for  5  years 
additional  benefit  beyond  year  6  and  a  marginal  cost  per  breast  cancer  prevented  of 
£11,355.6  per  breast  cancer  prevented  for  a  protective  effect  continuing  for  15  years. 
The  discounted  marginal  cost  per  life  year  gained  is  £567.80  with  a  protective 
duration  of  15  years. 
194 7.  A  high  and  low  cost  scenario  for  cost  effectiveness 
Table  12  shows  a  number  of  estimates  for  cost  effectiveness  of  tamoxifen 
chemoprophylaxis  using  contrasting  assumptions  to  determine  the  extent  of  the 
extreme  difference  between  a  high  and  low  cost  scenario.  For  the  high  cost  scenario 
the  model  of  service  delivery  is  assumed  to  be  a  specialist  hospital  based  model. 
Morbidity  is  considered  to  accrue  to  the  cost  of  service  delivery  both  for  benign  breast 
disease  and  for  use  of  beta  blockers.  The  personal  costs  to  the  women  associated  with 
the  hospital  based  model  are  £43/woman.  The  results  are  expressed  as  the  cost  per 
breast  cancer  prevented  and  per  life  year  gained  for  the  assumption  of  either  a5  or  10 
year  duration  of  protective  effect.  The  low  cost  scenario  is  based  on  a  GP  model  of 
service  delivery  and  assumes  that  there  are  morbidity  benefits  for  women  taking 
tamoxifen  prophylaxis  resulting  in  both  reduced  use  of  beta  blockers  and  hospital 
visits  for  benign  breast  disease.  The  low  estimate  for  personal  costs  to  the  women 
themselves  of  £5/woman  is  included.  For  both  scenarios  the  costs  are  discounted  over 
5  years  and  the  savings  over  5  or  10  years  respectively. 
Table  12:  Cost  effectiveness  of  tamoxifen  chemoprophylaxis.  A  high  and  low  cost 
scenario  (based  on  the  net  incidence  estimates  set  out  in  Table  9). 
(a)  Scenario  1:  Highest  Cost 
Duration  of  Protective  effect 
5  (baseline  case)  10 
Costs  (discounted) 
Service  delivery  (at 
£535/woman) 
£41,917,250.0  £41,917,250.0 
Adverse  events  £81,311.6  £81,311.6 
Beta  Blockers 
(£7/woman) 
£548,450.0  £548,450.0 
Benign  Breast  Disease 
(£41  /woman) 
£3,212,350.0  £3,212,351.0 
Personal  costs 
(£43/woman) 
£3,369,050.0  £3,369,050.0 
Total  cost  £45,759,361.6  £45,759,361 
Savings 
Breast  cancer  prevented  £9,394,501.9  £5,795,089.5 
195 No.  s  of  breast  cancers  1966  3513 
prevented 
Discounted  breast  cancers  1540.4  2156.6 
prevented 
Cost  per  breast  cancer  £18,496.9  £11,376.1 
prevented 
Discounted  years  of  life  7697.9  21,566.3 
gained 
Cost  per  year  of  life  £4,724.0  £1,853.1 
gained 
(b)  Scenario  2:  Lowest  Cost 
Duration  of  protective  effect 
5  (baseline  case)  10 
Costs 
Service  Delivery 
(410/woman) 
£32,123,500.0  £32,123,500.0 
Adverse  events  £81,311.6  £81,311.6 
Personal  costs 
(£5/woman) 
£391,750.0  £391,750.0 
Total  cost  £32,596,561.6  £32,596,561.6 
Savings 
Beta  Blockers 
(£7/woman) 
£548,450.0  £429,730.0 
Benign  breast  disease 
(£41  /woman) 
£3,212,350.0  £2,516,990.0 
Breast  cancer  prevented  £9,399,282.8  £  13,159,760.5 
Total  savings  £12,611,632.8  £15,676,750.5 
Nos.  of  breast  cancers 
prevented 
1966  3513 
Discounted  breast  cancers 
prevented 
7697.9  21566.3 
Cost  per  breast  cancer 
prevented 
£  10,165  £4,816 
Discounted  years  of  life 
gained 
9825  25130 
Cost  per  year  of  life 
gained 
£2,034.1  £481.6 
The  results  for  the  cost  per  breast  cancer  prevented  range  between  £18,496.9  and 
£10,165.3  per  breast  cancer  prevented  for  the  high  and  low  cost  scenario  respectively 
196 assuming  a5  year  duration  of  protective  effect.  This  is  an  extreme  difference  of 
£8,331.6.  Where  the  duration  of  protection  is  for  10  years  the  cost  per  breast  cancer 
prevented  is  £11,376.1  and  £4,816.3  for  the  high  and  low  cost  scenario  respectively. 
This  is  an  extreme  difference  of  £6,559.8.  For  cost  per  life  year  gained,  the  extreme 
difference  between  the  high  and  low  cost  model  for  a  5-year  duration  of  protective 
effect  is  £2,127.8  from  £4,724.0  and  £2,596.2  per  life  year  gained  respectively.  For  a 
10-year  duration  of  protective  effect  the  difference  is  £1,068.6  from  £1,853.1  per  year 
of  life  gained  to  £784,5  per  year  of  life  gained  respectively.  These  results  suggest  that 
there  is  only  a  small  impact  of  morbidity  and  indeed  of  women's  personal  costs  on  the 
cost  per  life  year  gained.  The  main  cost  drivers  are  the  cost  of  service  delivery  and  the 
risk  status  of  the  women  involved.  The  differences  found  between  the  5  and  the  10- 
year  duration  of  protective  effect  are  reduced  by  the  process  of  discounting  the 
benefits  of  chemoprophylaxis.  Since  this  is  a  preventive  intervention  it  could  be 
argued  that  the  benefits  should  not  be  discounted.  Without  discounting  the  benefits 
(years  of  life  gained)  the  extreme  differences  between  the  low  and  high  cost  scenarios 
are  lower  particularly  for  duration  of  effect  for  10  years.  The  extreme  differences  are 
£1667.2  per  life  year  gained  for  a  5-year  duration  of  protective  effect  and  £656  for  a 
10  year  duration. 
Discussion 
Chemoprophylaxis  for  breast  cancer  is  targeted  at  a  group  of  women  at  extremely 
high  lifetime  risk  of  breast  cancer  for  whom  few  effective  treatment  strategies  are 
available.  Two  different  approaches  are  taken  in  developing  estimates  of  cost 
effectiveness.  Both  yield  similar  results  and  provide  complementary  information 
about  the  factors  affecting  cost  and  cost  effectiveness.  Firstly,  the  decision  analysis 
based  on  an  average  District  Health  Authority  population  of  a  million  people  provides 
an  assessment  of  the  importance  of  the  risk  status  of  the  population.  Where  the 
absolute  benefits  of  chemoprevention  are  low,  high  costs  will  accrue  from  the  need  to 
treat  large  numbers  of  women  in  order  to  prevent  or  delay  a  single  breast  cancer. 
Moreover  in  an  average  District  Health  Authority  population  the  proportion  of  women 
at  high  risk  will  be  relatively  small.  Secondly  in  the  assessment  from  a  cohort  of 
women  using  results  from  NSABP  P-12  it  is  clear  that  the  cost  effectiveness  of 
tamoxifen  chemoprophylaxis  is  favourable  in  comparison  with  many  other  health  care 
197 interventions  when  targeted  at  high  risk  women  and  providing  that  the  protective 
effect  continues  beyond  the  period  of  active  treatment. 
Estimates  of  cost  effectiveness  based  on  the  results  from  the  NSABP  P-1  study  are 
more  likely  to  represent  the  true  magnitude  for  cost  effectiveness  since  the  population 
targeted  is  at  high  risk  for  breast  cancer  and  the  incidence  in  both  the  treated  and 
control  population  was  monitored  assiduously  over  a  number  of  years.  The  risk 
factors  defining  eligibility  for  the  study  and  indeed  those  underpinning  IBIS  are  a 
useful  basis  for  defining  a  target  population  for  tamoxifen  prophylaxis  in  health 
policy.  The  cost  effectiveness  range  is  within  the  range  of  many  routine  treatments  in 
the  NHS  and  low  for  those  concerned  with  preventing  early  mortality. 
There  are  however  a  number  of  limitations  to  this  analysis  including  a  number  of 
assumption  used  in  the  estimates  for  cost  effectiveness.  The  results  for  cost 
effectiveness  can  only  be  expressed  in  terms  of  breast  cancer  incidence  since  to  date 
there  is  no  information  about  the  possible  effects  on  mortality.  There  is  also  no 
evidence  to  address  the  question  of  whether  the  results  for  incidence  represent  a  delay 
in  the  development  of  cancers  or  a  permanent  benefit.  There  has  been  some 
speculation  of  an  increase  in  the  proportion  of  aggressive  breast  cancers  owing  to  the 
selection  of  tamoxifen  resistant  tumours.  The  effectiveness  of  adjuvant  tamoxifen  for 
women  taking  tamoxifen  at  the  time  of  diagnosis  is  not  known  and  the  mortality  rate 
for  these  women  may  be  high.  Long  term  adverse  effects  of  prolonged  tamoxifen  use 
will  be  monitored  by  ongoing  follow-up  in  the  UK  and  USA  studies  though  only  the 
known  increase  in  risk  of  endometrial  cancer  has  been  included. 
Fixed  costs  for  any  of  the  interventions  discussed  are  not  included  since  they  are 
integrated  within  the  charges  used  to  derive  cost  estimates.  Given  the  small  numbers 
of  women  who  might  be  eligible  for  chemoprophylaxis  within  the  average  health 
district  it  is  likely  that  any  increased  demand  would  be  absorbed  within  present  breast 
cancer  services  or  indeed  in  general  practice.  Moreover  fixed  costs  would  vary 
considerably  in  different  centres  and  the  emphasis  here  is  on  determining  the  main 
factors  affecting  cost  effectiveness.  Where  implementation  of  a  service  for  tamoxifen 
chemoprophylaxis  was  considered  the  fixed  costs  would  bear  on  the  start  up  costs.  In 
deriving  the  estimates  for  cost  effectiveness  compliance  is  assumed  to  be  100%  which 
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compliance  may  not  affect  the  cost  of  service  delivery,  though  will  reduce  the  efficacy 
of  the  intervention.  The  precise  impact  of  reduced  compliance  has  not  been 
calculated  though  is  arguably  likely  to  be  comparable  to  the  effect  found  for  changes 
in  efficacy  seen  in  Table  6. 
It  is  likely  that  a  reduction  in  compliance  would  have  its  main  effect  on  cost 
effectiveness  through  reducing  the  numbers  of  breast  cancers  prevented.  Based  on  the 
figures  shown  in  Table  10  a  reduction  in  compliance  to  70%  would  reduce  the  cost 
per  breast  cancer  prevented  to  £32,854  (assuming  that  the  savings  from  30%  fewer 
breast  cancers  prevented  would  be  £8,396,352  instead  of  £11,990,430).  This  would 
change  the  cost  per  breast  cancer  prevented  to  £32,854  instead  of  £21,166.5  shown  in 
the  table  -a  difference  of  just  over  50%.  The  impact  on  the  difference  in  cost  per  year 
of  life  saved  would  be  a  change  from  £4,235.5  to  £6,570.85.  The  effect  of  reduced 
compliance  may  be  less  were  the  cost  of  service  delivery  and  the  cost  of  adverse 
events  also  to  be  reduced.  The  effect  of  the  former  is  however  likely  to  be  small 
especially  if  women  continued  to  attend  clinic  sessions  for  checks  but  were  not 
complying  with  appropriate  ingestion  of  tamoxifen  on  a  daily  basis.  The  impact  on 
adverse  events  may  also  be  small  since  the  costs  associated  with  adverse  events  are 
relatively  low  in  comparison  with  the  cost  of  breast  cancers  prevented. 
The  cost  of  delivering  tamoxifen  prophylaxis  per  women  is  relatively  low  in 
comparison  with  many  other  health  care  interventions  yet  the  overall  cost 
effectiveness  estimates  are  substantially  influenced  by  the  numbers  of  women  who 
would  need  to  be  treated  in  order  to  prevent  one  breast  cancer  because  of  the  level  of 
absolute  risk  reduction.  For  women  at  moderate  or  low  absolute  risk  of  breast  cancer 
this  number  is  relatively  high  in  comparison  with  the  numbers  of  breast  cancers 
prevented. 
Cost  effectiveness  decreases  with.  increasing  risk  of  the  women  involved  and 
measured  over  the  six  year  period  of  the  NSABP  P-1  where  the  average  risk  in  the 
population  treated  was  6.76  per  1000  becomes  an  estimated  discounted  cost  per  breast 
cancer  prevented  of  £21,166.5  in  a  hospital  based  service  (see  Table  10).  This 
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intervention  and  that  all  visits  by  the  women  are  to  specialist  centres. 
At  a  discounted  cost  per  breast  cancer  prevented  of  £14,808.4  offering  prophylaxis 
through  general  practice  would  be  more  cost  effective  than  a  hospital  based  service 
albeit  nurse  led  with  specialist  support.  Such  an  approach  might  be  possible  with  only 
1  visit  to  a  specialist  at  the  initiation  of  tamoxifen  prophylaxis  and  anticipating  a 
reduced  number  of  follow  up  visits.  It  could  be  argued  that  mammography  would  be 
needed  only  to  check  eligibility  for  tamoxifen  and  that  routine  mammograms  for  a 
service  which  is  intended  to  reduce  the  risk  of  breast  cancer  is  an  inappropriate 
intervention  and  an  unnecessary  expense  outwith  the  routine  NHS  Breast  Screening 
Programme.  The  IBIS  estimate  for  cost  effectiveness  approximates  the  lowest 
estimate  found  for  a  GP  based  model  of  service  delivery.  It  is  likely  however  that  the 
research  costs  for  IBIS  underestimate  the  true  cost  of  the  intervention  with  some 
subsidy  from  the  host  breast  care  services  in  the  NHS. 
Using  the  results  from  Table  12  the  cost  effectiveness  of  tamoxifen  chemoprophylaxis 
appears  to  lie  between  £4,724  and  £784.5  per  life  year  gained.  The  former  assumes  a 
specialist  hospital  based  model  of  service  delivery  with  costs  of  morbidity  for  benign 
breast  disease  and  beta  blockers  both  accruing  to  overall  costs  and  with  the  personal 
costs  to  the  women  themselves  at  the  high  estimate  of  £43  per  woman.  The  estimate  is 
based  on  the  assumption  that  the  duration  of  the  protective  effect  for  tamoxifen 
prophylaxis  is  5  years  beyond  the  active  period  of  treatment.  By  contrast,  the  low 
estimate  includes  only  £5  per  woman  for  personal  costs.  Morbidity  is  assumed  to  be  a 
net  benefit  to  a  woman  taking  tamoxifen  for  both  benign  breast  disease  and  for  use  of 
beta  blockers.  The  duration  of  the  protective  effect  is  10  years.  Although  there  is  a 
three  fold  difference  between  the  high  and  low  estimates  the  cost  per  life  gained 
appears  to  lie  within  a  feasible  range  for  a  new  health  technology  though  would  of 
course  depend  on  the  importance  of  defining  and  successfully  targeting  a  high  risk 
population. 
There  is  some  debate  about  the  appropriateness  of  discounting  in  the  context  of 
prevention19.  The  effect  is  to  reduce  the  value  of  future  benefits  undermining  the 
relative  value  of  prevention  over  therapeutic  interventions.  The  consequence  of 
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become  more  distant  and  benefits  extend  to  an  additional  15  years  of  protective  effect 
Morbidity  arising  from  tamoxifen  prophylaxis  appears  to  be  low  with  little  overall 
impact  on  cost  effectiveness.  To  date,  no  comparable  estimates  have  been  published 
in  other  chemoprevention  trials.  Recent  reports  about  the  impact  of  the  main  adverse 
events  of  tamoxifen  chemoprophylaxis  particularly  an  increased  risk  of  endometrial 
cancer  suggest  that  the  extent  of  the  risk  and  the  clinical  impact  have  been 
exaggerated. 
Developing  the  model  for  chemoprevention  within  the  context  of  a  district  health 
authority  population  has  the  advantage  of  identifying  the  impact  on  the  costs  of  breast 
cancer  care  overall.  For  an  average  District  Health  Authority  population  the  impact 
on  breast  cancer  incidence  would  be  small.  This  is  mostly  because  the  proportion  of 
the  population  with  levels  of  risk  of  breast  cancer  high  enough  to  become  eligible  for 
chemoprophylaxis  are  small.  Where  a  programme  for  prophylaxis  was  developed 
eligibility  criteria  would  be  need  to  be  strictly  enforced  in  order  to  ensure  that  only 
high  risk  women  were  targeted.  Failure  to  achieve  a  high  risk  population  may  result 
in  expenditure  on  chemoprevention  at  the  expense  of  more  cost  effective  means  of 
reducing  mortality  and  morbidity  from  breast  cancer. 
Of  importance  in  targeting  tamoxifen  chemoprophylaxis  are  findings  from  the 
NSABP  P-12  trial  that  a  benefit  from  tamoxifen  was  identified  for  women  across  the 
spectrum  of  risk  factors  and  levels  of  risk.  The  trial  was  not  designed  to  assess 
whether  findings  for  high  risk  women  could  be  generalised  to  all  women  and  the  main 
effect  -  of  almost  50%  reduction  in  risk  of  breast  cancer  occurs  for  a  population  of 
women  at  high  risk.  The  study  did  however  provide  evidence  that  women  with  a 
history  of  LCIS  or  atypical  hyperplasia  were  more  likely  to  develop  invasive  cancer 
than  had  been  previously  expected  and  that  tamoxifen  chemoprophylaxis  could  reduce 
the  risk.  The  authors  conclude  that  eligibility  should  be  extended  to  three  main  groups 
of  women:  women  with  a  history  of  atypical  hyperplasia  or  LCIS,  the  group  of 
women  under  50  with  sufficient  risk  to  warrant  eligibility  to  the  NSABP  P-1  trial  and 
postmenopausal  women  at  high  risk  for  breast  cancer  who  have  had  a  hysterectomy. 
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3  fold  relative  risk  they  may  be  appropriate  criteria  for  targeting  women  in  the  UK. 
The  cost  effectiveness  estimates  can  be  compared  with  other  means  of  reducing  breast 
cancer  incidence  although  there  are  problems  of  comparability  particularly  in 
estimating  the  savings  from  the  cost  of  breast  cancer  prevented.  Boer  and  de 
Koning187  published  cost  effectiveness  estimates  for  the  current  NHS  Breast 
Screening  Programme  of  £25,142  per  death  prevented  and  £24,205  or  £27,865  for 
extending  the  age  range  to  65  or  reducing  the  interval  to  two  years  respectively.  The 
estimates  for  tamoxifen  prophylaxis  are  likely  to  fall  well  below  this  range  providing 
that  the  intervention  is  targeted  at  women  at  high  risk  for  breast  cancer  (at  least  3  fold 
relative  risk)  delivered  in  general  practice  and  that  the  effect  of  risk  reduction 
translates  into  a  mortality  benefit. 
The  cost  effectiveness  of  early  treatment  for  breast  cancer  to  year  10  of  between 
£10,625  ($17,000)  per  death  prevented  for  women  at  all  ages  in  the  highest  risk 
categories  to  £31,250  ($50,000)  for  women  at  any  age  at  a  lower  risk  of  death  is  lower 
than  that  found  for  breast  screening.  The  effectiveness  of  early  treatment  for  breast 
cancer  may  be  considered  comparable  to  the  findings  from  NSABP  P-1  since 
interventions  are  concerned  with  women  at  increased  risk  of  death  from  breast  cancer 
rather  than  with  women  at  average  population  risk. 
There  is  insufficient  information  on  the  present  management  of  women  at  high  risk 
for  breast  cancer  to  compare  with  the  costs  estimated  for  chemoprophylaxis  of  breast 
cancer.  Bilateral  prophylactic  mastectomy  has  been  a  treatment  choice  for  some 
women  though  there  are  few  routine  data  available  to  assess  the  frequency  of  use  of 
this  approach,  its  survival  advantage  or  cost  effectiveness".  Annual  mammography 
has  also  been  suggested  for  women  in  high  risk  categories  though  there  are  no  data  at 
present  to  assess  the  efficacy  of  this  approach. 
Summary  and  Conclusions 
Modelling  cost  effectiveness  for  tamoxifen  chemoprophylaxis  based  on  both  a  district 
health  authority  population  and  on  the  results  from  NSABP  P-1  highlights  the 
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Estimates  of  the  costs  of  service  delivery  and  the  possible  costs  of  morbidity  included 
in  the  model  are  taken  from  analysis  of  women  recruited  to  the  International  Breast 
Cancer  Intervention  Study  and  presented  in  previous  chapters.  The  baseline  case  is 
taken  as  a  consultant  based  service  in  a  hospital  setting  with  specialist  nurse 
involvement  costing  overall  £535  per  woman.  This  model  of  service  delivery  requires 
women  to  travel  to  specialist  centres  for  treatment  but  restricts  consultant  input  to  an 
initial  visit  to  determine  eligibility  and  to  exclude  the  possibility  of  breast  cancer. 
Measures  of  efficacy  are  taken  from  outcome  data  published  from  the  NSABP  P-1. 
The  costs  of  breast  cancer  have  been  developed  from  analysis  of  an  audit  carried  out 
by  the  Thames  Cancer  Registry  (TCR).  Other  costs  such  as  for  endometrial  cancer 
are  based  on  HRGs  currently  in  use  for  costing  procedures  in  the  NHS. 
Few  studies  have  been  published  on  which  to  base  cost  estimates  for  the  treatment  of 
early  breast  cancer.  The  TCR  audit  used  here  is  based  on  1,779  cases  of  breast  cancer 
in  17  different  hospital  trusts  in  the  Thames  region.  The  cost  of  breast  cancer  is 
estimated  at  £6,102  per  woman  and  includes  estimated  costs  for  advanced  disease  and 
for  palliative  care  taken  from  the  published  literature.  A  large  proportion  of  the 
overall  cost  is  for  radiotherapy  (24%);  the  cost  of  chemotherapy  for  advanced  disease 
is  a  small  proportion  of  the  total  cost  (<I%).  Estimates  for  cost  effectiveness  of 
prophylactic  tamoxifen  is  based  on  a  district  health  authority  population  with  a1 
million  population  and  120,000  women  aged  45-64.  It  is  assumed  that  around  7%  of 
women  are  at  increased  risk  of  breast  cancer  and  would  be  eligible  for 
chemoprevention  with  tamoxifen.  The  estimated  cost  of  breast  cancer  for  this 
population  is  about  1.5  million  per  year.  The  cost  of  delivering  tamoxifen  prophylaxis 
to  the  eligible  population  would  be  around  £100  per  woman  year. 
The  main  adverse  effect  included  is  the  cost  of  endometrial  cancer  (£2,261).  At  3  per 
10,000,  the  baseline  rate  of  endometrial  cancer  is  low  in  the  UK  compared  with  the 
USA.  The  relative  risk  of  endometrial  cancer  with  prolonged  tamoxifen  use  is 
insufficient  to  have  a  significant  effect  on  overall  cost  effectiveness. 
The  cost  effectiveness  derived  from  estimating  the  incidence  of  breast  cancer  in  a 
cohort  of  women  taking  tamoxifen  over  6  years  using  the  results  from  NSABP  P-1 
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cost  or  low  cost  scenario  is  used.  This  covers  the  possible  effects  of  long  term 
tamoxifen  use  on  morbidity,  the  inclusion  or  exclusion  of  personal  costs  to  the  women 
themselves  and  assumes  a5  or  10  year  protective  effect  respectively  for  tamoxifen  in 
reducing  breast  cancer  risk. 
The  sensitivity  analysis  explores  alternative  means  of  service  delivery  including  a  GP 
based  service  and  the  expenditure  assumptions  within  the  research  protocol  for  IBIS. 
Also  included  in  the  sensitivity  analysis  is  the  impact  of  morbidity  on  cost 
effectiveness.  Earlier  work  (chapters  4  &5)  found  no  significant  differences  between 
the  two  arms  of  the  trial  for  morbidity  assessed  either  as  rate  of  hospital  use  or  use  of 
medications.  There  were  however  non-significant  differences  in  the  rate  of  use  of 
hospital  visits  for  benign  breast  disease  and  for  the  use  of  beta  blockers  which  merit 
further  analysis  with  increasing  accrual  and  duration  of  the  study. 
The  costs  of  care  set  out  within  the  GP  led  service,  in  keeping  with  other  forms  of 
chemoprophylaxis  such  as  hormone  replacement  therapy  for  osteoporosis,  could 
possibly  be  reduced  from  the  £410  per  woman  included  here.  Lower  cost  might  be 
achieved  if,  for  example,  the  level  of  specialist  involvement  were  targeted  only 
towards  problems  or  difficult  cases.  Current  thinking  within  IBIS  does  however 
suggest  that  specialist  input  would  be  recommended.  In  general  practice  the  personal 
costs  for  the  women  themselves  would  be  low. 
For  developing  health  policy  in  relation  to  tamoxifen  chemoprophylaxis  the  level  of 
risk  of  the  target  population  is  clearly  of  considerable  importance  in  terms  of  cost 
effectiveness.  For  women  at  very  high  risk  (10-fold  risk)  the  cost  effectiveness  is 
around  five  times  lower  than  for  woman  at  2  fold  increased  risk  of  breast  cancer.  The 
eligibility  criteria  used  for  entry  to  the  NSABP  P-1  and  to  IBIS  provide  a  useful  basis 
for  deciding  access  to  tamoxifen  chemoprophylaxis  within  the  NHS  since  they  have 
achieved  a  high-risk  population  in  both  studies.  Developing  referral  criteria  on  this 
basis  would  provide  support  for  GPs  in  advising  women  and  ensure  cost-effective  use 
of  resources  available  for  care  and  prevention  of  breast  cancer. 
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service  delivery  and  including  or  excluding  costs  of  morbidity  at  either  £5  or 
£43  personal  costs  per  woman. 
1.  Cost  effectiveness  for  nurse  led  service  (E535/woman)  assuming  £5  personal  cost  per 
woman. 
Morbidity  scenario 
Cost  (£)  Plus  benign 
breast  disease 
plus  beta 
blockers 
Minus  benign 
breast  disease 
minus 
beta  blockers 
Plus  benign 
breast  disease 
minus  beta 
blockers 
Minus  benign 
breast  disease 
plus  beta 
blockers 
Cost  of  service  delivery  53,603,779.9  53,603,779.9  53,603,779.9  53,603,779.9 
Morbidity 
benign  breast  disease  16,081,133.97  16,081,133.97  16,081,133.97  16,081,133.97 
beta  blockers  107,207.5598  107,207.5598  107,207.5598  107,207.5598 
Personal  cost 
@£5  2,500,000  2,500,000  2,500,000  2,500,000 
Total  Cost  72,292,121.43  39,915,438.37  72,077,706.31  40,129,853.49 
Savings  (breast  cancer)  11,931,927.74  11,931,927.74  11,931,927.74  11,931,927.74 
Cost  per  breast  cancer 
prevented 
30,874.78  14,313.82  30,765.10  14,423.49 
2.  Cost  effectiveness  for  GP  led  service  (£410/woman) 
Assuming  £5  personal  cost  per  woman. 
Cost  (£) 
Plus  benign 
breast  disease 
plus  beta 
blockers 
Minus  benign 
breast  disease 
minus 
beta  blockers 
Plus  benign 
breast  disease 
minus  beta 
blockers 
Minus  benign 
breast  disease 
plus  beta 
blockers 
Cost  of  service  delivery  41,103,779.9  41,103,779.9  41,103,779.9  41,103,779.9 
Morbidity 
benign  breast  disease  16,081,133.97  16,081,133.97  16,081,133.97  16,081,133.97 
beta  blockers  82,207.5598  107,207.5598  107,207.5598  107,207.5598 
Personal  cost 
@  £5  2,500,000  2,500,000  2,500,000  2,500,000 
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Savings  (breast  cancer)  11,931,927.74  11,931,927.74  11,931,927.74  11,931,927.74 
Cost  per  breast  cancer  24,468.13  7,919.95  24,371.24  8,029.63 
prevented 
3.  Cost  effectiveness  assuming 
per  woman 
Cost 
Plus  benign 
breast  disease 
plus  beta 
blockers 
Minus  benign 
breast  disease 
minus 
beta  blockers 
Plus  benign 
breast  disease 
minus  beta 
blockers 
Minus  benign 
breast  disease 
plus  beta 
blockers 
Cost  of  service  delivery  20,103,779.9  20,103,779.9  20,103,779.9  20,103,779.9 
Morbidity 
benign  breast  disease  16,081,133.97  16,081,133.97  16,081,133.97  16,081,133.97 
beta  blockers  40,207.56  107,207.56  107,207.56  107,207.56 
Personal  cost 
@  £5  2,500,000  2,500,000  2,500,000  2,500,000 
Total  Cost  38,725,121.43  6,415,438.37  38,577,706.31  66,29,853.49 
Savings  (breast  cancer)  11,931,927.74  11,931,927.74  11,931,927.74  11,931,927.74 
Cost  per  breast  cancer  13,704.96  -  2,821.73  13,629.55  -2,712.06 
prevented 
4.  Cost  effectiveness  for  nurse  led  service(E535/woman) 
Assuming  £43  personal  cost  per  woman. 
Cost 
Plus  benign 
breast  disease 
plus  beta 
blockers 
Minus  benign 
breast  disease 
minus 
beta  blockers 
Plus  benign 
breast  disease 
minus  beta 
blockers 
Minus  benign 
breast  disease 
plus  beta 
blockers 
Cost  of  service  delivery  53,603,779.9  53,603,779.9  53,603,779.9  53,603,779.9 
Morbidity 
benign  breast  disease  16,081,133.97  16,081,133.97  16,081,133.97  16081,133.97 
beta  blockers  107,207.56  107,207.56  107,207.56  107,207.56 
Personal  cost 
@£43  21,600,000  21,600,000  21,600,000  21,600,000 
206 Total  Cost  91,392,121.43  59,015,438.37  91,177,706.31  59,229,853.49 
Savings  (breast  cancer)  11,931,927.74  11,931,927.74  11,931,927.74  11,931,927.74 
Cost  per  breast  cancer  40,644.60  24,083.64  40,534.92  24,193.312 
prevented 
5.  Cost  effectiveness  for  IBIS  model  (E200/woman) 
assuming  £43  personal  cost  per  woman. 
Cost 
Plus  benign  Minus  benign 
breast  disease  breast  disease 
plus  beta  minus 
blockers  beta  blockers 
Plus  benign 
breast  disease 
minus  beta 
blockers 
Minus  benign 
breast  disease 
plus  beta 
blockers 
Cost  of  service  delivery  20,103,779.9  20,103,779.9  20,103,779.9  20,103,779.9 
Morbidity 
benign  breast  disease  16,081,133.97  16,081,133.97  16,081,133.97  16,081,133.97 
beta  blockers  40,207.56  107,207.56  107,207.56  107,207.56 
Personal  cost 
@£43  21,600,000  21,600,000  21,600,000  21,600,000 
1 
Total  Cost  57,825,121.43  25,515,438.37  57,677,706.31  25,729,853.49 
Savings  (breast  cancer)  11,931,927.74  11,931,927.74  11,931,927.74  11,931,927.74 
Cost  per  breast  cancer  23,474.78  6,948.09  23,399.37  7,057.76 
prevented 
6.  Cost  effectiveness  for  GP  led  service(£410/woman) 
Assuming  £0  personal  cost  per  woman. 
Cost 
Plus  benign 
breast  disease 
plus  beta 
blockers 
Minus  benign 
breast  disease 
minus 
beta  blockers 
Plus  benign 
breast  disease 
minus  beta 
blockers 
Minus  benign 
breast  disease 
plus  beta 
blockers 
Cost  of  service  delivery  20,103,779.9  20,103,779.9  20,103,779.9  20,103,779.9 
Morbidity 
benign  breast  disease  16,081,134.0  16,081,134.0  16,081,134.0  16,081,134.0 
beta  blockers  40,207.6  107,207.6  107,207.6  107,207.6 
207 Personal  cost 
£0 
Total  Cost  36,225,121.4  3,915,438.4  36,077,706.3  4,129,853.5 
Savings  (breast  cancer)  11,931,927.7  11,931,927.7  11,931,927.7  11,931,927.7 
Cost  per  breast  cancer  12,426.2  -4,100.5  12,350.8  -3,990.8 
prevented 
208 Recommendations 
1.  Where  tamoxifen  chemoprophylaxis  for  breast  cancer  is  introduced  into  routine 
health  care,  protocols  for  ensuring  that  eligibility  criteria  are  met  will  be  needed  in 
order  to  maximise  cost  effectiveness.  Consideration  should  be  given  to  restricting 
eligibility  for  tamoxifen  chemoprophylaxis  to  the  groups  of  women  eligible  for 
NSABP  P1  or  IBIS.  This  would  include  broadly  three  main  groups  of  women  1) 
women  with  a  history  of  atypical  hyperplasia  or  LCIS  2)  a  group  of  women  eligible 
because  of  a  combination  of  age  and  family  history  -  following  the  principle  that 
younger  women  would  need  a  higher  level  of  family  involvement  to  be  risk 
equivalent  and  postmenopausal  women  at  high  risk  for  breast  cancer  who  have  had  a 
hysterectomy.  The  priority  would  be  to  secure  a  group  of  women  with  at  least  3  fold 
relative  risk. 
2.  The  level  of  specialist  support  for  tamoxifen  chemoprophylaxis  for  breast  cancer 
should  be  established  with  the  aim  of  avoiding  unnecessary  investigations  and  follow- 
up.  Service  delivery  in  primary  care  with  referral  into  routine  breast  services  for 
consultant  or  specialist  nurse  advice  when  needed  is  feasible  given  the  likely  level  of 
demand  within  health  districts  and  should  be  fully  evaluated.. 
3.  Decisions  regarding  the  availability  of  mammography  screening  for  women  taking 
tamoxifen  will  need  to  be  made  in  the  light  of  findings  from  research  addressing  the 
value  of  more  frequent  mammography  for  women  at  high  risk  for  breast  cancer.  Any 
protocol  for  service  delivery  will  need  to  ensure  integration  with  the  NHS  Breast 
Screening  Programme  in  order  to  avoid  duplication  and  wasted  resources. 
4.  Further  research  is  needed  to: 
>  Monitor  the  long  term  consequences  of  tamoxifen  use  on  the  general  health  and 
morbidity  of  women.  Long  term  breast  cancer  adjuvant  studies  are  useful  in 
providing  information  on  the  safety  of  trials  for  tamoxifen  prophylaxis  but  more 
detailed  studies  are  needed  to  assess  the  effect  of  long  term  exposure  to  tamoxifen 
for  chemoprevention  of  breast  cancer  in  healthy  asymptomatic  women.  In 
209 addition,  small  changes  in  the  use  of  hospital  services  or  prescribed  medications 
for  the  age  group  targeted  in  prevention  trials  could  have  a  significant  impact  on 
the  overall  cost  of  tamoxifen  chemoprophylaxis  because  of  the  potentially  large 
numbers  of  women  involved.  The  long  term  impact  on  vascular  symptoms  and  on 
benign  breast  disease  in  particular  is  unclear  and  will  require  further  research  to 
establish  fully. 
¢  Further  assessments  of  well  being  and  quality  of  life  are  also  needed  since  the 
women  studied  here  are  self  selected  women  and  likely  to  be  highly  motivated 
with  a  positive  attitude  towards  the  prospect  for  chemoprevention. 
¢  Assess  whether  the  reduction  in  incidence  of  breast  cancer  found  in  the  NSABP  P- 
1  study  will  act  to  delay  the  onset  of  disease  or  will  reduce  mortality.  The  precise 
duration  of  the  effect  after  cessation  of  the  period  of  active  intervention  with 
tamoxifen  treatment  is  also  uncertain. 
¢  Clarify  the  impact  of  age  on  efficacy  of  the  intervention  in  order  to  understand 
fully  the  value  of  chemoprophylaxis  for  women  at  high  risk  for  breast  cancer  by 
virtue  of  age. 
¢  In  general  research  on  alternative  means  of  preventing  mortality  and  morbidity 
from  breast  cancer  should  be  pursued.  For  example,  an  understanding  of  the 
biological  plausibility  of  casual  link  between  dietary  fat  and  breast  cancer 
discussed  in  this  study  cannot  exclude  the  possible  importance  of  diet  at  key 
development  stages.  In  particular,  the  relationship  with  onset  of  menarche  and 
early  adolescence  where  the  impact  of  diet  on  breast  carcinogenesis  may  be 
profound.  A  number  of  randomised  controlled  trials  are  underway  in  the  USA 
although  these  are  focussing  only  on  the  recruitment  of  adult  women.  Further 
studies  on  the  use  of  other  chemopreventive  agents  are  also  underway. 
210 Conclusions 
Findings  from  this  study  suggest  that  the  cost  effectiveness  of  tamoxifen 
chemoprophylaxis  for  breast  cancer  could  realistically  be  set  in  the  range  between 
£4,724.0  and  £2,596.2  per  life  year  gained  with  a5  year  duration  of  protective  effect. 
The  upper  and  lower  limits  are  defined  by  putting  together  high  or  low  estimates  for 
key  elements  of  cost.  The  high  cost  scenario  includes 
"A  service  based  on  a  specialist  hospital  model  at  £535  per  woman 
"  The  cost  of  excess  morbidity  from  long  term  tamoxifen  use 
"  Personal  costs  to  the  woman  due  to  clinic  visits  of  £43  per  person  over  the  5  year 
period  of  active  intervention. 
The  low  cost  scenario  includes 
"A  service  model  based  in  primary  care 
No  excess  costs  due  to  morbidity  arising  from  tamoxifen  use 
"  Health  benefits  reducing  the  cost  of  general  health  care  in  addition  to  reducing  the 
risk  of  breast  cancer  for  women  taking  tamoxifen 
"  Personal  costs  to  the  woman  due  to  clinic  visits  of  £5  per  person  or  less  over  the  5 
year  period  of  active  intervention 
The  study  found  that  the  cost  of  delivering  breast  cancer  chemoprevention  per  women 
is  relatively  low  in  comparison  with  many  other  health  care  interventions.  Yet  the 
overall  cost  effectiveness  is  sensitive  to  a  number  of  factors  including  the  baseline 
risk  of  the  women  and  the  magnitude  and  duration  of  the  protective  effect.  Changing 
the  risk  status  of  eligible  women  from  2  fold  to  5  fold  average  population  risk  results 
in  a  50%  improvement  in  the  cost  effectiveness  estimate.  For  women  at  moderate  or 
low  absolute  risk  of  breast  cancer  the  number  who  need  to  take  tamoxifen  to  prevent 
one  breast  cancer  is  relatively  high  in  comparison  with  the  numbers  of  breast  cancers 
prevented.  Even  where  a  high  risk  population  can  be  successfully  targeted  a  large 
211 proportion  of  the  cost  lies  in  the  number  of  women  who  need  to  be  treated  in  order  to 
prevent  one  breast  cancer. 
Introducing  tamoxifen  chemoprophylaxis  for  breast  cancer  into  the  NHS  will  rely  on 
effective  means  of  targeting  women  at  high  risk  and  of  ensuring  lowest  possible  costs 
of  service  delivery.  Given  the  small  numbers  of  women  who  might  be  eligible  for 
chemoprophylaxis  within  the  average  health  district  it  is  likely  that  any  increased 
demand  would  be  absorbed  within  present  breast  cancer  services  or  indeed  in  general 
practice. 
Chemoprevention  trials  have  not  been  designed  to  assess  whether  findings  for  high 
risk  women  can  be  generalised  to  all  women.  The  outcome  found  in  the  NSABP  P1  - 
of  almost  50%  reduction  in  risk  of  breast  cancer  is  for  a  population  of  women  at 
around  3  fold  baseline  risk.  The  NSABP  P1  trial  did  however  provide  evidence  that 
women  with  a  history  of  LCIS  or  atypical  hyperplasia  were  more  likely  to  develop 
invasive  cancer  than  had  been  previously  expected  and  that  tamoxifen 
chemoprophylaxis  could  reduce  the  risk.  Introducing  tamoxifen  chemoprophylaxis 
into  the  NHS  will  require  consideration  of  the  appropriate  level  of  service  based  on 
criteria  for  referral  and  precise  assessment  of  the  need  for  specialist  support  and  the 
importance  of  integration  with  the  NHS  Breast  Screening  Programme.  Delivering 
tamoxifen  chemoprophylaxis  through  primary  care  does  however  seem  feasible. 
Despite  the  frequency  of  visits  to  clinic  settings  for  women  enrolled  into  IBIS 
specialist  clinical  input  at  consultant  level  is  minimal  and  mainly  focussed  on  the 
initial  visit.  A  reduced  number  of  visits  to  hospital  is  possible  providing  the  woman 
has  access  to  her  GP  for  follow  up.  Referral  for  mammography  could  also  be  reduced 
to  the  initial  visit.  More  frequent  mammography  may  be  inappropriate  for  a  health 
intervention  targeted  towards  reducing  the  risk  of  breast  cancer. 
Eligibility  for  tamoxifen  chemoprophylaxis  could  cover  three  main  groups  of  women: 
women  with  a  history  of  atypical  hyperplasia  or  LCIS,  the  group  of  women  under  50 
with  sufficient  risk  to  warrant  eligibility  to  the  NSABP  Pltrial  and  postmenopausal 
women  at  high  risk  for  breast  cancer  who  have  had  a  hysterectomy.  Since  women  in 
these  categories  are  likely  to  have  an  average  relative  risk  of  at  least  3  fold  relative 
risk  these  may  well  be  appropriate  criteria  for  targeting  women  in  the  UK. 
212 Interest  in  the  possible  use  of  the  drug  tamoxifen  for  chemoprophylaxis  of  breast 
cancer  came  about  as  a  result  of  findings  of  a  35%  reduction  in  the  risk  of  breast 
cancer  in  the  contralateral  breast  for  women  taking  tamoxifen.  This  could  potentially 
have  substantial  public  health  significance  if  applicable  to  prevention  for  women 
without  diagnosed  disease  -  potentially  reducing  the  death  rate  to  around  40  per 
100,000  per  year  preventing  more  than  5000  deaths  per  year.  Even  where  a 
prophylactic  application  may  be  verified  empirically  such  a  broad  scale  improvement 
is  unlikely  from  tamoxifen  chemoprophylaxis  since  the  intervention  is  aimed  at  high 
risk  women  in  the  age  range  40-65  while  over  60%  of  breast  cancer  deaths  are  in 
women  aged  65  and  over.  6  Moreover  costs  are  highest  where  the  risk  status  of  the 
women  involved  is  equivalent  to  that  in  the  general  population. 
Recent  evidence  suggest  that  there  is  a  reverse  in  the  previously  rising  trend  of 
incidence  and  mortality  from  breast  cancer  in  the  UK.  Analysis  of  trends  in  mortality 
in  birth  cohorts  since  the  1930  presented  here  support  the  view  that  the  decline  is  most 
likely  to  be  due  to  the  assiduous  application  of  effective  therapeutic  regimen.  There 
may  also  be  a  role  for  changes  in  the  distribution  of  risk  in  birth  cohorts  or  period 
effects.  The  effect  cannot  be  attributed  to  the  NHS  Breast  Screening  Programme. 
Background  figures  for  incidence,  with  which  to  compare  a  preventive  intervention, 
are  difficult  to  ascertain  because  of  the  impact  of  the  NHS  Breast  Screening 
Programme  on  the  rate  for  registration  of  breast  cancer.  Since  the  introduction  of  the 
NHS  Breast  Screening  Programme  the  lifetime  probability  of  acquiring  breast  cancer 
for  a  woman  aged  30  (with  a  life  expectancy  of  83)  was  1  in  11  in  1982  and  1  in  9  in 
1992.  The  breast-screening  programme  was  introduced  in  1988.  Mortality  endpoints 
are  most  desirable  in  assessing  the  efficacy  of  chemoprevention  since  the  prospect 
that  tamoxifen  modifies  the  rate  of  or  blocks  carcinogenesis  rather  than  inhibiting  the 
inset  of  disease  cannot  be  ruled  out.  Nevertheless  possible  effects  of  chemo 
prevention  in  risk  reduction,  compressing  or  delaying  the  development  of  breast 
cancer  may  be  beneficial.  Cost  effectiveness  will  depend  on  the  duration  and 
magnitude  of  the  effect  and  the  absolute  risk  reduction  in  the  treated  population. 
213 Hitherto,  efforts  to  reduce  mortality  and  morbidity  from  breast  cancer  have  focussed 
on  secondary  prevention  through  the  NHS  Breast  Screening  Programme  and  treatment 
of  disease  through  appropriate  application  of  adjuvant  therapy.  Estimates  of  the  likely 
reduction  in  risk  of  death  from  breast  cancer  with  chemoprevention  have  been 
predicted  from  adjuvant  studies  where  a  review  of  long  term  follow  up  has  shown  a 
consistent  improvement  of  around  50%  in  ten  year  survival  with  use  of  tamoxifen 
after  surgical  resection  of  disease.  Consistent  with  this  finding,  a  recent  report  from 
the  NSABP  Breast  Cancer  Prevention  Trial  found  a  49%  reduction  in  risk  of  invasive 
breast  cancer  in  healthy  women  taking  tamoxifen.  This  has  not  been  confirmed  by  the 
publication  of  two  further  preliminary  reports  from  chemoprevention  studies. 
Differences  in  the  study  populations  may  however  may  be  responsible  for  these 
contrary  findings. 
The  screening  trials  have  proposed  a  relative  risk  reduction  in  mortality  of  around 
24%  -  for  screened  women.  Results  from  international  regression  analysis  for  the 
effect  of  dietary  fat  reduction  on  population  mortality  from  breast  cancer  suggest  a 
possible  24%  reduction  with  a  low  fat  dietary  intervention.  A  review  of 
epidemiological  evidence  for  the  relationship  between  diet  and  breast  cancer  however 
cannot  confirm  these  findings.  Better  designed  studies  are  able  to  control  for  family 
history  or  reproductive  risk  factors,  but  none  has  sufficient  heterogeneity  in  fat  intake 
to  detect  adequately  the  effect  of  a  reduction  in  mortality  of  anything  near  the  24% 
seen  in  international  regression  analysis. 
This  study  shows  that  the  cost  effectiveness  of  tamoxifen  chemoprophylaxis  of  breast 
cancer  is  within  acceptable  limits  for  implementation  in  comparison  with  the  present 
programme  for  care  and  prevention  of  breast  cancer  providing  certain  conditions  are 
met.  For  an  average  district  health  authority  population  of  250,000  people  with  about 
100  deaths  from  breast  cancer  per  year  full  implementation  of  effective  adjuvant 
therapy  may  prevent  around  30-40  deaths,  the  screening  programme  may  prevent  10- 
15  deaths.  For  preventive  interventions  the  scope  for  dietary  effects  though  far  from 
proven  may  have  the  potential  of  saving  20-25  deaths;  with  tamoxifen 
chemoprophylaxis  targeted  only  at  say  the  10%  high  risk  women  in  the  population 
would  prevent  only  5-10  deaths. 
214 There  are  few  other  studies  available  with  which  to  compare  the  validity  of  the 
approach  used  in  seeking  to  understand  the  likely  impact  of  long  term  tamoxifen 
chemoprophylaxis  on  the  changed  morbidity  experience  of  women.  The  use  of 
hospital  services  is  frequently  cited  in  studies  of  needs  assessment  as  a  proxy  for 
morbidity  in  the  population  187,188,189  and  a  linear  relationship  might  be  expected. 
Where  the  relationship  is  less  than  perfect  it  is  possible  that  the  methodology  may 
have  underestimated  the  true  impact  on  morbidity.  The  study  does  however  review 
other  possible  means  by  which  morbidity  may  have  been  expressed  either  through 
changes  in  the  quality  of  life  of  the  women  involved  or  through  changes  in  the  use  of 
primary  care  services  -  reported  visits  to  general  practice.  Neither  of  these  showed 
any  significant  changes  in  reported  morbidity  or  in  decrements  in  quality  of  life 
though  attention  should  be  given  to  this  issue  in  further  follow  up. 
Efforts  were  made  to  ensure  accuracy  and  completeness  of  reports  from  the  women 
through  hand  searching  of  records.  Validation  of  the  approach  was  sought  through 
reference  to  routine  sources  of  information.  In  the  case  of  hospital  resource  use 
validation  of  the  information  on  reasons  for  use  of  health  services  including  diagnosis 
and  procedures  undertaken  was  sought  through  comparison  with  the  rate  of 
admissions  to  hospital  by  women  in  the  general  population  reported  in  the  Hospital 
Episode  Statistics.  For  the  rate  of  use  of  medications  further  information  with  which 
to  validate  the  approach  was  sought  through  comparison  with  the  National  Morbidity 
Survey  and  through  review  of  data  for  women  of  the  same  age  registered  with  a  large 
general  practice. 
There  were  no  significant  findings  in  this  study  to  suggest  that  long  term  tamoxifen 
use  in  the  context  of  chemoprevention  affects  morbidity.  There  were  no  significant 
differences  for  women  allocated  to  tamoxifen  or  placebo  in  the  self  reported  rate  of 
use  of  hospital  services  or  use  of  prescribed  medications.  Further  recruitment  to  IBIS 
or  indeed  detailed  analysis  of  morbidity  trends  in  other  prevention  studies  is  needed  to 
explore  this  further  since  confirmation  of  the  non  significant  trend  that  did  emerge  in 
changed  use  of  hospital  visits  for  benign  breast  disease  may  change  the  costs  of  breast 
cancer  chemoprevention  by  between  30  and  38%.  By  contrast,  confirmation  of  a  non 
significant  trend  of  increased  use  of  beta  blockers  for  the  relief  of  menopausal 
215 symptoms  as  often  experienced  by  women  taking  tamoxifen  would  affect  the  cost  by 
less  than  1  %. 
In  terms  of  the  distribution  of  cost  a  small  number  of  women  do  account  for  a  large 
proportion  of  the  overall  costs.  This  finding  suggests  that  it  will  be  the  impact  of 
tamoxifen  chemoprophylaxis  on  increasing  or  reducing  the  incidence  of  high  cost 
procedures,  which  determines  the  cost  impact  from  morbidity.  Adjuvant  studies  report 
that  acute  toxicity  of  tamoxifen  is  low  and  prolonged  exposure  in  adjuvant  studies 
does  not  appear  to  result  in  adverse  effects  on  coronary  heart  disease  or  bone  mineral 
density  despite  its  anti  -  oestrogenic  properties.  In  fact,  where  serum  levels  of  lipids 
and  lipoproteins  have  been  monitored  tamoxifen  appears  to  have  an  oestrogenic  effect 
improving  the  lipid  profile.  There  are  concerns  about  an  increase  in  the  relative  risk  of 
endometrial  cancer  for  women  taking  adjuvant  tamoxifen.  This  effect  appears  to  be 
dose  and  duration  dependent.  For  women  receiving  adjuvant  tamoxifen  at  a  dose  of 
20mg  per  day  the  relative  risk  appears  to  be  between  two  and  three  fold 
. 
Estimates 
from  chemoprevention  studies  are  now  as  high  as  a  five-fold  increase  although  the 
absolute  numbers  are  low.  The  median  cumulative  dose  of  tamoxifen  needed  before 
diagnosis  of  endometrial  cancer  estimated  from  the  Stockholm  Trial  was  29g.  This 
level  would  be  reached  after  four  years  of  treatment  with  a  daily  intake  of  20mg  as 
given  in  IBIS. 
There  is  both  clinical  and  biochemical  evidence  of  an  increased  risk  of 
thromboembolic  events  in  women  taking  tamoxifen.  The  effect  is  clearly  complex 
and  multifactorial  influenced  also  in  adjuvant  studies  by  the  presence  of  disease  and 
the  impact  of  chemotherapy.  The  relative  risk  for  women  taking  tamoxifen  alone 
either  as  an  adjuvant  therapy  or  for  prophylaxis  may  be  between  three  and  five  fold 
although  was  less  than  two  for  all  thromboembolic  disease  in  the  NSABP  Breast 
Cancer  Prevention  Trial.  The  relative  risk  appears  to  increase  when  tamoxifen  is 
taken  in  combination  with  chemotherapy  with  implications  for  treatment  options;  the 
effect  is  greater  in  postmenopausal  women. 
The  impact  of  long  term  exposure  to  tamoxifen  on  cardiac  health  may  be  at  least  as 
important  as  the  end  point  of  primary  breast  cancer  reduction.  Consistent  findings  of 
an  effect  on  lipid  lowering  may  give  rise  to  a  relative  protective  effect  of  tamoxifen 
216 on  mortality  from  myocardial  infarction  of  around  2.0  though  the  recent  updated 
overview  of  randomised  trials  of  adjuvant  therapy  among  women  with  early  breast 
cancer  showed  no  significant  difference  in  the  aggregate  of  all  cardiac  or  vascular 
deaths  after  about  five  years  of  tamoxifen.  The  long  term  impact  on  cardiac 
morbidity  in  general  is  unclear  and  will  require  further  research  to  establish  fully.  The 
precise  duration  of  the  effect  after  cessation  of  tamoxifen  treatment  is  also  uncertain. 
The  impact  of  tamoxifen  on  bone  mineral  density  in  postmenopausal  women  seems  to 
be  an  increase  primarily  in  the  lumbar  spine  and  hip  by  an  annual  increment  of  around 
1.5%  though  this  increase  appears  to  occur  only  during  the  early  years  of  tamoxifen 
use.  Some  evidence  also  suggests  that  the  protective  effect  on  BMD  may  be  lost  after 
cessation  of  use  and  similar  effects  on  radial  bones  appear  doubtful.  Larger  studies 
are  needed  to  confirm  the  reduction  in  bone  mineral  density  in  premenopausal  women 
suggested  in  results  from  the  Royal  Marsden  prevention  pilot  and  to  assess  both  the 
duration  of  this  effect  and  the  clinical  significance. 
The  overall  cost  for  delivering  tamoxifen  prophylaxis  within  the  context  of  IBIS  is 
estimated  at  £1,116  per  woman  per  5  years.  The  largest  proportion  of  cost  (57%)  is  in 
staff  time.  The  cost  of  Doctor  time  is  the  largest  element;  the  amount  of  time  spent  by 
the  Doctor  explains  the  difference  in  cost  between  the  centres.  Tests  and 
investigations  account  for  a  further  23%  of  the  cost  and  provision  of  the  drug 
tamoxifen  for  14%  of  the  cost.  Costs  of  administration  make  up  the  remainder  of  the 
cost  (6%). 
The  main  time  element  in  the  provision  of  tamoxifen  chemoprophylaxis  is  in 
discussing  the  concept  to  the  women  and  the  protocol  for  consent  to  enter  the  trial 
While  the  time  element  in  `consenting'  woman  may  translate  into  time  spent 
discussing  the  evidence  base  and  side  effects  of  tamoxifen  prophylaxis  if  the  approach 
was  adopted  in  routine  practice  some  savings  could  be  made.  Two  scenarios  for 
service  delivery  are  used  in  the  cost  effectiveness  analysis.  These  are  £535  for  a 
specialist  nurse  led  hospital  based  service  or  £410  for  a  service  run  in  general 
practice.  The  nurse  led  service  is  used  as  the  baseline  approach  for  the  model 
developed  in  chapter  7  and  the  GP  run  service  is  explored  through  the  sensitivity 
analysis.  Both  approaches  would  rely  on  minimal  input  from  a  consultant  surgeon  or 
217 equivalent  with  only  1  visit  included  for  the  5-year  period.  The  frequency  of 
mammography  would  be  a  maximum  of  3  times  in  the  5-year  period  of  active 
intervention.  Both  scenarios  exclude  the  costs  attributable  to  the  research  trial 
particularly  the  need  for  annual  mammography,  the  taking  and  processing  of  blood 
and  time  spent  recruiting  women  to  the  study. 
The  costs  borne  by  women  using  a  service  for  tamoxifen  chemoprophylaxis  based  on 
women  recruited  to  IBIS  range  from  £20  to  £30  per  year  of  recruitment  depending  on 
whether  time  spent  travelling  to  or  during  clinic  visits  is  excluded  or  costed  at  average 
hourly  earnings  for  women  in  this  age  group.  This  includes  both  the  cost  of  work  lost 
due  to  clinic  visits,  costs  of  travel  to  the  clinics  or  other  costs  associated  with  clinic 
visits.  Women  recruited  to  IBIS  are  willing  to  travel  long  distances  to  receive  the 
chance  of  taking  tamoxifen  chemoprophylaxis.  75%  of  journeys  are  longer  than  30 
minutes  with  half  of  these  being  over  1  hour.  Over  60  %  of  women  sampled  reported 
that  they  would  wish  to  take  tamoxifen  at  even  a  low  level  of  absolute  benefit  (1  death 
prevented  per  year);  84%  of  the  women  would  be  happy  to  travel  to  a  specialist  centre 
to  receive  tamoxifen.  There  was  no  difference  in  the  pattern  of  use  of  primary  care 
between  the  2  arms  of  the  trial. 
Including  the  personal  costs  to  the  women  themselves  in  the  cost  effectiveness 
analysis  increases  the  cost  by  between  1%  and  8%  depending  on  whether  an 
allowance  is  made  for  the  cost  of  time  spent  in  travelling  to  or  attending  clinic  visits. 
Where  the  service  was  made  available  in  primary  care  this  cost  would  be  minimal. 
Health  status  of  women  recruited  to  IBIS  was  measured  using  the  SF36.  This  proved 
to  be  a  practical  and  acceptable  instrument  for  use  in  a  postal  questionnaire. 
Responses  to  the  SF36  show  that  women  recruited  to  IBIS  have  the  same  pattern  of 
health  as  women  in  the  general  population  across  all  of  the  health  dimensions 
including  physical  functioning,  role  limitation  (includes  both  physical  and  emotional), 
social  functioning,  pain,  mental  health  energy/fatigue  and  general  health  perception. 
Energy  and  fatigue  has  the  lowest  score  for  both  groups.  There  is  also  no  significant 
difference  in  any  of  the  health  dimensions  between  the  2  arms  of  the  trial.  There 
appear  to  be  no  adverse  effects  on  quality  of  life  for  women  taking  long  teen 
218 tamoxifen  prophylaxis  and  no  adjustment  for  quality  of  life  is  needed  in  assessing  cost 
effectiveness. 
The  cost  effectiveness  of  tamoxifen  chemoprophylaxis  can  be  compared  with  other 
means  of  reducing  breast  cancer  incidence  although  there  are  problems  of 
comparability  particularly  in  estimating  the  savings  from  the  cost  of  breast  cancer 
prevented.  Boer  and  de  Koning  12  published  cost  effectiveness  estimates  for  the 
current  programme  of  £25,142  per  death  prevented  and  £24,205  or  £27,865  for 
extending  the  age  range  to  65  or  reducing  the  interval  to  two  years  respectively.  The 
estimates  for  cost  effectiveness  of  tamoxifen  prophylaxis  fall  below  this  range 
providing  that  the  effect  of  risk  reduction  translates  into  a  mortality  benefit.  Further 
assessment  of  whether  the  results  for  reduction  in  incidence  found  in  the  NSABP  P1 
represent  a  delay  in  the  development  of  cancers  or  a  permanent  benefit  is  also  an 
important  priority  for  further  research.  Estimates  for  the  cost  effectiveness  of  early 
treatment  for  breast  cancer  to  year  10  of  between  £10,625  ($17,000)  per  death 
prevented  for  women  at  all  ages  in  the  highest  risk  categories  to  £31,250  ($50,000)  for 
women  at  any  age  at  a  lower  risk  of  death  are  substantially  more  favourable  than  for 
breast  screening  outcomes  though  may  be  considered  comparable  to  the  range  of  cost 
effectiveness  reported  here  for  tamoxifen  chemoprophylaxis. 
There  is  insufficient  information  on  the  present  management  of  women  at  high  risk 
for  breast  cancer  to  compare  with  the  costs  estimated  for  chemoprophylaxis  of  breast 
cancer.  Bilateral  prophylactic  mastectomy  has  been  a  treatment  choice  for  some 
women  though  there  are  few  routine  data  available  to  assess  the  frequency  of  use  of 
this  approach,  its  survival  advantage  or  cost  effectiveness.  '  3  Annual  mammography 
has  also  been  suggested  for  women  in  high-risk  categories  though  there  are  no  data  at 
present  to  assess  the  efficacy  or  cost  effectiveness  of  this  approach. 
To  date  no  other  cost  effectiveness  studies  of  breast  cancer  chemoprevention  have 
been  published.  Yet  a  complete  understanding  of  the  value  of  chemoprophylaxis  of 
breast  cancer  will  rely  on  the  impact  of  long  term  drug  use  on  morbidity  and  on  the 
quality  of  life  and  the  well  being  of  the  women  as  well  as  the  cost  of  service  delivery. 
Further  research  is  needed  to 
219 "  Monitor  the  long  term  consequences  of  tamoxifen  use  on  the  general  health  and 
morbidity  of  women.  Small  changes  in  the  use  of  hospital  services  or  prescribed 
medications  for  the  age  group  targeted  in  prevention  trials  could  have  a  significant 
impact  on  the  overall  cost  of  tamoxifen  chemoprophylaxis  because  of  the 
potentially  large  numbers  of  women  involved. 
"  Further  work  is  needed  to  assess  whether  the  effects  found  in  the  NSABP  P1  study 
measure  a  delay  in  breast  cancer  mortality  rather  than  prevention. 
In  general  research  on  alternative  means  of  reducing  mortality  and  morbidity  from 
breast  cancer  should  be  pursued.  An  understanding  of  the  biological  plausibility  of 
causal  link  between  dietary  fat  and  breast  cancer  discussed  in  this  study  cannot 
exclude  the  possible  importance  of  diet  at  key  development  stages.  In  particular,  the 
relationship  with  onset  of  menarche  and  early  adolescence  where  the  impact  of  diet  on 
breast  carcinogenesis  may  be  profound.  Further  research  is  needed  to  address  this 
issue.  A  number  of  randomised  controlled  trials  are  underway  in  the  USA  although 
these  are  focussing  only  on  the  recruitment  of  adult  women.  There  are  difficulties  in 
undertaking  prevention  trials  because  of  the  concerns  raised  by  ethics  committees 
about  the  recruitment  of  healthy  women  and  because  of  the  numbers  of  women 
involved. 
Long  term  breast  cancer  adjuvant  studies  are  useful  in  providing  information  on  the 
safety  of  trials  for  tamoxifen  prophylaxis  but  more  detailed  studies  are  needed  to 
assess  the  effect  of  long  term  exposure  to  tamoxifen  for  chemoprevention  of  breast 
cancer  in  healthy  asymptomatic  women. 
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